<SEC-DOCUMENT>0001824293-23-000170.txt : 20231114
<SEC-HEADER>0001824293-23-000170.hdr.sgml : 20231114
<ACCEPTANCE-DATETIME>20231114165612
ACCESSION NUMBER:		0001824293-23-000170
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		68
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231114
DATE AS OF CHANGE:		20231114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GRI BIO, Inc.
		CENTRAL INDEX KEY:			0001824293
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824369909
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40034
		FILM NUMBER:		231407603

	BUSINESS ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 208
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		(619) 400-1171

	MAIL ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 208
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vallon Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20200910
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ck0001824293-20230930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:a8344312-8d5f-422d-bd63-4db6cc7ddad6,g:d0f905d4-70f6-4e32-afc7-d259f8c67a30,d:9543da0ac24342e79ce7f476be8c5f32--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ck0001824293="http://www.vallon-pharma.com/20230930" xmlns:srt="http://fasb.org/srt/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ck0001824293-20230930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-29">0001824293</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-30">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-31">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-32">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-33">FALSE</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-55" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-289">0.0333</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ck0001824293-20230930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ck0001824293:GRIBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesTWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ck0001824293:StockSubjectToPutRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ck0001824293:StockSubjectToPutRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ck0001824293:ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ck0001824293:ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ExchangeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-13</xbrli:startDate><xbrli:endDate>2022-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-13</xbrli:startDate><xbrli:endDate>2022-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="closing"><xbrli:measure>ck0001824293:closing</xbrli:measure></xbrli:unit><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-14</xbrli:startDate><xbrli:endDate>2022-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-14</xbrli:startDate><xbrli:endDate>2022-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:PutOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA1WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA2WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesTWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA2WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA1WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ExchangeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BankerWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BankerWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BankerWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsExchangeWarrantsAndBankerWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsExchangeWarrantsAndBankerWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsExchangeWarrantsAndBankerWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsExchangeWarrantsAndBankerWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInNovember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInDecember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJuly2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn24MonthsAfterRegistrationDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn24MonthsAfterRegistrationDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ck0001824293:AardvarkTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-22</xbrli:startDate><xbrli:endDate>2023-08-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:PrivateGRIPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:PrivateGRIPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ck0001824293:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9543da0ac24342e79ce7f476be8c5f32_1"></div><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:2.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-2">10-Q</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="f-3">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-5">September 30, 2023</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from_________to_________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-7">001-40034</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="ck0001824293-20230930_g1.jpg" alt="GRI_ LOGO SELECT_ColorJPG.jpg" style="height:101px;margin-bottom:5pt;vertical-align:text-bottom;width:201px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-8">GRI BIO, INC.</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-9">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-10">82-4369909</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Identification No.)&#160;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-11">2223 Avenida de la Playa</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-12">#208</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-13">La Jolla</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-14">CA</ix:nonNumeric>  <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-15">92037</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices, including zip code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-16">619</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-17">400-1170</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.0001<br/>per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">GRI</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:8pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">x</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-25">x</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-26">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-27">x</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of November 13, 2023, <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-28">3,246,354</ix:nonFraction> shares of the Registrant&#8217;s common stock were outstanding.</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div></div><div id="i9543da0ac24342e79ce7f476be8c5f32_7"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:8pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_13">PART&#160;I. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_19">Balance Sheets as of </a>September 30, 2023 (unaudited) and December 31, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations (unaudited) for the three and nine <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_22">months ended</a> September 30, 2023<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_22"> and</a> 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_25">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) (unaudited) for the three and </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_25">nine</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_25"> months ended </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_25">September</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_25"> 30, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2023<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_28"> and </a>2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_31">Notes to Unaudited Interim Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_85">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_85">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_85">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_109">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_109">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_109">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_112">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_112">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_112">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_115">PART&#160;II. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_115">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_115">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_118">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_118">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_118">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_121">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_121">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_121">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_124">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_124">Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_124">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_127">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_127">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_127">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_130">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_130">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_130">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_133">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_133">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_133">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_136">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_136">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_136">29</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_139">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9543da0ac24342e79ce7f476be8c5f32_139">30</a></span></div></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i9543da0ac24342e79ce7f476be8c5f32_13"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i9543da0ac24342e79ce7f476be8c5f32_16"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="i9543da0ac24342e79ce7f476be8c5f32_19"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"></td><td style="width:70.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-34">3,488</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="f-35">9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-36">879</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-37">303</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">4,367</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" scale="3" id="f-39">312</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-40">9</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-41">4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-42">28</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-43">67</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-44">4,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" scale="3" id="f-45">383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-46">988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">1,294</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">1,143</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-49">36</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances from employees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ck0001824293:EmployeeAdvancesCurrent" format="ixt:fixed-zero" scale="3" id="f-50">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ck0001824293:EmployeeAdvancesCurrent" scale="3" id="f-51">5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="f-52">18</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:fixed-zero" scale="3" id="f-53">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bridge promissory note, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-54">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NotesPayableCurrent" scale="3" id="f-55">602</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-56">28</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-57">57</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">2,177</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">1,994</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-60">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-61">14</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-62">2,177</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-63">2,008</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 12)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-64"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-65"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity (deficit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, <ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-66"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-67">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-68"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-69">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of September&#160;30, 2023 and December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-70"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-71">2,956,354</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-72"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-73">999,748</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September&#160;30, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="f-74">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="f-75">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in-capital</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-76">31,756</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-77">16,871</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-78">29,529</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-79">18,496</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-80">2,227</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-81">1,625</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity (deficit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-82">4,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="f-83">383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i9543da0ac24342e79ce7f476be8c5f32_22"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"><tr><td style="width:1.0%"></td><td style="width:50.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:10pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-84">1,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-85">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-86">2,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-87">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-88">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="f-89">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-90">7,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="f-91">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.35pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-92">2,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" scale="3" id="f-93">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-94">9,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" scale="3" id="f-95">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-96">2,439</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="f-97">186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-98">9,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="f-99">572</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" scale="3" id="f-100">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" format="ixt:fixed-zero" scale="3" id="f-101">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" scale="3" id="f-102">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" format="ixt:fixed-zero" scale="3" id="f-103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-104">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-106">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-107">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-108">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-109">165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-110">2,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-111">376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-112">2,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-113">351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-114">11,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-115">948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share of common stock, basic and diluted</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-116"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-117">0.52</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-118"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-119">0.39</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-120"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-121">3.83</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-122"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-123">1.06</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-124"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-125">4,124,478</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-126"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-127">896,117</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-128"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-129">2,883,537</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-130"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-131">894,669</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i9543da0ac24342e79ce7f476be8c5f32_25"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.083%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.896%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redeemable Convertible Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional&#160;Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217; Deficit</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance,&#160;December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-132">7,816</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="f-133">124</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-134">851,419</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-135">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-136">10,430</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-137">15,278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-138">4,848</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-139">302</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-140">302</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-141">7,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="f-142">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-143">851,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-145">10,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-146">15,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-147">5,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-148">295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-149">295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-150">7,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="f-151">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-152">851,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-154">10,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-155">15,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-156">5,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of warrants and non-contingent beneficial ownership feature in connection with convertible promissory note</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="3" id="f-157">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="3" id="f-158">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of warrants in connection with non-convertible promissory note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="f-159">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="f-160">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-161">351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-162">351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-163">7,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="f-164">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-165">851,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-166">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-167">10,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-168">16,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-169">5,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.083%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.896%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redeemable Convertible Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional&#160;Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity (Deficit)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance,&#160;December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-170">999,748</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-171">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-172">16,871</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-173">18,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-174">1,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-175">13</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-176">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock vesting</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="f-177">467</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrant issuance</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="f-178">532</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="f-179">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-180">2,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-181">2,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-182">1,000,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-183">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-184">17,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-185">20,646</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-186">3,230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-187">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-188">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-189">164,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrant exercise</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise" format="ixt:num-dot-decimal" scale="0" id="f-190">43,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueWarrantExercises" scale="3" id="f-191">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueWarrantExercises" scale="3" id="f-192">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in pre-closing financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesPreClosingFinancing" format="ixt:num-dot-decimal" scale="0" id="f-193">1,214,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing" format="ixt:num-dot-decimal" scale="3" id="f-194">11,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing" format="ixt:num-dot-decimal" scale="3" id="f-195">11,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for settlement of bridge note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesSettlementOfDebt" format="ixt:num-dot-decimal" scale="0" id="f-196">54,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-197">3,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-198">3,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for reverse recapitalization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" format="ixt:num-dot-decimal" scale="0" id="f-199">30,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-200">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-201">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock to Vallon stockholders in reverse recapitalization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalization" format="ixt:num-dot-decimal" scale="0" id="f-202">448,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-203">2,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-204">2,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-205">6,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-206">6,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-207">2,956,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-209">31,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-210">27,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-211">4,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-212">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-213">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-214">2,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-215">2,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-216">2,956,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-218">31,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-219">29,529</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-220">2,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i9543da0ac24342e79ce7f476be8c5f32_28"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-221">11,033</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-222">948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-223">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-224">2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discounts and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-225">2,104</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-226">45</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-227">352</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-228">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-229">18</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="f-230">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction in operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-231">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-232">35</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-233">836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-234">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-235">4,860</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-236">77</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-237">1,106</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-238">590</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-239">43</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-240">35</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-241">3,430</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="f-242">241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-243">8</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-244">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-245">8</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-246">&#8212;</ix:nonFraction></span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Advances from employees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:ProceedsFromAdvancesFromEmployees" scale="3" id="f-247">190</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:ProceedsFromAdvancesFromEmployees" scale="3" id="f-248">35</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of advances from employees</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:RepaymentOfAdvancesFromEmployees" scale="3" id="f-249">195</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:RepaymentOfAdvancesFromEmployees" scale="3" id="f-250">30</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of non-convertible promissory note</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:ProceedsFromNonConvertibleDebt" format="ixt:fixed-zero" scale="3" id="f-251">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:ProceedsFromNonConvertibleDebt" scale="3" id="f-252">125</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of convertible promissory note</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="f-253">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="f-254">125</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock in pre-closing financing</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-255">1,250</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-256">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of bridge promissory note</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-257">12,250</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="3" id="f-258">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from warrant exercise</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="f-259">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="f-260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net liabilities assumed in connection with reverse recapitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-261">2,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" format="ixt:fixed-zero" scale="3" id="f-262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of reverse recapitalization costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:PaymentOfReverseRecapitalizationCosts" format="ixt:num-dot-decimal" scale="3" id="f-263">2,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:PaymentOfReverseRecapitalizationCosts" format="ixt:fixed-zero" scale="3" id="f-264">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of deferred stock issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-265">517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="f-267">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-269">6,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-270">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-271">3,479</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="f-272">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-273">9</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-274">90</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-275">3,488</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-276">104</ix:nonFraction></span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Issuance of stock for repayment of bridge promissory note</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:StockIssuedForRepaymentOfNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-277">3,333</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:StockIssuedForRepaymentOfNotesPayable" format="ixt:fixed-zero" scale="3" id="f-278">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Recognition of debt discount and additional paid-in-capital for issuance of warrants in connection with the<br/>&#160;&#160;issuance of promissory notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" scale="3" id="f-279">532</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" scale="3" id="f-280">90</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Issuance of stock for payment of reverse recapitalization costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts" format="ixt:num-dot-decimal" scale="3" id="f-281">1,875</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts" format="ixt:fixed-zero" scale="3" id="f-282">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Issuance of warrants for payment of stock issuance costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:WarrantsIssued" scale="3" id="f-283">18</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:WarrantsIssued" format="ixt:fixed-zero" scale="3" id="f-284">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Merger costs included in accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:NoncashMergerRelatedCostsFinancingActivities" scale="3" id="f-285">72</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:NoncashMergerRelatedCostsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-286">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i9543da0ac24342e79ce7f476be8c5f32_31"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div id="i9543da0ac24342e79ce7f476be8c5f32_34"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-287" continuedAt="f-287-1" escape="true">ORGANIZATION AND DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="f-287-1"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date of inception.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. The Company&#8217;s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. The Company&#8217;s lead product candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T (iNKT I) cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). The Company&#8217;s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 Natural Killer T (NKT II) cells and is being developed for the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease (SLE) or lupus and multiple sclerosis (MS).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reverse Merger with Vallon Pharmaceuticals, Inc.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the Company (formerly Vallon Pharmaceuticals, Inc.(Vallon)) consummated a merger with GRI Bio Operations, Inc. (formerly GRI Bio, Inc.) (Private GRI) pursuant to an Agreement and Plan of Merger, as amended (the Merger Agreement), by and among the Company, Private GRI and Vallon Merger Sub, Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of the Company (Note 4). The Merger Agreement provided for the merger of Merger Sub with and into Private GRI, with Private GRI surviving the merger as a wholly-owned subsidiary of the Company (the Merger). In connection with the closing of the Merger (the Closing), the Company amended its certificate of incorporation and bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221; In addition, prior to the effective time of the Merger (the Effective Time), the Company effected a reverse stock split of the Company&#8217;s common stock at a ratio of 1 for 30 (the Reverse Stock Split). At the Effective Time, each share of Private GRI&#8217;s common stock outstanding immediately prior to the Effective Time automatically converted solely into the right to receive a number of shares of the Company's common stock equal to <ix:nonFraction unitRef="number" contextRef="c-54" decimals="4" name="ck0001824293:CommonStockExchangeRatio" scale="0" id="f-288">0.0374</ix:nonFraction> (the Exchange Ratio).</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise indicated or as the context requires, references herein to &#8220;GRI Bio,&#8221; the &#8220;Company,&#8221; or the &#8220;combined company,&#8221; refer to GRI Bio, Inc. on a post-Merger basis, and references to &#8220;Private GRI&#8221; refer to the business of  GRI Bio, Inc. prior to the completion of the Merger. References to &#8220;Vallon&#8221; refer to Vallon Pharmaceuticals, Inc. prior to the completion of the Merger.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the Merger was accounted for as reverse recapitalization under which the historical financial statements of the Company prior to the Merger are the historical financial statements of the accounting acquirer, Private GRI. All common stock, per share and related information presented in the consolidated financial statements and notes prior to the Merger has been retroactively adjusted to reflect the Exchange Ratio and Reverse Stock Split for all periods presented, to the extent applicable.</span></div></ix:continuation><div id="i9543da0ac24342e79ce7f476be8c5f32_40"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="f-290" continuedAt="f-290-1" escape="true">LIQUIDITY</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-290-1" continuedAt="f-290-2">These financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and as a result has incurred $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-291">29,529</ix:nonFraction> in accumulated deficit through September&#160;30, 2023. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of September&#160;30, 2023, the Company had cash of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-292">3,488</ix:nonFraction>. </ix:continuation></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><ix:continuation id="f-290-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered the Equity SPA pursuant to which the Investor agreed to invest $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:InvestmentCompanyCommittedCapital" format="ixt:num-dot-decimal" scale="3" id="f-293">12,250</ix:nonFraction> in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI common stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, Private GRI issued <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-294">6,787,219</ix:nonFraction> shares of Private GRI common stock (the Initial Shares) to the Investor and <ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="ck0001824293:CommonStockHeldIntoEscrowAccount" format="ixt:num-dot-decimal" scale="0" id="f-295">27,148,877</ix:nonFraction> shares of Private GRI common stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-296">11,704</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" scale="3" id="f-297">546</ix:nonFraction>.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="f-298">253,842</ix:nonFraction> shares of the Company&#8217;s common stock and the Additional Shares converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="ck0001824293:ConversionOfStockAdditionalSharesConverted" format="ixt:num-dot-decimal" scale="0" id="f-299">1,015,368</ix:nonFraction> shares of the Company&#8217;s common stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and the Investor authorized the escrow agent to, subject to beneficial ownership limitations, disburse to the Investor all of the shares of the Company&#8217;s common stock issued in exchange for the Additional Shares. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2024. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Series T Warrants issued in connection with the Merger are not presently subject to forced exercise by the Company as the equity conditions for their forced exercise, which include (among other things) a requirement that shares of the Company&#8217;s common stock have a value weighted average price of at least $<ix:nonFraction unitRef="usdPerShare" contextRef="c-60" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-300">9.21</ix:nonFraction> per share for the periods specified in the Series T Warrants, are not met. The Company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if the Company&#8217;s research and development efforts are successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of one year from the issuance of these financial statements. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.</span></div></ix:continuation><div id="i9543da0ac24342e79ce7f476be8c5f32_43"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-301" continuedAt="f-301-1" escape="true">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-301-1" continuedAt="f-301-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-302" escape="true">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2022 balance sheet was derived from the Company&#8217;s audited financial statements.</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited interim financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of September&#160;30, 2023, and the results of operations and stockholders&#8217; equity (deficit) for the three and nine months ended September&#160;30, 2023 and 2022 and cash flows for the three and nine months ended September&#160;30, 2023 and 2022. Results of operations for the three and nine months ended September&#160;30, 2023, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2023. The unaudited interim financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2022, which are included as Exhibit 99.2 of Amendment No. 2 to the Current Report on Form 8-K filed with the SEC on July 6, 2023. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-303" continuedAt="f-303-1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance and subsequent revaluations, </span></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><ix:continuation id="f-301-2" continuedAt="f-301-3"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-303-1">valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</ix:continuation></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-304" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of September&#160;30, 2023 and December&#160;31, 2022 included investments in money market funds. The Company maintains its cash and cash equivalent balances at domestic financial institutions. Bank deposits with US banks are insured up to $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashFDICInsuredAmount" scale="3" id="f-305">250</ix:nonFraction> by the Federal Deposits Insurance Corporation. The Company had an uninsured cash balances of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashUninsuredAmount" format="ixt:num-dot-decimal" scale="3" id="f-306">2,988</ix:nonFraction> at September&#160;30, 2023. The Company&#8217;s cash balance as of December&#160;31, 2022 was fully insured.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-307" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ASC 820) establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, the Company&#8217;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At September&#160;30, 2023, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon issued warrants in connection with a securities purchase agreement. Vallon evaluated the warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As a result, the warrants are recorded as a liability on the balance sheet. Vallon recorded the fair value of the warrants upon issuance using a Black-Scholes valuation model. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to revalue the warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrants liabilities is reflected in the statement of operations for the nine months ended September&#160;30, 2023.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredChargesPolicyTextBlock" id="f-308" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Stock Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred stock issuance costs represent incremental legal costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.</span></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtPolicyTextBlock" id="f-309" continuedAt="f-309-1" escape="true">Debt Discounts</ix:nonNumeric></span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><ix:continuation id="f-301-3"><ix:continuation id="f-309-1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relative fair values of warrants and common shares issued and call option rights assigned in connection with principal advances under promissory notes, the increases in fair values of embedded conversion options in connection with convertible promissory note modifications, and the intrinsic values of non-contingent beneficial conversion features were recorded as debt discounts that are amortized as additional interest expense over the estimated terms of the notes using the effective interest method.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs represent incremental legal costs and other costs incurred that are directly attributable to issuing debt. The costs are included as a direct reduction of the carrying amount of the respective liability and are amortized as additional interest expense over the estimated term of the debt using the effective interest method.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-310" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are recorded as a cumulative adjustment in the period the estimates are revised. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-311" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share are calculated by dividing the net loss by the applicable weighted-average number of common shares outstanding during the period. As the Company had a net loss in each of the three and nine months ended September&#160;30, 2023 and 2022, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-312" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-313">318,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-62" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-314">89,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-63" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-315">2,546,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-316">10,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock with repurchase rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-66" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-318">147,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock subject to put right</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-67" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-68" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-320">7,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible promissory note</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-69" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-322">150,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-323">2,864,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-324">405,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-325" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended September&#160;30, 2023 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i9543da0ac24342e79ce7f476be8c5f32_49"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-326" continuedAt="f-326-1" escape="true">MERGER WITH VALLON</ix:nonNumeric></span></div><ix:continuation id="f-326-1" continuedAt="f-326-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, pursuant to the Merger Agreement, Merger Sub was merged with and into Private GRI, with Private GRI surviving the Merger as a wholly owned subsidiary of the Company. In connection with the Closing, the Company amended its certificate of incorporation and bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Effective Time:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Each share of Private GRI&#8217;s common stock outstanding immediately prior to the Effective Time, including any shares of Private GRI&#8217;s common stock issued pursuant to the Equity SPA automatically converted solely into the right to receive a number of shares of the Company&#8217;s common stock equal to the Exchange Ratio.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Each option to purchase shares of Private GRI&#8217;s common stock (each, a GRI Option) outstanding and unexercised immediately prior to the Effective Time under the GRI Bio, Inc. 2015 Equity Incentive Plan (the GRI Plan), whether or not vested, converted into and became an option to purchase shares of the Company&#8217;s common stock, and the Company assumed the GRI Plan and each such GRI Option in accordance with the terms of the GRI Plan (the Assumed Options). The number of shares of the Company&#8217;s common stock subject to each Assumed Option was determined by multiplying (i) the number of shares of Private GRI&#8217;s common stock that were subject to such GRI Option, as in effect immediately prior to the Effective Time, by (ii) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of the Company&#8217;s common stock. The per share exercise price for the Company&#8217;s common stock issuable upon exercise of each Assumed Option was determined by dividing (A) the per share exercise price of such Assumed Option, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio and rounding the resulting per share exercise price up to the nearest whole cent. Any restriction on the exercise of any Assumed Option continued in full force and effect and the term, exercisability, vesting schedule, and any other provisions of such Assumed Option otherwise remained unchanged.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Each warrant to purchase shares of Private GRI&#8217;s common stock outstanding immediately prior to the Effective Time other than the Bridge Warrants (as defined below) (the GRI Warrants), was assumed by the Company and converted into a warrant to purchase shares of the Company&#8217;s common stock (the Assumed Warrants) and thereafter (i) each Assumed Warrant became exercisable solely for shares of the Company&#8217;s common stock; (ii) the number of shares of the Company&#8217;s common stock subject to each Assumed Warrant was determined by multiplying (A) the number of shares of Private GRI&#8217;s common stock that were subject to such GRI Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of the Company&#8217;s common stock; (iii) the per share exercise price for shares of the Company&#8217;s common stock issuable upon exercise of each Assumed Warrant was determined by dividing (A) the exercise price per share of Private GRI&#8217;s common stock subject to such GRI Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Bridge Warrants (Note 8) were exchanged for warrants (the Exchange Warrants) to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-327">421,589</ix:nonFraction> shares of the Company&#8217;s common stock. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-71" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-328">14.73</ix:nonFraction> per share.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All rights with respect to Private GRI restricted stock awards were assumed by the Company and converted into Company restricted stock awards with the number of shares subject to each restricted stock award multiplied by the Exchange Ratio and rounding the resulting number down to the nearest whole number of shares of the Company&#8217;s common stock. The term, exercisability, vesting schedule and other provisions of the Private GRI restricted stock awards otherwise remained unchanged.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger is accounted for as a reverse recapitalization under U.S. GAAP because the primary assets of Vallon were cash and cash equivalents. For accounting purposes, GRI has been determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i)  the equity holders of Private GRI immediately prior to the Merger owned, or held rights to acquire, in the aggregate approximately <ix:nonFraction unitRef="number" contextRef="c-72" decimals="2" name="ck0001824293:CommonStockOwnershipPercentage" scale="-2" id="f-329">85</ix:nonFraction>% of the outstanding shares of the Company&#8217;s common stock and the Company&#8217;s stockholders immediately prior to the Merger owned approximately <ix:nonFraction unitRef="number" contextRef="c-73" decimals="2" name="ck0001824293:CommonStockOwnershipPercentage" scale="-2" id="f-330">15</ix:nonFraction>% of the outstanding shares of the Company&#8217;s common stock (ii) Private GRI holds the majority (4 out of 5) of board seats of the combined company, and (iii) Private GRI&#8217;s management holds the majority of </span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><ix:continuation id="f-326-2" continuedAt="f-326-3"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">key positions in the management of the combined company. Immediately after the Merger, there were <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-331"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-332">2,956,354</ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s common stock outstanding.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="f-333" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the net liabilities assumed in the Merger:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 21, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="f-334">941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="f-335">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="f-336">4,190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" sign="-" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-337">2,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: Transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="f-338">2,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net liabilities assumed plus transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" sign="-" name="ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="f-339">5,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-326-3">In addition to the transaction costs noted above, at the Effective Time, <ix:nonFraction unitRef="shares" contextRef="c-55" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" format="ixt:num-dot-decimal" scale="0" id="f-340">30,542</ix:nonFraction> shares of the Company&#8217;s common stock were issued to Private GRI&#8217;s financial advisor for services related to the Merger.</ix:continuation> </span></div><div id="i9543da0ac24342e79ce7f476be8c5f32_52"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-341" continuedAt="f-341-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="f-341-1" continuedAt="f-341-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the guidance in ASC 820 to account for financial assets and liabilities measured on a recurring basis. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The guidance requires that fair value measurements be classified and disclosed in one of the following 3 categories:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities; and</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. There were no transfers between Level 1, 2 and 3 during the nine months ended September&#160;30, 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-342" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s liabilities that are measured at fair value on a recurring basis at September&#160;30, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:fixed-zero" scale="3" id="f-343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:fixed-zero" scale="3" id="f-344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="f-345">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-348">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><ix:continuation id="f-341-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-349" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the Level 3 liability:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant Liability </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-350">185</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-351">167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of September&#160;30, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-352">18</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-353" continuedAt="f-353-1" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-81" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-354">167.7</ix:nonFraction>&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-82" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-355">139.9</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-83" decimals="1" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-356">2.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-84" decimals="1" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-357">2.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-85" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-358">0.0</ix:nonFraction>&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-359">0.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-87" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-360">4.92</ix:nonFraction>&#160;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-88" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-361">4.32</ix:nonFraction>&#160;%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9543da0ac24342e79ce7f476be8c5f32_55"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-362" continuedAt="f-362-1" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="f-362-1"><div style="margin-bottom:8pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-363" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-364">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-365">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-366">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-367">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-368">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-369">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-370">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-371">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-372">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-373">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-374">3</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-375">2</ix:nonFraction> for the nine months ended September&#160;30, 2023 and 2022, respectively.</span></div></ix:continuation><div id="i9543da0ac24342e79ce7f476be8c5f32_58"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-376" continuedAt="f-376-1" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:continuation id="f-376-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-377" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="f-378">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:fixed-zero" scale="3" id="f-379">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" scale="3" id="f-380">188</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" format="ixt:fixed-zero" scale="3" id="f-381">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-382">880</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-383">36</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-384">1,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-385">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9543da0ac24342e79ce7f476be8c5f32_61"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-386" continuedAt="f-386-1" escape="true">PROMISSORY NOTES</ix:nonNumeric></span></div><ix:continuation id="f-386-1" continuedAt="f-386-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bridge Financing</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, Private GRI entered into a Securities Purchase Agreement, dated as of December 13, 2022 (Bridge SPA), with Altium Growth Fund, LP (the Investor), pursuant to which Private GRI issued senior secured promissory notes (Bridge Notes) in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-387">3,333</ix:nonFraction>, in exchange for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-388">2,500</ix:nonFraction>. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bridge Notes were issued in <ix:nonFraction unitRef="closing" contextRef="c-95" decimals="INF" name="ck0001824293:DebtInstrumentNumberOfClosings" format="ixt-sec:numwordsen" scale="0" id="f-389">two</ix:nonFraction> closings: (i) the first closing for $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-390">1,667</ix:nonFraction> in aggregate principal amount (in exchange for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-391">1,250</ix:nonFraction>) closed on December 14, 2022; and (ii) the second closing for $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-392">1,667</ix:nonFraction> in aggregate principal amount (in exchange for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-393">1,250</ix:nonFraction>) closed on March 9, 2023. The Bridge Notes were secured by a lien on all of the Company&#8217;s assets. </span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><ix:continuation id="f-386-2" continuedAt="f-386-3"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, upon the funding of each tranche, the Investor received warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-394">1,252,490</ix:nonFraction> shares of the Company&#8217;s common stock (the Bridge Warrants). The Bridge Warrants had an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-100" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-395">1.33</ix:nonFraction> per share, were exercisable at any time on or after the applicable issuance date and had a term of <ix:nonNumeric contextRef="c-100" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-396">60</ix:nonNumeric> months from the date all shares underlying the Bridge Warrants were freely tradable. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-397">1,250</ix:nonFraction> of proceeds from the first closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-398">679</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-399">571</ix:nonFraction>, respectively. The $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-400">1,250</ix:nonFraction> of proceeds from the second closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-401">718</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-402">532</ix:nonFraction>, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Bridge SPA, and also in connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered into the Equity SPA (Note 9) pursuant to which the Investor agreed to invest $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:InvestmentCompanyCommittedCapital" format="ixt:num-dot-decimal" scale="3" id="f-403">12,250</ix:nonFraction> in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI&#8217;s common stock immediately prior to the consummation of the Merger. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the Company completed the Merger and the outstanding principal and accrued interest on the Bridge Notes was cancelled and the Bridge Warrants were exchanged for the Exchange Warrants. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-71" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-404">14.73</ix:nonFraction> per share subject to adjustments for splits and recapitalization events.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bridge Notes were accounted for as share-settled debt under the accounting guidance in ASC 835-30 and, as such, the initial net carrying amounts were accreted to the redemption amounts using the effective interest method. The Company incurred debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="f-405">205</ix:nonFraction> during the year ended December&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="f-406">90</ix:nonFraction> during the nine months ended September&#160;30, 2023 related to its issuance of debt under the Bridge SPA. Unamortized debt discounts and debt issuance costs totaled $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-407">1,065</ix:nonFraction> as of December&#160;31, 2022. Interest expense stemming from amortization of debt discounts and issuance costs was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-408">2,104</ix:nonFraction> for the nine months ended September&#160;30, 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TEP Note</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Private GRI and TEP Biotech, LLC (TEP) entered into a convertible note and warrant purchase agreement pursuant to which TEP agreed to fund up to $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-409">5,000</ix:nonFraction> to Private GRI in exchange for a convertible promissory note (the TEP Note) and a warrant to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-410">25,245</ix:nonFraction> shares of Private GRI&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-106" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-411">0.27</ix:nonFraction> per share. The TEP Note was secured by Private GRI&#8217;s assets and accrued simple interest on the outstanding principal balance at a rate of <ix:nonFraction unitRef="number" contextRef="c-105" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-412">12</ix:nonFraction>% per annum. The total outstanding principal and accrued interest balance was initially due on the earlier of Private GRI&#8217;s next financing, as defined, and May 2, 2020. The initial $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="INF" name="us-gaap:ProceedsFromNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-413">2,500</ix:nonFraction> tranche under the TEP Note was funded upon execution of the agreement in November 2018. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Private GRI and TEP amended the TEP Note. In lieu of TEP funding the second $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-414">2,500</ix:nonFraction> tranche, TEP made a first additional advance of $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-415">500</ix:nonFraction> to Private GRI in exchange for a convertible promissory note, a warrant to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-416">17,269</ix:nonFraction> shares of Private GRI&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-110" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-417">0.27</ix:nonFraction> per share, and the assignment of Private GRI&#8217;s rights under a certain call option agreement. The call option agreement, which was entered into in 2015, provided Private GRI with the right to repurchase up to <ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-418">39,720</ix:nonFraction> shares of Private GRI&#8217;s common stock held by the counterparty for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-111" decimals="2" name="ck0001824293:CallOptionPrice" scale="0" id="f-419">26.74</ix:nonFraction> per share at any time before April 1, 2025. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the TEP Note maturity date was extended to August 31, 2020, and in March 2021, TEP agreed to forbear on its available right to exercise remedies on account of Private GRI&#8217;s failure to pay the past due principal and accrued interest balance until October 31, 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, Private GRI and TEP amended the TEP Note, and TEP agreed to make a second additional advance of $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-420">500</ix:nonFraction> to Private GRI in exchange for a convertible promissory note with separate, modified conversion options. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Private GRI and TEP further amended the TEP Note, and TEP agreed to make a third additional advance of $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-421">125</ix:nonFraction> to Private GRI in exchange for a convertible promissory note and a warrant to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-422">1,169</ix:nonFraction> shares of Private GRI&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-114" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-423">0.27</ix:nonFraction> per share.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Private GRI and TEP entered into a conversion agreement pursuant to which, effective upon the full execution of the Merger Agreement (Note 4), $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="ck0001824293:DebtConversionConvertedInstrumentPrincipalAmountOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-424">3,500</ix:nonFraction> of outstanding principal under the TEP Note together with $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="ck0001824293:DebtConversionConvertedInstrumentAmountOfInterest" scale="3" id="f-425">650</ix:nonFraction> of related accrued interest was to </span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><ix:continuation id="f-386-3"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">automatically convert into <ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="ck0001824293:DebtInstrumentConvertibleSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="f-426">155,210</ix:nonFraction> shares of Private GRI&#8217;s common stock at a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-116" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-427">26.74</ix:nonFraction> per share. Further, upon the closing of the first tranche of the Bridge Notes, Private GRI was to repay, in cash, the $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="f-428">125</ix:nonFraction> third additional advance under the TEP Note along with the $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="3" id="f-429">15</ix:nonFraction> of related accrued interest. Upon issuance of the <ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="ck0001824293:DebtInstrumentConvertibleSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="f-430">155,210</ix:nonFraction> conversion shares and payment of the $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="ck0001824293:LongTermDebtIncludingInterest" scale="3" id="f-431">140</ix:nonFraction> principal and accrued interest balance, Private GRI would fully satisfy all of its obligations under the TEP Note.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, upon the full execution of the Merger Agreement and the closing of the first tranche of the Bridge Notes Private GRI issued the <ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-432">155,210</ix:nonFraction> conversion shares and paid the $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="f-433">140</ix:nonFraction> principal and accrued interest balance as per the terms of the conversion agreement. The share numbers and exercise or conversion prices in this section of Note 8 entitled &#8220;TEP Note&#8221; reflect the Exchange Ratio retroactively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the conversion, the $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="3" id="f-434">4,150</ix:nonFraction> of converted principal and accrued interest, along with $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="ck0001824293:AccruedInterestForfeited" scale="3" id="f-435">863</ix:nonFraction> of related forfeited accrued interest through the conversion date, were credited to stockholders&#8217; deficit. Interest expense recognized on the TEP Note was $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:InterestExpenseBorrowings" scale="3" id="f-436">142</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:InterestExpenseBorrowings" scale="3" id="f-437">352</ix:nonFraction> for the three and nine months ended September&#160;30, 2022.</span></div></ix:continuation><div id="i9543da0ac24342e79ce7f476be8c5f32_64"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-438" continuedAt="f-438-1" escape="true">STOCKHOLDERS&#8217; EQUITY </ix:nonNumeric></span></div><ix:continuation id="f-438-1" continuedAt="f-438-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered the Equity SPA pursuant to which the Investor agreed to invest $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:InvestmentCompanyCommittedCapital" format="ixt:num-dot-decimal" scale="3" id="f-439">12,250</ix:nonFraction> in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI&#8217;s common stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, Private GRI issued <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-440">6,787,219</ix:nonFraction> shares of Private GRI&#8217;s common stock (the Initial Shares) to the Investor and <ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="ck0001824293:CommonStockHeldIntoEscrowAccount" format="ixt:num-dot-decimal" scale="0" id="f-441">27,148,877</ix:nonFraction> shares of Private GRI&#8217;s common stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-442">11,704</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" scale="3" id="f-443">546</ix:nonFraction>.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="f-444">253,842</ix:nonFraction> shares of the Company&#8217;s common stock and the Additional Shares converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="ck0001824293:ConversionOfStockAdditionalSharesConverted" format="ixt:num-dot-decimal" scale="0" id="f-445">1,015,368</ix:nonFraction> shares of the Company&#8217;s common stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and the Investor authorized the escrow agent to, subject to beneficial ownership limitations, disburse to the Investor all of the shares of the Company&#8217;s common stock issued in exchange for the Additional Shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Common Stock</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Private GRI entered into an agreement with a stockholder pursuant to which the stockholder had the right to require Private GRI to purchase all or a portion of <ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-446">7,816</ix:nonFraction> shares of Private GRI&#8217;s common stock held by the stockholder for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-122" decimals="2" name="ck0001824293:PutOptionSharePrice" scale="0" id="f-447">15.88</ix:nonFraction> per share (the Put Right). The Put Right was exercisable (i) for a period commencing thirty days prior to the day Private GRI completed an equity or debt financing and ending fifteen business days thereafter, or (ii) at any time following a breach of the agreement by Private GRI.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed the Put Right and determined that (i) it was not freestanding and, therefore, was not required to be classified as a liability and (ii) it could be exercised by the stockholder at any time, which was not within Private GRI&#8217;s control. Therefore, the common shares subject to the Put Right were classified in mezzanine equity. In December 2022, the stockholder exercised the Put Right and Private GRI redeemed the <ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-448">7,816</ix:nonFraction> shares of Private GRI&#8217;s common stock for $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="f-449">124</ix:nonFraction> ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-450">15.88</ix:nonFraction> per share). The redeemed shares were retired by Private GRI. The share numbers and exercise or conversion prices in this section of Note 9 entitled &#8220;Redeemable Common Stock&#8221; reflect the Exchange Ratio retroactively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Equity SPA, on May 8, 2023, the Company issued to the Investor (i) Series A-1 Warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-451">1,269,210</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-452">13.51</ix:nonFraction>, (ii) Series A-2 Warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-453">1,142,289</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-454">14.74</ix:nonFraction> , and (iii) Series T Warrants to purchase (x) <ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-455">814,467</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-456">12.28</ix:nonFraction> and (y) upon exercise of the Series T Warrants, <ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-457"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-458">814,467</ix:nonFraction></ix:nonFraction> additional Series </span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><ix:continuation id="f-438-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-1 Warrants and Series A-2 Warrants, each to purchase <ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-459"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-460">814,467</ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-461">13.51</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-126" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-462">14.74</ix:nonFraction>, respectively (collectively, the Equity Warrants). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A-1 Warrants have a term of <ix:nonNumeric contextRef="c-123" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-463">60</ix:nonNumeric> months from the date all shares underlying the Series A-1 Warrants are freely tradable. The A-2 warrants have a <ix:nonNumeric contextRef="c-124" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-464">2-year</ix:nonNumeric> term and expire in June 2025. Series T Warrants have a term of <ix:nonNumeric contextRef="c-125" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-465">24</ix:nonNumeric> months from the date all shares underlying Series T Warrants are freely tradable. As noted in Note 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Liquidity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company may force the exercise of the Series T Warrants subject to the satisfaction of certain equity conditions. The Equity Warrants include certain contingent cashless exercise features and contain certain other rights with regard to asset distributions and fundamental transactions. The exercise price of the Series A-1 Warrants is subject to adjustment for certain dilutive issuances, and all of the Equity Warrants are subject to standard antidilution adjustments. All of the Equity Warrants were outstanding as of September&#160;30, 2023. The Equity Warrants were classified as equity and the allocated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-466">5,675</ix:nonFraction> is included in additional paid in capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Bridge SPA, upon the funding of each tranche of the Bridge Note, the Investor received the Bridge Warrants. The Bridge Warrants had an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-129" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-467">1.33</ix:nonFraction> per share, were exercisable at any time on or after the applicable issuance date and had a term of <ix:nonNumeric contextRef="c-129" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-468">60</ix:nonNumeric> months from the date all shares underlying the Bridge Warrants are freely tradable. Upon the completion of the Merger the Bridge Warrants were exchanged for the Exchange Warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-129" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-469">421,589</ix:nonFraction> shares of the Company&#8217;s common stock. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-130" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-470">14.73</ix:nonFraction> per share subject to adjustments for splits and recapitalization events. All of the Bridge Warrants were outstanding as of September&#160;30, 2023. The Bridge Warrants were classified as equity and the allocated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-471">2,860</ix:nonFraction> is included in additional paid in capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Closing, Private GRI granted its financial advisor warrants (the Advisor Warrants) to purchase shares of Private GRI&#8217;s common stock, which, at the Effective Time, became exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-472">2,402</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-132" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-473">61.39</ix:nonFraction> per share. The Advisor Warrants have a <ix:nonNumeric contextRef="c-133" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-474">five-year</ix:nonNumeric> term. All of the Advisor Warrants were outstanding as of September&#160;30, 2023. The Advisor Warrants were classified as equity and the fair value of $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="f-475">18</ix:nonFraction> is included in additional paid in capital. </span></div><ix:continuation id="f-353-1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the fair value of the Equity Warrants, the Exchange Warrants and the Advisor Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-135" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-476">167.6</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-136" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-477">1.69</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-137" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-478">0.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-138" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-479">4.37</ix:nonFraction>&#160;%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-480" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, the Company had the following warrants outstanding to purchase common stock. </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-481">8,629</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-139" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-482">34.76</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-483">1,438</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-140" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-484">34.76</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-141" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-485">1,142,289</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-141" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-486">14.74</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-487">3,758</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-142" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-488">300.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-143" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-489">24,667</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-143" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-490">28.15</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-144" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-491">1,168</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-144" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-492">0.01</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-145" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-493">2,402</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-145" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-494">61.39</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-495">421,590</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-146" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-496">14.73</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-147" name="ck0001824293:ClassOfWarrantOrRightExpirationPeriod" format="ixt-sec:durmonth" id="f-497">60</ix:nonNumeric> months after registration date</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-498">1,269,210</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-148" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-499">13.51</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-149" name="ck0001824293:ClassOfWarrantOrRightExpirationPeriod" format="ixt-sec:durmonth" id="f-500">60</ix:nonNumeric> months after registration date</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-501">814,467</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-150" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-502">12.28</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-151" name="ck0001824293:ClassOfWarrantOrRightExpirationPeriod" format="ixt-sec:durmonth" id="f-503">24</ix:nonNumeric> months after registration date</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i9543da0ac24342e79ce7f476be8c5f32_70"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="c-1" name="us-gaap:AssetAcquisitionTextBlock" id="f-504" continuedAt="f-504-1" escape="true">ASSET PURCHASE AGREEMENT</ix:nonNumeric></span></div><ix:continuation id="f-504-1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 22, 2023, the Company entered into Asset Purchase Agreement (the Aardvark Agreement) with Aardvark Therapeutics, Inc. (Aardvark), pursuant to which Aardvark agreed to purchase (i) the Company&#8217;s license agreement with Medice Arzneimittel P&#369;tter GmbH &amp; Co. KG, dated January 6, 2020, (ii) certain patents related to the Company&#8217;s ADAIR product candidate, and (iii) files (of contract manufacturing and FDA correspondence) for a formulation described in IND No. 133072, ADAIR for the Treatment of ADHD and Narcolepsy, filed with the United States FDA. Under the terms of the Aardvark Agreement, the Company received an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="3" id="f-505">250</ix:nonFraction>, which was recognized as other income. The Company is also eligible to receive potential additional milestone payments contingent upon Aardvark achieving certain future ADAIR regulatory and sales milestones. Other than the upfront payment, the Company does not anticipate the receipt of any milestone payments from Aardvark in the near term, which potential milestone payments may or may not be achieved, paid or received in the future.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Aardvark Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the text of the Aardvark Agreement that is filed as Exhibit 10.2 to this Quarterly Report on Form 10-Q.</span></div></ix:continuation><div id="i9543da0ac24342e79ce7f476be8c5f32_67"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-506" continuedAt="f-506-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="f-506-1" continuedAt="f-506-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private GRI adopted the GRI Bio, Inc. 2015 Equity Incentive Plan, as amended (the Private GRI Plan), that provided Private GRI with the ability to grant stock options, restricted stock awards and other equity-based awards to employees, directors, and consultants. Stock options granted under the Private GRI Plan generally had a contractual life of up to <ix:nonNumeric contextRef="c-153" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-507">10</ix:nonNumeric> years. Upon completion of the Merger, the Company assumed the Private GRI Plan and <ix:nonFraction unitRef="shares" contextRef="c-154" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-508">89,472</ix:nonFraction> outstanding and unexercised options issued thereunder, and ceased granting awards under the Private GRI Plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated 2018 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the stockholders of the Company approved the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan, formerly the Vallon Pharmaceuticals, Inc. 2018 Equity Incentive Plan (the A&amp;R 2018 Plan). The A&amp;R 2018 Plan had previously been approved by the Company&#8217;s board of directors, subject to stockholder approval. The A&amp;R 2018 Plan became effective on April 21, 2023, with the stockholders approving the amendment to the A&amp;R 2018 Plan to, among other things, (i) to increase the aggregate number of shares by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-155" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-509">168,905</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="c-156" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-510">216,666</ix:nonFraction> shares of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company&#8217;s common stock </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for issuance as awards under the A&amp;R 2018 Plan, (ii) to extend the term of the A&amp;R 2018 Plan through January 1, 2033, (iii) to prohibit any action that would be treated as a &#8220;repricing&#8221; of an award without further approval by the stockholders of Company, and (iv) to revise the limits on awards to non-employee directors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The A&amp;R 2018 Plan provides the Company with the ability to grant stock options, restricted stock and other equity-based awards to employees, directors and consultants. Stock options granted by the Company under the A&amp;R 2018 Plan generally have a contractual life of up to <ix:nonNumeric contextRef="c-157" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-511">10</ix:nonNumeric> years. As of September&#160;30, 2023, awards granted under the A&amp;R 2018 Plan representing the right to purchase or contingent right to receive up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-512">228,542</ix:nonFraction> shares of the Company's common stock were outstanding and <ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-513">216,666</ix:nonFraction> shares of the Company&#8217;s common stock were reserved for issuance under the A&amp;R 2018 Plan. The number of shares reserved for issuance under the A&amp;R 2018 Plan may be increased pursuant to the A&amp;R 2018 Plan&#8217;s &#8220;evergreen&#8221; provision on the first day of each calendar year beginning January 1, 2024 and ending on and including January 1, 2033, by a number of shares not to exceed 4% of the aggregate number of shares of the Company&#8217;s common stock outstanding on the final day of the immediately preceding calendar year.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-514" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to stock options issued under the Private GRI Plan and the A&amp;R 2018 Plan in the following expense categories of its accompanying statements of operations for the three and nine months ended September&#160;30, 2023 and 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-515">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-516">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-517">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-518">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-519">326</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-520">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-521">351</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-522">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-523">326</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-524">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-525">351</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-526">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><ix:continuation id="f-506-2" continuedAt="f-506-3"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period for certain performance-based awards. The Company records expense for performance-based awards if it concludes that it is probable that the performance condition will be achieved.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-527" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the nine months ended September&#160;30, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-528">112,612</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-529">39.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-167" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-530">4.71</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-531">221,265</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-532">2.38</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-533">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-534">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-535">15,863</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-536">128.13</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-537">318,014</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-538">9.35</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-539">7.92</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2023</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-540">318,014</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-541">9.35</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-542">7.92</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-543" continuedAt="f-543-1" escape="true">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</ix:nonNumeric></span></div><div><ix:continuation id="f-543-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-168" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-544">129.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-169" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-545">90.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-168" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-546">5.84</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-169" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-547">5.98</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-168" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-548">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-169" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-549">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-168" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-550">4.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-169" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-551">2.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-170" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-552">2.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-171" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-553">3.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-506-3">As of September&#160;30, 2023, the unrecognized compensation cost related to unvested stock options expected to vest was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="f-554">424</ix:nonFraction>. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of <ix:nonNumeric contextRef="c-168" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-555">3.16</ix:nonNumeric> years.</ix:continuation> </span></div><div id="i9543da0ac24342e79ce7f476be8c5f32_76"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-556" continuedAt="f-556-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-556-1" continuedAt="f-556-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation and Release Agreement</span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-556-2">In connection with the resignation of David Baker, the Company&#8217;s Former Chief Executive Officer, pursuant to the Merger, the Company and Mr. Baker entered into a Separation and Release Agreement on April 21, 2023 (the Separation Agreement). Pursuant to the terms of the Separation Agreement and his employment agreement, Mr. Baker will receive continuation of his current salary and certain COBRA benefits for <ix:nonNumeric contextRef="c-172" name="ck0001824293:COBRABenefitsPaymentPeriod" format="ixt-sec:durmonth" id="f-557">18</ix:nonNumeric> months payable in accordance with the Company&#8217;s payroll practices. Mr. Baker also received a lump sum payment equal to <ix:nonFraction unitRef="number" contextRef="c-172" decimals="INF" name="ck0001824293:PercentageOfTargetBonus" scale="-2" id="f-558">150</ix:nonFraction>% of his target bonus and agreed to reduce amounts payable with respect to certain future milestone payments.</ix:continuation> </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i9543da0ac24342e79ce7f476be8c5f32_85"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the Company&#8217;s financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q, the audited financial statements and notes thereto, as well as management&#8217;s discussion and analysis of financial condition and results of operations, included in Vallon&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 24, 2023, and Private GRI&#8217;s financial statements and related notes which are filed as Exhibit 99.1 of Amendment No. 2 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on July 6, 2023. Some of the information contained in this discussion and analysis, including information with respect to GRI&#8217;s plans and strategy for its business and related financing, includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 12E of the Securities Exchange Act, as amended, that involve risks and uncertainties. As a result of many factors, including those factors set out under the section entitled &#8220;Risk Factors&#8221; included in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 and this Quarterly Report on Form 10-Q, GRI&#8217;s actual results could differ materially from the results described in or implied by these forward-looking statements. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Except as otherwise indicated, references herein to &#8220;GRI Bio,&#8221; or the &#8220;Company,&#8221; refer to GRI Bio, Inc. on a post-Merger basis, and references to &#8220;Private GRI&#8221; refer to the business of  GRI Bio, Inc. prior to the completion of the Merger. References to &#8220;Vallon&#8221; refer to Vallon Pharmaceuticals, Inc. prior to the completion of the Merger.</span></div><div id="i9543da0ac24342e79ce7f476be8c5f32_88"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Our goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T (iNKT) cells. GRI-0621 is also an oral formulation of tazarotene, a synthetic retinoid acid receptor (RAR)-beta and gamma selective agonist, that is approved in the United States for topical treatment of psoriasis and acne. As of September 30, 2023, it has been evaluated in over 1,700 patients as an oral product for up to 52-weeks. We are developing GRI-0621 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung that affects approximately 140,000 people in the United States, with up to 40,000 new cases per year in the United States and some estimate that IPF affects 3 million globally. While there are currently two approved therapies for the treatment of lung fibrosis, neither has been associated with improvements in overall survival, and both therapies have been associated with significant side effects leading to poor therapeutic adherence. In preliminary data from our trials to date with GRI-0621, and earlier trials with oral tazarotene, we have observed GRI-0621 to be well-tolerated and to inhibit iNKT cell activity in subjects. We and others have shown that activated iNKT are upregulated in IPF, primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH), alcoholic liver disease (ALD), Systemic Lupus Erythematosus Disease (SLE), multiple sclerosis (MS), ulcerative colitis (UC) patients as well as other indications. In these patients activated iNKT cells are correlated with more severe disease. We are initiating a Phase 2a trial in 36 IPF patients in the second half of 2023 and expects topline results from this trial to be available in the second half of 2024.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells. We are developing GRI-0803 for the treatment of autoimmune disorders, with much of our preclinical work in SLE or lupus and MS. In lupus, the immune system mistakenly attacks its own healthy tissues, especially joints and skin, but can affect almost every organ and tissue of the body. The condition can be fatal, and often causes debilitating bouts of fatigue and pain that prevent nearly half of adult patients from working. Lupus affects between 160,000 - 200,000 patients in the United States, with around 80,000 &#8211; 100,000 patients in the United States suffering from kidney nephritis, one of the most serious manifestations of SLE, typically within five years of diagnosis. There is no cure for lupus, but medical interventions and lifestyle changes can help control it. SLE treatment consists primarily of immunosuppressive drugs that inhibit the activity of the immune system. Only two drugs have been approved for lupus in the past 50 years, and new treatment options are sorely needed. Subject to IND clearance, we intend to evaluate GRI-0803 in a Phase 1a and 1b trial initially targeting SLE. We expect to file an IND with respect to this Phase 1a and 1b trial in the first half of 2024. We will continue to evaluate indications to select the best fit for further development of the program, but our initial focus is on lupus.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger with Vallon Pharmaceuticals, Inc. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the Company (formerly Vallon Pharmaceuticals, Inc.) consummated a merger with GRI Bio Operations, Inc. (formerly GRI Bio, Inc.) (Private GRI) pursuant to an Agreement and Plan of Merger, as amended (the Merger Agreement), by and among the Company, Private GRI and Vallon Merger Sub, Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of the Company. The Merger Agreement provided for the merger of Merger Sub with and into Private GRI, with Private GRI continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the Merger). In connection with the closing of the Merger (the Closing), the Company amended its certificate of incorporation and bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, Private GRI entered into a Securities Purchase Agreement, dated as of December 13, 2022 (the Bridge SPA), with Altium Growth Fund, LP (the Investor), pursuant to which Private GRI issued senior secured promissory notes (the Bridge Notes) in the aggregate principal amount of $3.3 million, in exchange for an aggregate purchase price of $2.5 million. The Bridge Notes were issued in two closings: (i) the first closing for $1.67 million in aggregate principal amount (in exchange for an aggregate purchase price of $1.25 million) closed on December 14, 2022; and (ii) the second closing for $1.67 million in aggregate principal amount (in exchange for an aggregate purchase price of $1.25 million) closed on March 9, 2023. In addition, upon the funding of each tranche, the Investor received warrants to purchase an aggregate of 1,252,490 shares of Private GRI&#8217;s common stock (the Bridge Warrants).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Bridge SPA, and also in connection with signing the Merger Agreement, the Company, Private GRI and the Investor entered into a Securities Purchase Agreement on December 13, 2022 (the Equity SPA) pursuant to which the Investor agreed to invest $12.25 million in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI&#8217;s common stock immediately prior to the consummation of the Merger.  Pursuant to the Equity SPA, immediately prior to the Closing, Private GRI issued 6,787,219 shares of Private GRI&#8217;s common stock (the Initial Shares) to the Investor and 27,148,877 shares of Company common stock (the Additional Shares) into escrow with an escrow agent. At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 253,842 shares of the Company&#8217;s common stock and the Additional Shares converted into an aggregate of 1,015,368 shares of the Company&#8217;s common stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and the Investor authorized the escrow agent to, subject to beneficial ownership limitations, disburse to the Investor all of the shares of the Company&#8217;s common stock issued in exchange for the Additional Shares.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Equity SPA, on May 8, 2023, the Company issued to the Investor (i) Series A-1 Warrants to purchase 1,269,210 shares of the Company&#8217;s common stock  with an initial exercise price of $13.51 per share, (ii) Series A-2 Warrants to purchase 1,142,289 shares of the Company&#8217;s common stock  with an initial exercise price of $14.74 per share, and (iii) Series T Warrants to purchase at an exercise price of $12.28 per share (x) 814,467 shares of the Company&#8217;s common stock and (y) upon exercise of the Series T Warrants, an additional amount of Series A-1 Warrants and Series A-2 Warrants, each to purchase 814,467 shares of the Company&#8217;s common stock (collectively, the Equity Warrants).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the completion of the Merger, the outstanding principal and accrued interest on the Bridge Notes was cancelled and the Bridge Warrants were exchanged for warrants (the Exchange Warrants) to purchase an aggregate of 421,589 shares of the Company&#8217;s common stock.</span></div><div id="i9543da0ac24342e79ce7f476be8c5f32_91"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include personnel costs associated with research and development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses have consisted primarily of costs related to our development program for our lead product candidate GRI-0621. These expenses include:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">employee-related expenses, such as salaries, bonuses and benefits, consultant-related expenses such as consultant fees and bonuses, stock-based compensation, overhead-related expenses and travel-related expenses for our research and development personnel; and</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expenses incurred under agreements with CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities as well as consultants that support the implementation of our clinical and non-clinical studies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our direct research and development expenses are tracked by product candidate, we do not allocate employee costs and costs associated with our discovery efforts, laboratory supplies and facilities, including other indirect costs, to specific product candidates as these costs are deployed across multiple programs. We expect our research and development expenses to increase over the next several years as we conduct our planned clinical and preclinical activities for our product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of compensation and consulting related expenses for executives and other administrative personnel, professional fees and other corporate expenses, including legal and accounting fees, travel expenses, facilities-related expenses, and consulting services relating to corporate matters.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our general and administrative expenses will increase substantially as we incur costs associated with being a public company, including expenses related to services associated with maintaining compliance with The Nasdaq Capital Market and SEC requirements, directors&#8217; and officers&#8217; insurance, legal and accounting costs and investor relations costs, as well as an increase in personnel expenses as we hire additional personnel.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon issued warrants in connection with a securities purchase agreement. Vallon evaluated the warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As a result, the warrants were measured the fair value upon issuance using a Black-Scholes valuation model and are recorded as a liability on the balance sheet. The fair value of the warrants is measured at each reporting date and changes in fair value are recognized in the consolidated statements of operations in the period of change. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 22, 2023, we entered into Asset Purchase Agreement (the Aardvark Agreement) with Aardvark Therapeutics, Inc. (Aardvark), pursuant to which Aardvark agreed to purchase (i) our license agreement with Medice Arzneimittel P&#369;tter GmbH &amp; Co. KG, dated January 6, 2020, (ii) certain patents related to our ADAIR product candidate, and (iii) files (of contract manufacturing and FDA correspondence) for a formulation described in IND No. 133072, ADAIR for the Treatment of ADHD and Narcolepsy, filed with the United States FDA. Under the terms of the Agreement, we received an upfront cash payment of $0.3 million, which was recognized as other income. We are also eligible to receive potential additional milestone payments contingent upon Aardvark achieving certain future ADAIR regulatory and sales milestones. Other than the upfront payment, we do not anticipate the receipt of any milestone payments from Aardvark in the near term, which potential milestone payments may or may not be achieved, paid or received in the future.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Aardvark Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the text of the Aardvark Agreement that is filed as Exhibit 10.2 to this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income (Expense), net</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of amortization of debt discounts, debt issuance costs and interest expense related to the TEP Notes and the Bridge Notes. Interest income consists of interest earned on our cash and cash equivalents held with institutional banks.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i9543da0ac24342e79ce7f476be8c5f32_94"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended September&#160;30, 2023 and 2022 </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,439</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,439)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,137)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $1.2 million and $0.1 million for the three months ended September&#160;30, 2023 and 2022, respectively. The $1.1 million increase in research and development expenses was primarily due to increases of $0.8 million in expenses related to the development program of GRI-0621, $0.1 million in consulting fees and $0.2 million in personnel expenses. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $1.3 million and $0.1 million for the three months ended September&#160;30, 2023 and 2022, respectively. The $1.2 million increase was primarily related to increased costs for professional fees, including legal, accounting and investor relations fees of $0.4 million, personnel expenses of $0.6 million as a result of increased headcount, and increases in administrative and insurance expenses of $0.2 million as a result of operating as a public company.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of $0.1 million represents a decrease in the fair value of the warrants outstanding during the three months ended September&#160;30, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income was $0.3 million for the three months ended September&#160;30, 2023 as a result of payments received under the terms of the Aardvark Agreement entered into in August 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income (Expense)</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $0.2 million for the three months ended September&#160;30, 2022 and related to the outstanding promissory notes. Interest income was $6,000 for the three months ended September&#160;30, 2023. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Nine Months Ended September&#160;30, 2023 and 2022 </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,361</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,361)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(572)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,033)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $2.2 million and $0.2 million for the nine months ended September&#160;30, 2023 and 2022, respectively. The $2.0 million increase in research and development expenses was primarily due to </span><span style="background-color:#fff7c3;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ncreases of $1.1 million in expenses related to the development program of GRI-0621, $0.4 million in consulting fees and $0.5 million in personnel expenses. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $7.2 million and $0.4 million for the nine months ended September&#160;30, 2023 and 2022, respectively. The $6.8 million increase was primarily related to increased costs for professional fees, including legal, accounting and investment banking fees associated with the Merger of $4.9 million, personnel expenses of $1.5 million as a result of increased headcount, and increases in consulting, administrative and insurance expenses of $0.4 million as a result of operating as a public company.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Liability</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of $0.2 million represents a decrease in the fair value of the warrants outstanding during the nine months ended September&#160;30, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income was $0.3 million for the nine months ended September&#160;30, 2023 as a result of payments received under the terms of the Aardvark Agreement entered into in August 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, net</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net, was $2.1 million and $0.4 million for the nine months ended September&#160;30, 2023 and 2022, respectively, and related to the outstanding promissory notes. The increase in interest expense, net, was due to interest related to the Bridge Notes. </span></div><div id="i9543da0ac24342e79ce7f476be8c5f32_97"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred losses and expect to continue to incur losses for the foreseeable future. We incurred net losses of $11.0 million and $0.9 million for the nine months ended September&#160;30, 2023 and 2022, respectively. As of September&#160;30, 2023, we had an accumulated deficit of $29.5 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our working capital requirements to date through the issuance of common stock, warrants, convertible notes and promissory notes. As of September&#160;30, 2023, we had $3.5 million in cash. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,479&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2023 and 2022, $3.4 million and $0.2 million were used in operating activities, respectively. The $3.2 million increase was primarily due to a $10.1 million increase in net loss and a $0.8 million decrease in prepaid and other assets, offset by an increase in non-cash adjustments of $2.1&#160;million related to the amortization of debt discounts and debt issuance costs and $0.4&#160;million related to stock-based compensation expenses, as well as a $4.8&#160;million increase in accounts payable and a $0.5&#160;million increase in accrued expenses. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $8,000 for the nine months ended September&#160;30, 2023, which was related to the purchase of computer equipment.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $6.9&#160;million for the nine months ended September&#160;30, 2023 as a result of $12.3&#160;million of proceeds from the Equity SPA and $1.3&#160;million of proceeds from the funding of the second tranche of the Bridge Notes. These proceeds were offset by $2.9&#160;million of net liabilities assumed in the connection with the Merger, $3.0&#160;million in costs associated with the Merger, the payment of $0.5&#160;million of debt issuance costs related to the Bridge Notes and $0.2&#160;million of stock issuance costs related the Equity SPA. Net cash provided by financing activities was $0.3&#160;million for the nine months ended September&#160;30, 2022 and related to proceeds from promissory notes. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered the Equity SPA pursuant to which the Investor agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI&#8217;s common stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, Private GRI issued 6,787,219 shares of Private GRI&#8217;s common stock (the Initial Shares) to the Investor and 27,148,877 shares of Private GRI&#8217;s common stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $11,704, after deducting offering expenses of $546.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 253,842 shares of the Company&#8217;s common stock and the Additional Shares converted into an aggregate of 1,015,368 shares of the Company&#8217;s common stock. On May 8, 2023, in accordance with the terms of the Equity SPA, we, along with the Investor, authorized the escrow agent to, subject to beneficial ownership limitations, disburse to the Investor all of the shares of the Company&#8217;s common stock issued in exchange for the Additional Shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net losses were $11.0 million and $0.9 million for the nine months ended September&#160;30, 2023 and 2022, respectively. As of September&#160;30, 2023, we had $3.5 million in cash and an accumulated deficit of $29.5 million. We expect to devote substantial financial resources to our planned activities, particularly as we prepare for, initiate, and conduct our planned clinical trials of GRI-0621 and GRI-0803, advance our discovery programs and continue our product development efforts. In addition, we expect to incur additional costs associated with operating as a public company. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into the first quarter of 2024. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. The Series T Warrants issued in connection with the Merger are not presently subject to forced exercise by the Company as the equity conditions for their forced exercise, which include (among other things) a requirement that shares of the Company&#8217;s common stock have a value weighted average price of at least $9.21 per share for the periods specified in the Series T Warrants, are not met. We intend to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if our research and development efforts are successful. If we are unable to secure adequate additional funding, we will need to reevaluate our operating plans and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of our development programs, or relinquish rights to our technology on less favorable terms than we would otherwise choose or cease operations entirely. These actions could materially impact our business, results of operations and future prospects and the value of shares of our common stock. In addition, attempting to secure additional financing may divert the time and attention of management from day-to-day activities and distract from our discovery and product development efforts. As a result, there is substantial doubt about our ability to continue as a going concern. We expect to continue to incur significant and increasing operating losses at least for the foreseeable future. We do not expect to generate product revenue unless and until we successfully complete development, obtain regulatory approval for, and successfully commercialize our current, or any future, product candidates.</span></div><div id="i9543da0ac24342e79ce7f476be8c5f32_100"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not party to any off-balance sheet transactions. We have no guarantees or obligations other than those which arise out of normal business operations.</span></div><div id="i9543da0ac24342e79ce7f476be8c5f32_103"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of its financial condition and results of operations is based on its unaudited interim financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Management evaluates these estimates and judgments on an ongoing basis. Management bases its estimates on historical experience and on various other factors that it believes are reasonable under the circumstances. Actual results could differ from those estimates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in more detail in Note 1, &#8220;The Company and a Summary of its Significant Accounting Policies&#8221;, in the notes to its financial statements as of and for the years ended December&#160;31, 2022 and 2021, which is Exhibit 99.2 of Amendment No. 2 to the Current Report on Form 8-K filed with the SEC on July 6, 2023. </span></div><div id="i9543da0ac24342e79ce7f476be8c5f32_106"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not applicable to emerging growth companies. These exemptions include:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced disclosure about our executive compensation arrangements;</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no non-binding stockholder advisory votes on executive compensation or golden parachute arrangements; and</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken advantage of reduced reporting requirements in this report and may continue to do so until such time that we are no longer an emerging growth company. We will remain an &#8220;emerging growth company&#8221; until the earliest of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more, (b) December 31, 2026, the last day of the fiscal year following the fifth anniversary of the completion of the IPO, (c) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i9543da0ac24342e79ce7f476be8c5f32_109"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable to a smaller reporting company.</span></div><div id="i9543da0ac24342e79ce7f476be8c5f32_112"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of its disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e)) of the Securities Exchange Act of 1934 (the Exchange Act)) as of September&#160;30, 2023. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the evaluation of our disclosure controls and procedures as of September&#160;30, 2023, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures, as defined above, are effective.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the fiscal quarter covered by this report that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i9543da0ac24342e79ce7f476be8c5f32_115"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i9543da0ac24342e79ce7f476be8c5f32_118"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i9543da0ac24342e79ce7f476be8c5f32_121"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth below, there have been no material changes from the risk factors previously disclosed in Vallon&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A delisting of our common stock from Nasdaq could adversely affect our ability to raise additional capital through the public or private sale of equity securities and for investors to dispose of, or obtain accurate quotations as to the market value of, our common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules of the Nasdaq Capital Market require that we maintain a bid price of at least $1.00 per share for shares of our common stock and that we meet other requirements for continued listing which include, among other things, requirements that we maintain a market value of listed securities of at least $35 million or, alternatively, stockholders&#8217; equity of at least $2.5 million, or, alternatively, annual net income from continuing operations of at least $500 thousand as described in applicable listing requirements. As of the date of this Quarterly Report on Form 10-Q, the market value of our listed securities is less than $35 million, our reported stockholders&#8217; equity is less than the required $2.5 million and we have not earned net income in excess of $500 thousand in accordance with applicable listing requirements. Our stock may be subject to delisting. If our common stock is delisted by Nasdaq, our common stock may be eligible to trade on the OTC Markets or another over-the-counter market, but a delisting, threatened delisting or trading on these markets would likely result in it being more difficult for us to raise additional capital through the public or private sale of equity securities and for investors to dispose of, or obtain accurate quotations as to the market value of, our common stock. In addition, there can be no assurance that our common stock would be eligible for trading on any such alternative exchange or markets. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless our common stock is listed on a national securities exchange, such as the Nasdaq Capital Market, our common stock may also be subject to the regulations and restrictions regarding trading in &#8220;penny stocks,&#8221; which are those securities trading for less than $5.00 per share, and that are not otherwise exempted from the definition of a penny stock under other exemptions provided for in the applicable regulations. These requirements and regulations could severely limit the liquidity of securities in the secondary market because fewer brokers or dealers would likely to be willing to undertake related compliance activities. If our common stock is not listed on a national securities exchange, the rules and restrictions regarding penny stock transactions may limit an investor&#8217;s ability to sell to a third party and our trading activity in the secondary market may be reduced.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, our failure to maintain compliance with applicable Nasdaq listing requirements will also cause us to fail to meet the equity conditions for us to require the exercise the T Warrants and may result in our being liable for penalties in our various investor agreements. Any of these or the above circumstances could adversely affect our business, results of operation, prospects and the value of shares of our common stock. </span></div><div id="i9543da0ac24342e79ce7f476be8c5f32_124"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i9543da0ac24342e79ce7f476be8c5f32_127"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i9543da0ac24342e79ce7f476be8c5f32_130"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i9543da0ac24342e79ce7f476be8c5f32_133"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November14, 2023 the compensation committee of the Board recommended, and the Board approved and adopted, the GRI Bio, Inc. Clawback Policy (the Clawback Policy) which was established in accordance with the listing requirements of Nasdaq. The Clawback Policy provides for the recovery or &#8220;clawback&#8221; of certain erroneously awarded incentive-based compensation in the event that the Company is required to prepare an accounting restatement. The Clawback Policy is effective as of October 2, 2023. The foregoing description of the material terms of Clawback Policy is qualified in its entirety by reference to the full text of the Clawback Policy, which is filed as Exhibit 10.3 to this Quarterly Report on Form 10-Q and incorporated herein by reference.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i9543da0ac24342e79ce7f476be8c5f32_136"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Herewith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference File No. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Filed</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/ex31_arcoi.htm">Certificate of Incorporation of GRI Bio, Inc., as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/21/2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/ex32_amendedandrestatedbyl.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/26/2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1824293/000182429323000121/gribioinc-argribioinc2018e.htm">A&amp;R 2018 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/15/2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1824293/000182429323000147/ex106_aagroemploymentagree.htm">Employment Agreement, by and between GRI Bio, Inc. and Albert Agro, Ph.D., dated as of July 1, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/14/2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2&#9651;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1824293/000182429323000159/ex101_gri-aardvarkagreemen.htm">Asset Purchase Agreement, by and between GRI Bio, Inc. and Aardvark Therapeutics, Inc., dated August 22, 2023</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1824293/000182429323000159/ex101_gri-aardvarkagreemen.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/23/2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex103_gri-clawbackpolicyse.htm">GRI Bio, Inc. Clawback Policy </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex311_ceo302cert93023.htm">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex312_cfo302cert93023.htm">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex321_ceosection906cert930.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex322_cfosection906cert930.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unless otherwise indicated, exhibits are filed herewith.</span></div><div style="padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:0.1%"></td><td style="width:2.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicates a management contract or any compensatory plan, contract or arrangement.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except to the extent specifically incorporated by reference into such filing.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9651;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain information in this exhibit (indicated by &#8220;[***]&#8221;) has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both not material and is the type that the Company treats as private or confidential.</span></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i9543da0ac24342e79ce7f476be8c5f32_139"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9543da0ac24342e79ce7f476be8c5f32_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GRI BIO, INC.</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 14, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Leanne M. Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name: Leanne M. Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title: Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>ex103_gri-clawbackpolicyse.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0db9f6d9305242279c19590743b1e10d_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GRI BIO, INC.</font></div><div style="text-align:center"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CLAWBACK POLICY</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Introduction</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee of the Board of Directors (the &#8220;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Committee</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of GRI Bio, Inc. (the &#8220;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company&#8217;s pay-for-performance compensation philosophy.  The Committee has therefore adopted this policy which provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with financial reporting requirements under the federal securities laws (the &#8220;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policy</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  This Policy is designed to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Act</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and final rules and amendments adopted by the Securities and Exchange Commission (the &#8220;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEC</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to implement the aforementioned legislation.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">II.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Administration</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Policy shall be administered by the Committee. Any determinations made by the Committee shall be final and binding on all affected individuals.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">III.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Covered Executives</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Policy applies to the Company&#8217;s current and former executive officers, as determined by the Committee in accordance with the requirements of Section 10D of the Exchange Act and any applicable rules or standards adopted by the SEC and any national securities exchange on which the Company&#8217;s securities are listed, and such other employees who may from time to time be deemed subject to the Policy by the Committee (&#8220;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covered Executives</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IV.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Incentive-Based Compensation</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Policy, incentive-based compensation (&#8220;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incentive-Based Compensation</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) includes any compensation that is granted, earned, or vested based wholly or in part upon the attainment of any financial reporting measures that are determined and presented in accordance with the accounting principles (&#8220;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GAAP Measures</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) used in preparing the Company&#8217;s financial statements and any measures derived wholly or in part from such measures, as well as non-GAAP Measures, stock price, and total shareholder return (collectively, &#8220;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Reporting Measures</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59; however, it does not include&#58; (i) base salaries&#59; (ii) discretionary cash bonuses&#59; (iii) awards (either cash or equity) that are solely based upon subjective, strategic or operational standards or standards unrelated to Financial Reporting Measures, and (iv) equity awards that vest solely on completion of a specified employment period or without any performance condition.  Incentive-Based Compensation is considered received in the fiscal period during which the applicable reporting measure is attained, even if the payment or grant of such award occurs after the end of that period.  If an award is subject to both time-based and performance-based vesting conditions, the award is considered received upon satisfaction of the performance-based conditions, even if such an award continues to be subject to the time-based vesting conditions.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purposes of this Policy, Incentive-Based Compensation may include, among other things, any of the following&#58;</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Annual bonuses and other short- and long-term cash incentives.</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Stock options.</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Stock appreciation rights.</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Restricted stock or restricted stock units.</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Performance shares or performance units.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Policy, Financial Reporting Measures may include, among other things, any of the following&#58;</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Company stock price. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Total shareholder return.</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Revenues.</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Net income.</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Earnings before interest, taxes, depreciation, and amortization (&#8220;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EBITDA</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Funds from operations.</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Liquidity measures such as working capital or operating cash flow.</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Return measures such as return on invested capital or return on assets.</font></div><div style="margin-bottom:12pt;padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Earnings measures such as earnings per share.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">V.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recoupment&#59; Accounting Restatement</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Company is required to prepare an accounting restatement of its financial statements due to the Company&#8217;s material noncompliance with any financial reporting requirement under U.S. securities laws, including any required accounting restatement to correct an error in previously issued financial statements that (i) is material to the previously issued financial statements or (ii) is not material to previously issued financial statements, but that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period, the Committee will require reimbursement or forfeiture of any excess Incentive-Based Compensation received by any Covered Executive during the three completed fiscal years immediately preceding the date on which the Company is required to prepare the accounting restatement (the &#8220;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Look-Back Period</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  For the purposes of this Policy, the date on which the Company is required to prepare an accounting restatement is the earlier of (i) the date the Committee concludes or reasonably should have concluded that the Company is required to prepare a restatement to correct a material error, and (ii) the date a court, regulator, or other legally authorized body directs the Company to restate its previously issued financial statements to correct a material error. The Company&#8217;s obligation to recover erroneously awarded compensation is not dependent on if or when the restated financial statements are filed.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recovery of the Incentive-Based Compensation is only required when the excess award is received by a Covered Executive (i) after the beginning of their service as a Covered Executive, (ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">who served as an executive officer at any time during the performance period for that Incentive-Based Compensation, (iii) while the Company has a class of securities listed on a national securities exchange or a national securities association, and (iv) during the Look-Back Period immediately preceding the date on which the Company is required to prepare an accounting restatement.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VI.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Excess Incentive Compensation&#58; Amount Subject to Recovery</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of Incentive-Based Compensation subject to recovery is the amount the Covered Executive received in excess of the amount of Incentive-Based Compensation that would have been paid to the Covered Executive had it been based on the restated financial statements, as determined by the Committee.  The amount subject to recovery will be calculated on a pre-tax basis.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Incentive-Based Compensation received as cash awards, the erroneously awarded compensation is the difference between the amount of the cash award that was received (whether payable in a lump sum or over time) and the amount that should have been received applying the restated Financial Reporting Measure.  For cash awards paid from bonus pools, the erroneously awarded Incentive-Based Compensation is the pro rata portion of any deficiency that results from the aggregate bonus pool that is reduced based on applying the restated Financial Reporting Measure.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Incentive-Based Compensation received as equity awards that are still held at the time of recovery, the amount subject to recovery is the number of shares or other equity awards received or vested in excess of the number that should have been received or vested applying the restated Financial Reporting Measure.  If the equity award has been exercised, but the underlying shares have not been sold, the erroneously awarded compensation is the number of shares underlying the award.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In instances where the Company is not able to determine the amount of erroneously awarded Incentive-Based Compensation directly from the information in the accounting restatement, the amount will be based on the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s reasonable estimate of the effect of the accounting restatement on the applicable measure.  In such instances, the Company will maintain documentation of the determination of that reasonable estimate.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VII.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Method of Recoupment</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee will determine, in its sole discretion, subject to applicable law, the method for recouping Incentive-Based Compensation hereunder, which may include, without limitation&#58;</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">requiring reimbursement of cash Incentive-Based Compensation previously paid&#59;</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards&#59;</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">offsetting the recouped amount from any compensation otherwise owed by the Company to the Covered Executive&#59;</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">cancelling outstanding vested or unvested equity awards&#59; and&#47;or</font></div><div style="margin-bottom:12pt;padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">taking any other remedial and recovery action permitted by law, as determined by the Committee.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIII.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">No Indemnification&#59; Successors</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company shall not indemnify any Covered Executives against the loss of any incorrectly awarded Incentive-Based Compensation.  This Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IX.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exception to Enforcement</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee shall recover any excess Incentive-Based Compensation in accordance with this Policy unless such recovery would be impracticable, as determined by the Committee in accordance with Rule 10D-1 of the Exchange Act and any applicable rules or standards adopted by the SEC and the listing standards of any national securities exchange on which the Company&#8217;s securities are listed.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Interpretation</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy.  It is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act and any applicable rules or standards adopted by the SEC and any national securities exchange on which the Company&#8217;s securities are listed.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">XI.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Effective Date</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Policy shall be effective as of October 2, 2023 (the &#8220;</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Date</font><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and shall apply to Incentive-Based Compensation that is received by a Covered Executive on or after that date, as determined by the Committee in accordance with applicable rules or standards adopted by the SEC and the listing standards of any national securities exchange on which the Company&#8217;s securities are listed.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">XII.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Amendment&#59; Termination</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary to comply with any rules or standards adopted by the SEC and the listing standards of any national securities exchange on which the Company&#8217;s securities are listed. The Committee may terminate this Policy at any time.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">XIII.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Recoupment Rights</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex311_ceo302cert93023.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7802f775ed8a455dbd147d2ff29760ac_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, W. Marc Hertz, certify that&#58;</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September&#160;30, 2023 of GRI Bio, Inc.&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"></td><td style="width:31.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; November&#160;14, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; W. Marc Hertz</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">W. Marc Hertz</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex312_cfo302cert93023.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i88d865028afc4b0891bc7aa17163695c_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Leanne M. Kelly, certify that&#58;</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September&#160;30, 2023 of GRI Bio, Inc.&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.299%"><tr><td style="width:1.0%"></td><td style="width:29.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; November&#160;14, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne M. Kelly</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Leanne M. Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex321_ceosection906cert930.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iebaceeb54a734ab790342a5dcd17f63c_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, W. Marc Hertz, President and Chief Executive Officer of GRI Bio, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended September&#160;30, 2023 (the &#8220;Quarterly Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; November&#160;14, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; W. Marc Hertz</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">W. Marc Hertz</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ex322_cfosection906cert930.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iecb98510417a4bf78507e03bbb92d2ed_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Leanne M. Kelly,  Chief Financial Officer of GRI Bio, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended September&#160;30, 2023 (the &#8220;Quarterly Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; November&#160;14, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne M. Kelly</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Leanne M. Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ck0001824293-20230930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:a8344312-8d5f-422d-bd63-4db6cc7ddad6,g:d0f905d4-70f6-4e32-afc7-d259f8c67a30-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ck0001824293="http://www.vallon-pharma.com/20230930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vallon-pharma.com/20230930">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.vallon-pharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquityDeficit" roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit">
        <link:definition>0000005 - Statement - Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESS" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS">
        <link:definition>0000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITY" roleURI="http://www.vallon-pharma.com/role/LIQUIDITY">
        <link:definition>0000008 - Disclosure - LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000009 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLON" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLON">
        <link:definition>0000010 - Disclosure - MERGER WITH VALLON</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>0000011 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENT" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT">
        <link:definition>0000012 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES">
        <link:definition>0000013 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROMISSORYNOTES" roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTES">
        <link:definition>0000014 - Disclosure - PROMISSORY NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY">
        <link:definition>0000015 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ASSETPURCHASEAGREEMENT" roleURI="http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENT">
        <link:definition>0000016 - Disclosure - ASSET PURCHASE AGREEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>0000017 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000018 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9954471 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9954472 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLONTables" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONTables">
        <link:definition>9954473 - Disclosure - MERGER WITH VALLON (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>9954474 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTTables" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables">
        <link:definition>9954475 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables">
        <link:definition>9954476 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>9954477 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>9954478 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails">
        <link:definition>9954479 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITYDetails" roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails">
        <link:definition>9954480 - Disclosure - LIQUIDITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>9954481 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails">
        <link:definition>9954482 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLONNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails">
        <link:definition>9954483 - Disclosure - MERGER WITH VALLON - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails">
        <link:definition>9954484 - Disclosure - MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1">
        <link:definition>9954484 - Disclosure - MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails">
        <link:definition>9954485 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSScheduleofLiabilityMeasuredatEstimatedFairValueDetails" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofLiabilityMeasuredatEstimatedFairValueDetails">
        <link:definition>9954486 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Liability Measured at Estimated Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails">
        <link:definition>9954487 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Derivative Liability Measurement Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails">
        <link:definition>9954488 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails">
        <link:definition>9954489 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESDetails" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails">
        <link:definition>9954490 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROMISSORYNOTESBridgeFinancingDetails" roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails">
        <link:definition>9954491 - Disclosure - PROMISSORY NOTES - Bridge Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROMISSORYNOTESTEPNoteDetails" roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails">
        <link:definition>9954492 - Disclosure - PROMISSORY NOTES - TEP Note (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
        <link:definition>9954493 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails">
        <link:definition>9954494 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Estimate of the Fair Value of the Warrants and Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails">
        <link:definition>9954495 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ASSETPURCHASEAGREEMENTDetails" roleURI="http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails">
        <link:definition>9954496 - Disclosure - ASSET PURCHASE AGREEMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>9954497 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>9954498 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails">
        <link:definition>9954499 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Activity of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails">
        <link:definition>9954500 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Estimate Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>9954501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ck0001824293_PaymentOfReverseRecapitalizationCosts" abstract="false" name="PaymentOfReverseRecapitalizationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_WarrantLiabilityMember" abstract="true" name="WarrantLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" abstract="true" name="AmendedAndRestated2018EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInJune2025Member" abstract="true" name="WarrantsExpiringInJune2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_BridgeSecuritiesPurchaseAgreementMember" abstract="true" name="BridgeSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember" abstract="true" name="WarrantsExpiringIn24MonthsAfterRegistrationDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember" abstract="true" name="WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" abstract="false" name="StockIssuedDuringPeriodValueReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_COBRABenefitsPaymentPeriod" abstract="false" name="COBRABenefitsPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ck0001824293_ConversionOfStockAdditionalSharesConverted" abstract="false" name="ConversionOfStockAdditionalSharesConverted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_CommonStockOwnershipPercentage" abstract="false" name="CommonStockOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_StockSubjectToPutRightMember" abstract="true" name="StockSubjectToPutRightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" abstract="false" name="StockIssuedDuringPeriodValueSettlementOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_NoncashMergerRelatedCostsFinancingActivities" abstract="false" name="NoncashMergerRelatedCostsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion" abstract="false" name="DebtInstrumentConvertibleSharesIssuedUponConversion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_BankerWarrantsMember" abstract="true" name="BankerWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_PercentageOfTargetBonus" abstract="false" name="PercentageOfTargetBonus" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" abstract="false" name="NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_TEPNoteMember" abstract="true" name="TEPNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_ExchangeWarrantsMember" abstract="true" name="ExchangeWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_AccruedInterestForfeited" abstract="false" name="AccruedInterestForfeited" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" abstract="false" name="AccruedGeneralAndAdministrativeExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInJuly2027Member" abstract="true" name="WarrantsExpiringInJuly2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_EmployeeAdvancesCurrent" abstract="false" name="EmployeeAdvancesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedForRepaymentOfNotesPayable" abstract="false" name="StockIssuedForRepaymentOfNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ConvertiblePromissoryNoteMember" abstract="true" name="ConvertiblePromissoryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesA2WarrantsMember" abstract="true" name="SeriesA2WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" abstract="false" name="StockIssuedDuringPeriodValueWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest" abstract="false" name="DebtConversionConvertedInstrumentAmountOfInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ProceedsFromNonConvertibleDebt" abstract="false" name="ProceedsFromNonConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_PrivateGRIPlanMember" abstract="true" name="PrivateGRIPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInNovember2023Member" abstract="true" name="WarrantsExpiringInNovember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" abstract="false" name="StockIssuedDuringPeriodSharesReverseRecapitalization" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_ClassOfWarrantOrRightExpirationPeriod" abstract="false" name="ClassOfWarrantOrRightExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ck0001824293_ChangeInFairValueOfWarrantLiability" abstract="false" name="ChangeInFairValueOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_SeriesA1WarrantsMember" abstract="true" name="SeriesA1WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" abstract="false" name="StockIssuedDuringPeriodValuePreClosingFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" abstract="false" name="DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuanceCostsOfferingExpenses" abstract="false" name="StockIssuanceCostsOfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_DebtInstrumentAggregatePurchasePrice" abstract="false" name="DebtInstrumentAggregatePurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" abstract="false" name="StockIssuedDuringPeriodSharesWarrantExercise" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" abstract="false" name="StockIssuedDuringPeriodSharesPreClosingFinancing" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_DebtInstrumentNumberOfClosings" abstract="false" name="DebtInstrumentNumberOfClosings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" abstract="false" name="StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" abstract="false" name="StockIssuedDuringPeriodSharesSettlementOfDebt" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInApril2028Member" abstract="true" name="WarrantsExpiringInApril2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_LongTermDebtIncludingInterest" abstract="false" name="LongTermDebtIncludingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInFebruary2026Member" abstract="true" name="WarrantsExpiringInFebruary2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_BridgeWarrantsMember" abstract="true" name="BridgeWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_CommonStockHeldIntoEscrowAccount" abstract="false" name="CommonStockHeldIntoEscrowAccount" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_CommonStockExchangeRatio" abstract="false" name="CommonStockExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInDecember2023Member" abstract="true" name="WarrantsExpiringInDecember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_PrivateGRIMember" abstract="true" name="PrivateGRIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_RepaymentOfAdvancesFromEmployees" abstract="false" name="RepaymentOfAdvancesFromEmployees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" abstract="false" name="StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_ProceedsFromAdvancesFromEmployees" abstract="false" name="ProceedsFromAdvancesFromEmployees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_FormerChiefExecutiveOfficerMember" abstract="true" name="FormerChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember" abstract="true" name="WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_CallOptionPrice" abstract="false" name="CallOptionPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ck0001824293_SeriesTWarrantsMember" abstract="true" name="SeriesTWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_PutOptionSharePrice" abstract="false" name="PutOptionSharePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ck0001824293_WarrantsIssued" abstract="false" name="WarrantsIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt" abstract="false" name="DebtConversionConvertedInstrumentPrincipalAmountOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInMay2027Member" abstract="true" name="WarrantsExpiringInMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember" abstract="true" name="EquityWarrantsExchangeWarrantsAndBankerWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" abstract="false" name="StockIssuedForPaymentOfReverseRecapitalizationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_GRIBioIncMember" abstract="true" name="GRIBioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_AardvarkTherapeuticsIncMember" abstract="true" name="AardvarkTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_EquityWarrantsMember" abstract="true" name="EquityWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ck0001824293-20230930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:a8344312-8d5f-422d-bd63-4db6cc7ddad6,g:d0f905d4-70f6-4e32-afc7-d259f8c67a30-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_647ce36c-3f92-4d1a-87e5-42175ff7a3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_095e303d-32d4-402c-bf33-a2fd2a9ea5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_647ce36c-3f92-4d1a-87e5-42175ff7a3f4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_095e303d-32d4-402c-bf33-a2fd2a9ea5ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4d05b80f-ec60-4d0c-ba80-a6b20b42a8be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_647ce36c-3f92-4d1a-87e5-42175ff7a3f4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4d05b80f-ec60-4d0c-ba80-a6b20b42a8be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0a9a9493-d5e6-4876-b4bd-8529e68365d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4bd910b2-62ab-4c2d-9f40-2c50857d3048" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0a9a9493-d5e6-4876-b4bd-8529e68365d7" xlink:to="loc_us-gaap_AccountsPayableCurrent_4bd910b2-62ab-4c2d-9f40-2c50857d3048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e2f863ca-5daf-46fa-9595-4dadd51f773c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0a9a9493-d5e6-4876-b4bd-8529e68365d7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e2f863ca-5daf-46fa-9595-4dadd51f773c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_6041d76e-8f00-4dcc-a20e-0cb3e4589210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0a9a9493-d5e6-4876-b4bd-8529e68365d7" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_6041d76e-8f00-4dcc-a20e-0cb3e4589210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_EmployeeAdvancesCurrent_904901a3-0a89-4a0a-b0ce-227e52e44a84" xlink:href="ck0001824293-20230930.xsd#ck0001824293_EmployeeAdvancesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0a9a9493-d5e6-4876-b4bd-8529e68365d7" xlink:to="loc_ck0001824293_EmployeeAdvancesCurrent_904901a3-0a89-4a0a-b0ce-227e52e44a84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6720fa6b-3ba8-4e64-8e13-8baf297bd673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0a9a9493-d5e6-4876-b4bd-8529e68365d7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6720fa6b-3ba8-4e64-8e13-8baf297bd673" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_b3a3a22f-5b1a-46cb-be3e-e77b26eeecbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0a9a9493-d5e6-4876-b4bd-8529e68365d7" xlink:to="loc_us-gaap_NotesPayableCurrent_b3a3a22f-5b1a-46cb-be3e-e77b26eeecbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d718bbaa-766d-44c8-9ed3-8f31ab4cad5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_713443eb-d856-4d35-9f5f-51072989d104" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d718bbaa-766d-44c8-9ed3-8f31ab4cad5e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_713443eb-d856-4d35-9f5f-51072989d104" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7799581b-9568-4944-a2a8-6ddaec52baa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d718bbaa-766d-44c8-9ed3-8f31ab4cad5e" xlink:to="loc_us-gaap_LiabilitiesCurrent_7799581b-9568-4944-a2a8-6ddaec52baa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_494ccd89-62c4-4e03-b276-206e5639c2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fd5edfda-57bc-4713-8538-a2df76a5f578" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_494ccd89-62c4-4e03-b276-206e5639c2bc" xlink:to="loc_us-gaap_Liabilities_fd5edfda-57bc-4713-8538-a2df76a5f578" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dc9b8270-7d8e-41ff-abdd-f736fcc9475a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_494ccd89-62c4-4e03-b276-206e5639c2bc" xlink:to="loc_us-gaap_StockholdersEquity_dc9b8270-7d8e-41ff-abdd-f736fcc9475a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4e36f67f-8299-4ff6-bd7e-1b397b5b14f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_494ccd89-62c4-4e03-b276-206e5639c2bc" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4e36f67f-8299-4ff6-bd7e-1b397b5b14f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4bb45818-1515-4d8b-819e-1992389cb6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a6ba4142-6015-4218-bd77-f040f7d28120" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4bb45818-1515-4d8b-819e-1992389cb6f6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a6ba4142-6015-4218-bd77-f040f7d28120" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_93442fdf-4993-44f0-81d2-b3d9f3e3d450" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4bb45818-1515-4d8b-819e-1992389cb6f6" xlink:to="loc_us-gaap_CommonStockValueOutstanding_93442fdf-4993-44f0-81d2-b3d9f3e3d450" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_80dd7f61-1137-49bd-9cb9-9ead14b704af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4bb45818-1515-4d8b-819e-1992389cb6f6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_80dd7f61-1137-49bd-9cb9-9ead14b704af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e0088692-d1dd-4ea5-ba34-595392b0ffdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e15f766d-1784-45b6-95c2-8dbfb90bd0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e0088692-d1dd-4ea5-ba34-595392b0ffdc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e15f766d-1784-45b6-95c2-8dbfb90bd0fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a8eb8cd1-65c3-4e3a-a639-519991e34296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e0088692-d1dd-4ea5-ba34-595392b0ffdc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a8eb8cd1-65c3-4e3a-a639-519991e34296" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_931199e2-15f3-4b6e-9968-63c9446d8118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e0088692-d1dd-4ea5-ba34-595392b0ffdc" xlink:to="loc_us-gaap_AssetsCurrent_931199e2-15f3-4b6e-9968-63c9446d8118" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_45e02af3-ae79-4569-a4cc-b1e0e661a1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f300b609-3d62-425b-9fe0-ead6f7dca07c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_45e02af3-ae79-4569-a4cc-b1e0e661a1d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f300b609-3d62-425b-9fe0-ead6f7dca07c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_46f39c07-63ba-4e0a-b630-c07d8d446b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_45e02af3-ae79-4569-a4cc-b1e0e661a1d7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_46f39c07-63ba-4e0a-b630-c07d8d446b8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c6361774-f4b7-46a3-9fb4-3874f1c07239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1194e380-d0d4-4e85-830c-7759da2977ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c6361774-f4b7-46a3-9fb4-3874f1c07239" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1194e380-d0d4-4e85-830c-7759da2977ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_da9c7309-63ac-48fb-999a-604bafa4099c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c6361774-f4b7-46a3-9fb4-3874f1c07239" xlink:to="loc_us-gaap_OperatingIncomeLoss_da9c7309-63ac-48fb-999a-604bafa4099c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_791b3b95-6b72-4ec2-832d-ac9424257582" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ChangeInFairValueOfWarrantLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c6361774-f4b7-46a3-9fb4-3874f1c07239" xlink:to="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_791b3b95-6b72-4ec2-832d-ac9424257582" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3d0c37d0-11bb-44b8-b664-ea69566dbc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c6361774-f4b7-46a3-9fb4-3874f1c07239" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3d0c37d0-11bb-44b8-b664-ea69566dbc7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4c92c5e4-b75d-4524-82e3-a5ab65602f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_00c9c6f4-9f38-41b7-b1ea-2083c3d1f9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4c92c5e4-b75d-4524-82e3-a5ab65602f7c" xlink:to="loc_us-gaap_OperatingExpenses_00c9c6f4-9f38-41b7-b1ea-2083c3d1f9f1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2e3749c4-f4e7-49f2-8cb9-9a3cc45abaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_85b63fe4-c2c2-46d4-989e-4999c65e0b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2e3749c4-f4e7-49f2-8cb9-9a3cc45abaf2" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_85b63fe4-c2c2-46d4-989e-4999c65e0b8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_7e0abe4c-1639-4cad-b9f9-9906c8016d2b" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ProceedsFromAdvancesFromEmployees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2e3749c4-f4e7-49f2-8cb9-9a3cc45abaf2" xlink:to="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_7e0abe4c-1639-4cad-b9f9-9906c8016d2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_2926bbcd-8b1f-477c-96dc-4ea560405559" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PaymentOfReverseRecapitalizationCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2e3749c4-f4e7-49f2-8cb9-9a3cc45abaf2" xlink:to="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_2926bbcd-8b1f-477c-96dc-4ea560405559" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_c1fce32f-e5f7-4166-9a43-154f00dd883f" xlink:href="ck0001824293-20230930.xsd#ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2e3749c4-f4e7-49f2-8cb9-9a3cc45abaf2" xlink:to="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_c1fce32f-e5f7-4166-9a43-154f00dd883f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_07733810-adb8-4b72-9035-028d0715c717" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2e3749c4-f4e7-49f2-8cb9-9a3cc45abaf2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_07733810-adb8-4b72-9035-028d0715c717" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_d5a467bf-0985-4103-9dae-8645b2304cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2e3749c4-f4e7-49f2-8cb9-9a3cc45abaf2" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_d5a467bf-0985-4103-9dae-8645b2304cb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_703d569f-27a6-4069-9a20-ca70eb61a261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2e3749c4-f4e7-49f2-8cb9-9a3cc45abaf2" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_703d569f-27a6-4069-9a20-ca70eb61a261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_68862222-f0c4-455e-a898-d32f3db217dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2e3749c4-f4e7-49f2-8cb9-9a3cc45abaf2" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_68862222-f0c4-455e-a898-d32f3db217dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_a1db260e-c110-41a1-9608-85ee322a6d93" xlink:href="ck0001824293-20230930.xsd#ck0001824293_RepaymentOfAdvancesFromEmployees"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2e3749c4-f4e7-49f2-8cb9-9a3cc45abaf2" xlink:to="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_a1db260e-c110-41a1-9608-85ee322a6d93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromNonConvertibleDebt_7404921a-a72c-4237-9919-24a459eb2efd" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ProceedsFromNonConvertibleDebt"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2e3749c4-f4e7-49f2-8cb9-9a3cc45abaf2" xlink:to="loc_ck0001824293_ProceedsFromNonConvertibleDebt_7404921a-a72c-4237-9919-24a459eb2efd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_6038d32d-e899-41c9-9bc7-453244605829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2e3749c4-f4e7-49f2-8cb9-9a3cc45abaf2" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_6038d32d-e899-41c9-9bc7-453244605829" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aa09309e-b5ad-4e7a-b1f1-0de5c68b6a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f0b73764-56a8-4267-9a89-d0a624fe0a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aa09309e-b5ad-4e7a-b1f1-0de5c68b6a7d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f0b73764-56a8-4267-9a89-d0a624fe0a07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_092b7779-7902-4d66-ae9d-9da9c81c03b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14aee7f8-c766-4f68-9a2f-a59a138eb115" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_092b7779-7902-4d66-ae9d-9da9c81c03b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14aee7f8-c766-4f68-9a2f-a59a138eb115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1b119f67-4d56-4a01-b2cc-97135de7a9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_092b7779-7902-4d66-ae9d-9da9c81c03b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1b119f67-4d56-4a01-b2cc-97135de7a9fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1eefcffa-6336-4d77-9838-495cb2eed7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_092b7779-7902-4d66-ae9d-9da9c81c03b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1eefcffa-6336-4d77-9838-495cb2eed7e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b997ff01-aaed-4b70-b10a-9ac82b47f28f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f13c8901-a741-4631-b696-3420956fc6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b997ff01-aaed-4b70-b10a-9ac82b47f28f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f13c8901-a741-4631-b696-3420956fc6a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a0abb5ef-55c7-486b-a878-a16d886c03e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b997ff01-aaed-4b70-b10a-9ac82b47f28f" xlink:to="loc_us-gaap_Depreciation_a0abb5ef-55c7-486b-a878-a16d886c03e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_7a3600be-65b3-4dcf-9366-1b1dba280551" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b997ff01-aaed-4b70-b10a-9ac82b47f28f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_7a3600be-65b3-4dcf-9366-1b1dba280551" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_23af3f4e-c130-4499-ac8e-7ecc968dd9df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b997ff01-aaed-4b70-b10a-9ac82b47f28f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_23af3f4e-c130-4499-ac8e-7ecc968dd9df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_56a9412b-e8e3-49ed-98ab-4d9fd4ad158a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b997ff01-aaed-4b70-b10a-9ac82b47f28f" xlink:to="loc_us-gaap_ShareBasedCompensation_56a9412b-e8e3-49ed-98ab-4d9fd4ad158a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9c5f09ce-5ad7-4345-9f1b-09b036414d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b997ff01-aaed-4b70-b10a-9ac82b47f28f" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9c5f09ce-5ad7-4345-9f1b-09b036414d5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e448bc3c-2f59-403e-8e25-4339d723bc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b997ff01-aaed-4b70-b10a-9ac82b47f28f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e448bc3c-2f59-403e-8e25-4339d723bc1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_46e6d6f6-ed94-4d84-8ded-767d33dd4795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b997ff01-aaed-4b70-b10a-9ac82b47f28f" xlink:to="loc_us-gaap_NetIncomeLoss_46e6d6f6-ed94-4d84-8ded-767d33dd4795" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5da64cdb-cab7-4eab-a919-f626299042b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b997ff01-aaed-4b70-b10a-9ac82b47f28f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5da64cdb-cab7-4eab-a919-f626299042b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_a005e234-e025-4a29-88f7-c783741a15b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b997ff01-aaed-4b70-b10a-9ac82b47f28f" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_a005e234-e025-4a29-88f7-c783741a15b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e0d7b46a-2226-48b3-bcf3-18db66a37123" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_7417d6fe-00e8-4080-b89d-afc15306f842" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e0d7b46a-2226-48b3-bcf3-18db66a37123" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_7417d6fe-00e8-4080-b89d-afc15306f842" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_a64490f9-115e-4198-912b-ed190ca9e5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e0d7b46a-2226-48b3-bcf3-18db66a37123" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_a64490f9-115e-4198-912b-ed190ca9e5b9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_36b71d7c-febf-413c-a109-6033454cddfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_4a80a733-e95b-4097-9047-884edb9bde4b" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_36b71d7c-febf-413c-a109-6033454cddfb" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_4a80a733-e95b-4097-9047-884edb9bde4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c2d39d5b-5fce-4c83-984f-1419ceb3fa0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_36b71d7c-febf-413c-a109-6033454cddfb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c2d39d5b-5fce-4c83-984f-1419ceb3fa0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e26edafc-1afb-462a-9424-2122aa1a4fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_36b71d7c-febf-413c-a109-6033454cddfb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e26edafc-1afb-462a-9424-2122aa1a4fcf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_6c0de4fa-f8ab-487b-9507-d0c5a976c184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_cd4b6758-1d2e-48f6-9995-1c66c3130a30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_6c0de4fa-f8ab-487b-9507-d0c5a976c184" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_cd4b6758-1d2e-48f6-9995-1c66c3130a30" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cac37a36-f3f4-4431-8bfd-5b51a9f0f9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_84bdb010-e79e-4f3b-baf7-99ddde38a5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_cac37a36-f3f4-4431-8bfd-5b51a9f0f9d9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_84bdb010-e79e-4f3b-baf7-99ddde38a5a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8c76f297-65db-43c3-8dbb-e8516f423b77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_cac37a36-f3f4-4431-8bfd-5b51a9f0f9d9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8c76f297-65db-43c3-8dbb-e8516f423b77" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#ACCRUEDEXPENSESDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b08b9b13-3918-4958-ab9d-5cdca98ff974" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_cd1de285-6adf-49c6-a848-64fed1ce733d" xlink:href="ck0001824293-20230930.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b08b9b13-3918-4958-ab9d-5cdca98ff974" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_cd1de285-6adf-49c6-a848-64fed1ce733d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_29690124-afb0-4c31-a089-65ed97a3f85c" xlink:href="ck0001824293-20230930.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b08b9b13-3918-4958-ab9d-5cdca98ff974" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_29690124-afb0-4c31-a089-65ed97a3f85c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fcf8b981-3124-4e3f-8412-73d5254222d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b08b9b13-3918-4958-ab9d-5cdca98ff974" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fcf8b981-3124-4e3f-8412-73d5254222d7" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ck0001824293-20230930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:a8344312-8d5f-422d-bd63-4db6cc7ddad6,g:d0f905d4-70f6-4e32-afc7-d259f8c67a30-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#ConsolidatedStatementsofChangesinStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c01a5b80-bea7-4331-96a3-0245c388ce50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_341bd6b4-627e-4538-a2f4-211b25dbb692" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c01a5b80-bea7-4331-96a3-0245c388ce50" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_341bd6b4-627e-4538-a2f4-211b25dbb692" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_2bb8856d-0882-42ce-a1f0-22e51864fb45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_341bd6b4-627e-4538-a2f4-211b25dbb692" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_2bb8856d-0882-42ce-a1f0-22e51864fb45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_de815f0b-f663-4247-aee1-59d00ebd18e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_341bd6b4-627e-4538-a2f4-211b25dbb692" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_de815f0b-f663-4247-aee1-59d00ebd18e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1514089c-cc98-4e29-8da5-ec39e3c6db30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9b834e62-d557-4f6d-ad49-53eb0e156469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c01a5b80-bea7-4331-96a3-0245c388ce50" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8b579558-3228-4edb-b768-3c5801edc7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8b579558-3228-4edb-b768-3c5801edc7d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ad582fe7-691d-467b-a178-585688f956bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_us-gaap_StockholdersEquity_ad582fe7-691d-467b-a178-585688f956bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_734a915e-2ddd-4b7e-8d65-fc837e00ed09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_734a915e-2ddd-4b7e-8d65-fc837e00ed09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8ae44958-1e22-4482-b08d-1f9f4360209a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8ae44958-1e22-4482-b08d-1f9f4360209a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_849f1c7c-41ec-4126-ac50-10defbdfc048" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_849f1c7c-41ec-4126-ac50-10defbdfc048" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6b229e6f-f489-45e9-8e92-bdb2a564a991" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6b229e6f-f489-45e9-8e92-bdb2a564a991" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_b1f56bf1-335b-4ddc-a726-cf28af78e44e" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_b1f56bf1-335b-4ddc-a726-cf28af78e44e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_b4dbb1e0-7e45-4e52-8dd0-1cfb24cbef1e" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodValueWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_b4dbb1e0-7e45-4e52-8dd0-1cfb24cbef1e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_c2a82781-4a3e-41fa-86ab-f6390b04bf9b" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_c2a82781-4a3e-41fa-86ab-f6390b04bf9b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_2d5ef838-e98b-49fe-bbfc-b41c786354b2" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_2d5ef838-e98b-49fe-bbfc-b41c786354b2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_1ea051aa-3054-48f9-9451-d0ae60b88878" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_1ea051aa-3054-48f9-9451-d0ae60b88878" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_4125791d-9c9a-4d1b-8780-f9c976fa5f18" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_4125791d-9c9a-4d1b-8780-f9c976fa5f18" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_127c9567-eb1a-4676-b8b3-cebf73a43a71" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_127c9567-eb1a-4676-b8b3-cebf73a43a71" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_3df8ed87-35bb-43f5-88b6-69514ee99eae" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_3df8ed87-35bb-43f5-88b6-69514ee99eae" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_eeacf47e-d580-4e34-bfb2-959faf0fe531" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_eeacf47e-d580-4e34-bfb2-959faf0fe531" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_a7953170-509b-4ab2-8640-3b82436f8ba1" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_a7953170-509b-4ab2-8640-3b82436f8ba1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c97a9a7-5fc7-422e-8375-55b42085a063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_us-gaap_NetIncomeLoss_5c97a9a7-5fc7-422e-8375-55b42085a063" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_662300e0-3fa3-49ae-8640-d910168415ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_45e9dfbf-b32c-42b0-b2f0-f972d027d025" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c6f661cd-03ad-491f-92d5-d35a3e28d22d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c01a5b80-bea7-4331-96a3-0245c388ce50" xlink:to="loc_us-gaap_StatementTable_c6f661cd-03ad-491f-92d5-d35a3e28d22d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d8065713-8a39-4d6d-a932-1ac6b1344b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c6f661cd-03ad-491f-92d5-d35a3e28d22d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d8065713-8a39-4d6d-a932-1ac6b1344b8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d8065713-8a39-4d6d-a932-1ac6b1344b8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d8065713-8a39-4d6d-a932-1ac6b1344b8b" xlink:to="loc_us-gaap_EquityComponentDomain_d8065713-8a39-4d6d-a932-1ac6b1344b8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8b4f7afc-5aeb-486c-a1cd-35e97ffdc85b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d8065713-8a39-4d6d-a932-1ac6b1344b8b" xlink:to="loc_us-gaap_EquityComponentDomain_8b4f7afc-5aeb-486c-a1cd-35e97ffdc85b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_be9f3bb4-411e-4924-a434-549ceda3419a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8b4f7afc-5aeb-486c-a1cd-35e97ffdc85b" xlink:to="loc_us-gaap_CommonStockMember_be9f3bb4-411e-4924-a434-549ceda3419a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e1ea18a4-867d-4841-a37f-a85da809ac18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8b4f7afc-5aeb-486c-a1cd-35e97ffdc85b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e1ea18a4-867d-4841-a37f-a85da809ac18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_147dfe61-2454-42be-8100-2737defa0553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8b4f7afc-5aeb-486c-a1cd-35e97ffdc85b" xlink:to="loc_us-gaap_RetainedEarningsMember_147dfe61-2454-42be-8100-2737defa0553" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#LIQUIDITYDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_f0a38e0c-a569-418b-a6d1-ca2dacbe5b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_f0a38e0c-a569-418b-a6d1-ca2dacbe5b1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e2dc0946-3738-4000-b639-cef9343d19af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:to="loc_us-gaap_CommonStockSharesIssued_e2dc0946-3738-4000-b639-cef9343d19af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_23b80ab1-3195-41b3-8659-db858e589047" xlink:href="ck0001824293-20230930.xsd#ck0001824293_CommonStockHeldIntoEscrowAccount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:to="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_23b80ab1-3195-41b3-8659-db858e589047" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2027a119-a3d0-4cac-896b-caf39c0a6860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2027a119-a3d0-4cac-896b-caf39c0a6860" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_c3aef4ca-cee7-40dd-aa12-e3a65bafaa7b" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_c3aef4ca-cee7-40dd-aa12-e3a65bafaa7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_b057e8b4-1114-4861-a230-95d5ca3fdc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_b057e8b4-1114-4861-a230-95d5ca3fdc8a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_f24452a4-7c81-4598-82e8-c37ba7252e87" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:to="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_f24452a4-7c81-4598-82e8-c37ba7252e87" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_759cb0e1-2fb3-45da-8990-738005eecbca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:to="loc_us-gaap_SharePrice_759cb0e1-2fb3-45da-8990-738005eecbca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1d4d26f5-11d8-4883-aa30-9e2102f3490d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1d4d26f5-11d8-4883-aa30-9e2102f3490d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1f019181-23f7-4331-92cf-12d78ceae4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1d4d26f5-11d8-4883-aa30-9e2102f3490d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1f019181-23f7-4331-92cf-12d78ceae4e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1f019181-23f7-4331-92cf-12d78ceae4e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1f019181-23f7-4331-92cf-12d78ceae4e5" xlink:to="loc_us-gaap_RelatedPartyDomain_1f019181-23f7-4331-92cf-12d78ceae4e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9954218d-6e21-4e65-83a8-1c4416da2f63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1f019181-23f7-4331-92cf-12d78ceae4e5" xlink:to="loc_us-gaap_RelatedPartyDomain_9954218d-6e21-4e65-83a8-1c4416da2f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_dbd71b04-2f21-439f-9878-43b3b32e4509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9954218d-6e21-4e65-83a8-1c4416da2f63" xlink:to="loc_us-gaap_InvestorMember_dbd71b04-2f21-439f-9878-43b3b32e4509" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e4cfc8c1-79e4-4020-a600-e5f0841fc099" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1d4d26f5-11d8-4883-aa30-9e2102f3490d" xlink:to="loc_dei_LegalEntityAxis_e4cfc8c1-79e4-4020-a600-e5f0841fc099" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e4cfc8c1-79e4-4020-a600-e5f0841fc099_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e4cfc8c1-79e4-4020-a600-e5f0841fc099" xlink:to="loc_dei_EntityDomain_e4cfc8c1-79e4-4020-a600-e5f0841fc099_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b14093f2-d6f4-4742-97e8-076a0fc2059e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e4cfc8c1-79e4-4020-a600-e5f0841fc099" xlink:to="loc_dei_EntityDomain_b14093f2-d6f4-4742-97e8-076a0fc2059e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_4a6c2f84-3381-4046-ae45-ef5463d9992d" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PrivateGRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b14093f2-d6f4-4742-97e8-076a0fc2059e" xlink:to="loc_ck0001824293_PrivateGRIMember_4a6c2f84-3381-4046-ae45-ef5463d9992d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6ae3f028-5319-44dd-ba8e-2cb98b05103c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1d4d26f5-11d8-4883-aa30-9e2102f3490d" xlink:to="loc_srt_CounterpartyNameAxis_6ae3f028-5319-44dd-ba8e-2cb98b05103c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ae3f028-5319-44dd-ba8e-2cb98b05103c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6ae3f028-5319-44dd-ba8e-2cb98b05103c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ae3f028-5319-44dd-ba8e-2cb98b05103c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd3e8637-9aaa-4559-8728-3dcbbf38f57d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6ae3f028-5319-44dd-ba8e-2cb98b05103c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd3e8637-9aaa-4559-8728-3dcbbf38f57d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIBioIncMember_5bde6578-bcb9-42a7-8dd5-4546dae35e46" xlink:href="ck0001824293-20230930.xsd#ck0001824293_GRIBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd3e8637-9aaa-4559-8728-3dcbbf38f57d" xlink:to="loc_ck0001824293_GRIBioIncMember_5bde6578-bcb9-42a7-8dd5-4546dae35e46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cc21b3d3-5d70-467a-a815-0a7f7964427f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1d4d26f5-11d8-4883-aa30-9e2102f3490d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cc21b3d3-5d70-467a-a815-0a7f7964427f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cc21b3d3-5d70-467a-a815-0a7f7964427f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cc21b3d3-5d70-467a-a815-0a7f7964427f" xlink:to="loc_us-gaap_EquityComponentDomain_cc21b3d3-5d70-467a-a815-0a7f7964427f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_da5babea-5b75-472b-bbef-3049ad06b958" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cc21b3d3-5d70-467a-a815-0a7f7964427f" xlink:to="loc_us-gaap_EquityComponentDomain_da5babea-5b75-472b-bbef-3049ad06b958" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ad76bc10-db08-4d8f-8991-8dc353fd79be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_da5babea-5b75-472b-bbef-3049ad06b958" xlink:to="loc_us-gaap_CommonStockMember_ad76bc10-db08-4d8f-8991-8dc353fd79be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7f421ab7-9b6f-4489-99ad-2a371982c49c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1d4d26f5-11d8-4883-aa30-9e2102f3490d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7f421ab7-9b6f-4489-99ad-2a371982c49c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7f421ab7-9b6f-4489-99ad-2a371982c49c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7f421ab7-9b6f-4489-99ad-2a371982c49c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7f421ab7-9b6f-4489-99ad-2a371982c49c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3b5816ef-9cfa-4d96-8e74-c3097d9a45a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7f421ab7-9b6f-4489-99ad-2a371982c49c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3b5816ef-9cfa-4d96-8e74-c3097d9a45a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesTWarrantsMember_5c9ae12f-a61d-4039-9962-7ad821ba6cc3" xlink:href="ck0001824293-20230930.xsd#ck0001824293_SeriesTWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3b5816ef-9cfa-4d96-8e74-c3097d9a45a5" xlink:to="loc_ck0001824293_SeriesTWarrantsMember_5c9ae12f-a61d-4039-9962-7ad821ba6cc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_99eae6bd-40a6-4c26-a206-9b2bf7b69e6c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1d4d26f5-11d8-4883-aa30-9e2102f3490d" xlink:to="loc_srt_RangeAxis_99eae6bd-40a6-4c26-a206-9b2bf7b69e6c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_99eae6bd-40a6-4c26-a206-9b2bf7b69e6c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_99eae6bd-40a6-4c26-a206-9b2bf7b69e6c" xlink:to="loc_srt_RangeMember_99eae6bd-40a6-4c26-a206-9b2bf7b69e6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1a20e828-2c47-4f99-a050-6f045d1eb35c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_99eae6bd-40a6-4c26-a206-9b2bf7b69e6c" xlink:to="loc_srt_RangeMember_1a20e828-2c47-4f99-a050-6f045d1eb35c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_9667f2a1-b294-4205-9cfb-f1e7409cabc5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1a20e828-2c47-4f99-a050-6f045d1eb35c" xlink:to="loc_srt_WeightedAverageMember_9667f2a1-b294-4205-9cfb-f1e7409cabc5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ea88452c-c474-4851-b81e-52e9241c82a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2a50da1d-6067-49b5-a046-332bbbc52b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ea88452c-c474-4851-b81e-52e9241c82a5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2a50da1d-6067-49b5-a046-332bbbc52b94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d9a0be00-6d5d-4af2-9be2-de6ae5dfbff6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ea88452c-c474-4851-b81e-52e9241c82a5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d9a0be00-6d5d-4af2-9be2-de6ae5dfbff6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d12cb65c-6003-4479-9c9f-f34c1ecb9b34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d9a0be00-6d5d-4af2-9be2-de6ae5dfbff6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d12cb65c-6003-4479-9c9f-f34c1ecb9b34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d12cb65c-6003-4479-9c9f-f34c1ecb9b34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d12cb65c-6003-4479-9c9f-f34c1ecb9b34" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d12cb65c-6003-4479-9c9f-f34c1ecb9b34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_14e6537b-882a-4b75-ad2b-a93681649bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d12cb65c-6003-4479-9c9f-f34c1ecb9b34" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_14e6537b-882a-4b75-ad2b-a93681649bc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ab2cfb42-251f-48ba-a818-1db5c8e56d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_14e6537b-882a-4b75-ad2b-a93681649bc0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ab2cfb42-251f-48ba-a818-1db5c8e56d8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6bdb73c2-0f8e-446d-b0ba-b7e7f8c2cc83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_14e6537b-882a-4b75-ad2b-a93681649bc0" xlink:to="loc_us-gaap_WarrantMember_6bdb73c2-0f8e-446d-b0ba-b7e7f8c2cc83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_8eae1503-70b7-47b8-b306-ed749b528b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_14e6537b-882a-4b75-ad2b-a93681649bc0" xlink:to="loc_us-gaap_RestrictedStockMember_8eae1503-70b7-47b8-b306-ed749b528b62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockSubjectToPutRightMember_6d8a0d73-8218-44ba-9512-cae66410e38a" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockSubjectToPutRightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_14e6537b-882a-4b75-ad2b-a93681649bc0" xlink:to="loc_ck0001824293_StockSubjectToPutRightMember_6d8a0d73-8218-44ba-9512-cae66410e38a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNoteMember_718a5017-1e65-4ee9-90d4-f1aea861f56b" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_14e6537b-882a-4b75-ad2b-a93681649bc0" xlink:to="loc_ck0001824293_ConvertiblePromissoryNoteMember_718a5017-1e65-4ee9-90d4-f1aea861f56b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#MERGERWITHVALLONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_67720d10-9b74-4631-9ffd-17742c04a69e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_693ded60-ac85-4079-aab0-6d5bf1ef58a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67720d10-9b74-4631-9ffd-17742c04a69e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_693ded60-ac85-4079-aab0-6d5bf1ef58a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4fa3b946-3f41-4eda-a2b0-a49a98d70d75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67720d10-9b74-4631-9ffd-17742c04a69e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4fa3b946-3f41-4eda-a2b0-a49a98d70d75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockOwnershipPercentage_689b5773-eeb0-4ab4-a4a5-98cb3944c6f9" xlink:href="ck0001824293-20230930.xsd#ck0001824293_CommonStockOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67720d10-9b74-4631-9ffd-17742c04a69e" xlink:to="loc_ck0001824293_CommonStockOwnershipPercentage_689b5773-eeb0-4ab4-a4a5-98cb3944c6f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e4181ad6-b476-4abf-99aa-690cab408443" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67720d10-9b74-4631-9ffd-17742c04a69e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e4181ad6-b476-4abf-99aa-690cab408443" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_5a7b6367-6476-4047-be99-da35894d0d5a" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67720d10-9b74-4631-9ffd-17742c04a69e" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_5a7b6367-6476-4047-be99-da35894d0d5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f1de3b7-221b-40bc-aa6e-9d7b0cda821c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67720d10-9b74-4631-9ffd-17742c04a69e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f1de3b7-221b-40bc-aa6e-9d7b0cda821c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_65692dbf-88a1-4078-81f2-6f8905f560df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f1de3b7-221b-40bc-aa6e-9d7b0cda821c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_65692dbf-88a1-4078-81f2-6f8905f560df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_65692dbf-88a1-4078-81f2-6f8905f560df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_65692dbf-88a1-4078-81f2-6f8905f560df" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_65692dbf-88a1-4078-81f2-6f8905f560df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3cb7d7de-5f2c-461f-8285-cdbe83934563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_65692dbf-88a1-4078-81f2-6f8905f560df" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3cb7d7de-5f2c-461f-8285-cdbe83934563" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_e3a979c1-67d8-47f3-b553-93cf73f4f970" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3cb7d7de-5f2c-461f-8285-cdbe83934563" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_e3a979c1-67d8-47f3-b553-93cf73f4f970" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1d9196c2-2a34-4736-ba2e-35e4125ab202" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f1de3b7-221b-40bc-aa6e-9d7b0cda821c" xlink:to="loc_dei_LegalEntityAxis_1d9196c2-2a34-4736-ba2e-35e4125ab202" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1d9196c2-2a34-4736-ba2e-35e4125ab202_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1d9196c2-2a34-4736-ba2e-35e4125ab202" xlink:to="loc_dei_EntityDomain_1d9196c2-2a34-4736-ba2e-35e4125ab202_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_62d6f088-1903-46a1-ad2d-1f8522687431" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1d9196c2-2a34-4736-ba2e-35e4125ab202" xlink:to="loc_dei_EntityDomain_62d6f088-1903-46a1-ad2d-1f8522687431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_69610c52-d11e-4f65-94b7-f84ad1836d63" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PrivateGRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_62d6f088-1903-46a1-ad2d-1f8522687431" xlink:to="loc_ck0001824293_PrivateGRIMember_69610c52-d11e-4f65-94b7-f84ad1836d63" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_42af2a94-5ced-4da0-860a-fa4ec1acab42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b0c27afb-fa42-4be3-a70e-1086e658a36c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42af2a94-5ced-4da0-860a-fa4ec1acab42" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b0c27afb-fa42-4be3-a70e-1086e658a36c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_9ae619f5-3b25-40ca-b7fd-20777beee1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42af2a94-5ced-4da0-860a-fa4ec1acab42" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_9ae619f5-3b25-40ca-b7fd-20777beee1d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_09005793-ca59-4385-b634-dc0cea0a2d5e" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42af2a94-5ced-4da0-860a-fa4ec1acab42" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_09005793-ca59-4385-b634-dc0cea0a2d5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_81ea16ee-3bf1-4b09-8f90-7f0784c6145f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42af2a94-5ced-4da0-860a-fa4ec1acab42" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_81ea16ee-3bf1-4b09-8f90-7f0784c6145f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_984f8343-d4f1-45fd-86cd-7de1049ecd15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42af2a94-5ced-4da0-860a-fa4ec1acab42" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_984f8343-d4f1-45fd-86cd-7de1049ecd15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_4f9547ce-cb49-43e6-8af5-20246b9d26f8" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42af2a94-5ced-4da0-860a-fa4ec1acab42" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_4f9547ce-cb49-43e6-8af5-20246b9d26f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94f7ac95-2c53-4844-adf1-07202e795849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42af2a94-5ced-4da0-860a-fa4ec1acab42" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94f7ac95-2c53-4844-adf1-07202e795849" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_97826155-1c53-4e24-8377-281929be7325" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94f7ac95-2c53-4844-adf1-07202e795849" xlink:to="loc_dei_LegalEntityAxis_97826155-1c53-4e24-8377-281929be7325" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_97826155-1c53-4e24-8377-281929be7325_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_97826155-1c53-4e24-8377-281929be7325" xlink:to="loc_dei_EntityDomain_97826155-1c53-4e24-8377-281929be7325_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cc248170-787f-4cc8-9e22-45ccc9b62720" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_97826155-1c53-4e24-8377-281929be7325" xlink:to="loc_dei_EntityDomain_cc248170-787f-4cc8-9e22-45ccc9b62720" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_a67a4e86-ab2d-4b33-bcff-809ce403b027" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PrivateGRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_cc248170-787f-4cc8-9e22-45ccc9b62720" xlink:to="loc_ck0001824293_PrivateGRIMember_a67a4e86-ab2d-4b33-bcff-809ce403b027" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c00612dd-cdb4-4d17-ae16-61f237a6d309" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_5e390a26-55b0-4cb1-93fc-66ebaa144cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c00612dd-cdb4-4d17-ae16-61f237a6d309" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_5e390a26-55b0-4cb1-93fc-66ebaa144cd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_23018d93-27f0-4055-b54e-236413093b29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c00612dd-cdb4-4d17-ae16-61f237a6d309" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_23018d93-27f0-4055-b54e-236413093b29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0ded0de8-519d-4c94-a8c4-f41a52386777" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c00612dd-cdb4-4d17-ae16-61f237a6d309" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0ded0de8-519d-4c94-a8c4-f41a52386777" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b96d6564-e579-4bf2-9485-c1bb54765ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0ded0de8-519d-4c94-a8c4-f41a52386777" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b96d6564-e579-4bf2-9485-c1bb54765ea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b96d6564-e579-4bf2-9485-c1bb54765ea6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b96d6564-e579-4bf2-9485-c1bb54765ea6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b96d6564-e579-4bf2-9485-c1bb54765ea6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6d5a56c-f012-4666-afe7-e975f806e36b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b96d6564-e579-4bf2-9485-c1bb54765ea6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6d5a56c-f012-4666-afe7-e975f806e36b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3b79b622-8096-40ba-926c-31c01ae674ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6d5a56c-f012-4666-afe7-e975f806e36b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3b79b622-8096-40ba-926c-31c01ae674ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0ab1eb66-7113-412e-a96e-b39c4a78fe39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6d5a56c-f012-4666-afe7-e975f806e36b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0ab1eb66-7113-412e-a96e-b39c4a78fe39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_366fbc03-79c8-4193-a56a-022c7aac8ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6d5a56c-f012-4666-afe7-e975f806e36b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_366fbc03-79c8-4193-a56a-022c7aac8ebf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#FAIRVALUEMEASUREMENTSScheduleofLiabilityMeasuredatEstimatedFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_40b89d81-6a9e-49fb-b40f-95b22da7b945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b0e38cab-3afa-4cfb-a375-3d6280959452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_40b89d81-6a9e-49fb-b40f-95b22da7b945" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b0e38cab-3afa-4cfb-a375-3d6280959452" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2f0b3cf1-7795-40f7-b670-d43ef8e15ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_40b89d81-6a9e-49fb-b40f-95b22da7b945" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2f0b3cf1-7795-40f7-b670-d43ef8e15ed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_96b44ff4-117e-4297-b387-eea86854b780" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e744c4fe-fc79-4317-8dfb-ad13dc465804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_40b89d81-6a9e-49fb-b40f-95b22da7b945" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e744c4fe-fc79-4317-8dfb-ad13dc465804" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_12b0249f-6f4f-4be1-ae9c-487161e45239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e744c4fe-fc79-4317-8dfb-ad13dc465804" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_12b0249f-6f4f-4be1-ae9c-487161e45239" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_12b0249f-6f4f-4be1-ae9c-487161e45239_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_12b0249f-6f4f-4be1-ae9c-487161e45239" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_12b0249f-6f4f-4be1-ae9c-487161e45239_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b317e3e5-1023-406e-96db-0448fa4c64b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_12b0249f-6f4f-4be1-ae9c-487161e45239" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b317e3e5-1023-406e-96db-0448fa4c64b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityMember_0894488b-8204-4f9c-bb26-fdfc55814da6" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b317e3e5-1023-406e-96db-0448fa4c64b8" xlink:to="loc_ck0001824293_WarrantLiabilityMember_0894488b-8204-4f9c-bb26-fdfc55814da6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81fb3eb8-16d4-4b33-8df0-b40e85018ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_8e025787-6d8e-4a6e-939d-7cd49ce9381f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81fb3eb8-16d4-4b33-8df0-b40e85018ad0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_8e025787-6d8e-4a6e-939d-7cd49ce9381f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_45216b2b-e0d0-4941-a005-e6bbf9a826f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81fb3eb8-16d4-4b33-8df0-b40e85018ad0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_45216b2b-e0d0-4941-a005-e6bbf9a826f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b8bee598-315a-45fa-bd1d-aa61ab3381e5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_45216b2b-e0d0-4941-a005-e6bbf9a826f1" xlink:to="loc_srt_RangeAxis_b8bee598-315a-45fa-bd1d-aa61ab3381e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b8bee598-315a-45fa-bd1d-aa61ab3381e5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b8bee598-315a-45fa-bd1d-aa61ab3381e5" xlink:to="loc_srt_RangeMember_b8bee598-315a-45fa-bd1d-aa61ab3381e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5bf15b89-de32-40c4-b503-169e56146480" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b8bee598-315a-45fa-bd1d-aa61ab3381e5" xlink:to="loc_srt_RangeMember_5bf15b89-de32-40c4-b503-169e56146480" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_573d8513-7d41-47a1-9779-358f7a8c9f07" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5bf15b89-de32-40c4-b503-169e56146480" xlink:to="loc_srt_WeightedAverageMember_573d8513-7d41-47a1-9779-358f7a8c9f07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_ef546831-48f8-4207-95ff-0c16cbded13d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_45216b2b-e0d0-4941-a005-e6bbf9a826f1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_ef546831-48f8-4207-95ff-0c16cbded13d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_ef546831-48f8-4207-95ff-0c16cbded13d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ef546831-48f8-4207-95ff-0c16cbded13d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_ef546831-48f8-4207-95ff-0c16cbded13d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0e752276-38b6-4f07-a54d-662b5a8e488c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ef546831-48f8-4207-95ff-0c16cbded13d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0e752276-38b6-4f07-a54d-662b5a8e488c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_74bc0b25-3ae4-4928-bf17-4f392e17f488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0e752276-38b6-4f07-a54d-662b5a8e488c" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_74bc0b25-3ae4-4928-bf17-4f392e17f488" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_2b35f1fb-42bb-4737-90f6-aeaf6994d59e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0e752276-38b6-4f07-a54d-662b5a8e488c" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_2b35f1fb-42bb-4737-90f6-aeaf6994d59e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_e85d23d4-b586-4bda-a26a-f07ece6d7c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0e752276-38b6-4f07-a54d-662b5a8e488c" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_e85d23d4-b586-4bda-a26a-f07ece6d7c8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_feb8e9ff-20cb-47c0-99c0-37a44288816c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0e752276-38b6-4f07-a54d-662b5a8e488c" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_feb8e9ff-20cb-47c0-99c0-37a44288816c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f38ccb35-f97c-460a-ac55-77dd77b639c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_38d93fd9-4e95-4881-af00-0c7ca6a3c1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f38ccb35-f97c-460a-ac55-77dd77b639c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_38d93fd9-4e95-4881-af00-0c7ca6a3c1cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ed62249f-4601-49ec-91de-ce2eaec63f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f38ccb35-f97c-460a-ac55-77dd77b639c4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ed62249f-4601-49ec-91de-ce2eaec63f7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_838a40e0-2648-4196-8ca7-9fa64600662c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f38ccb35-f97c-460a-ac55-77dd77b639c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_838a40e0-2648-4196-8ca7-9fa64600662c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2d33b11-57a7-4863-a0c9-1fa1e2f5445b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f38ccb35-f97c-460a-ac55-77dd77b639c4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2d33b11-57a7-4863-a0c9-1fa1e2f5445b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_10507686-b8f1-4584-8b5c-1a7b2fda0ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2d33b11-57a7-4863-a0c9-1fa1e2f5445b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_10507686-b8f1-4584-8b5c-1a7b2fda0ed5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_10507686-b8f1-4584-8b5c-1a7b2fda0ed5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_10507686-b8f1-4584-8b5c-1a7b2fda0ed5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_10507686-b8f1-4584-8b5c-1a7b2fda0ed5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1bc77b6d-f6b8-4464-9c28-2d2de4ea7d39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_10507686-b8f1-4584-8b5c-1a7b2fda0ed5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1bc77b6d-f6b8-4464-9c28-2d2de4ea7d39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_44526712-3b62-4727-a80b-62484a423674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1bc77b6d-f6b8-4464-9c28-2d2de4ea7d39" xlink:to="loc_us-gaap_ComputerEquipmentMember_44526712-3b62-4727-a80b-62484a423674" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d23af8ac-ba00-472d-92fc-732c10110409" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1bc77b6d-f6b8-4464-9c28-2d2de4ea7d39" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d23af8ac-ba00-472d-92fc-732c10110409" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#PROMISSORYNOTESBridgeFinancingDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a0c041fd-e31f-4816-bb7b-7ec110a62243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a0c041fd-e31f-4816-bb7b-7ec110a62243" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice_cfa803f2-3f27-4280-8fff-ec1f03e6dffe" xlink:href="ck0001824293-20230930.xsd#ck0001824293_DebtInstrumentAggregatePurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice_cfa803f2-3f27-4280-8fff-ec1f03e6dffe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentNumberOfClosings_0b2a35e4-ed87-4c32-a505-8b34616f4c6c" xlink:href="ck0001824293-20230930.xsd#ck0001824293_DebtInstrumentNumberOfClosings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_ck0001824293_DebtInstrumentNumberOfClosings_0b2a35e4-ed87-4c32-a505-8b34616f4c6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f51bcf6e-a5e5-4e59-a8ca-e5cedac77dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f51bcf6e-a5e5-4e59-a8ca-e5cedac77dfe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b81ff975-a831-4676-a832-edc887febad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b81ff975-a831-4676-a832-edc887febad3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_17d6a8b9-9362-43e3-be6e-be77f2ea4f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_17d6a8b9-9362-43e3-be6e-be77f2ea4f51" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_45d635cd-a94a-4369-9f21-80b725403d42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_45d635cd-a94a-4369-9f21-80b725403d42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_95180bb1-4e74-4aa1-804e-28bb0081881e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_95180bb1-4e74-4aa1-804e-28bb0081881e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_58c88865-4c9b-47f7-859f-5a35531cb5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_58c88865-4c9b-47f7-859f-5a35531cb5b5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d9e582c8-1762-46b9-bb57-c7d64377c5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d9e582c8-1762-46b9-bb57-c7d64377c5bf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b6a6175d-5f94-439a-be5f-6f594b50e033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b6a6175d-5f94-439a-be5f-6f594b50e033" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a07c4c12-e058-4028-8513-af104ca2e039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_DebtInstrumentTable_a07c4c12-e058-4028-8513-af104ca2e039" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f4199454-9de9-4f44-bce3-008d4b9c7ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a07c4c12-e058-4028-8513-af104ca2e039" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f4199454-9de9-4f44-bce3-008d4b9c7ae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f4199454-9de9-4f44-bce3-008d4b9c7ae4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f4199454-9de9-4f44-bce3-008d4b9c7ae4" xlink:to="loc_us-gaap_RelatedPartyDomain_f4199454-9de9-4f44-bce3-008d4b9c7ae4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e873ee0f-6c99-422a-b160-5f6a54295882" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f4199454-9de9-4f44-bce3-008d4b9c7ae4" xlink:to="loc_us-gaap_RelatedPartyDomain_e873ee0f-6c99-422a-b160-5f6a54295882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_5cd061b8-101f-4c9e-98e0-ed8a6c003d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e873ee0f-6c99-422a-b160-5f6a54295882" xlink:to="loc_us-gaap_InvestorMember_5cd061b8-101f-4c9e-98e0-ed8a6c003d85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_920ba22b-e134-453b-b942-081a2f3713d1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a07c4c12-e058-4028-8513-af104ca2e039" xlink:to="loc_dei_LegalEntityAxis_920ba22b-e134-453b-b942-081a2f3713d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_920ba22b-e134-453b-b942-081a2f3713d1_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_920ba22b-e134-453b-b942-081a2f3713d1" xlink:to="loc_dei_EntityDomain_920ba22b-e134-453b-b942-081a2f3713d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e509e30f-489e-4595-897d-1a70ead6a775" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_920ba22b-e134-453b-b942-081a2f3713d1" xlink:to="loc_dei_EntityDomain_e509e30f-489e-4595-897d-1a70ead6a775" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_0806b1c9-35cf-4bef-9be4-cd6697ddf80f" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PrivateGRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e509e30f-489e-4595-897d-1a70ead6a775" xlink:to="loc_ck0001824293_PrivateGRIMember_0806b1c9-35cf-4bef-9be4-cd6697ddf80f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3b3596d7-ed4c-4ebf-b962-181908830b96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a07c4c12-e058-4028-8513-af104ca2e039" xlink:to="loc_us-gaap_DebtInstrumentAxis_3b3596d7-ed4c-4ebf-b962-181908830b96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3b3596d7-ed4c-4ebf-b962-181908830b96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3b3596d7-ed4c-4ebf-b962-181908830b96" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3b3596d7-ed4c-4ebf-b962-181908830b96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2eab3442-2d23-4c86-acd1-95065546fd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3b3596d7-ed4c-4ebf-b962-181908830b96" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2eab3442-2d23-4c86-acd1-95065546fd9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_190fd1c6-46ab-4aac-a1af-ec4262f647fe" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BridgeSecuritiesPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2eab3442-2d23-4c86-acd1-95065546fd9c" xlink:to="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_190fd1c6-46ab-4aac-a1af-ec4262f647fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_e406160f-c1dd-49e9-b4c3-0dd42c9fb770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a07c4c12-e058-4028-8513-af104ca2e039" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_e406160f-c1dd-49e9-b4c3-0dd42c9fb770" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_e406160f-c1dd-49e9-b4c3-0dd42c9fb770_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e406160f-c1dd-49e9-b4c3-0dd42c9fb770" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_e406160f-c1dd-49e9-b4c3-0dd42c9fb770_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_61d95eac-0e7c-4b8f-a6fd-072c9304c0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e406160f-c1dd-49e9-b4c3-0dd42c9fb770" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_61d95eac-0e7c-4b8f-a6fd-072c9304c0fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeWarrantsMember_af706131-99bc-4545-8a47-4cafd857db06" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BridgeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_61d95eac-0e7c-4b8f-a6fd-072c9304c0fd" xlink:to="loc_ck0001824293_BridgeWarrantsMember_af706131-99bc-4545-8a47-4cafd857db06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_89be39c3-e0fb-46ef-b5b1-3493adb31e9b" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_61d95eac-0e7c-4b8f-a6fd-072c9304c0fd" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_89be39c3-e0fb-46ef-b5b1-3493adb31e9b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#PROMISSORYNOTESTEPNoteDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_963b7e84-fdfb-4d64-b4df-3e0cf9e067f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_963b7e84-fdfb-4d64-b4df-3e0cf9e067f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_402540e6-11d5-473b-ad59-0ae6c7b9269c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_402540e6-11d5-473b-ad59-0ae6c7b9269c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7f8e4526-ea4a-4852-b99e-8b65e30e4ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7f8e4526-ea4a-4852-b99e-8b65e30e4ebb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1101c825-66ff-49a4-8ac4-a9fcdd88e922" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1101c825-66ff-49a4-8ac4-a9fcdd88e922" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_b23989d0-35b6-42d2-ad87-4228b2c63602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_b23989d0-35b6-42d2-ad87-4228b2c63602" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_34824e5c-f595-477c-80c3-54f16ecc505c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_CommonStockSharesIssued_34824e5c-f595-477c-80c3-54f16ecc505c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CallOptionPrice_89633622-b8f4-4a41-a669-589c1dd9212d" xlink:href="ck0001824293-20230930.xsd#ck0001824293_CallOptionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_ck0001824293_CallOptionPrice_89633622-b8f4-4a41-a669-589c1dd9212d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt_b14775ac-dcbf-4347-b920-578355a15cb3" xlink:href="ck0001824293-20230930.xsd#ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt_b14775ac-dcbf-4347-b920-578355a15cb3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest_8dc7ddba-2cca-4e0d-8d73-93befa26043b" xlink:href="ck0001824293-20230930.xsd#ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest_8dc7ddba-2cca-4e0d-8d73-93befa26043b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion_f32e43a7-775b-4a26-be42-2ef3b50cfef1" xlink:href="ck0001824293-20230930.xsd#ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion_f32e43a7-775b-4a26-be42-2ef3b50cfef1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_15afd1c2-add2-4915-be65-e7040b36742e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_15afd1c2-add2-4915-be65-e7040b36742e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_7d062d29-2fbe-449f-9548-c5afe607a99c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_7d062d29-2fbe-449f-9548-c5afe607a99c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_015257d8-2d70-4112-8b1f-124aac37ed70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_015257d8-2d70-4112-8b1f-124aac37ed70" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_LongTermDebtIncludingInterest_604d59c6-50eb-4f4d-845b-7c88a1b06baf" xlink:href="ck0001824293-20230930.xsd#ck0001824293_LongTermDebtIncludingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_ck0001824293_LongTermDebtIncludingInterest_604d59c6-50eb-4f4d-845b-7c88a1b06baf" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2a1b4b6b-1409-4f4f-a6e2-0b3222c570b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2a1b4b6b-1409-4f4f-a6e2-0b3222c570b3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_8397e269-f42b-4144-bd08-cb64e9dd4ede" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_8397e269-f42b-4144-bd08-cb64e9dd4ede" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_f9f79fb4-5184-4b4e-a4cf-a55bfdaab4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_f9f79fb4-5184-4b4e-a4cf-a55bfdaab4c9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedInterestForfeited_a43e3fc2-244c-419f-97f4-44dbf711f76f" xlink:href="ck0001824293-20230930.xsd#ck0001824293_AccruedInterestForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_ck0001824293_AccruedInterestForfeited_a43e3fc2-244c-419f-97f4-44dbf711f76f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseBorrowings_f9f08453-b268-49e4-9846-8441cfc012e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_InterestExpenseBorrowings_f9f08453-b268-49e4-9846-8441cfc012e8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_00a8c218-6527-4512-a37c-527b96d5cd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_DebtInstrumentTable_00a8c218-6527-4512-a37c-527b96d5cd0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_14ca3ac9-7acf-4446-998b-cab0162843e0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_00a8c218-6527-4512-a37c-527b96d5cd0d" xlink:to="loc_dei_LegalEntityAxis_14ca3ac9-7acf-4446-998b-cab0162843e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_14ca3ac9-7acf-4446-998b-cab0162843e0_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_14ca3ac9-7acf-4446-998b-cab0162843e0" xlink:to="loc_dei_EntityDomain_14ca3ac9-7acf-4446-998b-cab0162843e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2c192c13-dc34-4294-a46f-8c59c55ea542" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_14ca3ac9-7acf-4446-998b-cab0162843e0" xlink:to="loc_dei_EntityDomain_2c192c13-dc34-4294-a46f-8c59c55ea542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_3a7dfe76-3d5f-4475-b876-19b19ec44dfb" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PrivateGRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2c192c13-dc34-4294-a46f-8c59c55ea542" xlink:to="loc_ck0001824293_PrivateGRIMember_3a7dfe76-3d5f-4475-b876-19b19ec44dfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1aae2b78-a9b4-47f9-a24a-0b3f8df17299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_00a8c218-6527-4512-a37c-527b96d5cd0d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1aae2b78-a9b4-47f9-a24a-0b3f8df17299" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1aae2b78-a9b4-47f9-a24a-0b3f8df17299_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1aae2b78-a9b4-47f9-a24a-0b3f8df17299" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1aae2b78-a9b4-47f9-a24a-0b3f8df17299_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6a31c8dc-accd-4fb8-96dd-b15c008ef213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1aae2b78-a9b4-47f9-a24a-0b3f8df17299" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6a31c8dc-accd-4fb8-96dd-b15c008ef213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_bfc9f589-68dc-41bb-aee0-046cd24b2d15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6a31c8dc-accd-4fb8-96dd-b15c008ef213" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_bfc9f589-68dc-41bb-aee0-046cd24b2d15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1260d597-ace1-4baa-ac6d-db460315ab30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_00a8c218-6527-4512-a37c-527b96d5cd0d" xlink:to="loc_us-gaap_DebtInstrumentAxis_1260d597-ace1-4baa-ac6d-db460315ab30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1260d597-ace1-4baa-ac6d-db460315ab30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1260d597-ace1-4baa-ac6d-db460315ab30" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1260d597-ace1-4baa-ac6d-db460315ab30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_936b8527-2b98-4634-98e1-46cf1bd9c8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1260d597-ace1-4baa-ac6d-db460315ab30" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_936b8527-2b98-4634-98e1-46cf1bd9c8bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_TEPNoteMember_59948fcc-2a4b-4b20-9761-ba2d9913946f" xlink:href="ck0001824293-20230930.xsd#ck0001824293_TEPNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_936b8527-2b98-4634-98e1-46cf1bd9c8bd" xlink:to="loc_ck0001824293_TEPNoteMember_59948fcc-2a4b-4b20-9761-ba2d9913946f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_83ede335-bae3-4410-a3c4-9a0592358835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_00a8c218-6527-4512-a37c-527b96d5cd0d" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_83ede335-bae3-4410-a3c4-9a0592358835" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_83ede335-bae3-4410-a3c4-9a0592358835_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_83ede335-bae3-4410-a3c4-9a0592358835" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_83ede335-bae3-4410-a3c4-9a0592358835_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_77f8f386-f5be-43a9-85e0-65218e992082" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_83ede335-bae3-4410-a3c4-9a0592358835" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_77f8f386-f5be-43a9-85e0-65218e992082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember_1270e8e6-dd1a-40eb-be3f-51df37991de1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_77f8f386-f5be-43a9-85e0-65218e992082" xlink:to="loc_us-gaap_CallOptionMember_1270e8e6-dd1a-40eb-be3f-51df37991de1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_6967b182-6351-4732-94bd-57d2ffd7a6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_6967b182-6351-4732-94bd-57d2ffd7a6b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_33785847-ab31-4728-8fa6-c86cafd35ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_CommonStockSharesIssued_33785847-ab31-4728-8fa6-c86cafd35ea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_430f7516-c501-4c21-b49e-375938b70b57" xlink:href="ck0001824293-20230930.xsd#ck0001824293_CommonStockHeldIntoEscrowAccount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_430f7516-c501-4c21-b49e-375938b70b57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_022add15-76a8-4f28-b4d2-8c03ed32ec08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_022add15-76a8-4f28-b4d2-8c03ed32ec08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_5d801bf7-02aa-4239-9476-1c45411c5f22" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_5d801bf7-02aa-4239-9476-1c45411c5f22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_a2ad93f7-0aaf-4186-8798-c7291d1c237c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_a2ad93f7-0aaf-4186-8798-c7291d1c237c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_1512d857-8736-4887-90f0-f083eaa3801c" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_1512d857-8736-4887-90f0-f083eaa3801c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PutOptionSharePrice_81d3b773-ecf1-4f1e-86da-0045281d8851" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PutOptionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_ck0001824293_PutOptionSharePrice_81d3b773-ecf1-4f1e-86da-0045281d8851" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_95446332-74ca-4464-a73b-b4eee7dcfe05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_95446332-74ca-4464-a73b-b4eee7dcfe05" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_d418dd6f-c61e-47fc-b859-ad41ede8c158" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_d418dd6f-c61e-47fc-b859-ad41ede8c158" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_b5e22e84-f0a0-4155-94e7-1ebc77dff1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_b5e22e84-f0a0-4155-94e7-1ebc77dff1fb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4664bc7e-2424-4ebc-a58c-f388dc8573f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4664bc7e-2424-4ebc-a58c-f388dc8573f3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7611f69a-b03f-440e-9877-08d9ba21b889" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7611f69a-b03f-440e-9877-08d9ba21b889" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_17a52b93-31ef-4eff-b0b7-c6872f5345c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_17a52b93-31ef-4eff-b0b7-c6872f5345c5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_14f1d18f-ccf3-4466-b4ec-aaad43979f54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_14f1d18f-ccf3-4466-b4ec-aaad43979f54" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_a113d7d4-8351-4798-ada4-17b39a41b7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_a113d7d4-8351-4798-ada4-17b39a41b7d5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6bf84a8b-8346-411d-956a-2a656c4a5f85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6bf84a8b-8346-411d-956a-2a656c4a5f85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_72d9afe0-3d8b-41db-a5ea-7d1576286af2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6bf84a8b-8346-411d-956a-2a656c4a5f85" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_72d9afe0-3d8b-41db-a5ea-7d1576286af2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_72d9afe0-3d8b-41db-a5ea-7d1576286af2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_72d9afe0-3d8b-41db-a5ea-7d1576286af2" xlink:to="loc_us-gaap_RelatedPartyDomain_72d9afe0-3d8b-41db-a5ea-7d1576286af2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_546d072e-a1ad-4fd0-84be-b213cb15608e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_72d9afe0-3d8b-41db-a5ea-7d1576286af2" xlink:to="loc_us-gaap_RelatedPartyDomain_546d072e-a1ad-4fd0-84be-b213cb15608e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_4a279f57-bec6-4e68-9a74-416beb853f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_546d072e-a1ad-4fd0-84be-b213cb15608e" xlink:to="loc_us-gaap_InvestorMember_4a279f57-bec6-4e68-9a74-416beb853f5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_43b4f144-ffc0-4c64-81ac-f87969a56884" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6bf84a8b-8346-411d-956a-2a656c4a5f85" xlink:to="loc_dei_LegalEntityAxis_43b4f144-ffc0-4c64-81ac-f87969a56884" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_43b4f144-ffc0-4c64-81ac-f87969a56884_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_43b4f144-ffc0-4c64-81ac-f87969a56884" xlink:to="loc_dei_EntityDomain_43b4f144-ffc0-4c64-81ac-f87969a56884_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fed44b1d-5b22-4702-9b55-48a65ea29d98" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_43b4f144-ffc0-4c64-81ac-f87969a56884" xlink:to="loc_dei_EntityDomain_fed44b1d-5b22-4702-9b55-48a65ea29d98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_19ab512c-e0a4-4afb-b991-f9693b499ce6" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PrivateGRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_fed44b1d-5b22-4702-9b55-48a65ea29d98" xlink:to="loc_ck0001824293_PrivateGRIMember_19ab512c-e0a4-4afb-b991-f9693b499ce6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7381f845-6f54-4ea0-b83d-dbd73d868963" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6bf84a8b-8346-411d-956a-2a656c4a5f85" xlink:to="loc_srt_CounterpartyNameAxis_7381f845-6f54-4ea0-b83d-dbd73d868963" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7381f845-6f54-4ea0-b83d-dbd73d868963_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7381f845-6f54-4ea0-b83d-dbd73d868963" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7381f845-6f54-4ea0-b83d-dbd73d868963_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88f6dfee-582e-4523-b5ca-218c1a1f90b8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7381f845-6f54-4ea0-b83d-dbd73d868963" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88f6dfee-582e-4523-b5ca-218c1a1f90b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIBioIncMember_f2469fa8-b673-4805-95ed-1f37a3ce2440" xlink:href="ck0001824293-20230930.xsd#ck0001824293_GRIBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88f6dfee-582e-4523-b5ca-218c1a1f90b8" xlink:to="loc_ck0001824293_GRIBioIncMember_f2469fa8-b673-4805-95ed-1f37a3ce2440" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_751f41c7-4e3a-40d4-be94-c4cac8213eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6bf84a8b-8346-411d-956a-2a656c4a5f85" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_751f41c7-4e3a-40d4-be94-c4cac8213eaf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_751f41c7-4e3a-40d4-be94-c4cac8213eaf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_751f41c7-4e3a-40d4-be94-c4cac8213eaf" xlink:to="loc_us-gaap_EquityComponentDomain_751f41c7-4e3a-40d4-be94-c4cac8213eaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a2112b41-9941-407d-9049-2c1f1159fa2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_751f41c7-4e3a-40d4-be94-c4cac8213eaf" xlink:to="loc_us-gaap_EquityComponentDomain_a2112b41-9941-407d-9049-2c1f1159fa2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f896f222-22fd-4472-9e5b-fc99d84df0de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a2112b41-9941-407d-9049-2c1f1159fa2b" xlink:to="loc_us-gaap_CommonStockMember_f896f222-22fd-4472-9e5b-fc99d84df0de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8ed14f2f-fe02-4b5b-aef2-f2e061509d34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a2112b41-9941-407d-9049-2c1f1159fa2b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8ed14f2f-fe02-4b5b-aef2-f2e061509d34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_8a85ce5f-df7b-4357-a282-5c9e36008f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6bf84a8b-8346-411d-956a-2a656c4a5f85" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_8a85ce5f-df7b-4357-a282-5c9e36008f7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_8a85ce5f-df7b-4357-a282-5c9e36008f7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_8a85ce5f-df7b-4357-a282-5c9e36008f7c" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_8a85ce5f-df7b-4357-a282-5c9e36008f7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_08051a9d-2e8e-4072-8865-3747dc87ca1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_8a85ce5f-df7b-4357-a282-5c9e36008f7c" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_08051a9d-2e8e-4072-8865-3747dc87ca1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember_07e714e3-8538-42eb-a7f3-49c3aeead78e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PutOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_08051a9d-2e8e-4072-8865-3747dc87ca1a" xlink:to="loc_us-gaap_PutOptionMember_07e714e3-8538-42eb-a7f3-49c3aeead78e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f8247183-d662-48d3-9f9e-1af6efd81820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6bf84a8b-8346-411d-956a-2a656c4a5f85" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f8247183-d662-48d3-9f9e-1af6efd81820" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f8247183-d662-48d3-9f9e-1af6efd81820_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f8247183-d662-48d3-9f9e-1af6efd81820" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f8247183-d662-48d3-9f9e-1af6efd81820_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a18b63f8-361e-4c03-9ec3-99b4cf9ad1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f8247183-d662-48d3-9f9e-1af6efd81820" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a18b63f8-361e-4c03-9ec3-99b4cf9ad1b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_EquityWarrantsMember_67b35ad4-319f-44ca-85ce-62a822028b26" xlink:href="ck0001824293-20230930.xsd#ck0001824293_EquityWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a18b63f8-361e-4c03-9ec3-99b4cf9ad1b3" xlink:to="loc_ck0001824293_EquityWarrantsMember_67b35ad4-319f-44ca-85ce-62a822028b26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember_b6a7a1b6-13a7-4453-9a3a-b1fa98d22f87" xlink:href="ck0001824293-20230930.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ck0001824293_EquityWarrantsMember_67b35ad4-319f-44ca-85ce-62a822028b26" xlink:to="loc_ck0001824293_SeriesA1WarrantsMember_b6a7a1b6-13a7-4453-9a3a-b1fa98d22f87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA2WarrantsMember_a82b084d-1521-4e70-b809-a82e5b7c66f3" xlink:href="ck0001824293-20230930.xsd#ck0001824293_SeriesA2WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ck0001824293_EquityWarrantsMember_67b35ad4-319f-44ca-85ce-62a822028b26" xlink:to="loc_ck0001824293_SeriesA2WarrantsMember_a82b084d-1521-4e70-b809-a82e5b7c66f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesTWarrantsMember_e0536b1d-4939-4bb7-9aee-52adf9cb7179" xlink:href="ck0001824293-20230930.xsd#ck0001824293_SeriesTWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a18b63f8-361e-4c03-9ec3-99b4cf9ad1b3" xlink:to="loc_ck0001824293_SeriesTWarrantsMember_e0536b1d-4939-4bb7-9aee-52adf9cb7179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeWarrantsMember_85f985cc-354c-461c-bdd2-f741e3a38666" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BridgeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a18b63f8-361e-4c03-9ec3-99b4cf9ad1b3" xlink:to="loc_ck0001824293_BridgeWarrantsMember_85f985cc-354c-461c-bdd2-f741e3a38666" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_8eaf95b1-a345-4592-b837-4212e6526fb2" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a18b63f8-361e-4c03-9ec3-99b4cf9ad1b3" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_8eaf95b1-a345-4592-b837-4212e6526fb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BankerWarrantsMember_5ed829ae-c5ab-4fe0-93c0-d0972695b18e" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BankerWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a18b63f8-361e-4c03-9ec3-99b4cf9ad1b3" xlink:to="loc_ck0001824293_BankerWarrantsMember_5ed829ae-c5ab-4fe0-93c0-d0972695b18e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c1a02d0b-382e-4f24-92c1-8b5c7c80ef2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_b3522866-1f28-47e0-b43d-83c35742506f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a02d0b-382e-4f24-92c1-8b5c7c80ef2a" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_b3522866-1f28-47e0-b43d-83c35742506f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b2e8e596-0751-4d6b-93c2-fbcc28097563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a02d0b-382e-4f24-92c1-8b5c7c80ef2a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b2e8e596-0751-4d6b-93c2-fbcc28097563" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3450b25e-e916-445f-9d7b-66d1aa2c3803" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b2e8e596-0751-4d6b-93c2-fbcc28097563" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3450b25e-e916-445f-9d7b-66d1aa2c3803" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3450b25e-e916-445f-9d7b-66d1aa2c3803_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3450b25e-e916-445f-9d7b-66d1aa2c3803" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3450b25e-e916-445f-9d7b-66d1aa2c3803_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_47787f8f-826a-46dc-8b2f-0002bd2006b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3450b25e-e916-445f-9d7b-66d1aa2c3803" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_47787f8f-826a-46dc-8b2f-0002bd2006b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember_57d2fdcf-5748-4868-b173-c13a77149e6d" xlink:href="ck0001824293-20230930.xsd#ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_47787f8f-826a-46dc-8b2f-0002bd2006b6" xlink:to="loc_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember_57d2fdcf-5748-4868-b173-c13a77149e6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_072592ba-53ef-44b2-b5a4-b71120fb84bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b2e8e596-0751-4d6b-93c2-fbcc28097563" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_072592ba-53ef-44b2-b5a4-b71120fb84bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_072592ba-53ef-44b2-b5a4-b71120fb84bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_072592ba-53ef-44b2-b5a4-b71120fb84bd" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_072592ba-53ef-44b2-b5a4-b71120fb84bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8fe797f7-121e-43d0-ac35-4fadeedf5a02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_072592ba-53ef-44b2-b5a4-b71120fb84bd" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8fe797f7-121e-43d0-ac35-4fadeedf5a02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_f3781f88-d28d-47c9-83af-c0d9818bb392" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8fe797f7-121e-43d0-ac35-4fadeedf5a02" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_f3781f88-d28d-47c9-83af-c0d9818bb392" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_7c635711-5230-4ebc-ab7e-74d285cbb7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8fe797f7-121e-43d0-ac35-4fadeedf5a02" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_7c635711-5230-4ebc-ab7e-74d285cbb7ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_2c4cc43a-5c3d-4e3f-8ce2-de82450c407f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8fe797f7-121e-43d0-ac35-4fadeedf5a02" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_2c4cc43a-5c3d-4e3f-8ce2-de82450c407f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_a4643f82-fece-46c3-9ac6-54686ef57be3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8fe797f7-121e-43d0-ac35-4fadeedf5a02" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_a4643f82-fece-46c3-9ac6-54686ef57be3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cea1b18f-15ea-45c8-81e1-7c9b7f0f89d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b2e8e596-0751-4d6b-93c2-fbcc28097563" xlink:to="loc_srt_RangeAxis_cea1b18f-15ea-45c8-81e1-7c9b7f0f89d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cea1b18f-15ea-45c8-81e1-7c9b7f0f89d3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cea1b18f-15ea-45c8-81e1-7c9b7f0f89d3" xlink:to="loc_srt_RangeMember_cea1b18f-15ea-45c8-81e1-7c9b7f0f89d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e72b6812-7768-46e4-b49a-caa5440b3f71" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cea1b18f-15ea-45c8-81e1-7c9b7f0f89d3" xlink:to="loc_srt_RangeMember_e72b6812-7768-46e4-b49a-caa5440b3f71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_77698350-e16a-4532-b616-9daaa5025650" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e72b6812-7768-46e4-b49a-caa5440b3f71" xlink:to="loc_srt_WeightedAverageMember_77698350-e16a-4532-b616-9daaa5025650" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a65a171e-c988-4d04-89f9-a689d139584b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_79fc36e6-0925-46be-9e86-54e1f79f83dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a65a171e-c988-4d04-89f9-a689d139584b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_79fc36e6-0925-46be-9e86-54e1f79f83dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_65a36066-8466-4584-bb12-7528109cd3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a65a171e-c988-4d04-89f9-a689d139584b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_65a36066-8466-4584-bb12-7528109cd3b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantOrRightExpirationPeriod_7e8a5770-ca4b-44a3-b763-b5d40633bec9" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a65a171e-c988-4d04-89f9-a689d139584b" xlink:to="loc_ck0001824293_ClassOfWarrantOrRightExpirationPeriod_7e8a5770-ca4b-44a3-b763-b5d40633bec9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b187c4c5-d0e0-422b-b4e6-35c92dc3a552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_a65a171e-c988-4d04-89f9-a689d139584b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b187c4c5-d0e0-422b-b4e6-35c92dc3a552" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4da1bd64-4187-417d-aa30-64fb5ffd60f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b187c4c5-d0e0-422b-b4e6-35c92dc3a552" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4da1bd64-4187-417d-aa30-64fb5ffd60f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4da1bd64-4187-417d-aa30-64fb5ffd60f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4da1bd64-4187-417d-aa30-64fb5ffd60f8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4da1bd64-4187-417d-aa30-64fb5ffd60f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4da1bd64-4187-417d-aa30-64fb5ffd60f8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInNovember2023Member_462a9c11-a54a-4d2a-8b45-c2ac5a7ef1a3" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInNovember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringInNovember2023Member_462a9c11-a54a-4d2a-8b45-c2ac5a7ef1a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInDecember2023Member_f8ada7b7-fac1-4c4d-a78e-ce77e5d6c5dd" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInDecember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringInDecember2023Member_f8ada7b7-fac1-4c4d-a78e-ce77e5d6c5dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJune2025Member_47706480-0c32-406e-a843-b623011e2f0a" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringInJune2025Member_47706480-0c32-406e-a843-b623011e2f0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_5c198a69-90d7-4aa6-89ba-375efbd7a67d" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInFebruary2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_5c198a69-90d7-4aa6-89ba-375efbd7a67d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMay2027Member_3ef54d23-dce7-49c4-ada0-569f01cc9017" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringInMay2027Member_3ef54d23-dce7-49c4-ada0-569f01cc9017" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJuly2027Member_6f64450f-99e2-4eaf-bdf9-a9f78c638536" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInJuly2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringInJuly2027Member_6f64450f-99e2-4eaf-bdf9-a9f78c638536" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2028Member_9a01c59d-fac9-4d5a-9fcb-762928bfc338" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInApril2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2028Member_9a01c59d-fac9-4d5a-9fcb-762928bfc338" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember_20d820af-a539-4594-b83e-19d480c06032" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember_20d820af-a539-4594-b83e-19d480c06032" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember_46717332-091c-4b3d-8cf6-985ba003ce6f" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember_46717332-091c-4b3d-8cf6-985ba003ce6f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember_645e321b-b1aa-4341-ad21-5e326682a1ad" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember_645e321b-b1aa-4341-ad21-5e326682a1ad" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#ASSETPURCHASEAGREEMENTDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c6b450f8-6155-4ac6-871f-d607c121076b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_69b3614c-2f09-46b2-b800-1dbccb620566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c6b450f8-6155-4ac6-871f-d607c121076b" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_69b3614c-2f09-46b2-b800-1dbccb620566" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8f56aa8c-1166-4d95-9546-6b329c2dee2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c6b450f8-6155-4ac6-871f-d607c121076b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8f56aa8c-1166-4d95-9546-6b329c2dee2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f35c24dd-d6c5-4d1b-b5cf-7b4a9699f5cc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8f56aa8c-1166-4d95-9546-6b329c2dee2d" xlink:to="loc_srt_CounterpartyNameAxis_f35c24dd-d6c5-4d1b-b5cf-7b4a9699f5cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f35c24dd-d6c5-4d1b-b5cf-7b4a9699f5cc_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f35c24dd-d6c5-4d1b-b5cf-7b4a9699f5cc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f35c24dd-d6c5-4d1b-b5cf-7b4a9699f5cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eef4e3b9-855a-49ea-ada7-c21678bfe2ea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f35c24dd-d6c5-4d1b-b5cf-7b4a9699f5cc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eef4e3b9-855a-49ea-ada7-c21678bfe2ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AardvarkTherapeuticsIncMember_86208478-e3be-4898-804a-14f854aa004d" xlink:href="ck0001824293-20230930.xsd#ck0001824293_AardvarkTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eef4e3b9-855a-49ea-ada7-c21678bfe2ea" xlink:to="loc_ck0001824293_AardvarkTherapeuticsIncMember_86208478-e3be-4898-804a-14f854aa004d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7fa915e8-62e5-4f6a-a913-68c38f96cffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ce25f392-8ec3-48e4-abe9-568e036e910b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7fa915e8-62e5-4f6a-a913-68c38f96cffe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ce25f392-8ec3-48e4-abe9-568e036e910b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3169d3ca-d46d-435a-829a-1a7f5945b340" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7fa915e8-62e5-4f6a-a913-68c38f96cffe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3169d3ca-d46d-435a-829a-1a7f5945b340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0e0bfe97-ffd3-474b-8e54-d6fe8895d720" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7fa915e8-62e5-4f6a-a913-68c38f96cffe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0e0bfe97-ffd3-474b-8e54-d6fe8895d720" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c740e34e-1b08-4c50-9388-8f6f59f768f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7fa915e8-62e5-4f6a-a913-68c38f96cffe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c740e34e-1b08-4c50-9388-8f6f59f768f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_36502d69-aa53-4237-bb50-180126005e89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7fa915e8-62e5-4f6a-a913-68c38f96cffe" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_36502d69-aa53-4237-bb50-180126005e89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_14dda011-5ceb-43cb-90d1-4e1e0b1aa1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7fa915e8-62e5-4f6a-a913-68c38f96cffe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_14dda011-5ceb-43cb-90d1-4e1e0b1aa1e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7e7c7742-16ff-45c3-9516-0f1126284742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7fa915e8-62e5-4f6a-a913-68c38f96cffe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7e7c7742-16ff-45c3-9516-0f1126284742" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29a4f4fa-fc6a-4d67-8bbc-daeb604c6e84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7fa915e8-62e5-4f6a-a913-68c38f96cffe" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29a4f4fa-fc6a-4d67-8bbc-daeb604c6e84" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9ba19067-6f87-49f9-9fb2-f8e1e9abc7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29a4f4fa-fc6a-4d67-8bbc-daeb604c6e84" xlink:to="loc_us-gaap_PlanNameAxis_9ba19067-6f87-49f9-9fb2-f8e1e9abc7e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9ba19067-6f87-49f9-9fb2-f8e1e9abc7e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9ba19067-6f87-49f9-9fb2-f8e1e9abc7e1" xlink:to="loc_us-gaap_PlanNameDomain_9ba19067-6f87-49f9-9fb2-f8e1e9abc7e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1f5fd5a1-e346-4a55-b3ec-da66bed34809" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9ba19067-6f87-49f9-9fb2-f8e1e9abc7e1" xlink:to="loc_us-gaap_PlanNameDomain_1f5fd5a1-e346-4a55-b3ec-da66bed34809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIPlanMember_72eb10ed-8834-4886-9d31-b5412d34dfd0" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PrivateGRIPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1f5fd5a1-e346-4a55-b3ec-da66bed34809" xlink:to="loc_ck0001824293_PrivateGRIPlanMember_72eb10ed-8834-4886-9d31-b5412d34dfd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_ca1f6a1f-9043-4530-a56c-982704159f04" xlink:href="ck0001824293-20230930.xsd#ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1f5fd5a1-e346-4a55-b3ec-da66bed34809" xlink:to="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_ca1f6a1f-9043-4530-a56c-982704159f04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_82941dc8-e2d9-401e-a538-5466943477dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29a4f4fa-fc6a-4d67-8bbc-daeb604c6e84" xlink:to="loc_us-gaap_AwardTypeAxis_82941dc8-e2d9-401e-a538-5466943477dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82941dc8-e2d9-401e-a538-5466943477dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_82941dc8-e2d9-401e-a538-5466943477dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82941dc8-e2d9-401e-a538-5466943477dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_089c440b-0020-44a9-8cca-caf0c51a897b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_82941dc8-e2d9-401e-a538-5466943477dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_089c440b-0020-44a9-8cca-caf0c51a897b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_647fc8cb-e525-489a-8fe7-0646e749ede3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_089c440b-0020-44a9-8cca-caf0c51a897b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_647fc8cb-e525-489a-8fe7-0646e749ede3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a5d3bde2-aaed-4516-8dbf-be8f5f362860" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29a4f4fa-fc6a-4d67-8bbc-daeb604c6e84" xlink:to="loc_srt_RangeAxis_a5d3bde2-aaed-4516-8dbf-be8f5f362860" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a5d3bde2-aaed-4516-8dbf-be8f5f362860_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a5d3bde2-aaed-4516-8dbf-be8f5f362860" xlink:to="loc_srt_RangeMember_a5d3bde2-aaed-4516-8dbf-be8f5f362860_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6c0ff67b-0f1e-491d-941f-e5aae8351186" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a5d3bde2-aaed-4516-8dbf-be8f5f362860" xlink:to="loc_srt_RangeMember_6c0ff67b-0f1e-491d-941f-e5aae8351186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ae33d065-846b-426e-9956-6792c4f56772" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6c0ff67b-0f1e-491d-941f-e5aae8351186" xlink:to="loc_srt_MaximumMember_ae33d065-846b-426e-9956-6792c4f56772" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10274bfc-d67a-426d-85ee-81f9bb7c9d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_13c83c04-57f3-4138-8c0a-142b05e4e9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10274bfc-d67a-426d-85ee-81f9bb7c9d24" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_13c83c04-57f3-4138-8c0a-142b05e4e9d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_36e57cc8-5251-446e-870d-58e2fd9c3a20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10274bfc-d67a-426d-85ee-81f9bb7c9d24" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_36e57cc8-5251-446e-870d-58e2fd9c3a20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5db585c7-1b89-4abe-8f9b-5430fd6766fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_36e57cc8-5251-446e-870d-58e2fd9c3a20" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5db585c7-1b89-4abe-8f9b-5430fd6766fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5db585c7-1b89-4abe-8f9b-5430fd6766fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5db585c7-1b89-4abe-8f9b-5430fd6766fe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5db585c7-1b89-4abe-8f9b-5430fd6766fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3dc1ab07-ce76-4347-a48f-8eeef98f303c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5db585c7-1b89-4abe-8f9b-5430fd6766fe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3dc1ab07-ce76-4347-a48f-8eeef98f303c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_53c94b77-c313-4e24-8d3c-6ea196986246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3dc1ab07-ce76-4347-a48f-8eeef98f303c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_53c94b77-c313-4e24-8d3c-6ea196986246" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_b3e77b70-facd-4e86-af09-82f9778d4a90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3dc1ab07-ce76-4347-a48f-8eeef98f303c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_b3e77b70-facd-4e86-af09-82f9778d4a90" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_294de162-3f2c-4ee0-a9e3-19bfc782232d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bedc42b8-1c03-4b45-b893-6933de4c847b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_294de162-3f2c-4ee0-a9e3-19bfc782232d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bedc42b8-1c03-4b45-b893-6933de4c847b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9ee1a41b-a9b8-4803-903a-1c3a00a1d8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_294de162-3f2c-4ee0-a9e3-19bfc782232d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9ee1a41b-a9b8-4803-903a-1c3a00a1d8a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c40ef36e-a0e8-4d25-98f8-d7832227e623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_294de162-3f2c-4ee0-a9e3-19bfc782232d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c40ef36e-a0e8-4d25-98f8-d7832227e623" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_88ceb0b2-01be-41b6-a7cb-90a27625da4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_294de162-3f2c-4ee0-a9e3-19bfc782232d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_88ceb0b2-01be-41b6-a7cb-90a27625da4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_a6ce2dba-9c38-4a61-b629-adf762264be5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_294de162-3f2c-4ee0-a9e3-19bfc782232d" xlink:to="loc_us-gaap_SharePrice_a6ce2dba-9c38-4a61-b629-adf762264be5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5af328f9-769e-4a0b-858a-e6695e3d5523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_294de162-3f2c-4ee0-a9e3-19bfc782232d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5af328f9-769e-4a0b-858a-e6695e3d5523" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b82e0b56-9d3f-4d0f-9ea3-b9dbcb4325f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5af328f9-769e-4a0b-858a-e6695e3d5523" xlink:to="loc_us-gaap_AwardTypeAxis_b82e0b56-9d3f-4d0f-9ea3-b9dbcb4325f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b82e0b56-9d3f-4d0f-9ea3-b9dbcb4325f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b82e0b56-9d3f-4d0f-9ea3-b9dbcb4325f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b82e0b56-9d3f-4d0f-9ea3-b9dbcb4325f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0b91345-3752-41a0-9e3f-e84ff18e629c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b82e0b56-9d3f-4d0f-9ea3-b9dbcb4325f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0b91345-3752-41a0-9e3f-e84ff18e629c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_42631f7f-4eac-4d2c-a57e-407e578b35f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0b91345-3752-41a0-9e3f-e84ff18e629c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_42631f7f-4eac-4d2c-a57e-407e578b35f0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_d9dca288-8a16-4fc5-bc58-38a1121c3507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_COBRABenefitsPaymentPeriod_b44637c7-5f64-4161-b028-291255ba805e" xlink:href="ck0001824293-20230930.xsd#ck0001824293_COBRABenefitsPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d9dca288-8a16-4fc5-bc58-38a1121c3507" xlink:to="loc_ck0001824293_COBRABenefitsPaymentPeriod_b44637c7-5f64-4161-b028-291255ba805e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PercentageOfTargetBonus_39e327d0-2d06-4411-be2a-6253fcac7ae4" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PercentageOfTargetBonus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d9dca288-8a16-4fc5-bc58-38a1121c3507" xlink:to="loc_ck0001824293_PercentageOfTargetBonus_39e327d0-2d06-4411-be2a-6253fcac7ae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c853b586-43c1-461b-a8b4-3bb31d38bd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_d9dca288-8a16-4fc5-bc58-38a1121c3507" xlink:to="loc_us-gaap_LossContingenciesTable_c853b586-43c1-461b-a8b4-3bb31d38bd9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_34f7a68c-a039-41f4-ba99-e1a50d98afb8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c853b586-43c1-461b-a8b4-3bb31d38bd9e" xlink:to="loc_srt_TitleOfIndividualAxis_34f7a68c-a039-41f4-ba99-e1a50d98afb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_34f7a68c-a039-41f4-ba99-e1a50d98afb8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_34f7a68c-a039-41f4-ba99-e1a50d98afb8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_34f7a68c-a039-41f4-ba99-e1a50d98afb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_07d95c23-bca3-4b74-9e21-76b516e9eb2a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_34f7a68c-a039-41f4-ba99-e1a50d98afb8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_07d95c23-bca3-4b74-9e21-76b516e9eb2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_FormerChiefExecutiveOfficerMember_8b18128d-3a22-4129-a53f-0af07aed8aea" xlink:href="ck0001824293-20230930.xsd#ck0001824293_FormerChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_07d95c23-bca3-4b74-9e21-76b516e9eb2a" xlink:to="loc_ck0001824293_FormerChiefExecutiveOfficerMember_8b18128d-3a22-4129-a53f-0af07aed8aea" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ck0001824293-20230930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:a8344312-8d5f-422d-bd63-4db6cc7ddad6,g:d0f905d4-70f6-4e32-afc7-d259f8c67a30-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c60bdfb6-79a5-4e2b-8ec0-a485501a4f0e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in operating lease right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_9a08ddb6-c524-498c-a3d9-26bcccde5cb6_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for reverse recapitalization expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Reverse Recapitalization Expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Reverse Recapitalization Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_73d1d139-0364-4e7a-8a29-921fff062123_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_4f2e2b66-1730-4d42-8d46-093ed3e516c0_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in pre-closing financing (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Pre-closing Financing</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Pre-closing Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_27b67028-1999-41a4-b277-45b85f4e80e2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Stock Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f41ee7a3-e73d-4e96-918a-0d8f196803fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c9025b70-5cdf-411e-b93f-550af2f8f50c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_76f3b680-8198-4727-9529-402bd54aef71_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_dc4770bf-30da-4083-b61c-b25f2f4f9a99_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f96e0773-6c4e-4e0c-81a6-5dddf3e1f20e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_TEPNoteMember_ea1fcb6f-06ed-472d-a180-d151d4d33df8_terseLabel_en-US" xlink:label="lab_ck0001824293_TEPNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TEP Note</link:label>
    <link:label id="lab_ck0001824293_TEPNoteMember_label_en-US" xlink:label="lab_ck0001824293_TEPNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TEP Note [Member]</link:label>
    <link:label id="lab_ck0001824293_TEPNoteMember_documentation_en-US" xlink:label="lab_ck0001824293_TEPNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TEP Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_TEPNoteMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_TEPNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_TEPNoteMember" xlink:to="lab_ck0001824293_TEPNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_720debdf-4e63-4ff9-9da1-50479e5685dc_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_f2ddd608-28dc-40fe-b438-09ee6aa80310_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_60239eb2-b512-470b-9cd4-2c62a84858ba_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_316fa7a9-324d-45b1-acad-e742805c61e5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7c70ead6-1397-4159-a627-3dd182d01838_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock awards, contractual life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_50f26a58-ec1c-4655-86de-00d718fd2d82_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMay2027Member_1876e36c-f1f7-4e46-818d-4b6e4d41401d_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In May 2027</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMay2027Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In May 2027 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMay2027Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In May 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMay2027Member" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInMay2027Member" xlink:to="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_d25fecd3-9641-42a9-9592-6adfe096d46f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_709b8514-dfee-4b0a-a5af-2a752d5066fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Award Types</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_9248b616-11d1-41b8-bd3b-5dad156f0bc8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROMISSORY NOTES</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_a51427ac-16fa-4909-a54f-95d39f45dfbe_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_72c963fe-40c7-4bf3-8155-39c1aeccc818_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ChangeInFairValueOfWarrantLiability_dfe00487-3f80-4028-8014-12faee7a6896_terseLabel_en-US" xlink:label="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_ck0001824293_ChangeInFairValueOfWarrantLiability_label_en-US" xlink:label="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Warrant Liability</link:label>
    <link:label id="lab_ck0001824293_ChangeInFairValueOfWarrantLiability_documentation_en-US" xlink:label="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ChangeInFairValueOfWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:to="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtInstrumentNumberOfClosings_141a5202-0919-4c43-8752-0dc7ebf18625_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtInstrumentNumberOfClosings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of closings</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentNumberOfClosings_label_en-US" xlink:label="lab_ck0001824293_DebtInstrumentNumberOfClosings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Closings</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentNumberOfClosings_documentation_en-US" xlink:label="lab_ck0001824293_DebtInstrumentNumberOfClosings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Closings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentNumberOfClosings" xlink:href="ck0001824293-20230930.xsd#ck0001824293_DebtInstrumentNumberOfClosings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtInstrumentNumberOfClosings" xlink:to="lab_ck0001824293_DebtInstrumentNumberOfClosings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_fb0c100c-b69c-4891-884e-b555325a174f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_00d54e52-bc37-43e8-af02-441c19256065_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_CommonStockHeldIntoEscrowAccount_4024b30d-7590-4f4d-a223-a258dab99143_terseLabel_en-US" xlink:label="lab_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock placed into escrow (in shares)</link:label>
    <link:label id="lab_ck0001824293_CommonStockHeldIntoEscrowAccount_label_en-US" xlink:label="lab_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Held Into Escrow Account</link:label>
    <link:label id="lab_ck0001824293_CommonStockHeldIntoEscrowAccount_documentation_en-US" xlink:label="lab_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Held Into Escrow Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:href="ck0001824293-20230930.xsd#ck0001824293_CommonStockHeldIntoEscrowAccount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:to="lab_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_3a164990-698d-41bf-afe1-9267e779bf6d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_d81f7476-fa3b-4925-bbae-c601fc6b05c2_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased during period (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts_f340ef32-6410-4ba0-b45b-b7c60f055412_negatedTerseLabel_en-US" xlink:label="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of reverse recapitalization costs</link:label>
    <link:label id="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts_label_en-US" xlink:label="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Reverse Recapitalization Costs</link:label>
    <link:label id="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts_documentation_en-US" xlink:label="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Reverse Recapitalization Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PaymentOfReverseRecapitalizationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:to="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJune2025Member_9a97221c-71ac-4b1f-89fd-b02a137d627f_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJune2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In June 2025</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJune2025Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJune2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In June 2025 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJune2025Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJune2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In June 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJune2025Member" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInJune2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInJune2025Member" xlink:to="lab_ck0001824293_WarrantsExpiringInJune2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f03079f0-8b16-4f21-a206-4219bea4d0ee_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e7a92543-d24a-4fba-a890-00bcfa3b26be_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_d15bad9a-bbb0-4833-ae70-6ea9f70e44d2_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_b6b430ae-d634-476a-a844-7212104d9d31_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1bd92582-8646-4f28-a85b-a391c9d9bee6_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value as of December 31, 2022</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e38f21ef-e437-4f65-ae39-404a8e815723_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value as of September&#160;30, 2023</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_00a527b5-671d-4ec7-a314-d5991a215386_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Discounts and Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_3fc65f85-bf15-4a55-a6da-69b27661ef75_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares that became exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_9deb4c0a-82b5-4a17-9bba-ea6e38f3ad6e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_9e857a14-57fd-4af3-af2c-e92f6de16a6f_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for settlement of bridge note (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Settlement Of Debt</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Settlement Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_82fa253b-427e-4e4d-91e2-c1444b7c6cbb_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 12)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_a242290c-601a-4569-b3ab-d5a34ad13abc_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2b28a2a8-0f65-484d-bd6d-833f1bf5db03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_CommonStockExchangeRatio_7d174f46-24f8-4195-8346-f18724372a3f_terseLabel_en-US" xlink:label="lab_ck0001824293_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, exchange ratio</link:label>
    <link:label id="lab_ck0001824293_CommonStockExchangeRatio_label_en-US" xlink:label="lab_ck0001824293_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Exchange Ratio</link:label>
    <link:label id="lab_ck0001824293_CommonStockExchangeRatio_documentation_en-US" xlink:label="lab_ck0001824293_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Exchange Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockExchangeRatio" xlink:href="ck0001824293-20230930.xsd#ck0001824293_CommonStockExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_CommonStockExchangeRatio" xlink:to="lab_ck0001824293_CommonStockExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c70d0d4d-dd37-4944-93da-c3686e0aea47_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6661e482-9b8a-4ae9-a3bf-d10112455e25_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable_16a5bdfe-b2ab-4b24-8ab4-0edc932e550c_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock for repayment of bridge promissory note</link:label>
    <link:label id="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable_label_en-US" xlink:label="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued For Repayment Of Notes Payable</link:label>
    <link:label id="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued For Repayment Of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedForRepaymentOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:to="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5a3f0418-efc6-493c-8526-0a253caee7b2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock in pre-closing financing</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1bcdd9d1-a829-4d07-919c-88a17aa2d1ea_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_EquityWarrantsMember_5e84dbf1-28ce-4874-b380-27148ff38991_terseLabel_en-US" xlink:label="lab_ck0001824293_EquityWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants</link:label>
    <link:label id="lab_ck0001824293_EquityWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_EquityWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_EquityWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_EquityWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_EquityWarrantsMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_EquityWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_EquityWarrantsMember" xlink:to="lab_ck0001824293_EquityWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_9017d5b2-c60b-4bc1-b6e9-88f66869c470_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrant Exercises</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodValueWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fa9f4737-5db0-4285-8aab-6558ad08a480_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_c096847f-3c31-47b3-9d20-03f4b478a375_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0bfb8d6e-b77c-4fa1-a4a1-1e6cddd22da2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock vesting</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_99da1730-d0ed-4044-96a5-ed88e43cb760_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt_08f3c224-09cf-496a-a9a8-e7af591e415c_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of debt to be converted</link:label>
    <link:label id="lab_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt_label_en-US" xlink:label="lab_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Principal Amount Of Debt</link:label>
    <link:label id="lab_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt_documentation_en-US" xlink:label="lab_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Principal Amount Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt" xlink:href="ck0001824293-20230930.xsd#ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt" xlink:to="lab_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_18e4da18-edb4-4e41-8cdd-4dcec2cafd27_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_81a33921-3fd1-4a64-addf-164a630dc2b1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ac0efb7c-3463-4a88-8670-cd4803b59f5a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_087028b0-9b76-462a-9e6b-b1e1e85340c1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrant exercise</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_1419f7d3-0183-40b0-aac9-afcfdff84a5f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_16926531-b686-438f-92d2-9ab6425b2288_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_76c126b9-59aa-42ae-a41e-b6e1f27f3dce_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_1830b763-93a0-498d-bf0c-f6548da7a52d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockSubjectToPutRightMember_529b9b82-376c-4046-af97-c2154b5f1248_terseLabel_en-US" xlink:label="lab_ck0001824293_StockSubjectToPutRightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subject to put right</link:label>
    <link:label id="lab_ck0001824293_StockSubjectToPutRightMember_label_en-US" xlink:label="lab_ck0001824293_StockSubjectToPutRightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subject To Put Right [Member]</link:label>
    <link:label id="lab_ck0001824293_StockSubjectToPutRightMember_documentation_en-US" xlink:label="lab_ck0001824293_StockSubjectToPutRightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subject To Put Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockSubjectToPutRightMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockSubjectToPutRightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockSubjectToPutRightMember" xlink:to="lab_ck0001824293_StockSubjectToPutRightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_bbc57f62-c40d-451c-ae4e-363077bccbf5_negatedLabel_en-US" xlink:label="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net liabilities assumed in connection with reverse recapitalization</link:label>
    <link:label id="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_label_en-US" xlink:label="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Liabilities Assumed In Connection With Reverse Recapitalization</link:label>
    <link:label id="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_documentation_en-US" xlink:label="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Liabilities Assumed In Connection With Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:href="ck0001824293-20230930.xsd#ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:to="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_941699a4-e287-4bf8-bb9c-d46986475e08_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_adecb792-5e67-46b9-a211-45b09ca1736e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_81b37b83-ca75-44ac-8d19-9d7d79352302_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock with repurchase rights</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_badb3c85-b47f-4910-aa9c-5bfeb15d77e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_2aa9baa9-924f-4431-aafb-1cfcc9777568_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in pre-closing financing</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Pre-closing Financing</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Pre-closing Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c434ff4b-36d6-44db-bc46-4adcb4c58f7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_5e145e1e-39c1-40e1-95b1-87018dd43ae1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Fair Value of the Warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_42f255a1-8c51-4be3-a44e-594dcace0288_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_00161969-83de-4036-b93a-16e0f940cd52_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest_7a004633-4d27-4ac6-acca-b1ef738b288c_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of accrued interest to be converted</link:label>
    <link:label id="lab_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest_label_en-US" xlink:label="lab_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount Of Interest</link:label>
    <link:label id="lab_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest_documentation_en-US" xlink:label="lab_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount Of Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest" xlink:href="ck0001824293-20230930.xsd#ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest" xlink:to="lab_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1dd0afaa-3a36-4ebb-acf4-2a0a00792d0c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_581d623c-6559-4293-a97e-60d58119767d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentCompanyCommittedCapital_8939a817-33ea-49bb-aaa2-c81a94081813_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCommittedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in cash</link:label>
    <link:label id="lab_us-gaap_InvestmentCompanyCommittedCapital_label_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCommittedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Committed Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCompanyCommittedCapital" xlink:to="lab_us-gaap_InvestmentCompanyCommittedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e1c0293b-ad17-4f7c-a6b9-aeca68602046_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ddf50d4c-94b7-453c-91f5-8d5a29356955_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4080328c-ce68-4bc2-a2ef-2f6500f25957_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_dc0acc93-fd31-4b98-88a4-6e170788b27b_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_69368d2b-baed-4ea3-856e-acd81cdaef3e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_976672aa-2606-4f5d-8eed-34c820684d6d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60e2677c-0158-4a99-80ef-ebad625c1fdd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_47dd4d8d-0b7c-4b87-ac23-14309ba402f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2028Member_782e6c07-fb1d-4318-a58b-571061e2c909_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In April 2028</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2028Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In April 2028 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2028Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In April 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2028Member" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInApril2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInApril2028Member" xlink:to="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_012927fc-a204-449f-b81a-af3c2b207b13_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_RepaymentOfAdvancesFromEmployees_3bfd061e-89b0-497a-9c5c-da2de48944fc_negatedTerseLabel_en-US" xlink:label="lab_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of advances from employees</link:label>
    <link:label id="lab_ck0001824293_RepaymentOfAdvancesFromEmployees_label_en-US" xlink:label="lab_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Advances From Employees</link:label>
    <link:label id="lab_ck0001824293_RepaymentOfAdvancesFromEmployees_documentation_en-US" xlink:label="lab_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Advances From Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:href="ck0001824293-20230930.xsd#ck0001824293_RepaymentOfAdvancesFromEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:to="lab_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d3f7dd8c-810c-449e-97bc-13d47a3e7277_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_236b4922-6ceb-4a43-b974-6840ebe3d8c3_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a758ccba-35c6-4f05-861e-be81193d7b4b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e418dbcc-6d78-4c98-b734-2507896d92a8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_839da54e-e9c9-4649-9bef-5ec8c60017ea_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PutOptionMember_f9e12445-afb2-4ba6-9350-ef250548b3fd_terseLabel_en-US" xlink:label="lab_us-gaap_PutOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put Option</link:label>
    <link:label id="lab_us-gaap_PutOptionMember_label_en-US" xlink:label="lab_us-gaap_PutOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PutOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PutOptionMember" xlink:to="lab_us-gaap_PutOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_11585708-7536-42c2-ba39-66d7233dd598_terseLabel_en-US" xlink:label="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge SPA</link:label>
    <link:label id="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_label_en-US" xlink:label="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Securities Purchase Agreement [Member]</link:label>
    <link:label id="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_documentation_en-US" xlink:label="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Securities Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BridgeSecuritiesPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:to="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b7ef1ace-f6dc-4f6b-9d5d-cf7dda018e89_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_2aebbea3-f463-4dd3-9bcb-46599d8108ab_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_3d807ac6-dfc0-4940-b94f-3f37e1f2aaaf_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased during period, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a3583d85-b661-42ec-9959-7dac45856fed_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d50068fe-0b6c-4596-a5fa-841ea314bc7d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_aa632e86-8acd-450d-897e-48d759828de2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_61ba90db-e941-4f87-839e-74a8d1fe13ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ac95660c-df5a-49ae-a259-7c6591438522_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ba803a72-794c-44bb-8346-28706c8f2907_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9e101550-cb5d-4e8c-a123-f25400009e55_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_745adc3e-6243-4752-a3fd-8be555a7f3ea_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_63951d39-4f4c-40ff-975e-b889acde0b79_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront cash payment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_451cbf14-670d-4a0c-9da5-4c51337b96de_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a36fb18e-8943-4910-a778-46ba164f5f87_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_d4336627-240d-4cd1-92ae-00bd5d473cf1_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f0c4099b-cca8-4b16-8454-887e13a44c6b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c1ccab64-59e7-4844-95c2-59f035cae629_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f0c2e933-4d8a-4663-a26b-35342ed9bab3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3bb419f9-9811-4c91-a0d8-d989211042a6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1c6e01f0-52fd-4b58-b921-ee25df0a6819_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_824b1077-2df5-47e3-a2e4-df8a88f538ea_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock to Vallon stockholders in reverse recapitalization (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8e4bea95-2655-486a-8062-67a0f779bc67_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_7c8c0163-a668-46dc-a8ea-c94378245f42_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant issuance</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_4ec98937-5968-4079-8f80-a4ead47d0b55_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_f541edd4-a766-4c48-87bb-0b6d9c139360_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of bridge promissory note</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_fc9f84a9-5886-4583-8d28-970cb75e4ab2_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_dd3ded1a-6d31-4054-b4ed-42c985fb9895_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a5d5e96e-9e36-4e9c-88bd-da30902de075_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e9865187-6581-46f9-bffb-be927a64bdd9_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price per Share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_637c9c4e-e048-47d0-85be-a745cc023640_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for reverse recapitalization expenses (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization Expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4400e3b2-218a-4006-bb2c-33ec33bf7747_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a3754960-53be-4d4d-8bec-e101f0bde106_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Changes is the Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a6aa730a-94d5-4402-b491-3a5b80470419_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantLiabilityMember_72dd002b-d6eb-4026-a768-b99440b88a8d_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_ck0001824293_WarrantLiabilityMember_label_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantLiabilityMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantLiabilityMember" xlink:to="lab_ck0001824293_WarrantLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_806fcc30-7a8b-43df-a58a-5c0275cef9bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2caae085-08ba-4b08-ad3b-282f803fd8a1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7f6645d0-ad83-4a06-8624-c2a411c20acb_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8b186eeb-d6a7-4121-b774-d5ec0fdd5731_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_91ec8a95-dd32-493a-bbbe-a688e84e1aaa_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f34f6a5b-09ab-4c93-84de-772f8f7b540e_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_cce88845-6b1f-4aed-aba2-45dafb3c89e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity of Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember_41980f2c-520e-4934-8e23-c9a9fa2d51eb_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring in 24 Months After Registration Date</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In 24 Months After Registration Date [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In 24 Months After Registration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember" xlink:to="lab_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_COBRABenefitsPaymentPeriod_4c92c6a6-477d-440e-8fc3-b49b4492059a_terseLabel_en-US" xlink:label="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COBRA benefits, payment period (in months)</link:label>
    <link:label id="lab_ck0001824293_COBRABenefitsPaymentPeriod_label_en-US" xlink:label="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COBRA Benefits, Payment Period</link:label>
    <link:label id="lab_ck0001824293_COBRABenefitsPaymentPeriod_documentation_en-US" xlink:label="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COBRA Benefits, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_COBRABenefitsPaymentPeriod" xlink:href="ck0001824293-20230930.xsd#ck0001824293_COBRABenefitsPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_COBRABenefitsPaymentPeriod" xlink:to="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInDecember2023Member_65c2508b-ec5e-4095-8df0-f8d9d779f699_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInDecember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In December 2023</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInDecember2023Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInDecember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In December 2023 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInDecember2023Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInDecember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In December 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInDecember2023Member" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInDecember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInDecember2023Member" xlink:to="lab_ck0001824293_WarrantsExpiringInDecember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_6c77701e-e085-4454-b772-a4570336c208_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrants Outstanding to Purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_c72fcb20-cf43-486a-b278-7123440ae222_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_EmployeeAdvancesCurrent_9cc996be-0047-4cbf-a3ea-5080121087b5_verboseLabel_en-US" xlink:label="lab_ck0001824293_EmployeeAdvancesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances from employees</link:label>
    <link:label id="lab_ck0001824293_EmployeeAdvancesCurrent_label_en-US" xlink:label="lab_ck0001824293_EmployeeAdvancesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Advances, Current</link:label>
    <link:label id="lab_ck0001824293_EmployeeAdvancesCurrent_documentation_en-US" xlink:label="lab_ck0001824293_EmployeeAdvancesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Advances, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_EmployeeAdvancesCurrent" xlink:href="ck0001824293-20230930.xsd#ck0001824293_EmployeeAdvancesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_EmployeeAdvancesCurrent" xlink:to="lab_ck0001824293_EmployeeAdvancesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5061e03a-5206-45ec-9776-bff8bcca1bbc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_86f448e2-4435-4bdf-9ae3-9434bfeb4739_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_6b936a7b-74a3-4b4a-aff9-69b9e26b2632_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f20ff11a-96b5-45e2-95ce-4c94cbc1fd2a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesA2WarrantsMember_8b5b581e-29fc-4cd0-81ce-9383f6ed4861_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesA2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-2 Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesA2WarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesA2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-2 Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesA2WarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesA2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-2 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA2WarrantsMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_SeriesA2WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesA2WarrantsMember" xlink:to="lab_ck0001824293_SeriesA2WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_d617378d-ff4c-438c-b550-d948508ebb2a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of deferred stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e772875a-4fb1-4c67-951b-2cd935850999_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_109898f9-d9b1-4edb-8eae-07e60c3ad357_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_6b15f598-aebc-4ed9-9c3c-11e2577d5fc8_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2026Member_fad1cdd3-ac7c-4896-833b-a4c2f8e4e0c8_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In February 2026</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2026Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In February 2026 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2026Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In February 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInFebruary2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:to="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_322abb39-c6ea-49a1-8414-65cc392a3b18_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_f633654a-c1d7-4e6e-92c2-44ca599ff381_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_a4101d04-4333-4e0d-a281-110c3c3a3e63_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c12b0a6a-c4be-48cb-8a14-ce7c1c5f4b89_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_88aeb7d0-24a0-4468-b31b-5cc8487987f5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_eec3b186-f486-41a6-b4b4-ff0cfcaa21bd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ded0f7d3-4683-4eec-b482-4bfd18e43949_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d666c8fd-d9ea-48c3-a3b8-193e2d165319_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_9c3bf2d1-8e76-4553-adb6-5edbb8cc7261_negatedLabel_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_label_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses</link:label>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_documentation_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:to="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9443760d-c4b2-41a7-b798-bf8e0a99a4b8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_e5646293-9454-44a8-a04f-901cba0e39de_terseLabel_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net liabilities assumed plus transaction costs</link:label>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_label_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs</link:label>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_documentation_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:to="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_414f58f8-83ce-467c-a863-18a040c2a4de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_01d4832b-6cff-4d51-856a-1d8f507b20c8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_498628f3-ee58-43c4-b04d-ede4df36a60e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7249a6c9-5170-41e1-bbd0-7e72f707bf4a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_7f181093-61b6-41bb-970a-1fdd386b2912_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_752c9340-65fe-4f60-9bb4-3e1bffdf78fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Net Liabilities Assumed in the Merger</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashUninsuredAmount_778d443e-41ab-4606-b68e-9e9e697546f9_terseLabel_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uninsured cash balances</link:label>
    <link:label id="lab_us-gaap_CashUninsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashUninsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount" xlink:to="lab_us-gaap_CashUninsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_01c93050-6b9f-42ad-ba49-27803fab775e_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="ck0001824293-20230930.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_db17cf09-4d49-4a7f-b6b2-30df8b8a9653_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_98fdfd38-fc6b-4d3f-8f57-b78ed0adc8ec_terseLabel_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIQUIDITY</link:label>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_label_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_073b8f2f-beb8-4567-a4c6-b4ba731815e3_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, outstanding term (in months)</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_83820f61-9d35-46ea-b824-f08e5bbef45f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fdd98769-8e70-418c-820e-10a5a3b270fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5fb45760-b25a-4cc4-86d9-1ec601975757_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_09f92e49-24d8-4300-b11c-3cf91beb3548_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Calculation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1168ea8a-cd26-48e5-beda-2b64c44a588c_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_966c01ad-f2b9-4625-9175-3de38d7e343d_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4160108f-0386-403d-a246-f0f9edc2fe36_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities_a47153dd-d0ee-462e-bbee-413fed019fbe_terseLabel_en-US" xlink:label="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger costs included in accounts payable</link:label>
    <link:label id="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities_label_en-US" xlink:label="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Merger Related Costs, Financing Activities</link:label>
    <link:label id="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities_documentation_en-US" xlink:label="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Merger Related Costs, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NoncashMergerRelatedCostsFinancingActivities" xlink:href="ck0001824293-20230930.xsd#ck0001824293_NoncashMergerRelatedCostsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_NoncashMergerRelatedCostsFinancingActivities" xlink:to="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_503a244f-224d-44ed-9d6d-7cf41a867e13_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7d035df1-6478-48aa-9133-e262ebce8384_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f417dc8a-60d8-44f1-afa5-67bfc101dd28_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_efda95da-9e34-4215-953f-cb30ec85413d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities (in usd per share)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_81ce0f21-0752-4276-ae60-a5f6814d88aa_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_d12043f9-3e6b-4446-84df-45dd49fdc004_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4edee5fc-45d2-4af6-bdeb-255c991719f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_1b77e200-f5e7-4848-87a5-32175ed93ef0_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PercentageOfTargetBonus_f7b86064-5b9b-436e-bdbf-751a8abba4f3_terseLabel_en-US" xlink:label="lab_ck0001824293_PercentageOfTargetBonus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of target bonus (as a percent)</link:label>
    <link:label id="lab_ck0001824293_PercentageOfTargetBonus_label_en-US" xlink:label="lab_ck0001824293_PercentageOfTargetBonus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Target Bonus</link:label>
    <link:label id="lab_ck0001824293_PercentageOfTargetBonus_documentation_en-US" xlink:label="lab_ck0001824293_PercentageOfTargetBonus" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Target Bonus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PercentageOfTargetBonus" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PercentageOfTargetBonus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PercentageOfTargetBonus" xlink:to="lab_ck0001824293_PercentageOfTargetBonus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_88119fe0-bee5-4e8c-adfa-3389defcf180_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7d228d35-5926-4452-8449-0c9e0d8d4fff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_3cc831e2-02c2-461f-b875-2b90b21ca3c1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_98f5e091-52c6-4a62-8ea5-1e8cc5b9bf86_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_854e9e04-90e0-402a-808b-e423d62e07dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseBorrowings_3ca557ef-8c0b-4ec4-803d-37ee28a7790e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseBorrowings_label_en-US" xlink:label="lab_us-gaap_InterestExpenseBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseBorrowings" xlink:to="lab_us-gaap_InterestExpenseBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_4871da46-87e1-4334-8326-c9654347971b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plus: Transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_0bbb2dcc-b50c-4807-9ef3-71b3764effef_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_7353d96b-f80c-4881-837c-e0546d14041d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e285998e-6a50-4ee5-a581-e31f8c59a17d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_5e1db20a-9cf2-4ec9-80aa-c1da48218e97_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_bf19b6cb-4c7c-4a83-a7ae-39258a1f2fad_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_70d5c309-f8b3-48d8-8227-ab5d72574420_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d64cc222-98b6-412d-9c3d-4ae212c14598_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_bb266813-c322-4ab6-9a81-f3f72d66add1_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_label_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:to="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0f17070b-cbbf-4eda-b7ff-b81758e3f000_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55042644-efd7-47d1-b008-0eaa0606e434_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedInterestForfeited_303007c4-a39d-4239-86e2-930c55564f6b_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedInterestForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest forfeited</link:label>
    <link:label id="lab_ck0001824293_AccruedInterestForfeited_label_en-US" xlink:label="lab_ck0001824293_AccruedInterestForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest Forfeited</link:label>
    <link:label id="lab_ck0001824293_AccruedInterestForfeited_documentation_en-US" xlink:label="lab_ck0001824293_AccruedInterestForfeited" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedInterestForfeited" xlink:href="ck0001824293-20230930.xsd#ck0001824293_AccruedInterestForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedInterestForfeited" xlink:to="lab_ck0001824293_AccruedInterestForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_614e8e78-6c4c-4555-baa3-c6afe633ac8f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_616820cb-964b-4535-b2f8-30fa5392bd83_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesA1WarrantsMember_a8a8029c-c08f-4359-980b-b4212325625f_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-1 Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesA1WarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-1 Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesA1WarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-1 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesA1WarrantsMember" xlink:to="lab_ck0001824293_SeriesA1WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_2ad8693b-5df2-43fe-8c0b-9ac47cdfa3d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76f433cd-305f-452f-b570-912132ed31b0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_ad390646-58f8-4b16-9db7-b9abadef0e96_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_c52008fc-edbb-4ec1-af78-395bb0ee11c2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_daee5dce-eb3c-4441-8e16-0018c77f61ea_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_40070922-ec5b-4ac4-8d23-119fb73f3767_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_69396196-2a42-4cf2-bd5f-d6ab945a169c_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge promissory note, net</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_513480c5-dda1-4772-b4bf-b6d662203e27_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_a9a6adf4-30f3-4809-bf73-aeacdb200f51_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, 0.0001 par value; 250,000,000 shares authorized as of September&#160;30, 2023 and December&#160;31, 2022; 2,956,354 and 999,748 shares issued and outstanding as of September&#160;30, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_7b29c20d-a51c-4a39-b159-8efdcd9c2db7_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_da1555a5-a613-4dc9-b1e2-74924e60cd2b_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember_2bad8b1b-26ba-4bbf-b123-5e55eb97a91c_terseLabel_en-US" xlink:label="lab_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants, Exchange Warrants and Banker Warrants</link:label>
    <link:label id="lab_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants, Exchange Warrants And Banker Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants, Exchange Warrants And Banker Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember" xlink:to="lab_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c39ff706-a1b1-45f4-a0d6-69f75e620b07_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_244c4706-7a39-41ef-a758-7d0cbb2bfd85_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ConvertiblePromissoryNoteMember_11035393-5b9b-4ffe-a634-591926ec38a1_terseLabel_en-US" xlink:label="lab_ck0001824293_ConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible promissory note</link:label>
    <link:label id="lab_ck0001824293_ConvertiblePromissoryNoteMember_label_en-US" xlink:label="lab_ck0001824293_ConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Note [Member]</link:label>
    <link:label id="lab_ck0001824293_ConvertiblePromissoryNoteMember_documentation_en-US" xlink:label="lab_ck0001824293_ConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNoteMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ConvertiblePromissoryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ConvertiblePromissoryNoteMember" xlink:to="lab_ck0001824293_ConvertiblePromissoryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_e78e26f6-a251-4b34-8579-66e217eaaec9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_3d7a6a88-a879-46f3-8b69-a687d58239d7_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued General and Administrative Expenses, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued General and Administrative Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:href="ck0001824293-20230930.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:to="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_8a825f5f-1f9d-437b-9bd4-b02c839219d8_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of debt discount and additional paid-in-capital for issuance of warrants in connection with the issuance of promissory notes</link:label>
    <link:label id="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_label_en-US" xlink:label="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants</link:label>
    <link:label id="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_documentation_en-US" xlink:label="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:href="ck0001824293-20230930.xsd#ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:to="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_4f0be294-0628-4767-b83c-3c0d63f627f6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_87aa16ca-c447-42b1-90f2-eb684ad281ef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_8ccf53df-5e52-460c-9d88-c645d2d41c86_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_39a53243-b05a-43c5-ba1a-59eae3b43f05_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_e82a1422-9f59-4d44-bb54-a3e54af62c61_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of warrants and non-contingent beneficial ownership feature in connection with convertible promissory note</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8fcc3cd5-1a40-45fc-a08b-bfe68d35db75_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b14980fe-843b-429a-ae04-627950f8a084_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d80c64d6-1687-4817-b3dc-1c556bbb8052_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a2e94dc4-efbb-4a4c-b153-32dd2afeabb2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_561a936d-9df3-4a36-8b0c-2fd1880a701d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/Cancelled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c23bb6a8-d507-4819-8319-398cf3ce5e4d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_CommonStockOwnershipPercentage_944147ab-7934-46b3-a595-d7a2975a54be_terseLabel_en-US" xlink:label="lab_ck0001824293_CommonStockOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage in common stock (as a percent)</link:label>
    <link:label id="lab_ck0001824293_CommonStockOwnershipPercentage_label_en-US" xlink:label="lab_ck0001824293_CommonStockOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Ownership Percentage</link:label>
    <link:label id="lab_ck0001824293_CommonStockOwnershipPercentage_documentation_en-US" xlink:label="lab_ck0001824293_CommonStockOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockOwnershipPercentage" xlink:href="ck0001824293-20230930.xsd#ck0001824293_CommonStockOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_CommonStockOwnershipPercentage" xlink:to="lab_ck0001824293_CommonStockOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b4a9194d-b63b-4b71-8fea-6863a954d2fb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation, weighted average amortization period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_f586c514-a73c-4740-accc-29e1fa1cc823_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6be4cff0-e1da-468f-8b44-03ccb8239f8a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ProceedsFromAdvancesFromEmployees_c59d65b2-5fa0-4b2d-90bb-d9382023f4a4_verboseLabel_en-US" xlink:label="lab_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances from employees</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromAdvancesFromEmployees_label_en-US" xlink:label="lab_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Advances From Employees</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromAdvancesFromEmployees_documentation_en-US" xlink:label="lab_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Advances From Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ProceedsFromAdvancesFromEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:to="lab_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_2d78e7e3-41bb-43b7-bc82-48f8e7545491_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_e580e346-ddaf-4021-bf91-7cc81c90106c_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of option on grant date (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_54d4a9f1-f8ca-417a-9d90-d0ebaaff2059_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_74b8f6c8-82bd-45d8-ae5c-efec8cc61ef1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_20b66748-cff0-4d62-b3ab-ee87c18a6a82_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PutOptionSharePrice_ef58aca4-d101-462a-b8d4-7fd739bd1b40_terseLabel_en-US" xlink:label="lab_ck0001824293_PutOptionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put right, share price (in usd per share)</link:label>
    <link:label id="lab_ck0001824293_PutOptionSharePrice_label_en-US" xlink:label="lab_ck0001824293_PutOptionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put Option, Share Price</link:label>
    <link:label id="lab_ck0001824293_PutOptionSharePrice_documentation_en-US" xlink:label="lab_ck0001824293_PutOptionSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put Option, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PutOptionSharePrice" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PutOptionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PutOptionSharePrice" xlink:to="lab_ck0001824293_PutOptionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ca0adfd1-ffee-4710-abe5-4c4efce5949a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_FormerChiefExecutiveOfficerMember_2da52e15-f5b9-4ae9-af82-a94c38f7db67_terseLabel_en-US" xlink:label="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Chief Executive Officer</link:label>
    <link:label id="lab_ck0001824293_FormerChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Chief Executive Officer [Member]</link:label>
    <link:label id="lab_ck0001824293_FormerChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_FormerChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:to="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_3551ad42-f688-4dea-93cc-6884b18f3ade_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSET PURCHASE AGREEMENT</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_41ee04e3-8939-42ee-9706-2ff432b00e59_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_845f793d-4f64-4047-aca4-1f696c2f3d87_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outsanding warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsIssued_7724571f-37c0-4346-9920-38dc55a475e0_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of warrants for payment of stock issuance costs</link:label>
    <link:label id="lab_ck0001824293_WarrantsIssued_label_en-US" xlink:label="lab_ck0001824293_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued</link:label>
    <link:label id="lab_ck0001824293_WarrantsIssued_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIssued" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsIssued" xlink:to="lab_ck0001824293_WarrantsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_561012f0-2ad6-44cf-9f5d-4d844414d35e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_a114a7c3-b735-4e1f-a9cd-8a634eec0f96_terseLabel_en-US" xlink:label="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A&amp;R 2918 Plan</link:label>
    <link:label id="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_label_en-US" xlink:label="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated 2018 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated 2018 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:to="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a0d60165-40cf-4c8e-aba8-21ff827a4e82_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d06d38fe-b71a-4e4c-bb15-a5b175311c72_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c59a16ff-cda7-4a56-8cf8-98d44da00a91_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b0b2f55b-e2c9-4285-9c24-732001cc218f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6d74370e-5037-49b7-a4ad-21f9523ff2f5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_be4c65ec-7d56-43d9-bf26-21d304f5ff1d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6e662154-5643-4e28-82a0-f7d77a043184_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInNovember2023Member_24251e81-35a9-492f-8be5-53c52db55092_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInNovember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In November 2023</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInNovember2023Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInNovember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In November 2023 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInNovember2023Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInNovember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In November 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInNovember2023Member" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInNovember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInNovember2023Member" xlink:to="lab_ck0001824293_WarrantsExpiringInNovember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f710264-520e-420e-abe1-e3308b6c72f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_ac0e5e1d-85d4-4aa5-be3a-18bbc59c7bd8_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exercise</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_bddc49bf-0378-48c9-8f92-01acd10a6889_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a55b5626-5ea0-4a2a-9a05-90da718f3ea9_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_d4a2d89f-6df1-461a-9003-1f37ba494754_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_08a4b1a6-3f61-4e36-8dd8-9439427f41c1_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_40b646e4-0d9a-4494-bac1-16695f03ec3e_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_553febc3-1715-4c5d-bfed-7b325f1d8a84_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock for payment of reverse recapitalization costs</link:label>
    <link:label id="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_label_en-US" xlink:label="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued For Payment Of Reverse Recapitalization Costs</link:label>
    <link:label id="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued For Payment Of Reverse Recapitalization Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:to="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion_662e3cf5-8127-48be-bbab-088ca1bbb07a_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares to be issued upon conversion</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion_label_en-US" xlink:label="lab_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Shares Issued Upon Conversion</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion_documentation_en-US" xlink:label="lab_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Shares Issued Upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion" xlink:href="ck0001824293-20230930.xsd#ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion" xlink:to="lab_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ab370870-e5cc-4232-a984-8a3e12a48d52_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5fe80a58-79a0-457e-821b-ced7f0b0047c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_c9bc2e9a-0386-4850-aed7-0841652c3a1d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted_e7a1ff72-08c3-4ab0-9d26-0eeaf8b47341_terseLabel_en-US" xlink:label="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares converted into common stock (in shares)</link:label>
    <link:label id="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted_label_en-US" xlink:label="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Additional Shares Converted</link:label>
    <link:label id="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted_documentation_en-US" xlink:label="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Additional Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:to="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_308bbf2e-bf65-4bc0-8a57-9656261b3eb1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ExchangeWarrantsMember_6bd6a3e9-0508-4bb1-9393-0bc800077c7a_terseLabel_en-US" xlink:label="lab_ck0001824293_ExchangeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Warrants</link:label>
    <link:label id="lab_ck0001824293_ExchangeWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_ExchangeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_ExchangeWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_ExchangeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ExchangeWarrantsMember" xlink:to="lab_ck0001824293_ExchangeWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_9e07354d-6f2b-4485-847d-95c145ea0b17_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_0510e804-4b24-4cb8-8817-4d7d04ef897a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MERGER WITH VALLON</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_2dbfc718-161c-4e7c-927f-b3fe017ce7e4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_8764f320-f6bb-48b6-8a6c-752fd86edc25_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_1a810b98-2f68-4a57-9c60-0a53a61230f7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_70dd0639-62f0-4b01-9870-144a88526d13_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestorMember_5c354beb-bff6-4e28-a3e9-a9d260c12753_terseLabel_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor</link:label>
    <link:label id="lab_us-gaap_InvestorMember_label_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember" xlink:to="lab_us-gaap_InvestorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_9de49c2e-c488-4e7e-9644-931f348c6e53_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible notes to common stock</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_b3655532-c41d-4d03-8af2-7dacfcefa87b_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_27a706d2-df24-4b47-be3c-6ff947817629_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_36ee5783-217d-4aa4-910b-a4fe043864ed_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b8469c2a-3d23-46ab-b8b3-609a6ccaf5a5_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesTWarrantsMember_bf66e829-70cf-4d36-b50f-0b633654d937_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesTWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series T Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesTWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesTWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series T Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesTWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesTWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series T Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesTWarrantsMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_SeriesTWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesTWarrantsMember" xlink:to="lab_ck0001824293_SeriesTWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice_251819d6-46cb-46ee-841c-a4665ad673eb_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate purchase price</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice_label_en-US" xlink:label="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Aggregate Purchase Price</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice_documentation_en-US" xlink:label="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Aggregate Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:href="ck0001824293-20230930.xsd#ck0001824293_DebtInstrumentAggregatePurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:to="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_GRIBioIncMember_fb216d12-c2a9-4182-85bc-0efc627e824d_terseLabel_en-US" xlink:label="lab_ck0001824293_GRIBioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GRI Bio, Inc</link:label>
    <link:label id="lab_ck0001824293_GRIBioIncMember_label_en-US" xlink:label="lab_ck0001824293_GRIBioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GRI Bio, Inc [Member]</link:label>
    <link:label id="lab_ck0001824293_GRIBioIncMember_documentation_en-US" xlink:label="lab_ck0001824293_GRIBioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GRI Bio, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIBioIncMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_GRIBioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_GRIBioIncMember" xlink:to="lab_ck0001824293_GRIBioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember_36b0286d-2ad5-4d41-b04f-b0feff2cbdb1_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring in 60 Months After Registration Date</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In 60 Months After Registration Date Two [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In 60 Months After Registration Date Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember" xlink:to="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_27669c83-97b3-4830-b9ec-1e04c80e7447_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_b1ae1015-6884-4a83-9d6d-af9611177dac_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_e42bee68-8767-40ad-91e0-4d6a8c8bc92d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes, converted, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_4aec0cd9-845e-41ca-8607-f558ac7a0e92_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_3cb14b06-18b4-4675-aac0-2b03b972a10a_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for settlement of bridge note</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Settlement Of Debt</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Settlement Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_dc3a32ec-4e40-45fb-9cfc-2732f08a31f7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJuly2027Member_314aa450-67cb-4fa4-ae64-18b3bb650296_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In July 2027</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJuly2027Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In July 2027 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJuly2027Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In July 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInJuly2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:to="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_283b58f2-d4ae-420a-b344-332953046e79_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c95895e8-2749-4d3d-90d9-21031a484fdf_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_BridgeWarrantsMember_46900b11-3c8a-479c-839a-3c863038a5e5_terseLabel_en-US" xlink:label="lab_ck0001824293_BridgeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Warrants</link:label>
    <link:label id="lab_ck0001824293_BridgeWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_BridgeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_BridgeWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_BridgeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeWarrantsMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BridgeWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_BridgeWarrantsMember" xlink:to="lab_ck0001824293_BridgeWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f26eed7f-04f5-47cb-be81-c7ff9ffb4bb8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_19a8e62e-ece5-41b7-9ce5-edcf089fde68_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember_eac2fa89-a8c6-4695-95a8-5c74a99ccbca_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring in 60 Months After Registration Date</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In 60 Months After Registration Date One [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring In 60 Months After Registration Date One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember" xlink:to="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFDICInsuredAmount_87934134-49a6-4d28-a4df-52dd89486c77_terseLabel_en-US" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FDIC insured amount</link:label>
    <link:label id="lab_us-gaap_CashFDICInsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, FDIC Insured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFDICInsuredAmount" xlink:to="lab_us-gaap_CashFDICInsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_39ab20cd-11f6-44a5-bc1c-f94d3f561389_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_LongTermDebtIncludingInterest_422fff50-4670-4516-bb96-533179448ae4_terseLabel_en-US" xlink:label="lab_ck0001824293_LongTermDebtIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, including interest</link:label>
    <link:label id="lab_ck0001824293_LongTermDebtIncludingInterest_label_en-US" xlink:label="lab_ck0001824293_LongTermDebtIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Including Interest</link:label>
    <link:label id="lab_ck0001824293_LongTermDebtIncludingInterest_documentation_en-US" xlink:label="lab_ck0001824293_LongTermDebtIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Including Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_LongTermDebtIncludingInterest" xlink:href="ck0001824293-20230930.xsd#ck0001824293_LongTermDebtIncludingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_LongTermDebtIncludingInterest" xlink:to="lab_ck0001824293_LongTermDebtIncludingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_c56dc9d8-df64-4975-956e-6b2e2e6f2941_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income (expense), net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_6970804e-ee21-479e-9765-23214c812bd3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_787fef38-78c0-4938-81f7-d1b7c65149be_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PrivateGRIMember_71a73a87-9630-41ef-9e25-1e0e7af7c68d_terseLabel_en-US" xlink:label="lab_ck0001824293_PrivateGRIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private GRI</link:label>
    <link:label id="lab_ck0001824293_PrivateGRIMember_label_en-US" xlink:label="lab_ck0001824293_PrivateGRIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private GRI [Member]</link:label>
    <link:label id="lab_ck0001824293_PrivateGRIMember_documentation_en-US" xlink:label="lab_ck0001824293_PrivateGRIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private GRI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PrivateGRIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PrivateGRIMember" xlink:to="lab_ck0001824293_PrivateGRIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_843558f1-f25f-4242-b4b1-e8188bd4dd8c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_6905dd0c-d209-4880-9c1b-d23e06a1bead_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_db050247-892d-4f6f-a628-6f9dcfba76a6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7be0999e-f790-47f2-93b1-568130a11a55_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_664f599e-e8bb-40a5-ac5f-c7ae54caff9b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional&#160;Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9976f14c-8fba-4f42-9491-50a6009af65e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_41d074e4-6635-48d2-ae98-f315bb5b340a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d18ddad7-9808-4fff-ad52-b554f90662c9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_927fd451-3cff-4aa3-b7db-c2a733c94319_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_2115f6c7-d196-4de2-af04-a3527d405a26_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9fd6b3eb-6e11-4d6d-94a4-f5ef8d4200b2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a3db8579-f760-421a-a683-9d483d200f0b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AardvarkTherapeuticsIncMember_0505605a-b798-48cc-a7dd-5a2700faf28e_terseLabel_en-US" xlink:label="lab_ck0001824293_AardvarkTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aardvark Therapeutics, Inc.</link:label>
    <link:label id="lab_ck0001824293_AardvarkTherapeuticsIncMember_label_en-US" xlink:label="lab_ck0001824293_AardvarkTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aardvark Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_ck0001824293_AardvarkTherapeuticsIncMember_documentation_en-US" xlink:label="lab_ck0001824293_AardvarkTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aardvark Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AardvarkTherapeuticsIncMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_AardvarkTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AardvarkTherapeuticsIncMember" xlink:to="lab_ck0001824293_AardvarkTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_79635cfa-2cad-463b-86bd-08310681edef_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d9480931-5d26-4fb4-8d41-3115d9cfad04_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_6b2e38d0-6392-431c-aeb6-283c4e0853a7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of convertible promissory note</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_61d7b3af-d632-4b38-998c-0d7f99b08894_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b908d6a8-7354-42d7-ba49-8ad49202a2cb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_941c29d5-ac37-4b2f-9d91-6270057a9499_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b3b6f873-a8d3-4611-8fc7-0bce241de1fb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_b1910f5e-8cb7-4dea-9eee-8bd01cc5250e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6bc65637-1de9-4b32-a38a-07c43d7a1d93_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_BankerWarrantsMember_b65b0f4d-6742-44d1-b241-6dc169130888_terseLabel_en-US" xlink:label="lab_ck0001824293_BankerWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banker Warrants</link:label>
    <link:label id="lab_ck0001824293_BankerWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_BankerWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banker Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_BankerWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_BankerWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banker Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BankerWarrantsMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BankerWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_BankerWarrantsMember" xlink:to="lab_ck0001824293_BankerWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_ab46a5f6-9b26-444d-850a-6caa1cd4c308_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a5f1a82-3195-4118-8a28-3e9c6c26bbd3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_2ff7ab47-77d8-4245-ae8e-4af1502a9f87_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5893c390-d613-493c-be79-6868be1605c7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PrivateGRIPlanMember_e9ec89b4-913a-414a-89ae-5505d6ee9446_terseLabel_en-US" xlink:label="lab_ck0001824293_PrivateGRIPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Plan</link:label>
    <link:label id="lab_ck0001824293_PrivateGRIPlanMember_label_en-US" xlink:label="lab_ck0001824293_PrivateGRIPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private GRI Plan [Member]</link:label>
    <link:label id="lab_ck0001824293_PrivateGRIPlanMember_documentation_en-US" xlink:label="lab_ck0001824293_PrivateGRIPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private GRI Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIPlanMember" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PrivateGRIPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PrivateGRIPlanMember" xlink:to="lab_ck0001824293_PrivateGRIPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CallOptionMember_e093eaba-8d06-47ff-91e7-da5e7a3b79fb_terseLabel_en-US" xlink:label="lab_us-gaap_CallOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Option</link:label>
    <link:label id="lab_us-gaap_CallOptionMember_label_en-US" xlink:label="lab_us-gaap_CallOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CallOptionMember" xlink:to="lab_us-gaap_CallOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_176a165d-0cbd-43ca-9f5a-c390418dcb5c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f856fb2e-4abb-4aac-a064-21d9eb703d9d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0d19c655-a6ea-4baa-b3ce-40859a1024d4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24121171-8319-4106-9a75-8c093caf7965_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_7c051cef-ab9d-4c63-8846-ea0bba959a60_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_c63206cd-cbfc-4217-bc6a-000a91ce4131_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7221d5d5-bf8c-4f2d-b21a-0ccb3ace22c8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ClassOfWarrantOrRightExpirationPeriod_418f2205-b6b2-47d7-9091-742ccc5772ee_terseLabel_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantOrRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Period (in months)</link:label>
    <link:label id="lab_ck0001824293_ClassOfWarrantOrRightExpirationPeriod_label_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantOrRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Expiration Period</link:label>
    <link:label id="lab_ck0001824293_ClassOfWarrantOrRightExpirationPeriod_documentation_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantOrRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantOrRightExpirationPeriod" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ClassOfWarrantOrRightExpirationPeriod" xlink:to="lab_ck0001824293_ClassOfWarrantOrRightExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_69404a80-db43-4d87-bd55-329e3d4a07a3_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_CallOptionPrice_704c6be0-d408-460e-9c38-532b8f995050_terseLabel_en-US" xlink:label="lab_ck0001824293_CallOptionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call option price (in usd per share)</link:label>
    <link:label id="lab_ck0001824293_CallOptionPrice_label_en-US" xlink:label="lab_ck0001824293_CallOptionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Option Price</link:label>
    <link:label id="lab_ck0001824293_CallOptionPrice_documentation_en-US" xlink:label="lab_ck0001824293_CallOptionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Option Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CallOptionPrice" xlink:href="ck0001824293-20230930.xsd#ck0001824293_CallOptionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_CallOptionPrice" xlink:to="lab_ck0001824293_CallOptionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3d333e57-115e-4df0-b1b9-247e50abe54b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_1204b750-a533-43d3-ac35-da9682cbdfb7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_d46a5078-9b4c-4b79-9149-40cfdc24389d_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ProceedsFromNonConvertibleDebt_2fc87903-62ba-4a2b-8cf0-4d1f6808d60b_terseLabel_en-US" xlink:label="lab_ck0001824293_ProceedsFromNonConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of non-convertible promissory note</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromNonConvertibleDebt_label_en-US" xlink:label="lab_ck0001824293_ProceedsFromNonConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Non Convertible Debt</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromNonConvertibleDebt_documentation_en-US" xlink:label="lab_ck0001824293_ProceedsFromNonConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Non Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromNonConvertibleDebt" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ProceedsFromNonConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ProceedsFromNonConvertibleDebt" xlink:to="lab_ck0001824293_ProceedsFromNonConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_8a4cbf6e-ec17-47f5-bbfd-a4efd924d4f6_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_493977e5-4e46-4635-a353-876ad7316123_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7744c34a-f829-4a6d-b6c6-06cc0ac659c8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aba08182-05ba-48e2-b0f7-fd0862e560f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5b084168-a017-41ae-9f39-9116103f4ddb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares reserved for future awards (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_3acb4089-18aa-4f80-a751-1fa1afd76773_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_27f9c26b-00c8-4791-9983-9994f4813d08_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_d3cb8a82-07fc-49d3-9749-34bc56995e8f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_7d55c247-dd05-4292-9fcc-b1f78e83d9f7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_96ce1418-ab95-42b9-bb5d-3206765e2b67_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_944b2a6e-91b6-418f-8642-d21e2b4afe4f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba7c93e1-75e1-49c1-906a-605e80f6c54e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term&#160;(years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_d1641ad5-1b30-4639-98fd-7187c6f98a68_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock to Vallon stockholders in reverse recapitalization</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Reverse Recapitalization</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_22d5ff27-c956-4c36-8765-549420ae3438_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ck0001824293-20230930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:a8344312-8d5f-422d-bd63-4db6cc7ddad6,g:d0f905d4-70f6-4e32-afc7-d259f8c67a30-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/Cover" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f7d4ee7a-0547-4273-b4d4-12279c7c4786" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_DocumentType_f7d4ee7a-0547-4273-b4d4-12279c7c4786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_22edff3b-156e-4716-a291-9a7f6eccc119" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_DocumentQuarterlyReport_22edff3b-156e-4716-a291-9a7f6eccc119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e21b7cef-0661-4e9a-b34e-3cc5f8f6d27b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_DocumentPeriodEndDate_e21b7cef-0661-4e9a-b34e-3cc5f8f6d27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_de5e37d6-ad13-459d-8bfa-e1951fd275ba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_DocumentTransitionReport_de5e37d6-ad13-459d-8bfa-e1951fd275ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4ffce8f9-adf3-4aff-8d10-5aa7d4a03c2a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_EntityFileNumber_4ffce8f9-adf3-4aff-8d10-5aa7d4a03c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cbf65178-0657-43d6-a88b-1f42d33a7b10" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_EntityRegistrantName_cbf65178-0657-43d6-a88b-1f42d33a7b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c869ebd9-63c4-412f-87a9-02aa65c773c5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c869ebd9-63c4-412f-87a9-02aa65c773c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_53c40499-4d0a-4e5b-9794-b12bf0e02eca" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_EntityTaxIdentificationNumber_53c40499-4d0a-4e5b-9794-b12bf0e02eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_54efddb6-d081-4973-919d-5002ef4a51b7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_EntityAddressAddressLine1_54efddb6-d081-4973-919d-5002ef4a51b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_26ef6fad-e5fa-498d-9e44-2facb8de2321" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_EntityAddressAddressLine2_26ef6fad-e5fa-498d-9e44-2facb8de2321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_5690d15e-1dd0-4a24-8087-4ef66b4e3c7c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_EntityAddressCityOrTown_5690d15e-1dd0-4a24-8087-4ef66b4e3c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_73947343-4424-49bf-8cc5-ca0036537676" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_EntityAddressStateOrProvince_73947343-4424-49bf-8cc5-ca0036537676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d0f1542e-88cc-41ec-87b8-b9cc19d3752d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_EntityAddressPostalZipCode_d0f1542e-88cc-41ec-87b8-b9cc19d3752d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8e1dabc2-91bd-4e53-be97-1fe0ab362bc2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_CityAreaCode_8e1dabc2-91bd-4e53-be97-1fe0ab362bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0f9d3fc7-2484-4e10-b799-72527dbbd050" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_LocalPhoneNumber_0f9d3fc7-2484-4e10-b799-72527dbbd050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3b1964b5-ab09-4cdb-b754-b145537ce08a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_Security12bTitle_3b1964b5-ab09-4cdb-b754-b145537ce08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f5009209-4bd1-47d3-9e23-26790390c010" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_TradingSymbol_f5009209-4bd1-47d3-9e23-26790390c010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2dc9af00-0655-4d78-9805-43474416f1f0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_SecurityExchangeName_2dc9af00-0655-4d78-9805-43474416f1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a68adb13-95bb-4f95-a4d9-a937eb6fb5bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_EntityCurrentReportingStatus_a68adb13-95bb-4f95-a4d9-a937eb6fb5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_2d091647-a0f3-45a4-ac89-3fa75a165bfd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_EntityInteractiveDataCurrent_2d091647-a0f3-45a4-ac89-3fa75a165bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_5b16374b-5511-43d9-b9d6-b7b12df18470" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_EntityFilerCategory_5b16374b-5511-43d9-b9d6-b7b12df18470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7685e15b-556b-43a7-97f7-2bd4efa09f25" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_EntitySmallBusiness_7685e15b-556b-43a7-97f7-2bd4efa09f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3e6eccdc-42cb-479f-bb70-70832a1959ed" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_EntityEmergingGrowthCompany_3e6eccdc-42cb-479f-bb70-70832a1959ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_caa597e1-ea75-4ce8-839f-1b3a0c50a82a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_EntityExTransitionPeriod_caa597e1-ea75-4ce8-839f-1b3a0c50a82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6eb384d0-48e6-460d-8c27-adb9314e3001" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_EntityShellCompany_6eb384d0-48e6-460d-8c27-adb9314e3001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e1dd734f-1117-4098-bd3b-18c33d401709" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e1dd734f-1117-4098-bd3b-18c33d401709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_82034324-f806-4128-8e2f-d668403b193d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_EntityCentralIndexKey_82034324-f806-4128-8e2f-d668403b193d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4a0e8a03-9860-45da-a6a5-7cb836a0b982" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_CurrentFiscalYearEndDate_4a0e8a03-9860-45da-a6a5-7cb836a0b982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_78c73964-5854-4e3d-a0db-8b3578c6d4a5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_DocumentFiscalYearFocus_78c73964-5854-4e3d-a0db-8b3578c6d4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_4833be07-8d90-42c9-8b12-d5a04644d1c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_DocumentFiscalPeriodFocus_4833be07-8d90-42c9-8b12-d5a04644d1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2602ef4d-c5cb-40a8-9e02-45ab9d31bb74" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ba8e54b9-015a-4e2d-859f-4c219edbe688" xlink:to="loc_dei_AmendmentFlag_2602ef4d-c5cb-40a8-9e02-45ab9d31bb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fd0a7eff-2374-4de1-90f9-273390259ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_123810ea-bec7-4c88-ad15-f0740b3cff55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd0a7eff-2374-4de1-90f9-273390259ae4" xlink:to="loc_us-gaap_AssetsAbstract_123810ea-bec7-4c88-ad15-f0740b3cff55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0c2627d7-49f7-461a-bc26-834fedbcf3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_123810ea-bec7-4c88-ad15-f0740b3cff55" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0c2627d7-49f7-461a-bc26-834fedbcf3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_216c12b4-e909-4ef6-98b0-f27983001263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0c2627d7-49f7-461a-bc26-834fedbcf3ef" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_216c12b4-e909-4ef6-98b0-f27983001263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_19e3cdb9-4d69-4182-80a7-fcb3fe894534" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0c2627d7-49f7-461a-bc26-834fedbcf3ef" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_19e3cdb9-4d69-4182-80a7-fcb3fe894534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3734a613-dcd1-47e7-abd2-529417973a91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0c2627d7-49f7-461a-bc26-834fedbcf3ef" xlink:to="loc_us-gaap_AssetsCurrent_3734a613-dcd1-47e7-abd2-529417973a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6c298bf0-b9ec-4a88-ab0e-1f4fffede820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_123810ea-bec7-4c88-ad15-f0740b3cff55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6c298bf0-b9ec-4a88-ab0e-1f4fffede820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c54b45b7-f9a9-4776-a3e6-97cebf8db428" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_123810ea-bec7-4c88-ad15-f0740b3cff55" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c54b45b7-f9a9-4776-a3e6-97cebf8db428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_10940037-ce52-494d-ac40-704034e3bc0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_123810ea-bec7-4c88-ad15-f0740b3cff55" xlink:to="loc_us-gaap_Assets_10940037-ce52-494d-ac40-704034e3bc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f4c4028a-424f-4997-9788-3db5d1c0ddf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd0a7eff-2374-4de1-90f9-273390259ae4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f4c4028a-424f-4997-9788-3db5d1c0ddf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_eec87516-e9fe-4454-a474-d74569e192a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f4c4028a-424f-4997-9788-3db5d1c0ddf5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_eec87516-e9fe-4454-a474-d74569e192a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_456bf630-7b4a-45d8-a4d9-16b977737148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eec87516-e9fe-4454-a474-d74569e192a1" xlink:to="loc_us-gaap_AccountsPayableCurrent_456bf630-7b4a-45d8-a4d9-16b977737148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8bec59ea-a702-4c73-81a0-c99952b44d68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eec87516-e9fe-4454-a474-d74569e192a1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8bec59ea-a702-4c73-81a0-c99952b44d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_EmployeeAdvancesCurrent_3460da3f-0bf0-4127-8ece-324ca917e696" xlink:href="ck0001824293-20230930.xsd#ck0001824293_EmployeeAdvancesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eec87516-e9fe-4454-a474-d74569e192a1" xlink:to="loc_ck0001824293_EmployeeAdvancesCurrent_3460da3f-0bf0-4127-8ece-324ca917e696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_a8cc29d4-d23d-4a24-a999-f4884c7461ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eec87516-e9fe-4454-a474-d74569e192a1" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_a8cc29d4-d23d-4a24-a999-f4884c7461ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_249626bc-1700-44f1-a789-a742a91981ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eec87516-e9fe-4454-a474-d74569e192a1" xlink:to="loc_us-gaap_NotesPayableCurrent_249626bc-1700-44f1-a789-a742a91981ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_93186f12-15db-4179-bf5c-fb8c70a227f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eec87516-e9fe-4454-a474-d74569e192a1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_93186f12-15db-4179-bf5c-fb8c70a227f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1101c784-69de-41b2-b381-bdd6432ce9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eec87516-e9fe-4454-a474-d74569e192a1" xlink:to="loc_us-gaap_LiabilitiesCurrent_1101c784-69de-41b2-b381-bdd6432ce9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5fc49f1b-7b51-4fd3-bcc5-bd6dbac7e052" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f4c4028a-424f-4997-9788-3db5d1c0ddf5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5fc49f1b-7b51-4fd3-bcc5-bd6dbac7e052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_20866746-000d-41f6-a853-b43d8d1fff77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f4c4028a-424f-4997-9788-3db5d1c0ddf5" xlink:to="loc_us-gaap_Liabilities_20866746-000d-41f6-a853-b43d8d1fff77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_64f8e21b-42b1-4df6-920b-f5201595b59c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f4c4028a-424f-4997-9788-3db5d1c0ddf5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_64f8e21b-42b1-4df6-920b-f5201595b59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a54fb60a-0854-45a1-bbdc-1ad70fcef564" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f4c4028a-424f-4997-9788-3db5d1c0ddf5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a54fb60a-0854-45a1-bbdc-1ad70fcef564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_746dc0da-3872-4d3a-b112-b8b459f9f2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a54fb60a-0854-45a1-bbdc-1ad70fcef564" xlink:to="loc_us-gaap_CommonStockValueOutstanding_746dc0da-3872-4d3a-b112-b8b459f9f2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3a55256f-df04-4d0d-915f-d9a9a73e82f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a54fb60a-0854-45a1-bbdc-1ad70fcef564" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3a55256f-df04-4d0d-915f-d9a9a73e82f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5230f65f-741d-4e26-8c03-68c3273d3821" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a54fb60a-0854-45a1-bbdc-1ad70fcef564" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5230f65f-741d-4e26-8c03-68c3273d3821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_270cfb2a-e1f8-481e-a69c-e8f760945549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a54fb60a-0854-45a1-bbdc-1ad70fcef564" xlink:to="loc_us-gaap_StockholdersEquity_270cfb2a-e1f8-481e-a69c-e8f760945549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_982142b9-190c-437a-85a8-06e033d890ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f4c4028a-424f-4997-9788-3db5d1c0ddf5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_982142b9-190c-437a-85a8-06e033d890ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ed580d3c-747d-4612-8dac-0c15e80c3293" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_20e1d358-5696-499c-b008-338c6af71e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ed580d3c-747d-4612-8dac-0c15e80c3293" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_20e1d358-5696-499c-b008-338c6af71e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_feb98184-7d12-457b-a32e-e66c486921ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ed580d3c-747d-4612-8dac-0c15e80c3293" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_feb98184-7d12-457b-a32e-e66c486921ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5e7775a6-33e7-404f-b614-dd9df6307dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ed580d3c-747d-4612-8dac-0c15e80c3293" xlink:to="loc_us-gaap_CommonStockSharesIssued_5e7775a6-33e7-404f-b614-dd9df6307dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_738287c5-1c70-44bb-bcb6-7cb52e475a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ed580d3c-747d-4612-8dac-0c15e80c3293" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_738287c5-1c70-44bb-bcb6-7cb52e475a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_207a94f3-73fe-4c0c-afae-6307f90d7bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_17d012be-b972-42a9-8196-94cb18fa8b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_207a94f3-73fe-4c0c-afae-6307f90d7bdc" xlink:to="loc_us-gaap_OperatingExpensesAbstract_17d012be-b972-42a9-8196-94cb18fa8b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_460f9c9f-3d18-4926-9e75-ab4cbaaa84d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_17d012be-b972-42a9-8196-94cb18fa8b9f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_460f9c9f-3d18-4926-9e75-ab4cbaaa84d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_88282459-b8a3-43c2-a874-4a90aecc1f09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_17d012be-b972-42a9-8196-94cb18fa8b9f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_88282459-b8a3-43c2-a874-4a90aecc1f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_45edd9e7-0917-49aa-b183-c4c51a7411cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_17d012be-b972-42a9-8196-94cb18fa8b9f" xlink:to="loc_us-gaap_OperatingExpenses_45edd9e7-0917-49aa-b183-c4c51a7411cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_faa542ce-45dd-42c8-8cef-5ac8c82b29a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_207a94f3-73fe-4c0c-afae-6307f90d7bdc" xlink:to="loc_us-gaap_OperatingIncomeLoss_faa542ce-45dd-42c8-8cef-5ac8c82b29a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_0138c790-ae30-4869-b3c9-96c31ea16bb5" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ChangeInFairValueOfWarrantLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_207a94f3-73fe-4c0c-afae-6307f90d7bdc" xlink:to="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_0138c790-ae30-4869-b3c9-96c31ea16bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bf932a53-73a2-49e0-9183-994ebb001bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_207a94f3-73fe-4c0c-afae-6307f90d7bdc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bf932a53-73a2-49e0-9183-994ebb001bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_cf218f1f-d41e-4fb1-aa1f-42ccc57438a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_207a94f3-73fe-4c0c-afae-6307f90d7bdc" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_cf218f1f-d41e-4fb1-aa1f-42ccc57438a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_74c0f031-991f-48e5-b1b4-f9a6c23f5c76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_207a94f3-73fe-4c0c-afae-6307f90d7bdc" xlink:to="loc_us-gaap_NetIncomeLoss_74c0f031-991f-48e5-b1b4-f9a6c23f5c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4c350df4-588e-4dad-9f50-abd116367cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_207a94f3-73fe-4c0c-afae-6307f90d7bdc" xlink:to="loc_us-gaap_EarningsPerShareBasic_4c350df4-588e-4dad-9f50-abd116367cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_15c9c017-9249-4869-a171-ad83db2e1359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_207a94f3-73fe-4c0c-afae-6307f90d7bdc" xlink:to="loc_us-gaap_EarningsPerShareDiluted_15c9c017-9249-4869-a171-ad83db2e1359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_43566c84-c2c0-4275-bd53-92c5d3e3d640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_207a94f3-73fe-4c0c-afae-6307f90d7bdc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_43566c84-c2c0-4275-bd53-92c5d3e3d640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9bca70a0-2bfe-4b7c-ae70-556cdff3fb41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_207a94f3-73fe-4c0c-afae-6307f90d7bdc" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9bca70a0-2bfe-4b7c-ae70-556cdff3fb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#ConsolidatedStatementsofChangesinStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_29412474-2f97-43f6-b73e-4e227035544f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c6f661cd-03ad-491f-92d5-d35a3e28d22d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_29412474-2f97-43f6-b73e-4e227035544f" xlink:to="loc_us-gaap_StatementTable_c6f661cd-03ad-491f-92d5-d35a3e28d22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d8065713-8a39-4d6d-a932-1ac6b1344b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c6f661cd-03ad-491f-92d5-d35a3e28d22d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d8065713-8a39-4d6d-a932-1ac6b1344b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8b4f7afc-5aeb-486c-a1cd-35e97ffdc85b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d8065713-8a39-4d6d-a932-1ac6b1344b8b" xlink:to="loc_us-gaap_EquityComponentDomain_8b4f7afc-5aeb-486c-a1cd-35e97ffdc85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_be9f3bb4-411e-4924-a434-549ceda3419a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8b4f7afc-5aeb-486c-a1cd-35e97ffdc85b" xlink:to="loc_us-gaap_CommonStockMember_be9f3bb4-411e-4924-a434-549ceda3419a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e1ea18a4-867d-4841-a37f-a85da809ac18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8b4f7afc-5aeb-486c-a1cd-35e97ffdc85b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e1ea18a4-867d-4841-a37f-a85da809ac18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_147dfe61-2454-42be-8100-2737defa0553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8b4f7afc-5aeb-486c-a1cd-35e97ffdc85b" xlink:to="loc_us-gaap_RetainedEarningsMember_147dfe61-2454-42be-8100-2737defa0553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c01a5b80-bea7-4331-96a3-0245c388ce50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c6f661cd-03ad-491f-92d5-d35a3e28d22d" xlink:to="loc_us-gaap_StatementLineItems_c01a5b80-bea7-4331-96a3-0245c388ce50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_341bd6b4-627e-4538-a2f4-211b25dbb692" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c01a5b80-bea7-4331-96a3-0245c388ce50" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_341bd6b4-627e-4538-a2f4-211b25dbb692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_2bb8856d-0882-42ce-a1f0-22e51864fb45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_341bd6b4-627e-4538-a2f4-211b25dbb692" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_2bb8856d-0882-42ce-a1f0-22e51864fb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_de815f0b-f663-4247-aee1-59d00ebd18e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_341bd6b4-627e-4538-a2f4-211b25dbb692" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_de815f0b-f663-4247-aee1-59d00ebd18e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1514089c-cc98-4e29-8da5-ec39e3c6db30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_341bd6b4-627e-4538-a2f4-211b25dbb692" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1514089c-cc98-4e29-8da5-ec39e3c6db30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9b834e62-d557-4f6d-ad49-53eb0e156469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_341bd6b4-627e-4538-a2f4-211b25dbb692" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9b834e62-d557-4f6d-ad49-53eb0e156469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c01a5b80-bea7-4331-96a3-0245c388ce50" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8b579558-3228-4edb-b768-3c5801edc7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8b579558-3228-4edb-b768-3c5801edc7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ad582fe7-691d-467b-a178-585688f956bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_us-gaap_StockholdersEquity_ad582fe7-691d-467b-a178-585688f956bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_734a915e-2ddd-4b7e-8d65-fc837e00ed09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_734a915e-2ddd-4b7e-8d65-fc837e00ed09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8ae44958-1e22-4482-b08d-1f9f4360209a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8ae44958-1e22-4482-b08d-1f9f4360209a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_849f1c7c-41ec-4126-ac50-10defbdfc048" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_849f1c7c-41ec-4126-ac50-10defbdfc048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6b229e6f-f489-45e9-8e92-bdb2a564a991" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6b229e6f-f489-45e9-8e92-bdb2a564a991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_b1f56bf1-335b-4ddc-a726-cf28af78e44e" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_b1f56bf1-335b-4ddc-a726-cf28af78e44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_b4dbb1e0-7e45-4e52-8dd0-1cfb24cbef1e" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodValueWarrantExercises"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_b4dbb1e0-7e45-4e52-8dd0-1cfb24cbef1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_c2a82781-4a3e-41fa-86ab-f6390b04bf9b" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_c2a82781-4a3e-41fa-86ab-f6390b04bf9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_2d5ef838-e98b-49fe-bbfc-b41c786354b2" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_2d5ef838-e98b-49fe-bbfc-b41c786354b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_1ea051aa-3054-48f9-9451-d0ae60b88878" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_1ea051aa-3054-48f9-9451-d0ae60b88878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_4125791d-9c9a-4d1b-8780-f9c976fa5f18" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_4125791d-9c9a-4d1b-8780-f9c976fa5f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_127c9567-eb1a-4676-b8b3-cebf73a43a71" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_127c9567-eb1a-4676-b8b3-cebf73a43a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_3df8ed87-35bb-43f5-88b6-69514ee99eae" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_3df8ed87-35bb-43f5-88b6-69514ee99eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_eeacf47e-d580-4e34-bfb2-959faf0fe531" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_eeacf47e-d580-4e34-bfb2-959faf0fe531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_a7953170-509b-4ab2-8640-3b82436f8ba1" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_a7953170-509b-4ab2-8640-3b82436f8ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c97a9a7-5fc7-422e-8375-55b42085a063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_us-gaap_NetIncomeLoss_5c97a9a7-5fc7-422e-8375-55b42085a063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_662300e0-3fa3-49ae-8640-d910168415ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_662300e0-3fa3-49ae-8640-d910168415ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_45e9dfbf-b32c-42b0-b2f0-f972d027d025" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5562cd06-e058-4375-8587-178d8c0a382f" xlink:to="loc_us-gaap_StockholdersEquity_45e9dfbf-b32c-42b0-b2f0-f972d027d025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7ad6917a-cfb5-44ba-adfe-9bb213144c82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1f58aaf1-39a2-4d7c-8917-d30c414cb2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ad6917a-cfb5-44ba-adfe-9bb213144c82" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1f58aaf1-39a2-4d7c-8917-d30c414cb2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d2bc7291-4cda-4619-b7c1-6abef0323034" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1f58aaf1-39a2-4d7c-8917-d30c414cb2bd" xlink:to="loc_us-gaap_NetIncomeLoss_d2bc7291-4cda-4619-b7c1-6abef0323034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6aa0d3c2-83c8-4229-b878-d8a74de73d18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1f58aaf1-39a2-4d7c-8917-d30c414cb2bd" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6aa0d3c2-83c8-4229-b878-d8a74de73d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_6b6964c9-4f63-4b1c-96a3-d01e4d92d7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6aa0d3c2-83c8-4229-b878-d8a74de73d18" xlink:to="loc_us-gaap_Depreciation_6b6964c9-4f63-4b1c-96a3-d01e4d92d7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a1a57743-623c-49c0-b9e6-f54645947c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6aa0d3c2-83c8-4229-b878-d8a74de73d18" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a1a57743-623c-49c0-b9e6-f54645947c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_010878e6-f7db-45f6-9ec5-eef7c279e4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6aa0d3c2-83c8-4229-b878-d8a74de73d18" xlink:to="loc_us-gaap_ShareBasedCompensation_010878e6-f7db-45f6-9ec5-eef7c279e4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_f4ba9414-3b9d-40e6-a585-8c79ffc65aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6aa0d3c2-83c8-4229-b878-d8a74de73d18" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_f4ba9414-3b9d-40e6-a585-8c79ffc65aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b87f47a0-bb45-4c7e-a969-eda7fe94b5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6aa0d3c2-83c8-4229-b878-d8a74de73d18" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b87f47a0-bb45-4c7e-a969-eda7fe94b5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_571545d5-e2a6-46b9-af75-e08122d41ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6aa0d3c2-83c8-4229-b878-d8a74de73d18" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_571545d5-e2a6-46b9-af75-e08122d41ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a371e8dd-b84c-4734-8ad1-566c6eca684b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_571545d5-e2a6-46b9-af75-e08122d41ae9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a371e8dd-b84c-4734-8ad1-566c6eca684b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3a815d47-4c5c-48da-becf-6a0dbf0ff77b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_571545d5-e2a6-46b9-af75-e08122d41ae9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3a815d47-4c5c-48da-becf-6a0dbf0ff77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1e1ddfde-796b-4737-a791-928e7c443518" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_571545d5-e2a6-46b9-af75-e08122d41ae9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1e1ddfde-796b-4737-a791-928e7c443518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d620a51c-f4ff-4dec-b359-803873a57e81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_571545d5-e2a6-46b9-af75-e08122d41ae9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d620a51c-f4ff-4dec-b359-803873a57e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a679d1b-14cc-48d1-98d7-02aaf3d6b73d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6aa0d3c2-83c8-4229-b878-d8a74de73d18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a679d1b-14cc-48d1-98d7-02aaf3d6b73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_41da0b17-a9f8-4427-b669-263a28abba9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ad6917a-cfb5-44ba-adfe-9bb213144c82" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_41da0b17-a9f8-4427-b669-263a28abba9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e2318b45-589d-485f-9a35-13004daa2fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_41da0b17-a9f8-4427-b669-263a28abba9f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e2318b45-589d-485f-9a35-13004daa2fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d31b11c8-0cd0-4f03-a683-05eb7049772b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_41da0b17-a9f8-4427-b669-263a28abba9f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d31b11c8-0cd0-4f03-a683-05eb7049772b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b0ef25-34a0-4f76-aac6-c1226b4508a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ad6917a-cfb5-44ba-adfe-9bb213144c82" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b0ef25-34a0-4f76-aac6-c1226b4508a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_5587658e-5a68-4437-afab-032c383d6539" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ProceedsFromAdvancesFromEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b0ef25-34a0-4f76-aac6-c1226b4508a6" xlink:to="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_5587658e-5a68-4437-afab-032c383d6539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_3839bba7-0ae1-48cf-9194-a62381b55aee" xlink:href="ck0001824293-20230930.xsd#ck0001824293_RepaymentOfAdvancesFromEmployees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b0ef25-34a0-4f76-aac6-c1226b4508a6" xlink:to="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_3839bba7-0ae1-48cf-9194-a62381b55aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromNonConvertibleDebt_cd1f4672-de88-428a-bfc7-2a990061e463" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ProceedsFromNonConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b0ef25-34a0-4f76-aac6-c1226b4508a6" xlink:to="loc_ck0001824293_ProceedsFromNonConvertibleDebt_cd1f4672-de88-428a-bfc7-2a990061e463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_186e272c-b8ea-48e2-af18-2083216a10e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b0ef25-34a0-4f76-aac6-c1226b4508a6" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_186e272c-b8ea-48e2-af18-2083216a10e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dd59471c-a7e3-4862-a306-c480d1c67485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b0ef25-34a0-4f76-aac6-c1226b4508a6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dd59471c-a7e3-4862-a306-c480d1c67485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_7b0329c0-c944-4cb7-979e-60db4ed9129a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b0ef25-34a0-4f76-aac6-c1226b4508a6" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_7b0329c0-c944-4cb7-979e-60db4ed9129a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_4472db89-0acf-472f-9c3d-b489c13f08a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b0ef25-34a0-4f76-aac6-c1226b4508a6" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_4472db89-0acf-472f-9c3d-b489c13f08a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_f8bbb9a7-18de-4df4-af2b-2ef2976b8eb2" xlink:href="ck0001824293-20230930.xsd#ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b0ef25-34a0-4f76-aac6-c1226b4508a6" xlink:to="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_f8bbb9a7-18de-4df4-af2b-2ef2976b8eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_7ea52c6e-f17b-430b-8102-01e46823b8c7" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PaymentOfReverseRecapitalizationCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b0ef25-34a0-4f76-aac6-c1226b4508a6" xlink:to="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_7ea52c6e-f17b-430b-8102-01e46823b8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b37ac636-2a03-45b7-85b7-058c0ee94ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b0ef25-34a0-4f76-aac6-c1226b4508a6" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b37ac636-2a03-45b7-85b7-058c0ee94ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9f4a9fd8-4aef-4856-804e-c95aa9dbd26f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b0ef25-34a0-4f76-aac6-c1226b4508a6" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9f4a9fd8-4aef-4856-804e-c95aa9dbd26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d51c75d6-0252-4103-87c8-94d7d070cda4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b0ef25-34a0-4f76-aac6-c1226b4508a6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d51c75d6-0252-4103-87c8-94d7d070cda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f20eb1c6-3f48-44ad-9e0e-e59437d817a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ad6917a-cfb5-44ba-adfe-9bb213144c82" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f20eb1c6-3f48-44ad-9e0e-e59437d817a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_76ef0f6a-0ff7-468d-a720-dfa49eac7ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ad6917a-cfb5-44ba-adfe-9bb213144c82" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_76ef0f6a-0ff7-468d-a720-dfa49eac7ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b44a8431-ce12-4c60-8d0c-3c61cb6e3b55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ad6917a-cfb5-44ba-adfe-9bb213144c82" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b44a8431-ce12-4c60-8d0c-3c61cb6e3b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_77e648b2-ddec-43b5-b636-e9408a41482b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7ad6917a-cfb5-44ba-adfe-9bb213144c82" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_77e648b2-ddec-43b5-b636-e9408a41482b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable_b0b25292-6deb-4f47-b9f7-cab3c569034c" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedForRepaymentOfNotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_77e648b2-ddec-43b5-b636-e9408a41482b" xlink:to="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable_b0b25292-6deb-4f47-b9f7-cab3c569034c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_640f945b-bc71-41c5-a829-ee87cc7bf7ca" xlink:href="ck0001824293-20230930.xsd#ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_77e648b2-ddec-43b5-b636-e9408a41482b" xlink:to="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_640f945b-bc71-41c5-a829-ee87cc7bf7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_b983362d-66f6-4726-a4de-d7c35c1b74a7" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_77e648b2-ddec-43b5-b636-e9408a41482b" xlink:to="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_b983362d-66f6-4726-a4de-d7c35c1b74a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIssued_f088d7e6-60cd-468a-b86b-b65eeeeb5221" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_77e648b2-ddec-43b5-b636-e9408a41482b" xlink:to="loc_ck0001824293_WarrantsIssued_f088d7e6-60cd-468a-b86b-b65eeeeb5221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NoncashMergerRelatedCostsFinancingActivities_8aa6340b-166c-4c2b-8379-3950d0ac1b97" xlink:href="ck0001824293-20230930.xsd#ck0001824293_NoncashMergerRelatedCostsFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_77e648b2-ddec-43b5-b636-e9408a41482b" xlink:to="loc_ck0001824293_NoncashMergerRelatedCostsFinancingActivities_8aa6340b-166c-4c2b-8379-3950d0ac1b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a2104ebb-f2ea-403e-9649-93f4ee851485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_d308baf2-e1ca-407c-9092-851a3b576c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a2104ebb-f2ea-403e-9649-93f4ee851485" xlink:to="loc_us-gaap_NatureOfOperations_d308baf2-e1ca-407c-9092-851a3b576c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#LIQUIDITY"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_094135eb-0a5e-47fa-a495-4967e70c0fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_ac97c1e1-0714-4a86-a2d8-442728aeffa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_094135eb-0a5e-47fa-a495-4967e70c0fe1" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_ac97c1e1-0714-4a86-a2d8-442728aeffa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1a430699-6267-443f-86bb-1230b945dd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_3d152278-e408-4e04-9527-3e9361703d66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a430699-6267-443f-86bb-1230b945dd0a" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_3d152278-e408-4e04-9527-3e9361703d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLON" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#MERGERWITHVALLON"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLON" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_571b7e9e-443a-42a8-9405-080fd662d1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_6daf7739-d1b6-45b9-8216-817538239287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_571b7e9e-443a-42a8-9405-080fd662d1ab" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_6daf7739-d1b6-45b9-8216-817538239287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4bee54ad-9c6b-4d40-8fe6-3f5d373f99c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_bbe19fa0-fdd9-4da0-a8e6-b5846e3b7d05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4bee54ad-9c6b-4d40-8fe6-3f5d373f99c0" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_bbe19fa0-fdd9-4da0-a8e6-b5846e3b7d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#PROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b4014081-1ca5-4961-ae91-6b43d37770b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_d17fddae-6dd5-416d-8494-05d6edb0496a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b4014081-1ca5-4961-ae91-6b43d37770b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_d17fddae-6dd5-416d-8494-05d6edb0496a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0b9cfeb0-bb22-47ca-b963-aaec9e692741" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_a741f2e9-8c76-4bc7-97bd-4b55aa5dda40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0b9cfeb0-bb22-47ca-b963-aaec9e692741" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_a741f2e9-8c76-4bc7-97bd-4b55aa5dda40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTES" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#PROMISSORYNOTES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROMISSORYNOTES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d82f2bc1-95e1-4293-9701-8db1e1032d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_fb73ef75-c8bf-4ed8-9bf1-2e37c917dbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d82f2bc1-95e1-4293-9701-8db1e1032d8f" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_fb73ef75-c8bf-4ed8-9bf1-2e37c917dbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f7c70440-9c9e-4141-8368-c579f0a64d31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6b51afb0-d859-494d-a555-7eeb156fd5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f7c70440-9c9e-4141-8368-c579f0a64d31" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6b51afb0-d859-494d-a555-7eeb156fd5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENT" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#ASSETPURCHASEAGREEMENT"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_47508185-438b-44e8-b562-e43bb68ec3de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock_be7c072e-66a3-401e-8939-0fa88f430316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_47508185-438b-44e8-b562-e43bb68ec3de" xlink:to="loc_us-gaap_AssetAcquisitionTextBlock_be7c072e-66a3-401e-8939-0fa88f430316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37f4e989-e183-404e-b521-664442ffef5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_50ed061b-511d-42d8-83a8-468b6a57a1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37f4e989-e183-404e-b521-664442ffef5e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_50ed061b-511d-42d8-83a8-468b6a57a1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9d0c5b90-2c33-4fad-aa57-73b9be133bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_09628daa-4234-426d-b550-f7ca0a8bca07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9d0c5b90-2c33-4fad-aa57-73b9be133bc2" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_09628daa-4234-426d-b550-f7ca0a8bca07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0986d52c-cdf3-40a2-a5c0-7b0896f0675e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d183a30a-89bf-407a-a1bb-8e943c7d05ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0986d52c-cdf3-40a2-a5c0-7b0896f0675e" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d183a30a-89bf-407a-a1bb-8e943c7d05ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_e90fe50e-0cd5-40ac-bfda-8e1edaf85ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0986d52c-cdf3-40a2-a5c0-7b0896f0675e" xlink:to="loc_us-gaap_UseOfEstimates_e90fe50e-0cd5-40ac-bfda-8e1edaf85ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1399b8e4-3230-470a-bfb9-cb1a76c9c835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0986d52c-cdf3-40a2-a5c0-7b0896f0675e" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1399b8e4-3230-470a-bfb9-cb1a76c9c835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1cfecde6-70e3-413c-a228-44ba183b9b16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0986d52c-cdf3-40a2-a5c0-7b0896f0675e" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1cfecde6-70e3-413c-a228-44ba183b9b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_c04d8fdf-0dae-4b2a-b08c-4806929c45c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0986d52c-cdf3-40a2-a5c0-7b0896f0675e" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_c04d8fdf-0dae-4b2a-b08c-4806929c45c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_f499f9c2-951f-401d-8736-d7e147f6f221" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0986d52c-cdf3-40a2-a5c0-7b0896f0675e" xlink:to="loc_us-gaap_DebtPolicyTextBlock_f499f9c2-951f-401d-8736-d7e147f6f221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6427129c-d0be-4249-8e49-3861f7ed8454" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0986d52c-cdf3-40a2-a5c0-7b0896f0675e" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6427129c-d0be-4249-8e49-3861f7ed8454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_467aad15-0dbf-44da-bfc3-1d21cae7bf9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0986d52c-cdf3-40a2-a5c0-7b0896f0675e" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_467aad15-0dbf-44da-bfc3-1d21cae7bf9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fce6201a-1a0d-427e-bf0d-52c5fbe1f1df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0986d52c-cdf3-40a2-a5c0-7b0896f0675e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fce6201a-1a0d-427e-bf0d-52c5fbe1f1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_791bece1-f3a8-4b99-8738-bd6ca3b4afda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d0717a4f-6855-4d9a-ba89-104032a9907e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_791bece1-f3a8-4b99-8738-bd6ca3b4afda" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d0717a4f-6855-4d9a-ba89-104032a9907e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONTables" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#MERGERWITHVALLONTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3fa1beba-db61-4d61-b21d-470e20118f03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_3eb19da2-aaae-45f8-a37a-ffa218500dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3fa1beba-db61-4d61-b21d-470e20118f03" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_3eb19da2-aaae-45f8-a37a-ffa218500dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_77e41331-e15d-4bad-b69a-a04b58fcd4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d1175552-0a16-4a7d-93d0-0cb795ace7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_77e41331-e15d-4bad-b69a-a04b58fcd4c4" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d1175552-0a16-4a7d-93d0-0cb795ace7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a61c3a95-d8a8-4b4c-bb28-fcd167c4cc81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_77e41331-e15d-4bad-b69a-a04b58fcd4c4" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a61c3a95-d8a8-4b4c-bb28-fcd167c4cc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_bf73aef9-881c-4e72-a191-a9731322e10a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_77e41331-e15d-4bad-b69a-a04b58fcd4c4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_bf73aef9-881c-4e72-a191-a9731322e10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fbc80065-63d1-4799-aca9-bea651940404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e39181d1-c54c-4795-9f2e-f814d4956f03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fbc80065-63d1-4799-aca9-bea651940404" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e39181d1-c54c-4795-9f2e-f814d4956f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_349b8b04-b33a-4fef-9bf5-46f14f0f3d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_37753ddf-0f96-4d4b-b841-2755eb31d15c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_349b8b04-b33a-4fef-9bf5-46f14f0f3d5a" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_37753ddf-0f96-4d4b-b841-2755eb31d15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_dd02f1ba-8b8b-4168-a9b3-6161b7826083" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1741f6f2-ecbe-4dd3-8ef1-511d10cbb764" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dd02f1ba-8b8b-4168-a9b3-6161b7826083" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1741f6f2-ecbe-4dd3-8ef1-511d10cbb764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0bb7a18d-1a4f-458c-9abd-417bef1c2e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dd02f1ba-8b8b-4168-a9b3-6161b7826083" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0bb7a18d-1a4f-458c-9abd-417bef1c2e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a4b4caa-d64f-417f-9811-a66543edd9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bfc0b27b-6355-43b2-883c-d67ba5dec46c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a4b4caa-d64f-417f-9811-a66543edd9b2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bfc0b27b-6355-43b2-883c-d67ba5dec46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8e1a3665-54db-4f04-baf4-ee67c6bda074" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a4b4caa-d64f-417f-9811-a66543edd9b2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8e1a3665-54db-4f04-baf4-ee67c6bda074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3352dd92-f7a9-41eb-af87-3d3ef69d3c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a4b4caa-d64f-417f-9811-a66543edd9b2" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3352dd92-f7a9-41eb-af87-3d3ef69d3c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_85677367-e39b-4f02-a25d-f5088cd3d2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_29e883eb-fc32-4541-b7ab-cdef23b59ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_85677367-e39b-4f02-a25d-f5088cd3d2ed" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_29e883eb-fc32-4541-b7ab-cdef23b59ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockExchangeRatio_caf790f1-9588-4f17-ae4a-0994ce13ffda" xlink:href="ck0001824293-20230930.xsd#ck0001824293_CommonStockExchangeRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_85677367-e39b-4f02-a25d-f5088cd3d2ed" xlink:to="loc_ck0001824293_CommonStockExchangeRatio_caf790f1-9588-4f17-ae4a-0994ce13ffda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#LIQUIDITYDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635980e5-0d3b-458b-878a-414643afa56d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f7119b25-3e1b-4f39-b6f0-5b342cb48def" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635980e5-0d3b-458b-878a-414643afa56d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f7119b25-3e1b-4f39-b6f0-5b342cb48def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_082252ca-215e-4161-b553-4a8b89260804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635980e5-0d3b-458b-878a-414643afa56d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_082252ca-215e-4161-b553-4a8b89260804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1d4d26f5-11d8-4883-aa30-9e2102f3490d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635980e5-0d3b-458b-878a-414643afa56d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1d4d26f5-11d8-4883-aa30-9e2102f3490d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1f019181-23f7-4331-92cf-12d78ceae4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1d4d26f5-11d8-4883-aa30-9e2102f3490d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1f019181-23f7-4331-92cf-12d78ceae4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9954218d-6e21-4e65-83a8-1c4416da2f63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1f019181-23f7-4331-92cf-12d78ceae4e5" xlink:to="loc_us-gaap_RelatedPartyDomain_9954218d-6e21-4e65-83a8-1c4416da2f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_dbd71b04-2f21-439f-9878-43b3b32e4509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9954218d-6e21-4e65-83a8-1c4416da2f63" xlink:to="loc_us-gaap_InvestorMember_dbd71b04-2f21-439f-9878-43b3b32e4509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e4cfc8c1-79e4-4020-a600-e5f0841fc099" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1d4d26f5-11d8-4883-aa30-9e2102f3490d" xlink:to="loc_dei_LegalEntityAxis_e4cfc8c1-79e4-4020-a600-e5f0841fc099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b14093f2-d6f4-4742-97e8-076a0fc2059e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e4cfc8c1-79e4-4020-a600-e5f0841fc099" xlink:to="loc_dei_EntityDomain_b14093f2-d6f4-4742-97e8-076a0fc2059e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_4a6c2f84-3381-4046-ae45-ef5463d9992d" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PrivateGRIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b14093f2-d6f4-4742-97e8-076a0fc2059e" xlink:to="loc_ck0001824293_PrivateGRIMember_4a6c2f84-3381-4046-ae45-ef5463d9992d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6ae3f028-5319-44dd-ba8e-2cb98b05103c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1d4d26f5-11d8-4883-aa30-9e2102f3490d" xlink:to="loc_srt_CounterpartyNameAxis_6ae3f028-5319-44dd-ba8e-2cb98b05103c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd3e8637-9aaa-4559-8728-3dcbbf38f57d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6ae3f028-5319-44dd-ba8e-2cb98b05103c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd3e8637-9aaa-4559-8728-3dcbbf38f57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIBioIncMember_5bde6578-bcb9-42a7-8dd5-4546dae35e46" xlink:href="ck0001824293-20230930.xsd#ck0001824293_GRIBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd3e8637-9aaa-4559-8728-3dcbbf38f57d" xlink:to="loc_ck0001824293_GRIBioIncMember_5bde6578-bcb9-42a7-8dd5-4546dae35e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cc21b3d3-5d70-467a-a815-0a7f7964427f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1d4d26f5-11d8-4883-aa30-9e2102f3490d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cc21b3d3-5d70-467a-a815-0a7f7964427f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_da5babea-5b75-472b-bbef-3049ad06b958" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cc21b3d3-5d70-467a-a815-0a7f7964427f" xlink:to="loc_us-gaap_EquityComponentDomain_da5babea-5b75-472b-bbef-3049ad06b958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ad76bc10-db08-4d8f-8991-8dc353fd79be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_da5babea-5b75-472b-bbef-3049ad06b958" xlink:to="loc_us-gaap_CommonStockMember_ad76bc10-db08-4d8f-8991-8dc353fd79be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7f421ab7-9b6f-4489-99ad-2a371982c49c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1d4d26f5-11d8-4883-aa30-9e2102f3490d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7f421ab7-9b6f-4489-99ad-2a371982c49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3b5816ef-9cfa-4d96-8e74-c3097d9a45a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7f421ab7-9b6f-4489-99ad-2a371982c49c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3b5816ef-9cfa-4d96-8e74-c3097d9a45a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesTWarrantsMember_5c9ae12f-a61d-4039-9962-7ad821ba6cc3" xlink:href="ck0001824293-20230930.xsd#ck0001824293_SeriesTWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3b5816ef-9cfa-4d96-8e74-c3097d9a45a5" xlink:to="loc_ck0001824293_SeriesTWarrantsMember_5c9ae12f-a61d-4039-9962-7ad821ba6cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_99eae6bd-40a6-4c26-a206-9b2bf7b69e6c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1d4d26f5-11d8-4883-aa30-9e2102f3490d" xlink:to="loc_srt_RangeAxis_99eae6bd-40a6-4c26-a206-9b2bf7b69e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1a20e828-2c47-4f99-a050-6f045d1eb35c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_99eae6bd-40a6-4c26-a206-9b2bf7b69e6c" xlink:to="loc_srt_RangeMember_1a20e828-2c47-4f99-a050-6f045d1eb35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_9667f2a1-b294-4205-9cfb-f1e7409cabc5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1a20e828-2c47-4f99-a050-6f045d1eb35c" xlink:to="loc_srt_WeightedAverageMember_9667f2a1-b294-4205-9cfb-f1e7409cabc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1d4d26f5-11d8-4883-aa30-9e2102f3490d" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_f0a38e0c-a569-418b-a6d1-ca2dacbe5b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_f0a38e0c-a569-418b-a6d1-ca2dacbe5b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e2dc0946-3738-4000-b639-cef9343d19af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:to="loc_us-gaap_CommonStockSharesIssued_e2dc0946-3738-4000-b639-cef9343d19af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_23b80ab1-3195-41b3-8659-db858e589047" xlink:href="ck0001824293-20230930.xsd#ck0001824293_CommonStockHeldIntoEscrowAccount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:to="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_23b80ab1-3195-41b3-8659-db858e589047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2027a119-a3d0-4cac-896b-caf39c0a6860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2027a119-a3d0-4cac-896b-caf39c0a6860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_c3aef4ca-cee7-40dd-aa12-e3a65bafaa7b" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_c3aef4ca-cee7-40dd-aa12-e3a65bafaa7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_b057e8b4-1114-4861-a230-95d5ca3fdc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_b057e8b4-1114-4861-a230-95d5ca3fdc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_f24452a4-7c81-4598-82e8-c37ba7252e87" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:to="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_f24452a4-7c81-4598-82e8-c37ba7252e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_759cb0e1-2fb3-45da-8990-738005eecbca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48df568a-6f3f-4567-b4e6-381ec8ab3f59" xlink:to="loc_us-gaap_SharePrice_759cb0e1-2fb3-45da-8990-738005eecbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6affec48-e6b5-48c6-aadf-4858db98878d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFDICInsuredAmount_aabc316b-72c6-4068-a053-02d7c078b1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6affec48-e6b5-48c6-aadf-4858db98878d" xlink:to="loc_us-gaap_CashFDICInsuredAmount_aabc316b-72c6-4068-a053-02d7c078b1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_2f927f2f-e984-4d9c-85de-89903936d485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashUninsuredAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6affec48-e6b5-48c6-aadf-4858db98878d" xlink:to="loc_us-gaap_CashUninsuredAmount_2f927f2f-e984-4d9c-85de-89903936d485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8de89391-dd72-4fbc-a72c-a21bdaa1d13d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d9a0be00-6d5d-4af2-9be2-de6ae5dfbff6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8de89391-dd72-4fbc-a72c-a21bdaa1d13d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d9a0be00-6d5d-4af2-9be2-de6ae5dfbff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d12cb65c-6003-4479-9c9f-f34c1ecb9b34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d9a0be00-6d5d-4af2-9be2-de6ae5dfbff6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d12cb65c-6003-4479-9c9f-f34c1ecb9b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_14e6537b-882a-4b75-ad2b-a93681649bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d12cb65c-6003-4479-9c9f-f34c1ecb9b34" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_14e6537b-882a-4b75-ad2b-a93681649bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ab2cfb42-251f-48ba-a818-1db5c8e56d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_14e6537b-882a-4b75-ad2b-a93681649bc0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ab2cfb42-251f-48ba-a818-1db5c8e56d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6bdb73c2-0f8e-446d-b0ba-b7e7f8c2cc83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_14e6537b-882a-4b75-ad2b-a93681649bc0" xlink:to="loc_us-gaap_WarrantMember_6bdb73c2-0f8e-446d-b0ba-b7e7f8c2cc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_8eae1503-70b7-47b8-b306-ed749b528b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_14e6537b-882a-4b75-ad2b-a93681649bc0" xlink:to="loc_us-gaap_RestrictedStockMember_8eae1503-70b7-47b8-b306-ed749b528b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockSubjectToPutRightMember_6d8a0d73-8218-44ba-9512-cae66410e38a" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockSubjectToPutRightMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_14e6537b-882a-4b75-ad2b-a93681649bc0" xlink:to="loc_ck0001824293_StockSubjectToPutRightMember_6d8a0d73-8218-44ba-9512-cae66410e38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNoteMember_718a5017-1e65-4ee9-90d4-f1aea861f56b" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_14e6537b-882a-4b75-ad2b-a93681649bc0" xlink:to="loc_ck0001824293_ConvertiblePromissoryNoteMember_718a5017-1e65-4ee9-90d4-f1aea861f56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ea88452c-c474-4851-b81e-52e9241c82a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d9a0be00-6d5d-4af2-9be2-de6ae5dfbff6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ea88452c-c474-4851-b81e-52e9241c82a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2a50da1d-6067-49b5-a046-332bbbc52b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ea88452c-c474-4851-b81e-52e9241c82a5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2a50da1d-6067-49b5-a046-332bbbc52b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#MERGERWITHVALLONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6272d3ba-f2c3-4f31-aa0a-adfd26d5ac79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f1de3b7-221b-40bc-aa6e-9d7b0cda821c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6272d3ba-f2c3-4f31-aa0a-adfd26d5ac79" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f1de3b7-221b-40bc-aa6e-9d7b0cda821c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_65692dbf-88a1-4078-81f2-6f8905f560df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f1de3b7-221b-40bc-aa6e-9d7b0cda821c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_65692dbf-88a1-4078-81f2-6f8905f560df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3cb7d7de-5f2c-461f-8285-cdbe83934563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_65692dbf-88a1-4078-81f2-6f8905f560df" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3cb7d7de-5f2c-461f-8285-cdbe83934563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_e3a979c1-67d8-47f3-b553-93cf73f4f970" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3cb7d7de-5f2c-461f-8285-cdbe83934563" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_e3a979c1-67d8-47f3-b553-93cf73f4f970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1d9196c2-2a34-4736-ba2e-35e4125ab202" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f1de3b7-221b-40bc-aa6e-9d7b0cda821c" xlink:to="loc_dei_LegalEntityAxis_1d9196c2-2a34-4736-ba2e-35e4125ab202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_62d6f088-1903-46a1-ad2d-1f8522687431" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1d9196c2-2a34-4736-ba2e-35e4125ab202" xlink:to="loc_dei_EntityDomain_62d6f088-1903-46a1-ad2d-1f8522687431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_69610c52-d11e-4f65-94b7-f84ad1836d63" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PrivateGRIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_62d6f088-1903-46a1-ad2d-1f8522687431" xlink:to="loc_ck0001824293_PrivateGRIMember_69610c52-d11e-4f65-94b7-f84ad1836d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_67720d10-9b74-4631-9ffd-17742c04a69e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f1de3b7-221b-40bc-aa6e-9d7b0cda821c" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_67720d10-9b74-4631-9ffd-17742c04a69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_693ded60-ac85-4079-aab0-6d5bf1ef58a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67720d10-9b74-4631-9ffd-17742c04a69e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_693ded60-ac85-4079-aab0-6d5bf1ef58a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4fa3b946-3f41-4eda-a2b0-a49a98d70d75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67720d10-9b74-4631-9ffd-17742c04a69e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4fa3b946-3f41-4eda-a2b0-a49a98d70d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockOwnershipPercentage_689b5773-eeb0-4ab4-a4a5-98cb3944c6f9" xlink:href="ck0001824293-20230930.xsd#ck0001824293_CommonStockOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67720d10-9b74-4631-9ffd-17742c04a69e" xlink:to="loc_ck0001824293_CommonStockOwnershipPercentage_689b5773-eeb0-4ab4-a4a5-98cb3944c6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e4181ad6-b476-4abf-99aa-690cab408443" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67720d10-9b74-4631-9ffd-17742c04a69e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e4181ad6-b476-4abf-99aa-690cab408443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_5a7b6367-6476-4047-be99-da35894d0d5a" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67720d10-9b74-4631-9ffd-17742c04a69e" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_5a7b6367-6476-4047-be99-da35894d0d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2f414225-2923-4f6d-baee-9f7542953b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94f7ac95-2c53-4844-adf1-07202e795849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2f414225-2923-4f6d-baee-9f7542953b2a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94f7ac95-2c53-4844-adf1-07202e795849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_97826155-1c53-4e24-8377-281929be7325" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94f7ac95-2c53-4844-adf1-07202e795849" xlink:to="loc_dei_LegalEntityAxis_97826155-1c53-4e24-8377-281929be7325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cc248170-787f-4cc8-9e22-45ccc9b62720" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_97826155-1c53-4e24-8377-281929be7325" xlink:to="loc_dei_EntityDomain_cc248170-787f-4cc8-9e22-45ccc9b62720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_a67a4e86-ab2d-4b33-bcff-809ce403b027" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PrivateGRIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_cc248170-787f-4cc8-9e22-45ccc9b62720" xlink:to="loc_ck0001824293_PrivateGRIMember_a67a4e86-ab2d-4b33-bcff-809ce403b027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_42af2a94-5ced-4da0-860a-fa4ec1acab42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94f7ac95-2c53-4844-adf1-07202e795849" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_42af2a94-5ced-4da0-860a-fa4ec1acab42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b0c27afb-fa42-4be3-a70e-1086e658a36c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42af2a94-5ced-4da0-860a-fa4ec1acab42" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b0c27afb-fa42-4be3-a70e-1086e658a36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_9ae619f5-3b25-40ca-b7fd-20777beee1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42af2a94-5ced-4da0-860a-fa4ec1acab42" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_9ae619f5-3b25-40ca-b7fd-20777beee1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_09005793-ca59-4385-b634-dc0cea0a2d5e" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42af2a94-5ced-4da0-860a-fa4ec1acab42" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_09005793-ca59-4385-b634-dc0cea0a2d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_81ea16ee-3bf1-4b09-8f90-7f0784c6145f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42af2a94-5ced-4da0-860a-fa4ec1acab42" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_81ea16ee-3bf1-4b09-8f90-7f0784c6145f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_984f8343-d4f1-45fd-86cd-7de1049ecd15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42af2a94-5ced-4da0-860a-fa4ec1acab42" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_984f8343-d4f1-45fd-86cd-7de1049ecd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_4f9547ce-cb49-43e6-8af5-20246b9d26f8" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42af2a94-5ced-4da0-860a-fa4ec1acab42" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_4f9547ce-cb49-43e6-8af5-20246b9d26f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c0f4285d-f076-4c4a-bc9b-6d1461b3cf5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0ded0de8-519d-4c94-a8c4-f41a52386777" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c0f4285d-f076-4c4a-bc9b-6d1461b3cf5a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0ded0de8-519d-4c94-a8c4-f41a52386777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b96d6564-e579-4bf2-9485-c1bb54765ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0ded0de8-519d-4c94-a8c4-f41a52386777" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b96d6564-e579-4bf2-9485-c1bb54765ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6d5a56c-f012-4666-afe7-e975f806e36b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b96d6564-e579-4bf2-9485-c1bb54765ea6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6d5a56c-f012-4666-afe7-e975f806e36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3b79b622-8096-40ba-926c-31c01ae674ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6d5a56c-f012-4666-afe7-e975f806e36b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3b79b622-8096-40ba-926c-31c01ae674ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0ab1eb66-7113-412e-a96e-b39c4a78fe39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6d5a56c-f012-4666-afe7-e975f806e36b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0ab1eb66-7113-412e-a96e-b39c4a78fe39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_366fbc03-79c8-4193-a56a-022c7aac8ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6d5a56c-f012-4666-afe7-e975f806e36b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_366fbc03-79c8-4193-a56a-022c7aac8ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c00612dd-cdb4-4d17-ae16-61f237a6d309" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0ded0de8-519d-4c94-a8c4-f41a52386777" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c00612dd-cdb4-4d17-ae16-61f237a6d309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_5e390a26-55b0-4cb1-93fc-66ebaa144cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c00612dd-cdb4-4d17-ae16-61f237a6d309" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_5e390a26-55b0-4cb1-93fc-66ebaa144cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_23018d93-27f0-4055-b54e-236413093b29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c00612dd-cdb4-4d17-ae16-61f237a6d309" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_23018d93-27f0-4055-b54e-236413093b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#FAIRVALUEMEASUREMENTSScheduleofLiabilityMeasuredatEstimatedFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_635ce4eb-88bd-4c3b-8271-31108e1c222c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e744c4fe-fc79-4317-8dfb-ad13dc465804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_635ce4eb-88bd-4c3b-8271-31108e1c222c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e744c4fe-fc79-4317-8dfb-ad13dc465804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_12b0249f-6f4f-4be1-ae9c-487161e45239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e744c4fe-fc79-4317-8dfb-ad13dc465804" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_12b0249f-6f4f-4be1-ae9c-487161e45239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b317e3e5-1023-406e-96db-0448fa4c64b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_12b0249f-6f4f-4be1-ae9c-487161e45239" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b317e3e5-1023-406e-96db-0448fa4c64b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityMember_0894488b-8204-4f9c-bb26-fdfc55814da6" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b317e3e5-1023-406e-96db-0448fa4c64b8" xlink:to="loc_ck0001824293_WarrantLiabilityMember_0894488b-8204-4f9c-bb26-fdfc55814da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_40b89d81-6a9e-49fb-b40f-95b22da7b945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e744c4fe-fc79-4317-8dfb-ad13dc465804" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_40b89d81-6a9e-49fb-b40f-95b22da7b945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b0e38cab-3afa-4cfb-a375-3d6280959452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_40b89d81-6a9e-49fb-b40f-95b22da7b945" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b0e38cab-3afa-4cfb-a375-3d6280959452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2f0b3cf1-7795-40f7-b670-d43ef8e15ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_40b89d81-6a9e-49fb-b40f-95b22da7b945" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2f0b3cf1-7795-40f7-b670-d43ef8e15ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_96b44ff4-117e-4297-b387-eea86854b780" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_40b89d81-6a9e-49fb-b40f-95b22da7b945" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_96b44ff4-117e-4297-b387-eea86854b780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4bba6e06-9481-484e-90de-b4196793f139" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_45216b2b-e0d0-4941-a005-e6bbf9a826f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4bba6e06-9481-484e-90de-b4196793f139" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_45216b2b-e0d0-4941-a005-e6bbf9a826f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b8bee598-315a-45fa-bd1d-aa61ab3381e5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_45216b2b-e0d0-4941-a005-e6bbf9a826f1" xlink:to="loc_srt_RangeAxis_b8bee598-315a-45fa-bd1d-aa61ab3381e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5bf15b89-de32-40c4-b503-169e56146480" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b8bee598-315a-45fa-bd1d-aa61ab3381e5" xlink:to="loc_srt_RangeMember_5bf15b89-de32-40c4-b503-169e56146480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_573d8513-7d41-47a1-9779-358f7a8c9f07" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5bf15b89-de32-40c4-b503-169e56146480" xlink:to="loc_srt_WeightedAverageMember_573d8513-7d41-47a1-9779-358f7a8c9f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_ef546831-48f8-4207-95ff-0c16cbded13d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_45216b2b-e0d0-4941-a005-e6bbf9a826f1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_ef546831-48f8-4207-95ff-0c16cbded13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0e752276-38b6-4f07-a54d-662b5a8e488c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ef546831-48f8-4207-95ff-0c16cbded13d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0e752276-38b6-4f07-a54d-662b5a8e488c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_74bc0b25-3ae4-4928-bf17-4f392e17f488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0e752276-38b6-4f07-a54d-662b5a8e488c" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_74bc0b25-3ae4-4928-bf17-4f392e17f488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_2b35f1fb-42bb-4737-90f6-aeaf6994d59e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0e752276-38b6-4f07-a54d-662b5a8e488c" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_2b35f1fb-42bb-4737-90f6-aeaf6994d59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_e85d23d4-b586-4bda-a26a-f07ece6d7c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0e752276-38b6-4f07-a54d-662b5a8e488c" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_e85d23d4-b586-4bda-a26a-f07ece6d7c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_feb8e9ff-20cb-47c0-99c0-37a44288816c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0e752276-38b6-4f07-a54d-662b5a8e488c" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_feb8e9ff-20cb-47c0-99c0-37a44288816c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81fb3eb8-16d4-4b33-8df0-b40e85018ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_45216b2b-e0d0-4941-a005-e6bbf9a826f1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81fb3eb8-16d4-4b33-8df0-b40e85018ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_8e025787-6d8e-4a6e-939d-7cd49ce9381f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_81fb3eb8-16d4-4b33-8df0-b40e85018ad0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_8e025787-6d8e-4a6e-939d-7cd49ce9381f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6cda8db9-2789-4cce-ade4-05c90ff2368a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2d33b11-57a7-4863-a0c9-1fa1e2f5445b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6cda8db9-2789-4cce-ade4-05c90ff2368a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2d33b11-57a7-4863-a0c9-1fa1e2f5445b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_10507686-b8f1-4584-8b5c-1a7b2fda0ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2d33b11-57a7-4863-a0c9-1fa1e2f5445b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_10507686-b8f1-4584-8b5c-1a7b2fda0ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1bc77b6d-f6b8-4464-9c28-2d2de4ea7d39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_10507686-b8f1-4584-8b5c-1a7b2fda0ed5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1bc77b6d-f6b8-4464-9c28-2d2de4ea7d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_44526712-3b62-4727-a80b-62484a423674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1bc77b6d-f6b8-4464-9c28-2d2de4ea7d39" xlink:to="loc_us-gaap_ComputerEquipmentMember_44526712-3b62-4727-a80b-62484a423674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d23af8ac-ba00-472d-92fc-732c10110409" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1bc77b6d-f6b8-4464-9c28-2d2de4ea7d39" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d23af8ac-ba00-472d-92fc-732c10110409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f38ccb35-f97c-460a-ac55-77dd77b639c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2d33b11-57a7-4863-a0c9-1fa1e2f5445b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f38ccb35-f97c-460a-ac55-77dd77b639c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_38d93fd9-4e95-4881-af00-0c7ca6a3c1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f38ccb35-f97c-460a-ac55-77dd77b639c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_38d93fd9-4e95-4881-af00-0c7ca6a3c1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ed62249f-4601-49ec-91de-ce2eaec63f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f38ccb35-f97c-460a-ac55-77dd77b639c4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ed62249f-4601-49ec-91de-ce2eaec63f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_838a40e0-2648-4196-8ca7-9fa64600662c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f38ccb35-f97c-460a-ac55-77dd77b639c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_838a40e0-2648-4196-8ca7-9fa64600662c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#PROPERTYANDEQUIPMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d4c3910b-549e-4801-960f-966b89bb8573" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ca9e16b3-d7e9-48f9-a2d2-e24a485b828d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d4c3910b-549e-4801-960f-966b89bb8573" xlink:to="loc_us-gaap_Depreciation_ca9e16b3-d7e9-48f9-a2d2-e24a485b828d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#ACCRUEDEXPENSESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_59090d40-23e4-40c9-bd03-28a7013fe307" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_6f68d129-7c8c-4a4c-b74c-88a1ad42acc0" xlink:href="ck0001824293-20230930.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_59090d40-23e4-40c9-bd03-28a7013fe307" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_6f68d129-7c8c-4a4c-b74c-88a1ad42acc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_63926712-402f-4e16-8aa1-7bd5d5149f44" xlink:href="ck0001824293-20230930.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_59090d40-23e4-40c9-bd03-28a7013fe307" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_63926712-402f-4e16-8aa1-7bd5d5149f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_23b6dc90-fd88-4252-8d7a-b64916793344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_59090d40-23e4-40c9-bd03-28a7013fe307" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_23b6dc90-fd88-4252-8d7a-b64916793344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9232cf2d-a9b5-4130-929b-479433516776" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_59090d40-23e4-40c9-bd03-28a7013fe307" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9232cf2d-a9b5-4130-929b-479433516776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#PROMISSORYNOTESBridgeFinancingDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9a074cb9-f204-4494-9565-fc1f919825c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a07c4c12-e058-4028-8513-af104ca2e039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9a074cb9-f204-4494-9565-fc1f919825c2" xlink:to="loc_us-gaap_DebtInstrumentTable_a07c4c12-e058-4028-8513-af104ca2e039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f4199454-9de9-4f44-bce3-008d4b9c7ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a07c4c12-e058-4028-8513-af104ca2e039" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f4199454-9de9-4f44-bce3-008d4b9c7ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e873ee0f-6c99-422a-b160-5f6a54295882" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f4199454-9de9-4f44-bce3-008d4b9c7ae4" xlink:to="loc_us-gaap_RelatedPartyDomain_e873ee0f-6c99-422a-b160-5f6a54295882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_5cd061b8-101f-4c9e-98e0-ed8a6c003d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e873ee0f-6c99-422a-b160-5f6a54295882" xlink:to="loc_us-gaap_InvestorMember_5cd061b8-101f-4c9e-98e0-ed8a6c003d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_920ba22b-e134-453b-b942-081a2f3713d1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a07c4c12-e058-4028-8513-af104ca2e039" xlink:to="loc_dei_LegalEntityAxis_920ba22b-e134-453b-b942-081a2f3713d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e509e30f-489e-4595-897d-1a70ead6a775" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_920ba22b-e134-453b-b942-081a2f3713d1" xlink:to="loc_dei_EntityDomain_e509e30f-489e-4595-897d-1a70ead6a775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_0806b1c9-35cf-4bef-9be4-cd6697ddf80f" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PrivateGRIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e509e30f-489e-4595-897d-1a70ead6a775" xlink:to="loc_ck0001824293_PrivateGRIMember_0806b1c9-35cf-4bef-9be4-cd6697ddf80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3b3596d7-ed4c-4ebf-b962-181908830b96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a07c4c12-e058-4028-8513-af104ca2e039" xlink:to="loc_us-gaap_DebtInstrumentAxis_3b3596d7-ed4c-4ebf-b962-181908830b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2eab3442-2d23-4c86-acd1-95065546fd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3b3596d7-ed4c-4ebf-b962-181908830b96" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2eab3442-2d23-4c86-acd1-95065546fd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_190fd1c6-46ab-4aac-a1af-ec4262f647fe" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BridgeSecuritiesPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2eab3442-2d23-4c86-acd1-95065546fd9c" xlink:to="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_190fd1c6-46ab-4aac-a1af-ec4262f647fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_e406160f-c1dd-49e9-b4c3-0dd42c9fb770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a07c4c12-e058-4028-8513-af104ca2e039" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_e406160f-c1dd-49e9-b4c3-0dd42c9fb770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_61d95eac-0e7c-4b8f-a6fd-072c9304c0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e406160f-c1dd-49e9-b4c3-0dd42c9fb770" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_61d95eac-0e7c-4b8f-a6fd-072c9304c0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeWarrantsMember_af706131-99bc-4545-8a47-4cafd857db06" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BridgeWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_61d95eac-0e7c-4b8f-a6fd-072c9304c0fd" xlink:to="loc_ck0001824293_BridgeWarrantsMember_af706131-99bc-4545-8a47-4cafd857db06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_89be39c3-e0fb-46ef-b5b1-3493adb31e9b" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_61d95eac-0e7c-4b8f-a6fd-072c9304c0fd" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_89be39c3-e0fb-46ef-b5b1-3493adb31e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a07c4c12-e058-4028-8513-af104ca2e039" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a0c041fd-e31f-4816-bb7b-7ec110a62243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a0c041fd-e31f-4816-bb7b-7ec110a62243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice_cfa803f2-3f27-4280-8fff-ec1f03e6dffe" xlink:href="ck0001824293-20230930.xsd#ck0001824293_DebtInstrumentAggregatePurchasePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice_cfa803f2-3f27-4280-8fff-ec1f03e6dffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentNumberOfClosings_0b2a35e4-ed87-4c32-a505-8b34616f4c6c" xlink:href="ck0001824293-20230930.xsd#ck0001824293_DebtInstrumentNumberOfClosings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_ck0001824293_DebtInstrumentNumberOfClosings_0b2a35e4-ed87-4c32-a505-8b34616f4c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f51bcf6e-a5e5-4e59-a8ca-e5cedac77dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f51bcf6e-a5e5-4e59-a8ca-e5cedac77dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b81ff975-a831-4676-a832-edc887febad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b81ff975-a831-4676-a832-edc887febad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_17d6a8b9-9362-43e3-be6e-be77f2ea4f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_17d6a8b9-9362-43e3-be6e-be77f2ea4f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_45d635cd-a94a-4369-9f21-80b725403d42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_45d635cd-a94a-4369-9f21-80b725403d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_95180bb1-4e74-4aa1-804e-28bb0081881e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_95180bb1-4e74-4aa1-804e-28bb0081881e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_58c88865-4c9b-47f7-859f-5a35531cb5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_58c88865-4c9b-47f7-859f-5a35531cb5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d9e582c8-1762-46b9-bb57-c7d64377c5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d9e582c8-1762-46b9-bb57-c7d64377c5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b6a6175d-5f94-439a-be5f-6f594b50e033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a90ce2c-6567-48c7-bfbd-3fbf70e92256" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b6a6175d-5f94-439a-be5f-6f594b50e033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#PROMISSORYNOTESTEPNoteDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_14cd6388-b863-4962-a047-f3f08bdd4881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_00a8c218-6527-4512-a37c-527b96d5cd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_14cd6388-b863-4962-a047-f3f08bdd4881" xlink:to="loc_us-gaap_DebtInstrumentTable_00a8c218-6527-4512-a37c-527b96d5cd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_14ca3ac9-7acf-4446-998b-cab0162843e0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_00a8c218-6527-4512-a37c-527b96d5cd0d" xlink:to="loc_dei_LegalEntityAxis_14ca3ac9-7acf-4446-998b-cab0162843e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2c192c13-dc34-4294-a46f-8c59c55ea542" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_14ca3ac9-7acf-4446-998b-cab0162843e0" xlink:to="loc_dei_EntityDomain_2c192c13-dc34-4294-a46f-8c59c55ea542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_3a7dfe76-3d5f-4475-b876-19b19ec44dfb" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PrivateGRIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2c192c13-dc34-4294-a46f-8c59c55ea542" xlink:to="loc_ck0001824293_PrivateGRIMember_3a7dfe76-3d5f-4475-b876-19b19ec44dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1aae2b78-a9b4-47f9-a24a-0b3f8df17299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_00a8c218-6527-4512-a37c-527b96d5cd0d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1aae2b78-a9b4-47f9-a24a-0b3f8df17299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6a31c8dc-accd-4fb8-96dd-b15c008ef213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1aae2b78-a9b4-47f9-a24a-0b3f8df17299" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6a31c8dc-accd-4fb8-96dd-b15c008ef213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_bfc9f589-68dc-41bb-aee0-046cd24b2d15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6a31c8dc-accd-4fb8-96dd-b15c008ef213" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_bfc9f589-68dc-41bb-aee0-046cd24b2d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1260d597-ace1-4baa-ac6d-db460315ab30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_00a8c218-6527-4512-a37c-527b96d5cd0d" xlink:to="loc_us-gaap_DebtInstrumentAxis_1260d597-ace1-4baa-ac6d-db460315ab30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_936b8527-2b98-4634-98e1-46cf1bd9c8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1260d597-ace1-4baa-ac6d-db460315ab30" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_936b8527-2b98-4634-98e1-46cf1bd9c8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_TEPNoteMember_59948fcc-2a4b-4b20-9761-ba2d9913946f" xlink:href="ck0001824293-20230930.xsd#ck0001824293_TEPNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_936b8527-2b98-4634-98e1-46cf1bd9c8bd" xlink:to="loc_ck0001824293_TEPNoteMember_59948fcc-2a4b-4b20-9761-ba2d9913946f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_83ede335-bae3-4410-a3c4-9a0592358835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_00a8c218-6527-4512-a37c-527b96d5cd0d" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_83ede335-bae3-4410-a3c4-9a0592358835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_77f8f386-f5be-43a9-85e0-65218e992082" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_83ede335-bae3-4410-a3c4-9a0592358835" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_77f8f386-f5be-43a9-85e0-65218e992082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember_1270e8e6-dd1a-40eb-be3f-51df37991de1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_77f8f386-f5be-43a9-85e0-65218e992082" xlink:to="loc_us-gaap_CallOptionMember_1270e8e6-dd1a-40eb-be3f-51df37991de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_00a8c218-6527-4512-a37c-527b96d5cd0d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_963b7e84-fdfb-4d64-b4df-3e0cf9e067f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_963b7e84-fdfb-4d64-b4df-3e0cf9e067f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_402540e6-11d5-473b-ad59-0ae6c7b9269c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_402540e6-11d5-473b-ad59-0ae6c7b9269c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7f8e4526-ea4a-4852-b99e-8b65e30e4ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7f8e4526-ea4a-4852-b99e-8b65e30e4ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1101c825-66ff-49a4-8ac4-a9fcdd88e922" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1101c825-66ff-49a4-8ac4-a9fcdd88e922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_b23989d0-35b6-42d2-ad87-4228b2c63602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_b23989d0-35b6-42d2-ad87-4228b2c63602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_34824e5c-f595-477c-80c3-54f16ecc505c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_CommonStockSharesIssued_34824e5c-f595-477c-80c3-54f16ecc505c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CallOptionPrice_89633622-b8f4-4a41-a669-589c1dd9212d" xlink:href="ck0001824293-20230930.xsd#ck0001824293_CallOptionPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_ck0001824293_CallOptionPrice_89633622-b8f4-4a41-a669-589c1dd9212d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt_b14775ac-dcbf-4347-b920-578355a15cb3" xlink:href="ck0001824293-20230930.xsd#ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt_b14775ac-dcbf-4347-b920-578355a15cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest_8dc7ddba-2cca-4e0d-8d73-93befa26043b" xlink:href="ck0001824293-20230930.xsd#ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest_8dc7ddba-2cca-4e0d-8d73-93befa26043b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion_f32e43a7-775b-4a26-be42-2ef3b50cfef1" xlink:href="ck0001824293-20230930.xsd#ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion_f32e43a7-775b-4a26-be42-2ef3b50cfef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_15afd1c2-add2-4915-be65-e7040b36742e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_15afd1c2-add2-4915-be65-e7040b36742e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_7d062d29-2fbe-449f-9548-c5afe607a99c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_7d062d29-2fbe-449f-9548-c5afe607a99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_015257d8-2d70-4112-8b1f-124aac37ed70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_015257d8-2d70-4112-8b1f-124aac37ed70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_LongTermDebtIncludingInterest_604d59c6-50eb-4f4d-845b-7c88a1b06baf" xlink:href="ck0001824293-20230930.xsd#ck0001824293_LongTermDebtIncludingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_ck0001824293_LongTermDebtIncludingInterest_604d59c6-50eb-4f4d-845b-7c88a1b06baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2a1b4b6b-1409-4f4f-a6e2-0b3222c570b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2a1b4b6b-1409-4f4f-a6e2-0b3222c570b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_8397e269-f42b-4144-bd08-cb64e9dd4ede" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_8397e269-f42b-4144-bd08-cb64e9dd4ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_f9f79fb4-5184-4b4e-a4cf-a55bfdaab4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_f9f79fb4-5184-4b4e-a4cf-a55bfdaab4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedInterestForfeited_a43e3fc2-244c-419f-97f4-44dbf711f76f" xlink:href="ck0001824293-20230930.xsd#ck0001824293_AccruedInterestForfeited"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_ck0001824293_AccruedInterestForfeited_a43e3fc2-244c-419f-97f4-44dbf711f76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseBorrowings_f9f08453-b268-49e4-9846-8441cfc012e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowings"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d4e907-6135-4814-9945-e5451b1a8a2d" xlink:to="loc_us-gaap_InterestExpenseBorrowings_f9f08453-b268-49e4-9846-8441cfc012e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e4c0408c-b639-4d6c-8863-e5ed9bd43f14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6bf84a8b-8346-411d-956a-2a656c4a5f85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e4c0408c-b639-4d6c-8863-e5ed9bd43f14" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6bf84a8b-8346-411d-956a-2a656c4a5f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_72d9afe0-3d8b-41db-a5ea-7d1576286af2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6bf84a8b-8346-411d-956a-2a656c4a5f85" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_72d9afe0-3d8b-41db-a5ea-7d1576286af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_546d072e-a1ad-4fd0-84be-b213cb15608e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_72d9afe0-3d8b-41db-a5ea-7d1576286af2" xlink:to="loc_us-gaap_RelatedPartyDomain_546d072e-a1ad-4fd0-84be-b213cb15608e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_4a279f57-bec6-4e68-9a74-416beb853f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_546d072e-a1ad-4fd0-84be-b213cb15608e" xlink:to="loc_us-gaap_InvestorMember_4a279f57-bec6-4e68-9a74-416beb853f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_43b4f144-ffc0-4c64-81ac-f87969a56884" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6bf84a8b-8346-411d-956a-2a656c4a5f85" xlink:to="loc_dei_LegalEntityAxis_43b4f144-ffc0-4c64-81ac-f87969a56884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fed44b1d-5b22-4702-9b55-48a65ea29d98" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_43b4f144-ffc0-4c64-81ac-f87969a56884" xlink:to="loc_dei_EntityDomain_fed44b1d-5b22-4702-9b55-48a65ea29d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_19ab512c-e0a4-4afb-b991-f9693b499ce6" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PrivateGRIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_fed44b1d-5b22-4702-9b55-48a65ea29d98" xlink:to="loc_ck0001824293_PrivateGRIMember_19ab512c-e0a4-4afb-b991-f9693b499ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7381f845-6f54-4ea0-b83d-dbd73d868963" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6bf84a8b-8346-411d-956a-2a656c4a5f85" xlink:to="loc_srt_CounterpartyNameAxis_7381f845-6f54-4ea0-b83d-dbd73d868963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88f6dfee-582e-4523-b5ca-218c1a1f90b8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7381f845-6f54-4ea0-b83d-dbd73d868963" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88f6dfee-582e-4523-b5ca-218c1a1f90b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIBioIncMember_f2469fa8-b673-4805-95ed-1f37a3ce2440" xlink:href="ck0001824293-20230930.xsd#ck0001824293_GRIBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88f6dfee-582e-4523-b5ca-218c1a1f90b8" xlink:to="loc_ck0001824293_GRIBioIncMember_f2469fa8-b673-4805-95ed-1f37a3ce2440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_751f41c7-4e3a-40d4-be94-c4cac8213eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6bf84a8b-8346-411d-956a-2a656c4a5f85" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_751f41c7-4e3a-40d4-be94-c4cac8213eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a2112b41-9941-407d-9049-2c1f1159fa2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_751f41c7-4e3a-40d4-be94-c4cac8213eaf" xlink:to="loc_us-gaap_EquityComponentDomain_a2112b41-9941-407d-9049-2c1f1159fa2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f896f222-22fd-4472-9e5b-fc99d84df0de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a2112b41-9941-407d-9049-2c1f1159fa2b" xlink:to="loc_us-gaap_CommonStockMember_f896f222-22fd-4472-9e5b-fc99d84df0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8ed14f2f-fe02-4b5b-aef2-f2e061509d34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a2112b41-9941-407d-9049-2c1f1159fa2b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8ed14f2f-fe02-4b5b-aef2-f2e061509d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_8a85ce5f-df7b-4357-a282-5c9e36008f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6bf84a8b-8346-411d-956a-2a656c4a5f85" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_8a85ce5f-df7b-4357-a282-5c9e36008f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_08051a9d-2e8e-4072-8865-3747dc87ca1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_8a85ce5f-df7b-4357-a282-5c9e36008f7c" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_08051a9d-2e8e-4072-8865-3747dc87ca1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember_07e714e3-8538-42eb-a7f3-49c3aeead78e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PutOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_08051a9d-2e8e-4072-8865-3747dc87ca1a" xlink:to="loc_us-gaap_PutOptionMember_07e714e3-8538-42eb-a7f3-49c3aeead78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f8247183-d662-48d3-9f9e-1af6efd81820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6bf84a8b-8346-411d-956a-2a656c4a5f85" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f8247183-d662-48d3-9f9e-1af6efd81820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a18b63f8-361e-4c03-9ec3-99b4cf9ad1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f8247183-d662-48d3-9f9e-1af6efd81820" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a18b63f8-361e-4c03-9ec3-99b4cf9ad1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_EquityWarrantsMember_67b35ad4-319f-44ca-85ce-62a822028b26" xlink:href="ck0001824293-20230930.xsd#ck0001824293_EquityWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a18b63f8-361e-4c03-9ec3-99b4cf9ad1b3" xlink:to="loc_ck0001824293_EquityWarrantsMember_67b35ad4-319f-44ca-85ce-62a822028b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember_b6a7a1b6-13a7-4453-9a3a-b1fa98d22f87" xlink:href="ck0001824293-20230930.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_EquityWarrantsMember_67b35ad4-319f-44ca-85ce-62a822028b26" xlink:to="loc_ck0001824293_SeriesA1WarrantsMember_b6a7a1b6-13a7-4453-9a3a-b1fa98d22f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA2WarrantsMember_a82b084d-1521-4e70-b809-a82e5b7c66f3" xlink:href="ck0001824293-20230930.xsd#ck0001824293_SeriesA2WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_EquityWarrantsMember_67b35ad4-319f-44ca-85ce-62a822028b26" xlink:to="loc_ck0001824293_SeriesA2WarrantsMember_a82b084d-1521-4e70-b809-a82e5b7c66f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesTWarrantsMember_e0536b1d-4939-4bb7-9aee-52adf9cb7179" xlink:href="ck0001824293-20230930.xsd#ck0001824293_SeriesTWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a18b63f8-361e-4c03-9ec3-99b4cf9ad1b3" xlink:to="loc_ck0001824293_SeriesTWarrantsMember_e0536b1d-4939-4bb7-9aee-52adf9cb7179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeWarrantsMember_85f985cc-354c-461c-bdd2-f741e3a38666" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BridgeWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a18b63f8-361e-4c03-9ec3-99b4cf9ad1b3" xlink:to="loc_ck0001824293_BridgeWarrantsMember_85f985cc-354c-461c-bdd2-f741e3a38666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_8eaf95b1-a345-4592-b837-4212e6526fb2" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a18b63f8-361e-4c03-9ec3-99b4cf9ad1b3" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_8eaf95b1-a345-4592-b837-4212e6526fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BankerWarrantsMember_5ed829ae-c5ab-4fe0-93c0-d0972695b18e" xlink:href="ck0001824293-20230930.xsd#ck0001824293_BankerWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a18b63f8-361e-4c03-9ec3-99b4cf9ad1b3" xlink:to="loc_ck0001824293_BankerWarrantsMember_5ed829ae-c5ab-4fe0-93c0-d0972695b18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6bf84a8b-8346-411d-956a-2a656c4a5f85" xlink:to="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_6967b182-6351-4732-94bd-57d2ffd7a6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_6967b182-6351-4732-94bd-57d2ffd7a6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_33785847-ab31-4728-8fa6-c86cafd35ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_CommonStockSharesIssued_33785847-ab31-4728-8fa6-c86cafd35ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_430f7516-c501-4c21-b49e-375938b70b57" xlink:href="ck0001824293-20230930.xsd#ck0001824293_CommonStockHeldIntoEscrowAccount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_430f7516-c501-4c21-b49e-375938b70b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_022add15-76a8-4f28-b4d2-8c03ed32ec08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_022add15-76a8-4f28-b4d2-8c03ed32ec08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_5d801bf7-02aa-4239-9476-1c45411c5f22" xlink:href="ck0001824293-20230930.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_5d801bf7-02aa-4239-9476-1c45411c5f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_a2ad93f7-0aaf-4186-8798-c7291d1c237c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_a2ad93f7-0aaf-4186-8798-c7291d1c237c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_1512d857-8736-4887-90f0-f083eaa3801c" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_1512d857-8736-4887-90f0-f083eaa3801c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PutOptionSharePrice_81d3b773-ecf1-4f1e-86da-0045281d8851" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PutOptionSharePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_ck0001824293_PutOptionSharePrice_81d3b773-ecf1-4f1e-86da-0045281d8851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_95446332-74ca-4464-a73b-b4eee7dcfe05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_95446332-74ca-4464-a73b-b4eee7dcfe05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_d418dd6f-c61e-47fc-b859-ad41ede8c158" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_d418dd6f-c61e-47fc-b859-ad41ede8c158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_b5e22e84-f0a0-4155-94e7-1ebc77dff1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_b5e22e84-f0a0-4155-94e7-1ebc77dff1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4664bc7e-2424-4ebc-a58c-f388dc8573f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4664bc7e-2424-4ebc-a58c-f388dc8573f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7611f69a-b03f-440e-9877-08d9ba21b889" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7611f69a-b03f-440e-9877-08d9ba21b889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_17a52b93-31ef-4eff-b0b7-c6872f5345c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_17a52b93-31ef-4eff-b0b7-c6872f5345c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_14f1d18f-ccf3-4466-b4ec-aaad43979f54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_14f1d18f-ccf3-4466-b4ec-aaad43979f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_a113d7d4-8351-4798-ada4-17b39a41b7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78d2c9b2-daca-4efc-800a-f460ec1302bb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_a113d7d4-8351-4798-ada4-17b39a41b7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_85b252c3-cd94-4ce1-9285-f578d472ca1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b2e8e596-0751-4d6b-93c2-fbcc28097563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_85b252c3-cd94-4ce1-9285-f578d472ca1e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b2e8e596-0751-4d6b-93c2-fbcc28097563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3450b25e-e916-445f-9d7b-66d1aa2c3803" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b2e8e596-0751-4d6b-93c2-fbcc28097563" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3450b25e-e916-445f-9d7b-66d1aa2c3803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_47787f8f-826a-46dc-8b2f-0002bd2006b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3450b25e-e916-445f-9d7b-66d1aa2c3803" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_47787f8f-826a-46dc-8b2f-0002bd2006b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember_57d2fdcf-5748-4868-b173-c13a77149e6d" xlink:href="ck0001824293-20230930.xsd#ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_47787f8f-826a-46dc-8b2f-0002bd2006b6" xlink:to="loc_ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember_57d2fdcf-5748-4868-b173-c13a77149e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_072592ba-53ef-44b2-b5a4-b71120fb84bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b2e8e596-0751-4d6b-93c2-fbcc28097563" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_072592ba-53ef-44b2-b5a4-b71120fb84bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8fe797f7-121e-43d0-ac35-4fadeedf5a02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_072592ba-53ef-44b2-b5a4-b71120fb84bd" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8fe797f7-121e-43d0-ac35-4fadeedf5a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_f3781f88-d28d-47c9-83af-c0d9818bb392" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8fe797f7-121e-43d0-ac35-4fadeedf5a02" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_f3781f88-d28d-47c9-83af-c0d9818bb392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_7c635711-5230-4ebc-ab7e-74d285cbb7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8fe797f7-121e-43d0-ac35-4fadeedf5a02" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_7c635711-5230-4ebc-ab7e-74d285cbb7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_2c4cc43a-5c3d-4e3f-8ce2-de82450c407f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8fe797f7-121e-43d0-ac35-4fadeedf5a02" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_2c4cc43a-5c3d-4e3f-8ce2-de82450c407f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_a4643f82-fece-46c3-9ac6-54686ef57be3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8fe797f7-121e-43d0-ac35-4fadeedf5a02" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_a4643f82-fece-46c3-9ac6-54686ef57be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cea1b18f-15ea-45c8-81e1-7c9b7f0f89d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b2e8e596-0751-4d6b-93c2-fbcc28097563" xlink:to="loc_srt_RangeAxis_cea1b18f-15ea-45c8-81e1-7c9b7f0f89d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e72b6812-7768-46e4-b49a-caa5440b3f71" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cea1b18f-15ea-45c8-81e1-7c9b7f0f89d3" xlink:to="loc_srt_RangeMember_e72b6812-7768-46e4-b49a-caa5440b3f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_77698350-e16a-4532-b616-9daaa5025650" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e72b6812-7768-46e4-b49a-caa5440b3f71" xlink:to="loc_srt_WeightedAverageMember_77698350-e16a-4532-b616-9daaa5025650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c1a02d0b-382e-4f24-92c1-8b5c7c80ef2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b2e8e596-0751-4d6b-93c2-fbcc28097563" xlink:to="loc_us-gaap_ClassOfStockLineItems_c1a02d0b-382e-4f24-92c1-8b5c7c80ef2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_b3522866-1f28-47e0-b43d-83c35742506f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a02d0b-382e-4f24-92c1-8b5c7c80ef2a" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_b3522866-1f28-47e0-b43d-83c35742506f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fa885c6a-7029-405d-8d7d-202083a031a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b187c4c5-d0e0-422b-b4e6-35c92dc3a552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fa885c6a-7029-405d-8d7d-202083a031a2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b187c4c5-d0e0-422b-b4e6-35c92dc3a552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4da1bd64-4187-417d-aa30-64fb5ffd60f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b187c4c5-d0e0-422b-b4e6-35c92dc3a552" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4da1bd64-4187-417d-aa30-64fb5ffd60f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4da1bd64-4187-417d-aa30-64fb5ffd60f8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInNovember2023Member_462a9c11-a54a-4d2a-8b45-c2ac5a7ef1a3" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInNovember2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringInNovember2023Member_462a9c11-a54a-4d2a-8b45-c2ac5a7ef1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInDecember2023Member_f8ada7b7-fac1-4c4d-a78e-ce77e5d6c5dd" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInDecember2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringInDecember2023Member_f8ada7b7-fac1-4c4d-a78e-ce77e5d6c5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJune2025Member_47706480-0c32-406e-a843-b623011e2f0a" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInJune2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringInJune2025Member_47706480-0c32-406e-a843-b623011e2f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_5c198a69-90d7-4aa6-89ba-375efbd7a67d" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInFebruary2026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_5c198a69-90d7-4aa6-89ba-375efbd7a67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMay2027Member_3ef54d23-dce7-49c4-ada0-569f01cc9017" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInMay2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringInMay2027Member_3ef54d23-dce7-49c4-ada0-569f01cc9017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJuly2027Member_6f64450f-99e2-4eaf-bdf9-a9f78c638536" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInJuly2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringInJuly2027Member_6f64450f-99e2-4eaf-bdf9-a9f78c638536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2028Member_9a01c59d-fac9-4d5a-9fcb-762928bfc338" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringInApril2028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2028Member_9a01c59d-fac9-4d5a-9fcb-762928bfc338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember_20d820af-a539-4594-b83e-19d480c06032" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember_20d820af-a539-4594-b83e-19d480c06032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember_46717332-091c-4b3d-8cf6-985ba003ce6f" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember_46717332-091c-4b3d-8cf6-985ba003ce6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember_645e321b-b1aa-4341-ad21-5e326682a1ad" xlink:href="ck0001824293-20230930.xsd#ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00093ea9-8d47-4b06-93d0-445b19148c35" xlink:to="loc_ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember_645e321b-b1aa-4341-ad21-5e326682a1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a65a171e-c988-4d04-89f9-a689d139584b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b187c4c5-d0e0-422b-b4e6-35c92dc3a552" xlink:to="loc_us-gaap_ClassOfStockLineItems_a65a171e-c988-4d04-89f9-a689d139584b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_79fc36e6-0925-46be-9e86-54e1f79f83dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a65a171e-c988-4d04-89f9-a689d139584b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_79fc36e6-0925-46be-9e86-54e1f79f83dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_65a36066-8466-4584-bb12-7528109cd3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a65a171e-c988-4d04-89f9-a689d139584b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_65a36066-8466-4584-bb12-7528109cd3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantOrRightExpirationPeriod_7e8a5770-ca4b-44a3-b763-b5d40633bec9" xlink:href="ck0001824293-20230930.xsd#ck0001824293_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a65a171e-c988-4d04-89f9-a689d139584b" xlink:to="loc_ck0001824293_ClassOfWarrantOrRightExpirationPeriod_7e8a5770-ca4b-44a3-b763-b5d40633bec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#ASSETPURCHASEAGREEMENTDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9c6b2328-bb7e-48be-bd79-c7a2fd143bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8f56aa8c-1166-4d95-9546-6b329c2dee2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9c6b2328-bb7e-48be-bd79-c7a2fd143bbb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8f56aa8c-1166-4d95-9546-6b329c2dee2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f35c24dd-d6c5-4d1b-b5cf-7b4a9699f5cc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8f56aa8c-1166-4d95-9546-6b329c2dee2d" xlink:to="loc_srt_CounterpartyNameAxis_f35c24dd-d6c5-4d1b-b5cf-7b4a9699f5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eef4e3b9-855a-49ea-ada7-c21678bfe2ea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f35c24dd-d6c5-4d1b-b5cf-7b4a9699f5cc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eef4e3b9-855a-49ea-ada7-c21678bfe2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AardvarkTherapeuticsIncMember_86208478-e3be-4898-804a-14f854aa004d" xlink:href="ck0001824293-20230930.xsd#ck0001824293_AardvarkTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eef4e3b9-855a-49ea-ada7-c21678bfe2ea" xlink:to="loc_ck0001824293_AardvarkTherapeuticsIncMember_86208478-e3be-4898-804a-14f854aa004d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c6b450f8-6155-4ac6-871f-d607c121076b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8f56aa8c-1166-4d95-9546-6b329c2dee2d" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_c6b450f8-6155-4ac6-871f-d607c121076b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_69b3614c-2f09-46b2-b800-1dbccb620566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c6b450f8-6155-4ac6-871f-d607c121076b" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_69b3614c-2f09-46b2-b800-1dbccb620566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4d7026a2-8641-43f9-baba-be164707f3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29a4f4fa-fc6a-4d67-8bbc-daeb604c6e84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4d7026a2-8641-43f9-baba-be164707f3b8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29a4f4fa-fc6a-4d67-8bbc-daeb604c6e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9ba19067-6f87-49f9-9fb2-f8e1e9abc7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29a4f4fa-fc6a-4d67-8bbc-daeb604c6e84" xlink:to="loc_us-gaap_PlanNameAxis_9ba19067-6f87-49f9-9fb2-f8e1e9abc7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1f5fd5a1-e346-4a55-b3ec-da66bed34809" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9ba19067-6f87-49f9-9fb2-f8e1e9abc7e1" xlink:to="loc_us-gaap_PlanNameDomain_1f5fd5a1-e346-4a55-b3ec-da66bed34809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIPlanMember_72eb10ed-8834-4886-9d31-b5412d34dfd0" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PrivateGRIPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1f5fd5a1-e346-4a55-b3ec-da66bed34809" xlink:to="loc_ck0001824293_PrivateGRIPlanMember_72eb10ed-8834-4886-9d31-b5412d34dfd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_ca1f6a1f-9043-4530-a56c-982704159f04" xlink:href="ck0001824293-20230930.xsd#ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1f5fd5a1-e346-4a55-b3ec-da66bed34809" xlink:to="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_ca1f6a1f-9043-4530-a56c-982704159f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_82941dc8-e2d9-401e-a538-5466943477dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29a4f4fa-fc6a-4d67-8bbc-daeb604c6e84" xlink:to="loc_us-gaap_AwardTypeAxis_82941dc8-e2d9-401e-a538-5466943477dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_089c440b-0020-44a9-8cca-caf0c51a897b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_82941dc8-e2d9-401e-a538-5466943477dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_089c440b-0020-44a9-8cca-caf0c51a897b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_647fc8cb-e525-489a-8fe7-0646e749ede3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_089c440b-0020-44a9-8cca-caf0c51a897b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_647fc8cb-e525-489a-8fe7-0646e749ede3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a5d3bde2-aaed-4516-8dbf-be8f5f362860" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29a4f4fa-fc6a-4d67-8bbc-daeb604c6e84" xlink:to="loc_srt_RangeAxis_a5d3bde2-aaed-4516-8dbf-be8f5f362860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6c0ff67b-0f1e-491d-941f-e5aae8351186" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a5d3bde2-aaed-4516-8dbf-be8f5f362860" xlink:to="loc_srt_RangeMember_6c0ff67b-0f1e-491d-941f-e5aae8351186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ae33d065-846b-426e-9956-6792c4f56772" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6c0ff67b-0f1e-491d-941f-e5aae8351186" xlink:to="loc_srt_MaximumMember_ae33d065-846b-426e-9956-6792c4f56772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7fa915e8-62e5-4f6a-a913-68c38f96cffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29a4f4fa-fc6a-4d67-8bbc-daeb604c6e84" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7fa915e8-62e5-4f6a-a913-68c38f96cffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ce25f392-8ec3-48e4-abe9-568e036e910b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7fa915e8-62e5-4f6a-a913-68c38f96cffe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ce25f392-8ec3-48e4-abe9-568e036e910b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3169d3ca-d46d-435a-829a-1a7f5945b340" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7fa915e8-62e5-4f6a-a913-68c38f96cffe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3169d3ca-d46d-435a-829a-1a7f5945b340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0e0bfe97-ffd3-474b-8e54-d6fe8895d720" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7fa915e8-62e5-4f6a-a913-68c38f96cffe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0e0bfe97-ffd3-474b-8e54-d6fe8895d720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c740e34e-1b08-4c50-9388-8f6f59f768f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7fa915e8-62e5-4f6a-a913-68c38f96cffe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c740e34e-1b08-4c50-9388-8f6f59f768f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_36502d69-aa53-4237-bb50-180126005e89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7fa915e8-62e5-4f6a-a913-68c38f96cffe" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_36502d69-aa53-4237-bb50-180126005e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_14dda011-5ceb-43cb-90d1-4e1e0b1aa1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7fa915e8-62e5-4f6a-a913-68c38f96cffe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_14dda011-5ceb-43cb-90d1-4e1e0b1aa1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7e7c7742-16ff-45c3-9516-0f1126284742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7fa915e8-62e5-4f6a-a913-68c38f96cffe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7e7c7742-16ff-45c3-9516-0f1126284742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62f7e374-d001-4665-8688-6977d6f03e47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_36e57cc8-5251-446e-870d-58e2fd9c3a20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62f7e374-d001-4665-8688-6977d6f03e47" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_36e57cc8-5251-446e-870d-58e2fd9c3a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5db585c7-1b89-4abe-8f9b-5430fd6766fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_36e57cc8-5251-446e-870d-58e2fd9c3a20" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5db585c7-1b89-4abe-8f9b-5430fd6766fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3dc1ab07-ce76-4347-a48f-8eeef98f303c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5db585c7-1b89-4abe-8f9b-5430fd6766fe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3dc1ab07-ce76-4347-a48f-8eeef98f303c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_53c94b77-c313-4e24-8d3c-6ea196986246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3dc1ab07-ce76-4347-a48f-8eeef98f303c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_53c94b77-c313-4e24-8d3c-6ea196986246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_b3e77b70-facd-4e86-af09-82f9778d4a90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3dc1ab07-ce76-4347-a48f-8eeef98f303c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_b3e77b70-facd-4e86-af09-82f9778d4a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10274bfc-d67a-426d-85ee-81f9bb7c9d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_36e57cc8-5251-446e-870d-58e2fd9c3a20" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10274bfc-d67a-426d-85ee-81f9bb7c9d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_13c83c04-57f3-4138-8c0a-142b05e4e9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10274bfc-d67a-426d-85ee-81f9bb7c9d24" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_13c83c04-57f3-4138-8c0a-142b05e4e9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c65dc7ef-0703-4257-bcaf-27e56d16d0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d7aed76c-4fe2-409f-b0c5-ad73f629476f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c65dc7ef-0703-4257-bcaf-27e56d16d0cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d7aed76c-4fe2-409f-b0c5-ad73f629476f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f96d8db7-27e7-498b-aae9-55e946864b06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d7aed76c-4fe2-409f-b0c5-ad73f629476f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f96d8db7-27e7-498b-aae9-55e946864b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_aa981aa6-1020-45bd-b79e-00ed7b9bd3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d7aed76c-4fe2-409f-b0c5-ad73f629476f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_aa981aa6-1020-45bd-b79e-00ed7b9bd3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21e563e9-9000-4d31-89f7-d5bc2a081efb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d7aed76c-4fe2-409f-b0c5-ad73f629476f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21e563e9-9000-4d31-89f7-d5bc2a081efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_16efd09e-97d2-4fbc-9581-d4e71a1d7347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d7aed76c-4fe2-409f-b0c5-ad73f629476f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_16efd09e-97d2-4fbc-9581-d4e71a1d7347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_848c9f90-dab8-4e7a-9a83-f5050ac5b050" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d7aed76c-4fe2-409f-b0c5-ad73f629476f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_848c9f90-dab8-4e7a-9a83-f5050ac5b050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_453c4b7b-862f-4e46-96fa-3d4b156e3f11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c65dc7ef-0703-4257-bcaf-27e56d16d0cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_453c4b7b-862f-4e46-96fa-3d4b156e3f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2407b45-d9f8-4ea2-9f13-4a63954f6fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c65dc7ef-0703-4257-bcaf-27e56d16d0cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2407b45-d9f8-4ea2-9f13-4a63954f6fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6d4e5334-dab9-415d-a383-2f5a5b613767" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2407b45-d9f8-4ea2-9f13-4a63954f6fcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6d4e5334-dab9-415d-a383-2f5a5b613767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4cf3ee1b-cf15-4901-9298-7a962c7c719f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2407b45-d9f8-4ea2-9f13-4a63954f6fcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4cf3ee1b-cf15-4901-9298-7a962c7c719f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8f79db8c-02f0-44df-9ab3-8570a51b7778" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2407b45-d9f8-4ea2-9f13-4a63954f6fcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8f79db8c-02f0-44df-9ab3-8570a51b7778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6f35e1c3-03a9-4e32-808a-74d2bdd473c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2407b45-d9f8-4ea2-9f13-4a63954f6fcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6f35e1c3-03a9-4e32-808a-74d2bdd473c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_77433b18-09cb-4824-9a48-533598fd7ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2407b45-d9f8-4ea2-9f13-4a63954f6fcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_77433b18-09cb-4824-9a48-533598fd7ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_30a89f6a-b82f-44b1-84a4-07c35dd50c21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c65dc7ef-0703-4257-bcaf-27e56d16d0cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_30a89f6a-b82f-44b1-84a4-07c35dd50c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5359e771-e9b6-492e-aa51-4d8bb09c4d70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c65dc7ef-0703-4257-bcaf-27e56d16d0cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5359e771-e9b6-492e-aa51-4d8bb09c4d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3a35e8f2-357b-4547-ac18-61b41e43d808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5359e771-e9b6-492e-aa51-4d8bb09c4d70" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3a35e8f2-357b-4547-ac18-61b41e43d808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a581cad4-7c60-41b8-b363-a5407e8a10b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5359e771-e9b6-492e-aa51-4d8bb09c4d70" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a581cad4-7c60-41b8-b363-a5407e8a10b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e246945a-8278-4e5f-a8bc-f12dc25e577b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5af328f9-769e-4a0b-858a-e6695e3d5523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e246945a-8278-4e5f-a8bc-f12dc25e577b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5af328f9-769e-4a0b-858a-e6695e3d5523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b82e0b56-9d3f-4d0f-9ea3-b9dbcb4325f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5af328f9-769e-4a0b-858a-e6695e3d5523" xlink:to="loc_us-gaap_AwardTypeAxis_b82e0b56-9d3f-4d0f-9ea3-b9dbcb4325f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0b91345-3752-41a0-9e3f-e84ff18e629c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b82e0b56-9d3f-4d0f-9ea3-b9dbcb4325f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0b91345-3752-41a0-9e3f-e84ff18e629c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_42631f7f-4eac-4d2c-a57e-407e578b35f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0b91345-3752-41a0-9e3f-e84ff18e629c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_42631f7f-4eac-4d2c-a57e-407e578b35f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_294de162-3f2c-4ee0-a9e3-19bfc782232d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5af328f9-769e-4a0b-858a-e6695e3d5523" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_294de162-3f2c-4ee0-a9e3-19bfc782232d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bedc42b8-1c03-4b45-b893-6933de4c847b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_294de162-3f2c-4ee0-a9e3-19bfc782232d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bedc42b8-1c03-4b45-b893-6933de4c847b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9ee1a41b-a9b8-4803-903a-1c3a00a1d8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_294de162-3f2c-4ee0-a9e3-19bfc782232d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9ee1a41b-a9b8-4803-903a-1c3a00a1d8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c40ef36e-a0e8-4d25-98f8-d7832227e623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_294de162-3f2c-4ee0-a9e3-19bfc782232d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c40ef36e-a0e8-4d25-98f8-d7832227e623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_88ceb0b2-01be-41b6-a7cb-90a27625da4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_294de162-3f2c-4ee0-a9e3-19bfc782232d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_88ceb0b2-01be-41b6-a7cb-90a27625da4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_a6ce2dba-9c38-4a61-b629-adf762264be5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_294de162-3f2c-4ee0-a9e3-19bfc782232d" xlink:to="loc_us-gaap_SharePrice_a6ce2dba-9c38-4a61-b629-adf762264be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="ck0001824293-20230930.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_19d39b7a-8df8-4322-8cc1-83c34d0d9f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c853b586-43c1-461b-a8b4-3bb31d38bd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_19d39b7a-8df8-4322-8cc1-83c34d0d9f0b" xlink:to="loc_us-gaap_LossContingenciesTable_c853b586-43c1-461b-a8b4-3bb31d38bd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_34f7a68c-a039-41f4-ba99-e1a50d98afb8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c853b586-43c1-461b-a8b4-3bb31d38bd9e" xlink:to="loc_srt_TitleOfIndividualAxis_34f7a68c-a039-41f4-ba99-e1a50d98afb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_07d95c23-bca3-4b74-9e21-76b516e9eb2a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_34f7a68c-a039-41f4-ba99-e1a50d98afb8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_07d95c23-bca3-4b74-9e21-76b516e9eb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_FormerChiefExecutiveOfficerMember_8b18128d-3a22-4129-a53f-0af07aed8aea" xlink:href="ck0001824293-20230930.xsd#ck0001824293_FormerChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_07d95c23-bca3-4b74-9e21-76b516e9eb2a" xlink:to="loc_ck0001824293_FormerChiefExecutiveOfficerMember_8b18128d-3a22-4129-a53f-0af07aed8aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_d9dca288-8a16-4fc5-bc58-38a1121c3507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c853b586-43c1-461b-a8b4-3bb31d38bd9e" xlink:to="loc_us-gaap_LossContingenciesLineItems_d9dca288-8a16-4fc5-bc58-38a1121c3507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_COBRABenefitsPaymentPeriod_b44637c7-5f64-4161-b028-291255ba805e" xlink:href="ck0001824293-20230930.xsd#ck0001824293_COBRABenefitsPaymentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d9dca288-8a16-4fc5-bc58-38a1121c3507" xlink:to="loc_ck0001824293_COBRABenefitsPaymentPeriod_b44637c7-5f64-4161-b028-291255ba805e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PercentageOfTargetBonus_39e327d0-2d06-4411-be2a-6253fcac7ae4" xlink:href="ck0001824293-20230930.xsd#ck0001824293_PercentageOfTargetBonus"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d9dca288-8a16-4fc5-bc58-38a1121c3507" xlink:to="loc_ck0001824293_PercentageOfTargetBonus_39e327d0-2d06-4411-be2a-6253fcac7ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ck0001824293-20230930_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ck0001824293-20230930_g1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M
M   18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=
M @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN
M9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D
M;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P
M  @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@
M*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M$G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR
M+C$
M         %A96B        #S40 !     1;,6%E:(
M  !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:
M(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                                    9&5S8P
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="                             &1E<V,
M        +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV
M-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ                                  !V:65W
M       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58
M4    %<?YVUE87,          0                        */     G-I
M9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #(
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M(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U
M#5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/
MLP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%
M$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5
M-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA
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M.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"-
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M)*75\.*CY6;"@T2D)?%D_]H # ,!  (1 Q$ /P"_P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MF8X8IKIG#BJARY?5<Q=OT6ZJ:.355$<$3T?#7Q$8:X
M
M
M
M
M                      %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M
M8]J1Z./$EFGIB5L                 )'O!_P#K2>@+Y5G#7YY8UB'?]\R>
MU/P'F_8JG:R?MNWZ./%; Z 9>0
M
M
M
M
M     "L5Z6C]5MKWRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V
M               $CW@__6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>
M*V!T R\@
M
M
M
M                                               %8KTM'ZK;7OE6
M<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O
M!_\ K2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
M
M
M
M
M                              "L5Z6C]5MKWRK.)?S-Y5;G<Q/Y[+OP
M'FO9<LI6L>U(]''B2S3TQ*V                 $CW@_P#UI/0%\JSAK\\L
M:Q#O^^9/:GX#S?L53M9/VW;]''BM@= ,O(
M
M
M
M
M             !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)
M9IZ8E;                 "1[P?_K2>@+Y5G#7YY8UB'?\ ?,GM3\!YOV*I
MVLG[;M^CCQ6P.@&7D
M
M
M
M                                                         K%>
MEH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M      !(]X/_ -:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
M
M
M
M
M                                        5BO2T?JMM>^59Q+^9O*K
M<[F)_/9=^ \U[+EE*UCVI'HX\26:>F)6P                 D>\'_ZTGH"
M^59PU^>6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
M
M
M
M
M                      K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K
M'M2/1QXDLT],2M@                !(]X/_P!:3T!?*LX:_/+&L0[_ +YD
M]J?@/-^Q5.UD_;=OT<>*V!T R\@
M
M
M
M
M      %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L
M                )'O!_P#K2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ
M./%; Z 9>0
M
M
M
M                                                 "L5Z6C]5MKW
MRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V                 $
MCW@__6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
M
M
M
M
M                               %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?
M@/->RY92M8]J1Z./$EFGIB5L                 )'O!_\ K2>@+Y5G#7YY
M8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
M
M
M
M
M              "L5Z6C]5MKWRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B
M2S3TQ*V                 $CW@_P#UI/0%\JSAK\\L:Q#O^^9/:GX#S?L5
M3M9/VW;]''BM@= ,O(
M
M
M
M                                                         !6*
M]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M       "1[P?_K2>@+Y5G#7YY8UB'?\ ?,GM3\!YOV*IVLG[;M^CCQ6P.@&7
MD
M
M
M
M                                         K%>EH_5;:]\JSB7\S>5
M6YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !(]X/_ -:3
MT!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
M
M
M
M
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MHF>%H2HHUQ@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0]:TR)G4LGFLO$1$_7;5RWP3.$>;ICCG@CIRY(KHJ\S,3X;GJEOH
M
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M/%)\_P!ZK/?EW+V2/D!W)_%;0_>EKU)VYF_7*^O)],!XI/G^]5GOR[E[)'R
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MY[^,D].>2,81A&$81A'LB_:='TBFJ*J<KEHJB<8F+5&,3Z4Y573EPE4GR
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MF*J:HFFJF8XXJIG"8F.C$QB[<3$QC'$^@XGZ
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MQ,3$\3L92]>G-6XFNJ8FN.C/3:NR#5=P
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M:JIGJNC<OWKOV2NJKP9EY@7HX0
M
M &A]Z'E\1_J<^577^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P
M           I3>F6_P!FO03[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*
M&:3Y;X
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M3T!?*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M.,N/NV_
M                                              &A]Z'E\1_J<^57
M7^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P                 I3>F
M6_V:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9I/EO@
M
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MR9>>+&:X[%RIBFB]7*OY;/V,SP4SR;G2GQNGXO43)->W=
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M7*O*]*."/_'@XHT68W5
M
M :'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M          "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAF
MD^6^
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MPKHF,:;ENK#&BY1-5%<<--4QPKBMW+=VB*[<Q-$NZ%NOL
M      !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
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M'$<C&[R9FFN]7"W,UG[^:X)GDVNE'C]/Q.HAD;#NB
M
M                         T/O0\OB/]3GRJZ_P1<;(F^^ ?.3HOP''XUF
M%R:-]@K]'XT+<[0Q6                 %*;TRW^S7H)]O/4!^(.*4C/>]?
MRQM1[FR/U>94/6_,V_!GQE#-)\M\
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M=FN>5&$U437;PKFZ,KG+6;HQHX*XXXZ,>3'52A,+.V
M   K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
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MJJF9JGHRXH[SY
M                                                          :'
MWH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M       "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6
M^
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M +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M\51'+O1]-F)B)C'DVHIIY55RV<[J->8F;=O&FQ]&?!ZG4ZZMHW!4L
M
M                                       !H?>AY?$?ZG/E5U_@BXV1
M-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL                 *4WIEO]FO03
M[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*&:3Y;X
M
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M9NS$133F+43$5Q$1%=,TW*(B*IIHNW)9RC-V\>*Y'''CQU)2[L".X
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M.*/'GJ^(AK;".B
M
M  T/O0\OB/\ 4Y\JNO\ !%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M              4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?
M&4,TGRWP
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MSAK\\L:Q#O\ OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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M2
M                                                  :'WH>7Q'^I
MSY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K                 "
ME-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M
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MJVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M   "1[P?_K2>@+Y5G#7YY8UB'?\ ?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
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M7M;7*:
M                                                        T/O0
M\OB/]3GRJZ_P1<;(F^^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6
M     %*;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE#-)\M\
M
M                          !H!^BM>*36Y3X]O_#FYIV.:YWWB/"76R=-
MN7RUUW[K9>)K*;RFP\9PN+NO&M=Y3C.M7A=8NC)WYHZ_6J4I):=#%0[T5_/>
MW)TZ)JU.]S9VSAI>?N1;U"FF."WFI^QYC"(PBG,1')N3.'U^(JF9JO\ !<6D
MYOET]K5SY:/,^!TO"\3P%R)'PK0                "L5Z6C]5MKWRK.)?S
M-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V                 $CW@_\
MUI/0%\JSAK\\L:Q#O^^9/:GX#S?L53M9/VW;]''BM@= ,O(
M                         !1%])]\8N?/Y//>&CTU[7V8+"W<E'JXW; W
M<)OPQG;*XH75EP+C<A;S?R=CK]W0EN-K\E-&:M?0I8N>:G"VR5O7DXYE_-^C
M*V;6^/;"Q_S5RG'2[-<>8HF)B<[53/TUR)Y.6QXJ.5?B)Y=FNF@:KG<9[5M3
MP?33XWD];IJ2B1]0@
M
M       &A]Z'E\1_J<^577^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P
M                 I3>F6_V:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFW
MX,^,H9I/EO@
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M >;]BJ=K)^V[?HX\5L#H!EY
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M1$1$80M.9F9QGC?@<K\
M
M          :'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H
M8K                 "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?
MF;?@SXRAFD^6^
M                                          NJ^B+==\VO[WR[X>^\
MYJ?\%;_0ON<."*-]=TH4;;<=>QUM9\JZABZ=:::YJU]BU*RM,W1MZ791H28+
M(UHR]^O/-&.?GZ;L8S>EY#>MIEN.SY6:<GG9IB<9M7*IG+7:L."(MW9JLS5/
M#,WK5..%,0KFCYC"JK+5<4\,>#T8ZW#X4KZ",!<                "L5Z6
MC]5MKWRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V
M     $CW@_\ UI/0%\JSAK\\L:Q#O^^9/:GX#S?L53M9/VW;]''BM@= ,O(
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MW3V3,WHC"<QFJXCLMV>CAC$46XGAIM46Z)F>3BLW-9BK,WINU<70CI1T(_\
M'1>#&4'7
M
M:'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M         "E-Z9;_ &:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9
MI/EO@
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M^59Q+^9O*K<[F)_/9=^ \U[+EE*UCVI'HX\26:>F)6P
MD>\'_P"M)Z OE6<-?GEC6(=_WS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
M                              *.'I9GB33R2ZEX:G%6=[):TF Y6ZH+
MO'7$(]Z2%23*<4\3WLU.O&,.RI2I[3E+>I2A'U,)/3J?_P 1325<Q7<_$]GW
MQ:Y:X8FO+:=%4?Z.9S4<'5G+6ZHG\)B8\Q*@ZOFN+*T>#5XT>/UE&E):H(
M
M                                                  #0^]#R^(_U
M.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M
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MRLNY75=KFY7YJ9Q=3JZ^
M
M             &A]Z'E\1_J<^577^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A
M;G:&*P                 I3>F6_P!FO03[>>H#\0<4I&>]Z_EC:CW-D?J\
MRH>M^9M^#/C*&:3Y;X
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ME6<-?GEC6(=_WS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
M                 *(OI=/7E5RFT<0^'GH><J0QVL4+'G+GVC9S3227&PY6
MVN;+B33;ZK)4ISS?@C!5[W.75K/+/0J1R6+K0CY6AV22<<PO=A38R6?WL:I:
MCLUZ:LGD9GH6Z9B<U=IC^O7%%FFJ)BJ.QWJ>*KAH&L9C&:<M3Q1PSXT>/UE)
M1(^H0
M                                                          #0
M^]#R^(_U.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M        4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGR
MWP
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ME1_R.G92W9B<,)KJICZY<JC&<*KMR:KE7#YJJ<%E7KE5Z[5=JXZIQ>?%UN(
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MA>&I_EY=#7S2^ _< ?+1OB^-FTO^*9W[^=JY7UNWZ6/(/HPO#4_R\NAKYI?
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MH?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL
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M:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M !(]X/\ ]:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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MJY<KJZ=5=<S55/5F9E58B*8Y-,1$0Y ZC]
M                                            9&/CA_6T==O[<\M^
M)L*GGYMGS$[,?!E/U=:S\_[<N>B14,X.F                 T/O0\OB/\
M4Y\JNO\ !%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M  4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
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M%VC&.53C,3$TUT556ZJ*ZK6O6;F7N3;N1A5'T>K'4>7%ZN$
M     !KY^#/N,^]>%7T#YN>M+6FL>F?C;3H3RUJ%Q"63CO$2\?TZ/?MY*=.6
M:WIZQ"G&2,._3C+W)XS3RS1C 9SA=/C3-]^U.6B,.5K.8N\4Q]GJ[/CP]/LF
M./%/'&$3"\LE5RLI;G^K$=;@29,-NT              K%>EH_5;:]\JSB7\
MS>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !(]X/\
M]:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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MQT(=K*&^P
M                    &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/\
MMRYZ)%0S@Z8                #0^]#R^(_U.?*KK_!%QLB;[X!\Y.B_ <?
MC687)HWV"OT?C0MSM#%8                 4IO3+?[->@GV\]0'X@XI2,]
M[U_+&U'N;(_5YE0];\S;\&?&4,TGRWP                $Y7HVOUTW1C_>
M)_PH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
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M5%VU<HG&FNW<IBJBNF>C353,3$]*5HU1-,S35P51+C;N/D
M   !JZ^CI9FKG?!FZ*KVM1IT)Z&&YGPT)*<TTTLU+7>H_F'7Z%:,9O5\I<T<
M9+4GA]R$TT80]3L0;<[;+TY;G#;1VZ9F8FYE*_#N:?E+DQX4U81U(7=ILXY*
MCP_JI38-<7>              5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U[+E
ME*UCVI'HX\26:>F)6P                 D>\'_ .M)Z OE6<-?GEC6(=_W
MS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
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MG&9GAF9GCF9Z,RN%_5\@
M                                #(Q\</ZVCKM_;GEOQ-A4\_-L^8G9
MCX,I^KK6?G_;EST2*AG!TP                &A]Z'E\1_J<^577^"+C9$W
MWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P                 I3>F6_V:]!/M
MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9I/EO@                )R
MO1M?KINC'^\3_A0YU:T\\#^'7:+^P?I/)._IGMZCP_J9:K:#Y=H
M                                          #/$]+-Z#L?PYU(<<=;
M?'^"DQVG]35I<:CRK+C[2%''V7.&D8ZA-99RX\C3I6MM=\CZ'3IU/)RPC4N+
MW W]W5FFJ5YXI8^8KO/N[0;(9S=OJMV:]0T:J+N6Y4XU3D[U4XT1CC,QE[^,
M8\5-%^U13$13"W-7R_(NQ?ICRM?'X,>3'B2J*M]%&                  :
MKGHVOU+/1C_>)_Q7\ZH/N>!_$5M%_8/T9DEVZ9[1H\/ZJ4Y+6EWP
M     %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L
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MKU55=ZNJ:JJJIF:JJIG&9F9X9F9X9F>&9X973Q<$<3];C
M                                                           &
M1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M     -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M              !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9
M\90S2?+?                 3E>C:_73=&/]XG_  H<ZM:>>!_#KM%_8/TG
MDG?TSV]1X?U,M5M!\NT
M          !"]Z01TW6/4KX475'C?P?+>;)PUK5#J-TVYC#O5,5DN&YZNQ;3
M>4)/^W5N^,)L_8]GW>[>1C#MC"$&Q'-5VPN;';\M$O<ODY/4;TY"['GJ<WA;
MMQ/4C,]@K_T'1U&UV7*5QT:8Y4>%_1BR>TYZT0                 &JYZ-
MK]2ST8_WB?\ %?SJ@^YX'\16T7]@_1F27;IGM&CP_JI3DM:7?
M   5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U[+EE*UCVI'HX\26:>F)6P
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M;5%BW%JCS,1_XGPWH9:;D
M                                    9&/CA_6T==O[<\M^)L*GGYMG
MS$[,?!E/U=:S\_[<N>B14,X.F                 T/O0\OB/\ 4Y\JNO\
M!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3+?
M[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M    $Y7HVOUTW1C_ 'B?\*'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M                                                  <&Y/T?'\G<
M:<A\;9:G0JXKD+1MMT?)TKJG"M;5,?MF R&!O:=Q2FEGEJT)[:_FA/+&6,)I
M>V'9%4]%U*[HNLY36+$S%_*9FU>IF.">5:KIKC">A.-/ ^:Z8KHFF>*8F&(W
M=6MS8W-Q97MO7L[RSKUK6[M+JC4M[FUN;>I-2KV]Q0JRR5:%>A5DC+/)-"$T
MLT(PC"$8/2#171<HBY;F*K=41,3$XQ,3PQ,3'!,3'%*QGYWV_
M      &JYZ-K]2ST8_WB?\5_.J#[G@?Q%;1?V#]&9)=NF>T:/#^JE.2UI=\
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MG'@PNW;U%48T1*Y-(RW(MSF*O-5<7@?TSXD+<C0U6
M                                                         &1C
MXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M   -#[T/+XC_ %.?*KK_  1<;(F^^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6
M               %*;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!
MGQE#-)\M\                !.5Z-K]=-T8_P!XG_"ASJUIYX'\.NT7]@_2
M>2=_3/;U'A_4RU6T'R[0
M            &(GR?_:5R'[>=M_'^0>D31?R/E/<UKZBE8M7FI\%P94WR
M              U7/1M?J6>C'^\3_BOYU0?<\#^(K:+^P?HS)+MTSVC1X?U4
MIR6M+O@             *Q7I:/U6VO?*LXE_,WE5N=S$_GLN_ >:]ERRE:Q[
M4CT<>)+-/3$K8                 2/>#_]:3T!?*LX:_/+&L0[_OF3VI^
M\W[%4[63]MV_1QXK8'0#+R                                 <0Y!W
M3#\;Z%N_(FPU/(X#0M0V7=,Y5[TLGDL/JV&O<YDZG?F^]D[EE8SQ[8^I#L=_
M2M.S&L:IEM)RD8YK-9BW9HCIUW*XHI^C5#YJJBFF:IXHC%B7[IMN:W[<=LWO
M9+B6[V+==ESNVY^ZEA/++<YK8\I=9C*W$LM2>K4A+6OKRI-"$TTT?5]6,?NO
M1WIV0RVEZ?8TS)QR<IEK-%JB.E1;IBBF.AQ4Q"QZIFJJ:IXYEQEW7R
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M,44Q33P4Q&$.6N@_0
M                                &1CXX?UM'7;^W/+?B;"IY^;9\Q.S
M'P93]76L_/\ MRYZ)%0S@Z8                #0^]#R^(_U.?*KK_!%QLB
M;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3+?[->@G
MV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP                $
MY7HVOUTW1C_>)_PH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M                                            !B)\G_VE<A^WG;?Q
M_D'I$T7\CY3W-:^HI6+5YJ?!<&5-\@                -5ST;7ZEGHQ_O$
M_P"*_G5!]SP/XBMHO[!^C,DNW3/:-'A_52G):TN^              K%>EH_
M5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M   !(]X/_P!:3T!?*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M+@
M                   9&/CA_6T==O[<\M^)L*GGYMGS$[,?!E/U=:S\_P"W
M+GHD5#.#I@                -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-
M9A<FC?8*_1^-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO
M7\L;4>YLC]7F5#UOS-OP9\90S2?+?                 3E>C:_73=&/]XG
M_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4RU6T'R[0
M                               &(GR?_:5R'[>=M_'^0>D31?R/E/<U
MKZBE8M7FI\%P94WR                 U7/1M?J6>C'^\3_ (K^=4'W/ _B
M*VB_L'Z,R2[=,]HT>']5*<EK2[X             "L5Z6C]5MKWRK.)?S-Y5
M;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V                 $CW@__ %I/
M0%\JSAK\\L:Q#O\ OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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M,.">7CU5WZ=:[%E*(Z,QC/A_T8)E&O;N@
M                                                 ,C'QP_K:.NW
M]N>6_$V%3S\VSYB=F/@RGZNM9^?]N7/1(J&<'3                 :'WH>
M7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M    "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M               G*]&U^NFZ,?[Q/^%#G5K3SP/X==HO[!^D\D[^F>WJ/#^I
MEJMH/EV@
M,1/D_P#M*Y#]O.V_C_(/2)HOY'RGN:U]12L6KS4^"X,J;Y
M   :KGHVOU+/1C_>)_Q7\ZH/N>!_$5M%_8/T9DEVZ9[1H\/ZJ4Y+6EWP
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MF[]RJY75/'5775-554]69F97Q$13&$<4/MNL_0
M                                                      &1CXX?
MUM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M-#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M         !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2
M?+?                 3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;
MU'A_4RU6T'R[0
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M/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
M         4*?3*MMJ7O+/0EHD:E2-+6^.^<MMDI1DMH4I*FZ[+QQAJE22I)#
MUY-4J2Z!)":6I'R4L))8T_OHU$H7>]LA%O0MI]4PCE7LWD[6/#C]9MYBOP/]
MO/%P\,X\&"W]:GR]NGI1/T</(4L$BJA@                 )J_1X^)8<O>
M+WTB6%S:S7&(T3/[MRUEZL+>:YDL8\:\<[9LNMW566$TDM*6;=[7%49:DTT(
M4YZTLT(330A)-KGSL==[@;@]?NT587\U:LY6F,<.5VQF+5NY$=/ZS-R<.C$3
MQ1PQWM-HY><HCH1,SUH\EJ](-%W
M                                             ,C'QP_K:.NW]N>6
M_$V%3S\VSYB=F/@RGZNM9^?]N7/1(J&<'3                 :'WH>7Q'^
MISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M"E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M           G*]&U^NFZ,?[Q/^%#G5K3SP/X==HO[!^D\D[^F>WJ/#^IEJMH
M/EV@
M                               *Q7I:/U6VO?*LXE_,WE5N=S$_GLN_
M >:]ERRE:Q[4CT<>)+-/3$K8                 2/>#_\ 6D] 7RK.&OSR
MQK$._P"^9/:GX#S?L53M9/VW;]''BM@= ,O(
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MCF:JNE1XLPT9T1RY0
M                                  &1CXX?UM'7;^W/+?B;"IY^;9\Q
M.S'P93]76L_/^W+GHD5#.#I@                -#[T/+XC_4Y\JNO\$7&R
M)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@                !2F],M_LUZ"
M?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+?
M3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4RU6T'R[0
M
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M57J%VJ.'Z6,G11/2X>5<ZL8=")X:]HE/#<J]#'BKT:,Y7@
M
M   &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M         -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,
M5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS
M-OP9\90S2?+?                 3E>C:_73=&/]XG_  H<ZM:>>!_#KM%_
M8/TGDG?TSV]1X?U,M5M!\NT
M                                                  !6*]+1^JVU
M[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M"1[P?_K2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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MG^M'B+DR/=6@
M                             &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P9
M3]76L_/^W+GHD5#.#I@                -#[T/+XC_ %.?*KK_  1<;(F^
M^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6                 %*;TRW^S7H)]O
M/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE#-)\M\                !.5
MZ-K]=-T8_P!XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4RU6T'R[0
M
M                   %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J
M1Z./$EFGIB5L                 )'O!_\ K2>@+Y5G#7YY8UB'?]\R>U/P
M'F_8JG:R?MNWZ./%; Z 9>0                                #+<])
MV^N(Y_\ :-P+\#6FIKN9C_#_ *5[ISOXW=6IJGMVKP(\2%?UM2IP
M         #0^]#R^(_U.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#
M%8
M                    9&/CA_6T==O[<\M^)L*GGYMGS$[,?!E/U=:S\_[<
MN>B14,X.F                 T/O0\OB/\ 4Y\JNO\ !%QLB;[X!\Y.B_ <
M?C687)HWV"OT?C0MSM#%8                 4IO3+?[->@GV\]0'X@XI2,
M][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP                $Y7HVOUTW1C_
M 'B?\*'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M
M          5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U[+EE*UCVI'HX\26:>F
M)6P                 D>\'_P"M)Z OE6<-?GEC6(=_WS)[4_ >;]BJ=K)^
MV[?HX\5L#H!EY                                 ,MSTG;ZXCG_P!H
MW OP-::FNYF/\/\ I7NG._C=U:FJ>W:O CQ(5_6U*G
M-#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M
M          !D8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8
M                #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<FC?8
M*_1^-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>Y
MLC]7F5#UOS-OP9\90S2?+?                 3E>C:_73=&/\ >)_PH<ZM
M:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M
M!6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M          "1[P?_ *TGH"^59PU^>6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.
M@&7D                                 RZ_2@L;>V/C <UW5U1\E0S/
M''!.2QL_E*4_KFRI<6Z]AZE;NTZD\]'NY'%7%/NU(23Q\GWH0[LTLT9JN9;>
MMW=P.FT43C5;SF=IJX^"9S-RO#J^5JIG@QCAPXXF%J:K&&=J\"/$5[FUJG
M                - 7T.+.>N.FKK)UKU_Y3\$\Y:'G/P9V__P '_2'0:]AZ
M_P"[W?4_"7]&/)]O;'M]:_<AV>K%=WP7+<C;'9[.<G#LFF7Z.5T^QWXJY/\
MH]DQ_P!)<6BS]:KC^M'B+D"/E6@
M                                            &1CXX?UM'7;^W/+?
MB;"IY^;9\Q.S'P93]76L_/\ MRYZ)%0S@Z8                #0^]#R^(_
MU.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M 4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M           $Y7HVOUTW1C_>)_PH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M
M!\NT
M                               !6*]+1^JVU[Y5G$OYF\JMSN8G\]EW
MX#S7LN64K6/:D>CCQ)9IZ8E;                 "1[P?\ ZTGH"^59PU^>
M6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
M        S+_2M\-5Q?BMWM]4K4ZLFQ].G#F9H222S0FMJ5"OM^O1HU8S>I/4
MFK8&>I",/4[M2$/NPBF3YCF8IO;C:;<1,39U?-T3U9F+5S&/"KB/!A:^KQAF
M_!IA6J;B*6                  O&^AF[;W:_B"Z+7JS1C4H]-.VXNA"E1A
M++Y&?G'#YVK4K]Z%Q--/ZXQT)).R:2$)9H]LL8_?1J]\,R&-.RFITQQ3J%JJ
M<9Z/:==$8<70N8SQ\7'T*]HD_9*?0^.O,(TE>
M                                                       9&/CA
M_6T==O[<\M^)L*GGYMGS$[,?!E/U=:S\_P"W+GHD5#.#I@
M  -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M           !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90
MS2?+?                 3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3
M/;U'A_4RU6T'R[0
M                                          %8KTM'ZK;7OE6<2_F;
MRJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_P#K
M2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
M                  #.3]+\UW\'^(MP;LE*A:4;?8NC?2;6M/1^]NKK*X'F
M7G*G<W-Y+"2$)NS&9&RI4Y^]&,9:7=[(0DAVRY\P7-]EW2:GDZIJFNSM#>F,
M>**:\IDL(C_2IKF8ZN/16UK,?\S3/3HCQ951F\BD                  +9
M7H@7(%+!]?//G'=S7\C1W_I7S>7LI(R2S0N\WHW)_&]2VM832VM2M3J0PNR9
M&M",:M*E&6C-":$\\:7=T5Y_6E3F=UNEZM1&-65URBF>I1>RV8QGCP\W;MQQ
M3/#P81RL:QHU6&8JIZ='B3#1;1)+D
M                                               9&/CA_6T==O[<
M\M^)L*GGYMGS$[,?!E/U=:S\_P"W+GHD5#.#I@                -#[T/+
MXC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M   !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+?
M              3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4R
MU6T'R[0
M                                  %8KTM'ZK;7OE6<2_F;RJW.YB?S
MV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_P#K2>@+Y5G#
M7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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MD9RCI3C'7CR6K0@Z7:
M                                    R,?'#^MHZ[?VYY;\385//S;/
MF)V8^#*?JZUGY_VY<]$BH9P=,                !H?>AY?$?ZG/E5U_@BX
MV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL                 *4WIEO]FO
M03[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*&:3Y;X
M "<KT;7ZZ;HQ_O$_X4.=6M// _AUVB_L'Z3R3OZ9[>H\/ZF6JV@^7:
M
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M9C+WLIF*\KF:9HS%JNJBJF>.FJF9BJ)ZL3$Q*]XF)C&.)])POT
M
M      !D8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8
M            #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^
M-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7
MF5#UOS-OP9\90S2?+?                 3E>C:_73=&/\ >)_PH<ZM:>>!
M_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M                                                        !6*]
M+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M      "1[P?_ *TGH"^59PU^>6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
M                                 K5>E;\>S;IX4EYLD)._#B/J+X<Y
M"FF[9X>2ER5#;^*._P#>75O+'MFY.A+]])7E^^_U(1[*E/</F-ZM&G;\:<GC
M[?TC-V/2S:S/2G\&Z<>#T)I>KT\K*8]*J)\6/'9EZ91:X
M   #6Q\"?J1I=3_A7=).Y7%[Z[V30^/Z/!>Y25*TMQ>T,]PE<5>/+.ODJLL9
MHS7V?U7"8W+31FC&I-)D)9I_OHQ01<YO9"K8O?=KVGTT\G)YK-SG;7!A$T9R
M.SS%,>=HNUW+7!P8VYB.!>&0N]ERE%71B,)\+@\3A2Z,"NX
M
M    R,?'#^MHZ[?VYY;\385//S;/F)V8^#*?JZUGY_VY<]$BH9P=,
M         !H?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVA
MBL                 *4WIEO]FO03[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^
M9M^#/C*&:3Y;X                "<KT;7ZZ;HQ_O$_X4.=6M// _AUVB_L
M'Z3R3OZ9[>H\/ZF6JV@^7:
M                                                  K%>EH_5;:]
M\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !
M(]X/_P!:3T!?*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
M                           $5OC>\71Y@\)OKLU&6WFNIL9P7F.3)*,D
MTLDT:G"F6PW,U.I+WJ=7OS4)]"A/"2$.]/W>[+&6:,)H9OYMNM]P-^NS&?QY
M,5ZG1E\?=E->4ZG'V?#'H<<X\3J9^CEY.Y']7'K</C,BQ/0LX
M       !=R]#UZLY,?L74_T2;#E>Y2V&TQ/49QACZUQ&G1_"V(EQ^A<L6]M2
MJ=M.O?9+$U=8N))*<99X4,;<3QA/++&-.-[G_P"PDW<IHN\C*48U6JJLAF:H
MCAY-?*OY69GH4TU1F*9F>#&Y3'!,\-=T:]A-=B>CY:/$GQE[-&2KX
M
M         #(Q\</ZVCKM_;GEOQ-A4\_-L^8G9CX,I^KK6?G_ &Y<]$BH9P=,
M                !H?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z
M/QH6YVABL                 *4WIEO]FO03[>>H#\0<4I&>]Z_EC:CW-D?
MJ\RH>M^9M^#/C*&:3Y;X                "<KT;7ZZ;HQ_O$_X4.=6M//
M_AUVB_L'Z3R3OZ9[>H\/ZF6JV@^7:
M                                                         K%>
MEH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
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MT[.7M/S]NJUGK%VJW<HJC"JBNBJ::Z*HZ%5-43$QT)A>D3%4153PQ+[KK/T
M
M              !D8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0
MS@Z8                #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<
MFC?8*_1^-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L
M;4>YLC]7F5#UOS-OP9\90S2?+?                 3E>C:_73=&/\ >)_P
MH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M
M    !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
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M.9[)9[!5YNCB\#^CBZRUBT=5<
M                                        !D8^.'];1UV_MSRWXFPJ
M>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8                #0^]#R^(_U.?*K
MK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3
M+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M      $Y7HVOUTW1C_>)_P *'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M
M                            5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U
M[+EE*UCVI'HX\26:>F)6P                 D>\'_ZTGH"^59PU^>6-8AW
M_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
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MRB[;BY1.-,P[F6\^P
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M77,4Q%,355.$1$<40CT_BOZI?.4Y^]^/D3W1KP[@:#^!93[C;]2VI^1#<O\
M%#9?_"LC]X/XK^J7SE.?O?CY$]T9W T'\"RGW&WZD^1#<O\ %#9?_"LC]X/X
MK^J7SE.?O?CY$]T9W T'\"RGW&WZD^1#<O\ %#9?_"LC]X/XK^J7SE.?O?CY
M$]T9W T'\"RGW&WZD^1#<O\ %#9?_"LC]X/XK^J7SE.?O?CY$]T9W T'\"RG
MW&WZD^1#<O\ %#9?_"LC]X/XK^J7SE.?O?CY$]T9W T'\"RGW&WZD^1#<O\
M%#9?_"LC]X6B?1X.4N3>3M.ZI:_)/(V]\A5\/LW%5+$UMXV[8-LJXNE>8O>I
M[RECJF>R%_/94[J>WIQJ2THRPGC3EC-V]V'9@K?#D,CD<SD(R5FU9BJB[CR*
M*:,<)HPQY,1CAT,4,O?6-B]CMCM?V+M[(Z3IFE6\QD]2F[&3RMC+1<FBYDXI
MFY%FBB*YIBJJ*9JQPY4X88RL>L,HE
M                                           %8KTM'ZK;7OE6<2_F
M;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_\
MK2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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M&,)I9H1[81A]U$!,3$X3QKF?Z?@
M                                         R,?'#^MHZ[?VYY;\385
M//S;/F)V8^#*?JZUGY_VY<]$BH9P=,                !H?>AY?$?ZG/E5
MU_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL                 *4WI
MEO\ 9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M        G*]&U^NFZ,?[Q/\ A0YU:T\\#^'7:+^P?I/)._IGMZCP_J9:K:#Y
M=H    #/B\7[ZR#JC]M6J?!KI3;W=W^I>0^UU^R5O4US#?X2-B_<69_2&;1L
M+T;=@    +9GHU']2>K;VU<0_BCD!K_OK]M:?]KO>+;0==][_6+87W%JGLN1
M6>&#D-X
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MCA5T
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M\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
M                                                         %8K
MTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L
M       )'O!_^M)Z OE6<-?GEC6(=_WS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
M                                  ,K+TC3I+J]*WBD<UWV+Q7X.T'J
M/DL>I+2:E*G-ZVJW/(5>^H\DV_E)8>MZ=W1Y9Q&<K>MY8PFHV=S;31EA+4DC
M&;SFC[=T[;[E--MWZ^7JFD35I]['CB+$1.7GIX3E:[,<KHUTU\.,2M/4K/8<
MW5AYFKRT>'Q_1Q03MFU/                     7-_!6])=R7%%GJ72OXB
MVP938^-K*ECM<XSZG+BE=9?:="L;>E0Q^-UKF"A:4;C)[=J5M1IRRT,_)+6R
M]AV1EO9;VA/"O91X\XOF<V==N7]M]TEJBSK%4U7,QIT3%%N_,S-55S*S,Q3:
MNS/'8F8M5\=N;=4<FY6\CJDT86LS.-/0JZ7@]/P>-?,U';]4W_6,#NVB[+@=
MRT[:<7:9O6MJU;+V&>UW8,/?TI:]CE<-FL77NL=D\?=T9H34ZU&I/3GECVPC
M%&#G\AGM*SMW3=3LW<OJ%BN:+EJY351<HKIG"::Z*HBJFJ)X)B8B87!%451R
MJ9B:9<B=1^@
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MV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
M
M  K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
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M?@
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MZ_;6G_:[WBVT'7?>_P!8MA?<6J>RY%9X8.0W@
M                                                  *Q7I:/U6VO
M?*LXE_,WE5N=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8
M2/>#_P#6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M_1PXS3%=,3-%6'T]NK&BN."::Z:HF(F,%E7;=5JY5;J\U3.#I1<;C
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M;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE#-)\M\
M        !.5Z-K]=-T8_WB?\*'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+
MM     9\7B_?60=4?MJU3X-=*;>[N_U+R'VNOV2MZFN8;_"1L7[BS/Z0S:-A
M>C;L    !;,]&H_J3U;>VKB'\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<
MBL\,'(;P
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MQ;ICBPM7JJ;D=&>V*^A0M[6,OR:XS%/%5P3X,<77CQ%,A(<H@
M
M                                          #0^]#R^(_U.?*KK_!%
MQLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3+?[-
M>@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M  $Y7HVOUTW1C_>)_P *'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M 9\7B_?60=4?MJU3X-=*;>[N_P!2\A]KK]DK>IKF&_PD;%^XLS^D,VC87HV[
M     6S/1J/ZD]6WMJXA_%'(#7_?7[:T_P"UWO%MH.N^]_K%L+[BU3V7(K/#
M!R&\
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M%43A+KY57R
M
M   T/O0\OB/]3GRJZ_P1<;(F^^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6
M            %*;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE
M#-)\M\                !.5Z-K]=-T8_WB?\*'.K6GG@?PZ[1?V#])Y)W]
M,]O4>']3+5;0?+M     9\7B_?60=4?MJU3X-=*;>[N_U+R'VNOV2MZFN8;_
M  D;%^XLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_?7[:T_[7>\6V@Z
M[[W^L6PON+5/9<BL\,'(;P
M                                   %8KTM'ZK;7OE6<2_F;RJW.YB?
MSV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_\ K2>@+Y5G
M#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
M               "AOZ63X;,^N[7JGB3<5X'LP>XSX+B_J8ML=;PA)CMNM+6
M3&<8\G7=.A0FFEH;)B+277LC<U)Y*-*ZL<5)+":M>U)HR>\Q;?!&;R-_<_K=
MW_F<O%>9TZ:I\U:F>5F<O&,\=NJ>SVZ8B9FFN_,X4VXA;^KY7"8S5'%/!5X/
M0GQNLI1)&E#
M
M    :'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M             "E-Z9;_ &:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,
M^,H9I/EO@                )RO1M?KINC'^\3_ (4.=6M// _AUVB_L'Z3
MR3OZ9[>H\/ZF6JV@^7:     SXO%^^L@ZH_;5JGP:Z4V]W=_J7D/M=?LE;U-
M<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/XHY :_[Z_;6G_:[WBV
MT'7?>_UBV%]Q:I[+D5GA@Y#>
M                                      K%>EH_5;:]\JSB7\S>56YW
M,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !(]X/_P!:3T!?
M*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M75HJ\S,Q'+MS1<B,*X6;F+%67O3:KZ'T8Z$O&;(;@
M
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M)ZMO;5Q#^*.0&O\ OK]M:?\ :[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
M
M       K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M                !(]X/_UI/0%\JSAK\\L:Q#O^^9/:GX#S?L53M9/VW;]'
M'BM@= ,O(                                     !7L](5\*"7Q#^F
M*')_$F MKCJQZ<<7E]@X\A;4(29+E#0>[-D=PX=KUZ4._=Y"[\C'(ZY"K"I+
M2S%.:UDC;T\G=UY=KN:AOSG=-MGW%UZ[,;"ZO711?QGRN6O^9M9N(GBIC'L>
M8PPQM3%<\N;-%,T[4<IVS:Y=$?7J>+JQT8\CJ^"R\Z]"O:UZUK=4:MM<VU6I
M0N+>O3GHUZ%>C/&G5HUJ52$M2E5I5)8RS2S0A&6,.R/JIIZ:J:Z8KHF)HF,8
MF.&)B>*8GHQ*U7\7T_
M
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MVN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
M                                           *Q7I:/U6VO?*LXE_,
MWE5N=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8                 2/>#_\
M6D] 7RK.&OSRQK$._P"^9/:GX#S?L53M9/VW;]''BM@= ,O(
M                          !GY^DX^#K5X=W/->(OTXZSV<3\BYVE-U*Z
M;AK6;R7'7).=NI*-OREC[:WIQDHZ;R-DJT*>5A&$L+#8*LM2$T]/)0DM)4^9
MGS@:=H-.M[I-KKW_ /=REJ>Y]VN>',9>B,9RU4SQW<O3&-KS]B)C")LXW+=U
M3)<BKMFU'E)GRT=*>GX$^+X*G,D$44
M
M                    !H?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;
M[!7Z/QH6YVABL                 *4WIEO]FO03[>>H#\0<4I&>]Z_EC:C
MW-D?J\RH>M^9M^#/C*&:3Y;X                "<KT;7ZZ;HQ_O$_X4.=6
MM// _AUVB_L'Z3R3OZ9[>H\/ZF6JV@^7:     SXO%^^L@ZH_;5JGP:Z4V]W
M=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/XHY
M:_[Z_;6G_:[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
M                                                    K%>EH_5;
M:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M !(]X/\ ]:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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MH,&S#H
M                                                        -#[T
M/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M     !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+?
M                3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_
M4RU6T'R[0    &?%XOWUD'5'[:M4^#72FWN[O]2\A]KK]DK>IKF&_P )&Q?N
M+,_I#-HV%Z-NP    %LST:C^I/5M[:N(?Q1R U_WU^VM/^UWO%MH.N^]_K%L
M+[BU3V7(K/#!R&\
M                            !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S
M7LN64K6/:D>CCQ)9IZ8E;                 "1[P?_ *TGH"^59PU^>6-8
MAW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
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M:[%SAFU<PC'"JBK"NBNF+2S>4KRESDU<-$\4]/\ IZ:+AFMU
M
M                                     &A]Z'E\1_J<^577^"+C9$WW
MP#YR=%^ X_&LPN31OL%?H_&A;G:&*P                 I3>F6_P!FO03[
M>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*&:3Y;X                "<
MKT;7ZZ;HQ_O$_P"%#G5K3SP/X==HO[!^D\D[^F>WJ/#^IEJMH/EV@    ,^+
MQ?OK(.J/VU:I\&NE-O=W?ZEY#[77[)6]37,-_A(V+]Q9G](9M&PO1MV
MMF>C4?U)ZMO;5Q#^*.0&O^^OVUI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
M
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M9NV*Y\Q=BF(Q\I7%-<32M/-Y2YE*^35PT3Q3T_Z>HBM9O=0
M
M                                  !H?>AY?$?ZG/E5U_@BXV1-]\ ^
M<G1?@./QK,+DT;[!7Z/QH6YVABL                 *4WIEO\ 9KT$^WGJ
M _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^                 G*]&
MU^NFZ,?[Q/\ A0YU:T\\#^'7:+^P?I/)._IGMZCP_J9:K:#Y=H    #/B\7[
MZR#JC]M6J?!KI3;W=W^I>0^UU^R5O4US#?X2-B_<69_2&;1L+T;=@    +9G
MHU']2>K;VU<0_BCD!K_OK]M:?]KO>+;0==][_6+87W%JGLN16>&#D-X
M                                        #H;E'JBZ=.$L_9ZKR[S7
MQOQQLF0P]OL%C@]PVK%8/)W6#N[W(8VVRM"TOKBE5J6->_Q-S1EJ0AW8U*$\
MO;VRQ53(Z)K&I6IOZ?EKUZS%7)FJBF:HBJ(B9C&.CA,3X<,C[(;H-Z6\#3*]
M9V(T#5=5TJU?JLUW<KE[EZW3=IHHKJMS513,17%%RW5-/'%-=,]&'6_T@?1#
MYU?!?OB:]_ZQW?\ *>TWX#FON=7D+J_=GYP?Q-VB]Y7_ %)]('T0^=7P7[XF
MO?\ K#_*>TWX#FON=7D'[L_.#^)NT7O*_P"I/I ^B'SJ^"_?$U[_ -8?Y3VF
M_ <U]SJ\@_=GYP?Q-VB]Y7_4GT@?1#YU?!?OB:]_ZP_RGM-^ YK[G5Y!^[/S
M@_B;M%[RO^I/I ^B'SJ^"_?$U[_UA_E/:;\!S7W.KR#]V?G!_$W:+WE?]2?2
M!]$/G5\%^^)KW_K#_*>TWX#FON=7D'[L_.#^)NT7O*_ZEV1Q=U1=.G-N?O-5
MXBYKXWY'V3'X>XV"^P>G[5BLYD[7!VE[C\;<Y6O:6-Q5JT[&A?Y:VHS5(P[L
M*E>27M[9H.EGM$UC3;47]0RUZS9FKDQ573-,35,3,1C/1PB9\*5J[7[H-Z6[
M_3*-9VWT#5=*TJ[?ILT7<UE[EFW5=JHKKIMQ573$37-%NY5%/'--%4]"7?*E
ML<                   *Q7I:/U6VO?*LXE_,WE5N=S$_GLN_ >:]ERRE:Q
M[4CT<>)+-/3$K8                 2/>#_ /6D] 7RK.&OSRQK$._[YD]J
M?@/-^Q5.UD_;=OT<>*V!T R\@
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MFJNS,S=M1$S]<MTS<6QG<A<RL\NGRUGI]+P?)XD"#:)3@
M
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MK;VU<0_BCD!K_OK]M:?]KO>+;0==][_6+87W%JGLN16>&#D-X
M                                  "GYZ0)\<GC3Y,NF_"GS.V"W4?J
M[>]VU^Q64XW>S_F(U;]K<U^C]+08,GI$     $Y_H_?QR>2_DR[E\*?##&&]
M?]7;/NVCV*\CO[YA\Q&D_M;E?T?JBX&U]0<@                  *Q7I:/
MU6VO?*LXE_,WE5N=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8
M    2/>#_P#6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
M                                        'R-@U_ [9@LSJ^U83$;-
MK.Q8N^PFP:[L&-LLS@L[A<I;5++)XC,XC(T;G'Y/%Y&SK3TJ]O7ISTJU*>,L
M\L98Q@[&5S>:R&:MYW(W+EG.6:Z:[=RBJ:*Z*Z9QIKHJIF*J:J9B)IJB8F)C
M&)Q?DQ$QA/#$J,?B]^BZY'#S[5U%>&AC*^6P\?7F=V_I)N+FK<9C%RRPJW.0
MO>"<U?W%2MG+2:'W\NKWT_KRG&6>7'7-S&>WQU*2[<'SU;.8BQLEOCKBWF."
MBUJD1A15Q13&=HIC"B>AVS1'(G@F]11A7>F@YS2IC&[E>+HT^1Y'6Z2E'G<#
MG-6S>7UK9L-E==V/ 9*]PV>P&=QUYB,WA,OC;BI9Y'%9?%9"C;WV-R5A=T9Z
M5>A6IR5:526,LTL)H1@D:RN:RV=RUO.9.Y1>REVB*Z*Z*HJHKHJC&FJFJF9I
MJIJB8F*HF8F)QB5#F)B<)X)A\ESOP
M
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MG_:[WBVT'7?>_P!8MA?<6J>RY%9X8.0W@
M                  *?GI GQR>-/DRZ;\*?,[8+=1^KM[W;7[%93C=[/^8C
M5OVMS7Z/TM!@R>D0     3G^C]_')Y+^3+N7PI\,,8;U_P!7;/NVCV*\CO[Y
MA\Q&D_M;E?T?JBX&U]0<@                  *Q7I:/U6VO?*LXE_,WE5N
M=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8                 2/>#_\ 6D]
M7RK.&OSRQK$._P"^9/:GX#S?L53M9/VW;]''BM@= ,O(
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MT=..+^CPT73-;J
M                                                          -#
M[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M       !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+
M?                 3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'
MA_4RU6T'R[0    &?%XOWUD'5'[:M4^#72FWN[O]2\A]KK]DK>IKF&_PD;%^
MXLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_ 'U^VM/^UWO%MH.N^]_K
M%L+[BU3V7(K/#!R&\
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M,\C,VOMMBO"Y3&/!%?)FW5/F*ZHX5"OY:]EYPNTS'5Z$^&\3LCN
M
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M4GJV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_P!8MA?<6J>RY%9X8.0W@
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M1.,3''$CPOS7X87AX]1'KZMS!T9=.^UY7)=OKW:*'&6N:ON]QV]G^MO>H6>
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MK\\L:M'?]\R>U/P'F_8JG+D_;=OT<>*V!T R\@
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M8X8F."8='BX)?F?;\
M                                                        :'WH
M>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M     "E-Z9;_ &:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9I/EO
M@                )RO1M?KINC'^\3_ (4.=6M// _AUVB_L'Z3R3OZ9[>H
M\/ZF6JV@^7:     SXO%^^L@ZH_;5JGP:Z4V]W=_J7D/M=?LE;U-<PW^$C8O
MW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_UB
MV%]Q:I[+D5GA@Y#>
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M<]PX5YB]7=F,>A3RZIBBGI4TQ%,1$1$1$/JBW;M1R;=,4QU(P=S+>?8
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MJ(Y-=,Q/!Q<'4XNM@F8:\NZ
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M;2[.[39;MS9S/Y+/Y28\WEK]N_1Z:W55'T71KMUVYPKIFF>K&#JU6WP
M
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M]6WMJXA_%'(#7_?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
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MT5U3%,353$S,88S$8XS"VFP*A6
M
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M0C&G7MKB2G6HU(0C]R:6$7?M7;=ZW%VS537:JC&)IF)B8ZDQP2_.+C?D<C\
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M7_?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
M
M
M
M                         &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76
ML_/^W+GHD5#.#I@                -#[T/+XC_ %.?*KK_  1<;(F^^ ?.
M3HOP''XUF%R:-]@K]'XT+<[0Q6
M         &?%XOWUD'5'[:M4^#72FWN[O]2\A]KK]DK>IKF&_P )&Q?N+,_I
M#-HV%Z-NP    %LST:C^I/5M[:N(?Q1R U_WU^VM/^UWO%MH.N^]_K%L+[BU
M3V7(K/#!R&\
M
M
M                                                          !D
M8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8
M    #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M                                          !GQ>+]]9!U1^VK5/@U
MTIM[N[_4O(?:Z_9*WJ:YAO\ "1L7[BS/Z0S:-A>C;L    !;,]&H_J3U;>VK
MB'\4<@-?]]?MK3_M=[Q;:#KOO?ZQ;"^XM4]ER*SPP<AO
M
M
M
M                                8_'C 9C\.>*3U^WOX0_"?D.JSF7#
M^N?+>7\G_1[<LE@/P?W^V/=_!/X,]:]S_P#Q^1[GJ=U/SN"R_:VY/9:WR.1C
MH>4KPPP^R6J:^5_I<KE8]'''HK-SDXYNYZ.?%1PLO.J
MT6?0^<--0\/SJ'V&-Q+-)E.L;9\-+:PIQA-1FP/"G"-]/<1J]^,)Y;F&QRRP
ME[L.[Y*,>V/>]2)+G^YB*MZNDY3#AHV?MUX]/EYS.1AAU.Q_1ZBY=&C_ )>J
M?Z_C0MF-%57                                           9\7B_?
M60=4?MJU3X-=*;>[N_U+R'VNOV2MZFN8;_"1L7[BS/Z0S:-A>C;L    !;,]
M&H_J3U;>VKB'\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
M          %(;Q0NMWJ^XOZ\^HK0^.NI+F/2M+UW9-;ML%J^M[UG<5A,1;W.
M@ZG?W%&PQ]K=T[>VIUKV[JU9H2PA",]2:/W8MG]A=E]G<]LGD\WG,EEKN9KH
MJFJJJBF:IPN5QPS,</!$0]&?,SYN>X?;/FR[)[3;6;(Z!J.T.;RF8JO9C,9.
MS=O7:J<[F:*9KKJIFJJ8HIIIC&>"*8CH/&6,\4[Q"L1&TC:]5_*=7UE"26C^
M$[[%YN$\))>[#UW#,XN_AD(QA]V-?RD9H^K'MBN6O8/8^YCRM/L</2B:>MA,
M8>%@V!SG,LYJV>[)V?8C1:>R8X]CHN6<,?.]BN4<CJ<CDX=!VWKGC9>)1KWD
MI*G4#;[#:49)Y9;/8^+>)+WO1GN(7$U2KD+71['-5I_]:G#OW4TLM.?LEA#N
MR1EI][=CL5>X8R<T53T:;MV/H37-/T/'6-JW>[>:)JG*JHV6JRM^J8\M8U'4
MZ.*GDX115G*[,1Q3.%N)FJ,9F<:L?2FE^D1=:V!GI4MLTC@7>[.$9?+U+K5-
MLU[,5)83S330HWN"W:ABJ$9Y)N[VS8^IV=V6,(?ZW>HF9W.[,W8QR]W-VJNI
M715'6JHQ_P!:&(=H>]2\WC4Z:J]#U':?3+_TL4YG+7[4<'1HO92J[.$QCP7Z
M>.>IA[-X\])2P%;R-ORQTL9?'=V2C"XS''G)%EF?+SQ]2XFHZWLFLX'UK)+V
M=Z26;*UHS=O=C&'9WHVUG-RMZ.'3\_35U+EN:?\ 6IJJQ])#7[:OO0^IV^5=
MV'VUL7<9GDVL]D*[6$?2XYC+YB]RIZ$S&6HPPQB)QPB0OBWQSO#SY)FM[?*\
MB;=Q+D+J,LE&PY2T/,64L*DT9(=VXS6F3;OK%E"7O1[9Z]_3IP[L?OON=MH9
M_=9MADL9MV;>8HCHVKD3_JU\BJ?"IF6JVVG>V^=3LC%5W):3D-=RM$3,UZ=G
M;5?!&/F;6;[3S%?4BBS55PQP<:3'C/FOAWF?&S9CB+E3CSD[&TZ=.I7N]"W+
M7]KIVD*GJ2R7T,)D+V>PKRS_ 'LU.M"G4DGA&6:6$T(PA9&>TS4=-K['J-B]
M8KZ5RBJC'P.5$8^$T]VPW=[?;OLY&0V[T35=&SDS,4TYW*W\M-6'1H[-11%<
M8<,54<JF8PF)F)B79SHK.                       5A_&G\0[K#Z2NJ70
M>..GWE_^@&F9K@'5MVR>&_H!Q=M7KG9\ER)RI@KW)_A'=M)V3*T?+8K6[*EY
M&G7DMY?(]Z6G">>I--G'=GL?LYM!H-[.ZOE^S9FG-U41/9+M&%,6[541A173
M''55..&/#QX1"9#O>?-4W";\MR^I[6[TM![J;09?:C,Y2W=[=U'+<G+V\CIM
MZBWR,IF\O;G"YF+M7+JHFN>7A-4TTTQ3$)]-AXF_G,?^S73]^ZED3Y,MA_P'
M_P!;,??6^'\N[F=?$_\ ZKK?_<CZ;#Q-_.8_]FNG[]U)\F6P_P" _P#K9C[Z
M?R[N9U\3_P#JNM_]R/IL/$W\YC_V:Z?OW4GR9;#_ (#_ .MF/OI_+NYG7Q/_
M .JZW_W(^FP\3?SF/_9KI^_=2?)EL/\ @/\ ZV8^^G\N[F=?$_\ ZKK?_<CZ
M;#Q-_.8_]FNG[]U)\F6P_P" _P#K9C[Z?R[N9U\3_P#JNM_]R/IL/$W\YC_V
M:Z?OW4GR9;#_ (#_ .MF/OI_+NYG7Q/_ .JZW_W),UX)_B ]7/5QSYRMI74+
MRU^D'6=:X@J;3A,9_0/C+5/66=EW/5L3"^]>:1IFM9"Y[,?D:U/R56K4H_?]
M[N=Z$L88UWF[([/;/:3E\SH^7[#?KS')JGLEVO&GD53AA775$<,1PQ&*/OOB
M/-=W%;BMV&B;1;J]"[EZQG->C+7KG;NH9GEV>U,S=Y'(SF;S%%/E[=%7*III
MKX,.5A,Q-EEA1$&                        \K<M=<72#P9-=V_*?4;Q+
MJV3L)ZM.\UV.WXW-;;;ST(1C5DJ:?KM3+[1WY(P[.R%G&/>^]^[ZBO:?LOM%
MJL15D,EF+EN>*KD331Z>K"GZ+->PW-PW\;R8MW=BMDM<SN3NQ$TW^U;EG+51
M/%,9J_%K+83Q_9>+AXN%'!R1Z01T(:=4N+?3:',7+=:2>:2VN]3T2AK^&KQE
MFCV5:USR)FM.S-O;SRP[81ACZE3MC"$9(>K&%Z9+=%M7F8B<S.6R\=&*[G*G
MK6Z:X_UH\%MKLCWK;G+Z_33=U^K0-"MS&-5.9SDW[L=2*<C9S5JJJ.CC?IIX
M\*IX(GQ!NWI*U>,]:AQQTG49*<.]ZWRN[<L3U)Y_5FA)Y;7\%H]*6EV2PA&/
M=R<_;&,8>IV=L;HRNY2,(G.ZA./2HM?_ %55_P#TMCMG>]"VHIIN[6[<537]
M-;RFFQ$1T\+][.3CX>7CBQZ.$>6]E](LZT,G5FEUWC?IVU>SA5EJ4^W5M^S>
M3[D):LL:%>\O>2*-A4I3QGEFC&2SIS]Z2'9-"$8PC7;&YO9JB/KU[.7*O16Z
M8ZT6\?HRS/I'>G^;WDZ(G5M7VKSE_DX3_P SDK-O'@\M%-&0FN)C"8X;M483
MQ8X3'2>2\=_Q%[Z>E/:\B:'AI:<D99Z6-XJTVK)6C&/;"I5CF+#+5(3RP]2'
M<FDE[/NPC'U53HW4[&T1A59NU>#=K\:89%R?>T.:?EJ9IO:3J>8F9X)N:EFX
MF.I'8J[48>#$SU7"*_C:>)I6KUJM/J0I6M.K5J5)+:APWP+-0MY)YXS2T*,U
MSQ?<7,U*C+'NRQJ5*D\80^^FFCVQCVHW8[$1$1.2QGI]FO\ #UKL0N*UWNOF
M>6[=-%6R-5=5-,1-56JZUC5,1YJ>3J--.,\<\FFF,>*(C@?TL_&W\3*VN:5>
MMU%VV0I4XQC/9WG#G!4EM7A&6:6$M6:PXTL;R$)8Q[T.Y5DCVPAVQC#MA'\J
MW8;$54X1DYIGIQ>OX_1N3'T'S?[W3S/;UFJW;V3KM5SQ5TZKK,U1X$5ZA73U
M.&F>OPN=X?QY?$2QD\9[W>>.]BEC5HU(4LQQ9J]"2$E*,8ST(1U^C@ZODKB$
M>R>,9HSPA#[R:6/JNK<W4;'5QA3:O4>!=J_^KE<2VM0[V9S4<Y3R<OINK92>
M3,8VM1S$SC/%5]?F]&-/0X,//14[OU?TC'K&QL]&GM/%G3SM%I)/"-6>UU_D
M#7<K6EC7EGJ2>O*/(>2QM/LM^]3DC"Q[98]DTW?[(PFI=_<WLY7&-B_G+=75
MJMU1UNQQ/^LQSK/>G-P6<IJJT76MJ\E?F."*K^2OVXGDX1/)G(V[D^6PF?KW
M#&,1R<8F/4^C^DJV<WK>WY)Z3[FCV0D]=9?1^5J5SWYO)RPJ1M]=SVDVGDX1
MJPC-+";*3=DLT)8Q[9>]-0<UN4JX9R6H1/2BNUA_K4US]2PKM'WH6_'*N[([
M<45<?)M9S39IPX>#E7[.;JQX,(G#+QPQCT<(]Q<;^/YT"[K-1H[9>\L<15YX
M4X5JN[\?5<SCJ=6:,83PI7/&N3WN\JT)(P_UY[:E&,(PC&6'JPA:^=W2;6Y;
M&<O&7S$?U+G)GK7(MQ]&6N&UW>ON<]L]%5S0[>AZ[;C'",IGHM7)CH8TY^WD
MZ(F>E%RKACCG@QDEXAZQ>E?GN:VH<0=0'%.\Y.[C++1UW%;CB*.V]L\>RGY7
M3LC<66TV\*LWJ21J6<L)XPC"';&$>RRM1V<U[2<9U'*9BU1'TTT3R/3QC3/7
M:C;>;@]]6[&*[FWFR^MZ;DZ.._<RMV<KP<>&:MTUY:K#H\F[.$83/'#TDHK$
M0
M
M                #%]ZX=QEY$ZU.K_D"2K-6EWGJBZ@-QEK3R6U*:M+LW+&
MVYJ%6:G9U*UG3FJ0O>V,M*>:E",>R6,9>R+T0[M=/G2=W6@:5,83EM$R-K#A
MG#L>5M48<.$]#HQ$]/A63?JY5^NKIUS/T7EQ>SA                 :2GH
MC&%_!?AB\D7WKGR_]).LCE+->2\CY+UEY#BC@C7?6W?\K4]<=[\ ^6[_ &4^
MSRO<[OWO>FA_Y^>8[/OGR=K##L.SV6HQQQQQS.=N8\7!YO##AXL<>'"+FT>,
M,K/5KGQ(6D6E"K                                           ,^+
MQ?OK(.J/VU:I\&NE-O=W?ZEY#[77[)6]37,-_A(V+]Q9G](9M&PO1MV
MMF>C4?U)ZMO;5Q#^*.0&O^^OVUI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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MFJM MX_\_D\,YDN3&'EJ[MCE3EXF9PB,U18JF8X*9C"9]TK5:U@
M
M
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M]2>K;VU<0_BCD!K_ +Z_;6G_ &N]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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M^J11FKU-7!PV+,T4Y;+83CR*[5F+\4SR:KU?#,QF+V;A
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MI%CAH/,33/)JX)A_T?@
M
M                           "'+Q^.=;?@/PENL#-0N_(9?D?0[;@K VT
MM2%*MD[CFG-8_0,_:49H^I-ZWTC,Y6[J2_\ :H6T\(>K&#8+FM;,U[4[]M R
MW)QR^3S4YVN>.*8RE%5^B9\&]1:ICI550Z6H7.QY.N>C,8=?@\1DSIU5H
M               -:SP$]%CQWX0G0W@(T9J'X0XOS6]=R;RW;-#E#D;=N2X5
MH>7KW$_=N8;;Y2'9-"3LF^\EDE[))8(^=#J?=;?YM+FL<>1G:+/0_P#QLO9R
M^'!$<78L.GP<,S/#-X:?3R<G;CJ8]>9E+RP([@
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M.#9?<U^K%_W?7[%8>A7O37\.FM?MKG/T9HZ 5EI*      L1^C?_ !IN<_V
M5OA%TEAW?/\ D+*^Z_\ AUHI>^V?,MLW^U$?B&<7(6N" 0
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MW+U,<I(0M!JP
M
M                    H\^F&=6%K+C^EWHDP&2FGO:MYE>I/DNQHUX2RVUK
M;T,OQWQ/0N):?>FJS7M6ZVFO4I5(R0IPH6]3NS]^2:22?F ;"US=UO>1FJ,+
M<4TZ?EZICCF9HOYJ8Z6$1EHB8QQY5<8QA,30M9O>8L1Z*?$CQU&!)@H
M             #:/Z+^-YN'.CWI3XDJ4?6];C'IPX1T&YI1A2[\+O4>--9P-
MY-5C1J5J4]>I=6$\U2>$\_?GC&;O3=O;'SL[Q-8C:#;_ %S7HG&G.ZOG+\3P
M\5W,7*XPQPG#"J,(PC".#"%[V*>19HHZ5,1]!Z66<Y0
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MTW.?[ *WPBZ2P[OG_(65]U_\.M%+WVSYEMF_VHC\0SBY"UP0"
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M\=%RW7%-5%4=&*HB7WG$I@
M
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M<Q<F;E^[PQ$X57:JN1%7#3;Y%'%3"S,S>G,7JKL]&>#J1T/H/%S(K@
M           >B^D#B*?G_JOZ:.#I;?UU)RYSSQ+QU=THTX5:<N.V_>\%@\I7
MN))I9I/6EICKVK5K1FA&66E)-&/J0BM';[7HV6V&UG:69Y,Y#2\UF(GB\M:L
MUUTQ'5FJ(B.K,.6S1V2]3;\]5$=>6TT\ZR]P
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M&*,Q.
M
M        _E7KT+6A6NKJM2MK:VI5*]Q<5ZDE&A0H49(U*U:M6J1EITJ5*G+&
M::::,(2PAVQ]1]4TU5U111$S7,X1$<,S,\41'1F1GB>DA^-GB>J?-9#H1Z5-
MJI97IYTC8J%SS9R;@,A"OA^;]YUZ[M[K%ZIK=S;PEI9'C+0<W;1KSW<)ZMMG
M<S1HW%O#UK8VMS>2Q<T+FXW]B,O1O.VXL31M9F;,QD\O73A7D[-R)BJ[<B>&
MG,7Z)Y,4X159LS517Y>[71;MS4\]%V>U[,_6XGAGISY$?1E4:;YJ,
M           GR]&AX.FYG\6_@S*7%E+?8/@W5N2^<<_2F[>RE+K^JW.GZK>P
MFA_JS6'(F]86M#_\QD[/]+5SGC;2QL[N'U.Q15R<SJ=_+Y.B>GR[L7;L?Z5B
MS>CPU1TNWR\Y3/0IB9\;Q9AJ9H2UU@
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M.6:6>66:6:$TLT(32S2QA&6:6,.V$TL8=L(PC"/J18 0?S$TSR:N"8?]'X
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M:V*W?92+.6C"K,9BO"K,YR_$83?S-W")KKGAY-,13:M4SR+5%%$12\S*VS"
M                            ])]*W5?S+T=\J8SE?AG8I\5DZ/D+/8]?
MO(5+G5]XUV6[HW5WK&U8N6I3A>XR[C1AW:DDU.ZM:G95MZM*K++/"BZ]H&F[
M1Y"K3]2HY5$\--4<%5%6&$543T)CK3Q3$QP,1;Z]R&[_ '^;%7MB-X.4B_DZ
ML:[%^C"G,9._R9IIS&6N83R+E./#3,56[E/E+M%=$S3-\WH3Z]>'^NWBVWW+
M1;JAK^^8:A0M^2.*<CD:%SLFDY:,LLL]:GV26U7-ZGD*L>]C\K3HR4KB7^3J
M2T;FG6MZ6J.U6R>H[*Y^<MFHFO*53];NQ&%-<?1Y-<?343.,<<8TS$SYE^<K
MS9-O>;3MI7L_M+15FMF<Q5-60U*W;JIR^;M<.$3PU19S-$<%_+55S51/EJ*K
MEFJW=K]R+6:W@
M
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M<<,38IKB*KMVF>&+]RFF:9B)MV[=4<J;=SFIW,Q$V[6--GZ,^#Y"M W'4L
M                !>D]#CZ>)Z6(ZQNK#)V';3OLCH_3QI64[D(=V?%VT>2>
M3[#RD>V:/?ES&H5.R'9"'=[8]O;#NQG=\%VLBJ_L_L+9KX::+V?O4^BGM?+5
M?ZF:C_QPU_1;?!7>GJ1'BSXR\"C95T
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M73+5,1&;B(FJ[G<I1'!&:B,:\Q8IC#-1C=MQVSRJ<S;<:^(+P
M%+7TC3X[G%OR5](^%OG!LON:_5B_[OK]BL/0KWIK^'36OVUSGZ,T= *RTE
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M9'):;E:,CIUFUE\E:C"BW;HIHHHCI4T4Q%-,=2(B'0F9JG&J<9? =I^
M               -:KP(NE^KTH>%MTMZ3E<?^#]QW_4:G.N]R3RS27<=@YDN
M9MTQMID:,\E.:WR6OZ5?XG%5Z<8=LE2PC+&,8PC&,$G.<VTC;G?9K>I6*^7I
M^5S':5GI<C*1V&J:9Z--=ZF[=IGHQ7BO#3[78<I13/FIC&?#X?$2]L!NX
M                                         SXO%^^L@ZH_;5JGP:Z4
MV]W=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/X
MHY :_P"^OVUI_P!KO>+;0==][_6+87W%JGLN16>&#D-X
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M4PT"[7-S6<E:IX,M<KJ\MJ-BBG_\>Y5,=MVZ8^L7)G,1]9KN]@LT,(H>0
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MP]GD9.Q'*OWZHI[/G,Q5$1<S.8JIB.5<KPB(CS-NW31:MQ3;HIB/-JM,N
M      )+>EOPENM3JJDQV:UWC:IQMQ[D(4ZU+D?EV-[IF NK*K)3K4[S!8JI
M87>W;/;75"?MH7%ACJUC4GAW9KB3U8PLK7=X.S.@\JU>O]GSD?[.SA75$]*J
M<8HIF.C%545=26H&^CGR<WG<I5>T[5=7C5]J;6,3D-+Y&;OTUQ,Q--ZY%=.5
MR]5,QY>B]?HO4QPQ:JX(FP?T[^CS],/'\ECEN?\ ==QYZS].%&K<X&PJU^->
M/9:D9(3U;::RP60NMTR,*%:/=EK?AFTDK22]L]O+WHR0Q!K&^#7,W,V](M6\
MI9Z%4_7+G@XU1%$>!R)P\\BRWK=]3WR;457<CNNT[(;,:7.,4WJXIU#/88X1
M5R[U%.4M\J.&:.U+DT3.%-V<.5,SG$/3;P!P#8PQ_"_#?''&=.-*-&O=ZCJ6
M'Q68R$DW=[T<OGJ-K^',S5FA)+"-2[N*T\9999>WLEA"&-=1UK5]6KY>IYF]
M?GI5US,1X%./)I\*(1];>;W-Z&\_,]M;PMH-7UBKE8TTYK,W;EJB?]U9FKL-
MJ.&9Y-JBB,9F<,9G'NQ3&.P      '0',72KTW=0-M6M^9^$>->1*M:2$GX6
MV#5<75V2VEEE[D(X_:K>A;[+C)X2?>]ZWNZ4W=]3M[%7TW7M:TBJ)TW-7[,1
MT*:YY,^#3YF?#B64-@=]F]S=;>IN[OMH]7TJBF<>Q6,S<C+U='R^6JFK+W(Q
MX<+EJJ,>'C0N=0WH[?3ONE.^RW3KR-N/"N<GA/4M=9V::IR3H$9I>]-2LZ%7
M(7-CO.*A5C-W9[FMD\IW)80C"A-&$>]DO1]\6L9:8MZS9MYFUT:J?K=SP>")
MHGP(II\%(5NJ[ZWO6V>KMY'>QI.0VBTV,(JS&7PR&=ZM5444UY.YAQQ;HR^7
MQG&)N1&&%?CJD\*CK1Z3Z>1S6Y\95]XX^QM.K<7/)O%$]YNNHV=G1\I&K>YR
ME1L+/9]5LZ,DLL9[C*8ZSM833RRRU9HLNZ%M[LUM!--K+7XM9RKBM7<**YGI
M4\,TUSU*:IGJ)2-R_/9YO>^^NSIVS^L4Z;M3>F*:=/U**,IFJJYPPHLS-=67
MS-<S,X49:_=N81,S13".1>3;,        !Z*Z6.I_E+I"YFUGFGB?*QLLWA:
MGK/-8:XFFCA=SU2ZN+:KF]/V*VA":%QB,O3MI/OH0\K;7%.E<49I*]&E/+1]
M>T/(;1:;7IFH4XVJN&F?IJ*XQY-=,].,? F,8G&)F&*-]6YO8O?ON_SF[W;B
MQV33LQ'+LW:8^O93,TTU19S5BKZ6[:FJ>#'DW*)KM7(JMW*Z9T'ND7JNXPZR
MN$]9YHXPOI(6N3I2V.TZM<75.OG-#W"VH49\UJ.>DDDHS0NL?5JPFH5_)TZ=
M]:5*5S2AY*K*U"VAT#/;-ZG7IF>CRU/#35AY6Y1/F:Z>I/1C'RLXTSPP\L>_
M7<CMES?]XF<W>[96Y[-9JY>6S--,Q9SN5JF8M9JS,S,<FN(PKHY555F[379K
MGET5/3BAL.@                             ,MSTG;ZXCG_VC<"_ UIJ
M:[F8_P /^E>Z<[^-W5J:I[=J\"/$A7];4J<
M
M                       ]T>&CTHWO6WUU]-'393LJ]Y@=^Y+P]QR#-0[\
MDUEQ9J<*NX<GWL*\)8R6]>GHV"OY+:,\999[N>E3[>]/+".,]\>W-O=ONRUG
M;":HIS65R=<6,>CF;N%K+1AT8[-71-6'%3%4\42[&5L]GS%-KH3/#X''/T&Q
MQ0H4+6A1M;6C2MK:VI4Z%O;T*<E&A0H49(4Z-&C1IPEITJ5*G+"6666$(2PA
MV0]1Y]JJJJZIKKF9KF<9F>&9F>.9GHS*]']7R
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MBS.\#4J;=[5<W3'!7>B)Y&6LU3'*[5RO*JHM8X3<KJNYB::)N]CHCH7DVP
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M:TU-=S,?X?\ 2O=.=_&[JU-4]NU>!'B0K^MJ5.
M
M                          7F?1!>BB>G1Y]Z^]NQ522%QW^G;AFM=T(2
MRU*-.?#[;RWLEE+7AWZDD:TN#Q5K=T80D[U/)6_>C&%266-'G\[QHFK2]UN0
MKC@_Y_-Q$]'R]K*VYPZG9KE5,\/#9KPXIFO:-8\UF)]#'BSXWT5XQ&LKP
M                                         #/B\7[ZR#JC]M6J?!KI
M3;W=W^I>0^UU^R5O4US#?X2-B_<69_2&;1L+T;=@    +9GHU']2>K;VU<0_
MBCD!K_OK]M:?]KO>+;0==][_ %BV%]Q:I[+D5GA@Y#>
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MCM+I=B*=7M6Z>',Y*B,*,[A3PU7LE3Y6]5,535E,*JJJ:,I$56_&NR!P
M                        !EN>D[?7$<_^T;@7X&M-37<S'^'_ $KW3G?Q
MNZM35/;M7@1XD*_K:E3@
M
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M-JGBIC__ &?#EZD62Y0
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MB:H[/DIJG'&O)7*XHIQFJJK+UY>Y75RZZHB3I8[3D
M        !EN>D[?7$<_^T;@7X&M-37<S'^'_ $KW3G?QNZM35/;M7@1XD*_K
M:E3@
M                                                  %S;T37PY:^
M\<F[CXC')F%__P"2XHJ9CC'I[M[^VDFIYODS,XOUKR!O=K"K/+/ZTT74\I#%
M6M2%.I1N+[,W,9)Y*^-FA&/+GU;W*=-T;+[H]&N?\_GHHS.>FF?,9>BK&Q9G
M#HWKM/9:HQB::+5&,33>A6](RW*KG,U>9C@CP>C/A>/U%^]%JN$
M                                    !GQ>+]]9!U1^VK5/@UTIM[N[
M_4O(?:Z_9*WJ:YAO\)&Q?N+,_I#-HV%Z-NP    %LST:C^I/5M[:N(?Q1R U
M_P!]?MK3_M=[Q;:#KOO?ZQ;"^XM4]ER*SPP<AO
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MUQ'/_M&X%^!K34UW,Q_A_P!*]TYW\;NK4U3V[5X$>)"OZVI4X
M
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M&H_J3U;>VKB'\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
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M_5R8\I:U*WAVY1.'%VQRJ,W3-4XUW+F8BF.3:3H,6(V@
M          &6YZ3M]<1S_P"T;@7X&M-37<S'^'_2O=.=_&[JU-4]NU>!'B0K
M^MJ5.
M                                                  ?ZEEFGFEDD
MEFGGGFA+))+",TTTTT>R6666';&:::,>R$(?=?DS$1C/$-.+T=+PE*W0'T\5
M^>.;=9EQ_5CU&X3'7N>QN3LH4\SP]Q5/4I936N+YO+QFN,?L68JRT<MLM/NT
M)Y+V%M85:<9\9"K4AFYVV_>G>EM9&R^S=[E["Z1<JBBJF?*9O,\--S,\'!5;
MHC&UEYX8FCEW:9PO<F+ITW)]KV^R7(^O5?0CI>3_ $+(+4)4P
M                                   &?%XOWUD'5'[:M4^#72FWN[O]
M2\A]KK]DK>IKF&_PD;%^XLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_
M 'U^VM/^UWO%MH.N^]_K%L+[BU3V7(K/#!R&\
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M .E=MU>5SNHVY^P3,>:L9"K&F:<>37G(KJFF>U[%Q8A8=13
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MP-::FNYF/\/^E>Z<[^-W5J:I[=J\"/$A7];4J<
M
M                       N/>C0^"]<\N[;K/B)]3^I5:?$VBY>7*=,^AY^
MQEEH\F[WAKN:6CRQE+.ZEC-6T?0LI;QCAY8R0ER>;HPK][UM8QDO(^N>-SB*
M- R%[=+L7?B==S5ODZC>HJX<O9KCARM,QQ7K],_79Q^MV9Y.'+NXVZUI>1Y<
MQF;L>4CS,=.>GX$=#JM =%:N(
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M%%-.;JKG,VJ>#DTQ:SE.8IHMT\%%F;7!3$Q"458K3$
M       !EN>D[?7$<_\ M&X%^!K34UW,Q_A_TKW3G?QNZM35/;M7@1XD*_K:
ME3@
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MJIF9F9F9G%=$1%,81P1#[+KOT
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M975-A=K]4V*UNGDZOI.H9C)WHC'#LF6NUV:YIQ^EFJB9IGHTS$QP2YVZBV@
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MBU5-54<,Q1FZ,I%$3P4]FN3$Q-4Q5<T:V//P
M  RW/2=OKB.?_:-P+\#6FIKN9C_#_I7NG._C=U:FJ>W:O CQ(5_6U*G
M
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M>C4?U)ZMO;5Q#^*.0&O^^OVUI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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M<AJEV;NU.S-<:7F9JG&NNU:HIJR5Z>&9F*\K-%J:ZIY5=ZQ>JGIS$@R"WH
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MNG._C=U:FJ>W:O CQ(5_6U*G
M
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MZZYFJJNNJJ9JJJJJF9JJF9F9G&5Q1$4QA'!$/MNL_0
M                               &?%XOWUD'5'[:M4^#72FWN[O]2\A]
MKK]DK>IKF&_PD;%^XLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_ 'U^
MVM/^UWO%MH.N^]_K%L+[BU3V7(K/#!R&\
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MD[G*T39/(TV,(G&F<[FZ;>9S5<<.&,6^U;%7!$Q78JB9GH3HL6(V0
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M5MW+]=J(C@B;<TQP0D%6@U:                         9;GI.WUQ'/\
M[1N!?@:TU-=S,?X?]*]TYW\;NK4U3V[5X$>)"OZVI4X
M
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MO%^^L@ZH_;5JGP:Z4V]W=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8
M"V9Z-1_4GJV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
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MTU_#IK7[:YS]&:.@%9:2@     +$?HW_ ,:;G/\ 8!6^$726'=\_Y"RONO\
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MNG._C=U:FJ>W:O CQ(5_6U*G
M
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MO:R]'(M1A'T9\&7KQ8+F
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MIMN.+E1G[]O+WX]Z59BKJ\G#@B<8T#VHKRW
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MK::>5=T_:*K+8X3,TT9W*7KE4XQ&$4S7DK=,S,QY::(C&97%VN* H
M                 !EN>D[?7$<_^T;@7X&M-37<S'^'_2O=.=_&[JU-4]NU
M>!'B0K^MJ5.
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MHBF.!6\OD<OEN&B,:^G/#/\ 1X25Y@QW
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M7NG._C=U:FJ>W:O CQ(5_6U*G
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M$XTTW+D]BHF>/L5BGDV;6/1[';IB>BJMJQ9L1A:IBGQ>OQO4RR'*
M                                                 SXO%^^L@ZH_
M;5JGP:Z4V]W=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4G
MJV]M7$/XHY :_P"^OVUI_P!KO>+;0==][_6+87W%JGLN16>&#D-X
M                      #I/J6UJ&Y].//^GS4IZ\NU\)\JZU-1IVU2]J5H
M9W1,]BXTI+.E/3JW<]2%UV0I2S2S5(Q[L(PC'M5/1+_:VLY3,\78\U:JX\/,
MUTSQ]#BXV1-T&KSL_O9V7U^)BF<CM%IN8QFJ*(CL.<LW,9KF)BF(Y./*F)BG
MCF)P9D[=Y[$0     &C#X:.8GSO0'TDWM2%6$U#A'2\/"%:M&O/W-=L(:_2C
M">:$(RTHTL9"-.3[E.3LDAZDK3?;:W%K:W4*8Z.:KGTT\KQWDYYW^0ITWG/[
M=9>CDX5;1YN[P1R8QOU]GG@Z>-R>5/TTXU=%[C6LUP     4M?2-/CN<6_)7
MTCX6^<&R^YK]6+_N^OV*P]"O>FOX=-:_;7.?HS1T K+24     !8C]&_^--S
MG^P"M\(NDL.[Y_R%E?=?_#K12]]L^9;9O]J(_$,XN0M<$ @     #/5\6[-3
MY[Q&>J>^J37$TU#>,/A81N:T:U3N:WH^JZ[2EEGFC-&6WEIXN$*,GW*=*$LL
M.R$.QM_N]M1:V-R%,8<-J:N#^M775X_#U7JCYB^GTZ9S3=BLM1R8BK3;MWRL
M81CF,YF;\\'GL;D\J?IJL:NBCE7DVR     6V?1J]=IVW&_57ML).RKF]WXP
MUV>?R=6'>IZO@=NR=.3RL9XT9^Y-N$\>[++":7O=LT8PFEA#7W?7>FK.Y#+]
M"FU=J]-51'_T(,N^\ZM5>VMV)T.9\IEM.U&_$8QQYF]E;<\&&,8]JQPS.$X<
M$1,3C9K800[@                              *TOI)^L2W?$/3#N<:$
M)I\#R1O>L2W79;=ZC+MVL8G*ST(1F_\ &0A<QTF6:/D_Y+^2AY3[[R;-FY6_
MR=1SV6QX*[%%6'#])5,>!P<OP>'@Z*7WO1.LS8V\VRV?Y6%.:TC)YCD^6X>U
M<Q=MQ5P>5\KVW,</EO+>5X.6J*MA4[     "0CPI<O-A/$0Z4[V6:VEC6Y)_
M!';=QC+2C+L&NYW S2R1A5I?^)GER4848=L>VM&6'=F_U8VAM];[+L=GZ>'@
MLX\']6JFKK<'#U&K'/;R$:CS4]MLO,5S%.D=E\KQ_6+]F]P\$^5CL>-?!YCE
M<,<<:'C3UY40                        %9;Q*/1M]*\1CJXWSJNS75CM
M/%60WC":-AJNE8OB/$[99XZ72=0Q&I4KBGF[O?L#7N9LA3Q,*\TL;:3R<T\9
M81FA#O1W*W/<[_4=T>P>5V&R^A6,]:RUR]7%ZK-56IJ[-=KNS'(BQ7$<GE8>
M:G'#'@XE+S6F4YF]-Z:YC'#@PQXHPZ;P?]C2XU\_;>?F_P" _>LR?_,*UCXK
MY;W]7_=G7[B4^N3UOZ3[&EQKY^V\_-_P'[UC^85K'Q7RWOZO^['<2GUR>M_2
M?8TN-?/VWGYO^ _>L?S"M8^*^6]_5_W8[B4^N3UOZ3[&EQKY^V\_-_P'[UC^
M85K'Q7RWOZO^['<2GUR>M_2?8TN-?/VWGYO^ _>L?S"M8^*^6]_5_P!V.XE/
MKD];^D^QI<:^?MO/S?\  ?O6/YA6L?%?+>_J_P"['<2GUR>M_2X35]#$I1JU
M(T?$@GIT8SSQI4ZO2#+6JR4HS1C3DJ59.J"A+5GEE[(1FA))":/J]V'W%1I[
MX?.$<K9")JPX<-5P^AW.G#KSX+Y[B?[W_5_\S_'V,/\ ^R/_ )/?_E*_?YA_
M_P /_P"J_P#MIW$_WO\ J_\ F/L8?_V1_P#)[_\ *4_F'_\ P_\ ZK_[:=Q/
M][_J_P#F/L8?_P!D?_)[_P#*4_F'_P#P_P#ZK_[:=Q/][_J_^8^QA_\ V1_\
MGO\ \I3^8?\ _#_^J_\ MIW$_P![_J_^8^QA_P#V1_\ )[_\I3^8?_\ #_\
MJO\ [:=Q/][_ *O_ )C[&'_]D?\ R>__ "E/YA__ ,/_ .J_^VG<3_>_ZO\
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MOKSZD^R!>)7^N_H:]\KGS_IG/W^]SOYMVE][Y+_N)W&S7GK?7GU)]D"\2O\
M7?T->^5SY_TSG[_>YW\V[2^]\E_W$[C9KSUOKSZD^R!>)7^N_H:]\KGS_IG/
MW^]SOYMVE][Y+_N)W&S7GK?7GU)]D"\2O]=_0U[Y7/G_ $SG[_>YW\V[2^]\
ME_W$[C9KSUOKSZE\/->B,>)UB_6WK'DCHWV3R_EO*_@7E+E:AZR\EY+N>N?Z
M1<$X'O\ KCRD>YY'RO9Y.;O]W[WO=G+\_/<Q?Q[+D]H;.&&'+RV6G'''B['G
M:^+HXX<<88\.'Y.CYJ.*:)\.?(?"^R7>*5_Q!TJ>^UN/[JG:_?LW)^M:Y[UM
M?WE^=R,W_4Z_]!]DN\4K_B#I4]]K<?W5'[]FY/UK7/>MK^\G<C-_U.O_ $'V
M2[Q2O^(.E3WVMQ_=4?OV;D_6M<]ZVO[R=R,W_4Z_]!]DN\4K_B#I4]]K<?W5
M'[]FY/UK7/>MK^\G<C-_U.O_ $'V2[Q2O^(.E3WVMQ_=4?OV;D_6M<]ZVO[R
M=R,W_4Z_]!]DN\4K_B#I4]]K<?W5'[]FY/UK7/>MK^\G<C-_U.O_ $'V2[Q2
MO^(.E3WVMQ_=4?OV;D_6M<]ZVO[R=R,W_4Z_]!]DN\4K_B#I4]]K<?W5'[]F
MY/UK7/>MK^\G<C-_U.O_ $'V2[Q2O^(.E3WVMQ_=4?OV;D_6M<]ZVO[R=R,W
M_4Z_]!]DN\4K_B#I4]]K<?W5'[]FY/UK7/>MK^\G<C-_U.O_ $'V2[Q2O^(.
ME3WVMQ_=4?OV;D_6M<]ZVO[R=R,W_4Z_]#Y&9]%!\5;&4*5:R_AKV*I4J^3G
MM<-S#DZ%>A)W)IO+U9M@T;!6T:7>EA+V25)ZG;-#[WL[8PY\OSYMQ]ZJ:;G=
MBS$1QUY2F8GJ1V.]7./@Q$=5^3I&;CSO7_H<<^RN>+3_ ,'\&^_5A?8YW/WW
M=Q/X1J?O.OU3\[DYSI4]<^RN>+3_ ,'\&^_5A?8X_?=W$_A&I^\Z_5'<G.=*
MGKGV5SQ:?^#^#??JPOL<?ON[B?PC4_>=?JCN3G.E3US[*YXM/_!_!OOU87V.
M/WW=Q/X1J?O.OU1W)SG2IZY]E<\6G_@_@WWZL+[''[[NXG\(U/WG7ZH[DYSI
M4]<^RN>+3_P?P;[]6%]CC]]W<3^$:G[SK]4=R<YTJ>N?97/%I_X/X-]^K"^Q
MQ^^[N)_"-3]YU^J.Y.<Z5/7/LKGBT_\ !_!OOU87V./WW=Q/X1J?O.OU1W)S
MG2IZY]E<\6G_ (/X-]^K"^QQ^^[N)_"-3]YU^J.Y.<Z5/7/LKGBT_P#!_!OO
MU87V./WW=Q/X1J?O.OU1W)SG2IZ[E&&]$]\5/*6\*U]7Z9M<J1KQHQM,SR_F
MJ]Q"G"$G9=1FU[C_ #UIY";O1[(0JQJ_>Q[9(>IV]+,<^?<A9KY-N-9O1ACC
M1E:(CP/KE^B<?"PZK]C2,W/G8\/^AWMK'H>W7G=UX2[GU(](N MO+R2QJZQF
M.9=NKPMHR1C/6A;Y7B+2:<:\L_9"%/RL)9H>KWX?<C;&=Y_VZ^BG'3M'UZ[7
MAQ7*,I:C'I8TYJ]P=7#PG)&C9CZ:JCZ/D0]6Z)Z&CD9Y[6YY.Z^K*WIRRT)K
M[#Z)T\U[R>K--0A&YIVNR;!R[8PH2T+F,99)Y\54\K3AWHR4XQ[L+&U/OA=J
M(JHT;9:J9X<*[V?B,.'@QMV\K5CC''$78PG@QGC<U.B3]/<ZT?TO>/&7HB?A
MWZMY*YY'Y;ZH>5+Z3LA5M/Z6:%H^M5H?>1C'\'8+CZYV*G4C&6,.V&7[O=F[
M.[VP[S&.L\_7>SG<:-(R&BY&UT)[%?O7(_TJ[\6__2\AV*='RT>:JKGK1XWC
MI/N'/ B\)3@Z>C<:IT2\4[+?TO(S5+[E^?9N<8W%>C#LA<38[E[/[IA+:>>;
M[Z,EO:T:7>]6$D/487VAYSF_?:6)HSVTF>LVIQX,KV/)X1/0Y65HLUSX-54S
MU7:HT_)V^*W$^#P^+BE#TK0=%XVP-KJW'6E:EH.L6,L)++7-*US#ZM@;.66$
M)82VN(P5G88^WEA+#LA"2G#U&%=1U34]8S56=U?,W\UG:N.Y>N5W:Y\&NN:J
MI\.7:IIIIC"F(B.HY:Z#Z
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M\AR>&ULC9N<K'C[+J.HTX8=3L4SCCP\KJ<-A!B!%B
M            K]^D;V-K4Z,>)<E/2[;VTZGM5L;>MWZD/)VN0XJYAKWE+R<)
MX4I_+5<90CWII8S2]SLEC"$9NW+FYFJJ-I<Q1]+.1KGPXNV</%E*/WIC,WJ>
M<'KN4IG_ )>O8W,UU1A'#51J6E4TSCAC&$7*XPB<)QX8G",*7[95Z#@    '
MM+PY/CY](G[?^-/SEL5M;9_JGJ/N2Y]3+7KG9_PS;=_LOJ'XO6T<FF;R7@
M
M
M                                                           ,
M_#QC\=<8OQ*.I^VN8TXU*N<T#(R^2FC-+ZWR_$7'^6M(1C&66,*D+6]D[\.S
MLA/VPA&,(=L=NMV]<5[%9&JGBY-R.M>N1/T8>I'F!9JUG.:'L;>LX\B,MG:.
M'@\M:U3/6JO"Y5$X=.,)X.)&4O=N(     MF>C4?U)ZMO;5Q#^*.0&O^^OVU
MI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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M-%X!][76_P#T1_G/:S\XYO[I5Y)^]GSFOCWM1_B&8]6?1Q]!GFB\ ^]KK?\
MZ(_SGM9^<<W]TJ\D_>SYS7Q[VH_Q#,>K/HX^@SS1> ?>UUO_ -$?YSVL_..;
M^Z5>2?O9\YKX][4?XAF/5O0G$_"O$G!&NWNH\,\<ZAQCJ^1S5SL=_@=*P=E@
M,5=YZ\L<;C+K+W%G84J5&ID+C'X>UHSU8P[T:=O)+V]DL%'U#4]0U6]&8U*]
M<OWZ:8IBJNJ:IBF)F8C&>AC,SATYEBS;C>'MUO+U:WKN\#5L_K.LVLO38HO9
MN]7?N4V::[ERFU377,S%%-=VY7%/%%5=4\<R[/=%9H
M            " ;TC3XD?%ORJ-(^"3G!EO<U^L]_W!7[+82@=Z:_B+UK]BLY
M^D]'4M&RST*@    /:7AR?'SZ1/V_P#&GYRV*VML_P!4]1]R7/J9:]<[/^&;
M;O\ 9?4/Q>MHY-,WDO
M
M
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M)Y4S7&FUVXQPPPCL=V<)F)QJX(G&J8M7,"(30
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M]YMGR67GN\K0U3CKCK7)[7^EO)6[WMK<WMK@,/&\GDM,=86=C9UKO(Y&X_\
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MGB:*S3AY00
M
M
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ME;69RF;IJGI?9;=BGACZ;@F.*;G[6IY\0
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MV3'H<6/'"JZ1RNVIPXN1./T/':5*'A<X
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M3Y[#C7]&I3R_
M
M
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M9HY>;R61MZA1.$S-$:??M9N]5&'_ /S6K],S/!%-4SP<<:#[4)Y9
M                       $'_I /)M+2^@VKI,E;_QG,/*^AZE&VEGFEGGQ
M>N5K[D>]NYI8?>U+>VR.FV5.:$?N5*\D>SU/4RANCR,YG:OMK#RN6R]RO'JU
M86XCPXKJZTI&^]=['5[0\YFG:*JG_E] T/.YKE8<$7+\49"BG'H556\W>JC^
MK15"CVVA>CH    !]7!8:_V/-X;7L52\OE,]E<?AL;0^^_EK_*7=&QLZ7WDL
M\_\ *7%>6'J2QCZOJ0B^+MVBS:JO7."W13-4^!$8RZ6I:AE=)T[,:KG:N3DL
MM8KNW)Z5%NF:ZYX<(X*8F>&8:B^O82RUK 8/7,;+W,=K^'QF$L).[))W++%6
M5"PM9>Y2EDIR=VA0EAV2PA+#_1"$&BMZ[5?O5WJ_-UU35/@S.,O&-JNHYC6-
M4S.K9N<<WFLQ<O5SPSC7<KFNKAG&9X:IXYF>F^PXW0     4M?2-/CN<6_)7
MTCX6^<&R^YK]6+_N^OV*P]"O>FOX=-:_;7.?HS1T K+24     !8C]&_^--S
MG^P"M\(NDL.[Y_R%E?=?_#K12]]L^9;9O]J(_$,XN0M<$ @         #P5X
MC'AW<$^)?T\Y'@+F^EE,5&TRE+:^.>1-:A:2[=QKO5G9W=E9;!A_7M*M:9''
MW5I>U;7)8VXAY"_LZLTL)J-Q);W5OE#='O9VGW.;64;4[-S1<BJCL68L7,>Q
M9BS,Q,VZ\)B::HF(JMW*?+45Q$X543717U\SEK>:M]CN>%/2E2_S?H=_6K0W
MJ./USJCZ7,KQGZ]GDEV[-R<L8#>HXZ%6O"G=1X[L="V7 2WLU"6E--0_I1&2
M6>>:6%:,)(33R(Y;O@&[FK3.RYO1-;HUGD_8J.U:[/*PC@[/5?MUX8X^6[6Q
MPB)Y/#A%$G1K_*PBNCD^'CUL/'6T_"=\)#@[PI^),[JNC9J^Y+Y>Y'J8F]Y?
MYGSN)M,-?[/7PM*XDQ.OZS@;>XR$=3T;"U+VXJV]C->7UQ4N;BI5N+FK'R4M
M'1+?IOXVEWXZ]:SVIVZ<GH&3BJ,KE**IKIMQ7,<JY<KF*>RWJ\*8JKBBBF*:
M8IIHI\M-57R>3MY2C"GAKGCG_P =!W;X@GB1]+_AH<3XKECJ6V#/4J.TY>YU
M_0M"T;$6VQ\B\@YJQLX9#)V>KX2]RF#Q<MMB;*:2>[OLC?V&-M9J]"E5N):U
MS;TZMM[JMT&VN^/7;FA;'6K4U6+<5W[]ZN;>7L453R:9N5Q375C5.,446Z*[
ME6%4TT3317-/)F<U:RM'+NS/#Q1''+S_ .&KXUG1KXHF6VS2N$*O(6B\KZ5A
M([1F.*N7<#A<'M%]J5*\QV,O-MUF\U?9-NUS/8''Y;+6UK<=V]I7UO4KTYJM
MM3IU*<\]U;X>;GO"W*V+&H[21E,UH>9N=CHS.5KKKMTW9BJJ+5R+ENU<HKJI
MIJJI\I-%44S%-<S$Q''E<]8S<S3;QBN.A/\ XE+JP*[@
M             "BEX\?)DN_^(1M^ HUZ=>UXBX\X[XVH3T9H34_*U<7<<BY&
MGWI8QEFKVV3Y K4*G^F6>E&2/JRMJ=U.1[4V0MWIC"K,7KESZ/8XZ\6XF/!>
ME3O9VQ\[+\UC(:I<IFF_KNJY[/S$\>$7*<C1/@56\C173TXJBJ."4-#)"0$
M   !/1Z/!ID^?ZV]QVFI3CZTT/@7;[^G7[)XRRY;/;5I&O6=O'N5Z4(1KXR^
MOIX1FEJR_P E&'=A-&6>7%&^',]BV8MV(\U=S=$>%3175/T8IZ7&C*[ZQM!3
MIG-UT_1:)^OZGM/E:)C@^Q6<MG+]=7#$\5RBS'!-,^6X\(FF;KC65YWP
M
M
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M5=)U',Y.]&&'UW+7J[-S@X>#E43APSP=&7-W56X
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M%<VW;7:#E]CNT[/9NQ;JX,:;V<MSD[$QCP8Q>S%$QCCP]">*='5IF\EH
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M)M6-0SUVG'C[+7E\OEZII_J]AS,1/#CRIB,,)QM&,%(8P
M
M
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M0B*[M41$<$1A$1$<"\<C7->4MU5<?)PZW!XR4MA-VP
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MJ?\ 0S.;OT3Q>6IGP9E]8[:'
M
M
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ME?G/T<F)FJK)UTQ;U"W&'%33;BWFZY\[E,(X^&\^U9>;0
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M1'!$1$1P1#LETEH@
M
M
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M9N-IVUUFQV/:S:ZNWG*N5&%=&0HIF-/MSTHKHKN9O@XZ<U135PT81">R:D1
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M7C<KM7+<533%RJNNBJW5RKE454Q35=-SU>9B;=W[)3&./3CR5FIIJJ@
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M3$\GM&UF:<8X.551$\$X3?I:F/,,
M
M
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M<C&BJ:Z8HJGDU2K&EY.Y8Y5Z[&%5481'1PZJW T.5@
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MM,V9R79,Q$3P=OY^*+M5-41P53:RE&6FF<9FFJ_>HPIGE<JPBQ BP
M
M
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MPQPBN_<JN333CQ44<KD41]+1333'!#L-TUJ
M
M
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M3R]>&,3V?,4U9BJF<*J>U;%7#3=X;;;7Q!B
M
M
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M(X8GCIKHJC&FY:N4S%=J[1-5NY;JIKHJFF8EV2Z2T0
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M^7L[LS<FYG9HJQHNZG<HPY$X8Q/:-FJ;7'$TW[V9MUQC;C"PPP^BL
M 4M?2-/CN<6_)7TCX6^<&R^YK]6+_N^OV*P]"O>FOX=-:_;7.?HS1T K+24
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MZ)GA['E[%%NS1,\,TT1-6-4S+O-2F-@
M
M
M                                     %?SQY.AJ?FWANRZH^/L1&ZY
M,X'Q-Q0W6TL+:2>]VKAZ:YJ7^0KU)I98UJ]SQQ?5ZV2I2]L)9<?<Y":/>GEI
M2LN;J-J8TS4IT+.589'-U>4F9X*+V&$>%<C"F?ZT4=5*-WLWG(T[NMO[FYC:
MJ_R-C]IK]-64JKJF*,MJG)BBB(QG"FG/T4T9>J<)F;]O*Q&%,URI?-E7H/
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M_P#C3<Y_L K?"+I+#N^?\A97W7_PZT4O?;/F6V;_ &HC\0SBY"UP0"
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MNQ7"SDP>AS
M
M
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M4SO.T*FWE]2IX(JS%,Q,9?/TQ'!AF::*HO<G"*,S1=B**+=5GE14+];L@
M   /8?1MUP\Z]$'(<N[<19[RF%RE6TI[SQSFJEQ<:5O>-MJD8RV^8QU.K)&U
MRMK3GGA9Y*WC3O+.,\T)9YJ52K2J6[M)LOI6U&3[5U&CZ[3CR+E/!7;F>E/1
MB>C3/E9\&(F,";_^;ANUYQNRD[.[=Y7#4;--4Y//V8IIS>3N51YJU<F)Y5NJ
M8CLN7N<JU=PB9IBNFBNB\1T.>(OP!UU:G)>:!E8:MR9C+"2YW/AS9+VVAMVO
M3R>3IW-]BZDLEO1VW5H7%2$*62M*<(0EGDA<T;6M-Y&&KNU.QNK[*YCDYNGL
MF1JG"B]3$\BKI1/G*NG3/5Y,U1PO.'SC^:?O1YM>N38VHL=N['7KLTY35<O1
M5VK?B<9IHN1C5.5S/)B9JR]VJ9QBJ;-R];CLD^^5I-80
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M.KN4[OM*Y>5TJU/*C&S%7US.5T3AR;V<KB+DXTTU46:;%FO&JS-54DRRFHH
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MC/9W-Q$9N]=NQ3Q<NNJK#'CPQF<'Y%,1Q1$/O.J_0
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MLT5\FK,YJYA7F\Y=IC#LN9O81-4QC5R+=,46;7*JBU;HBJK'RXKK,X
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MHS,ON.)30
M
M
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M^5MY'(6K=C)6:*:+=NW3%%%%%,84T444Q%---,1$4TTQ$1$81&#\3Z=@
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MB>3.8O3]=S%<8\JN8HB>Q6K44^WUKM<@
M
M
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MW/Y^[<OYZ_<JN7+ERJJNY<N5U3577775,U5UUU3-5554S555,S,S,OVOEUP
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M9S-4<JJU3:G#8N1Q
M
M
M                             *^7C$^%%3ZAL7FNI_IXP="CSGKV)JWG
M(.CXNS[L_,F$Q-KWI<ABJ%K)VUN2\18V_DZ4G<FGS-O));PCZXI4):N7MW.W
M\Z/<IT+6*IG2JZL+=<S]AJF>*<?]G,\?G)QGBF<)3>8-SW:]U6=R^YK>KF:J
MMVV;OQ1D<Y<JX-*O7:O,7*JIX-/NUU<JJ<8C*7)JNX=BKNS13,JTJM"K5H5Z
M52C7HU)Z5:C5DFIU:56G-&2I2JTYX0GIU*<\(PFEC"$81AV1;)Q,3&,<,2]
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MS>-Q^ZJJB[L!LOH^G9VWAR<Q38INYJ,.+_F[_9<S/AW9Z?&\OJXS*
M   _[++---"66$9IIHPEEEEA&,TTT8]D(0A#U8QC$?DS%,8SP1"WGX-WA+U>
M+9,#U9=3^KPI\E5Z=EF.&.,\W;S0K\<V]22>M0WK;\;7EA"GO=W3J4Y\9959
M>]A*?\M6EAD)Y)+#7C>1O C/\O9_0[G_ "48Q>NT_P"T_J43ZW'TU4>;XH\I
MC-<$//\ N?)1MI5FMQ^YO.X[(4S7:U;4+-7!GZHF(JR>5N1QY*F8F,Q>IG#.
M3];MSVK355FK*#"J(D
M
M
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MBNBJ(JIKHJIF::J:J9B::HF8F)B8G!^1^N<
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ME!A5$2
M
M
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M:+E7#;S6J1'!CF,)QM92>&:,I$_7(F*\SC5R;5F<5BY'
M
M
M
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MFWYIHSN5G@BJJ;<3]>L<J8BC,VN5:JQBFJ;=WE6Z?$JYVQ0
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M*\WFZZ[N:NUU5UUUU357775,S5555,S-554S,U53,S,S,S.+]+Y<(
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MM?9G+W)JR>F6)FG*9:)QB*IC@G,9CDS,59F]C7.-5-N+5J8MT^Y5K-;@
M
M
M
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M+U++W**OIN3>F<O<HCJ53<HJF.#AMTSCP835-(KFG-<CH54S]#A:7:'-=
M  #JKG;^Q#F3]E7(?YHY=W]*_*F6]T6_JX7KNU^<;0/AO(_C5IF(-XGL@
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MU3/!$1Q0Y X5+
M
M
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MKJKKKKJFJNNNJ9JJKKJJF:JJJJIF:JIF9F9F9G%^M\N
M!2U](T^.YQ;\E?2/A;YP;+[FOU8O^[Z_8K#T*]Z:_ATUK]M<Y^C-'0"LM)0
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M[';IFO")KFJKA>@%(8N
M
M
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M&I7KN8S]ZN:[EV[75<N7*ZIQJKKKJF:JJJIX9JJF9F>&9?0?#J@
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MJGD6;>/%;M4T6XZ%,.U'064
M
M
M                                                       _)?6%
MCE+.YQ^2L[3(V%Y2GH7=C?6]&[L[JA4AV3T;FVN)*E&O2GAZD99I8PB^J*Z[
M=45T3--<<4Q.$QX$N?+9G,Y._1FLG<KM9JW5%5-=%4TU4S'%--5,Q,3'0F)Q
M1P<W^$5T!\[3WU_FN",+HFQWT]6K-LW$5W=<;WU.XKQA-<74V$P,U/2[^[KS
MP[T]2[Q5S/&>,TW;WIIHQO/2]X>UNE1%%K-U7;,?2WHBY'@<JKR\1U(JAMKN
MYY]G.@W:4V\KIVTV8U/2;<1':^J4TY^B:8X*:>S7HG-T4TQP13:S-N(C".*(
MB(G>7O1L\%6FN;W@3J5RV/EA&;UIK?+VHV>8FJ2S1[98W.ZZ97P4*,:<(=D8
M2X"?O]O;VR=G9-D#3M]-V,*=6R5,].JS7,=:BOE>R-X-@^^Z:E;BC+[SMD+%
MV?ILQI>:KM8=/DY3-Q>QQZN=IPPP\MCC$;')?@0>(7H,U2? :1H/+=I2C-&>
M[XXY%PE*,*<L8=E2&/Y#ET#*UXS=O^I1H59__P!=GJKUR6];8_-\%V[>R]72
MN6ZO%M]DCKS#;O9#OE_-6VGB*=3U'5-"OSAA3G\A>GAZ7+R/;MN/!JKICJO"
MN\=#G61QO-5CNG2[SQA;6C"$:F4CQ?M^0P4.V-3[V&P8K%7V$GJ0A2C&,L+B
M,T)>R,8=D81C=65VIV;SOM;/Y2JJ>AV6B*O2S,5?0;*;-\X_<!M=%/\ E[;/
M9G,7JN*WW1RM%[H?["Y<HO1'#'#-&&/!QQ+S1D\3E,+>5,?F<;D,3?T?^^L<
MG9W%A>4O5C#^4MKJG2K2>K"/W98?<5NBY;NT\NW5%5$]&)B8Z\,P9//9+4;$
M9K3[UJ_E:N*NW7373/@54S,3UWSWT[0   #M32^"^;N2)Z-/COASE3?9[B2E
M4MY-+X]VW:9Z\E:%"-&>C+@\1?1JR5875*,L9>V$WE)>S_6AV]#,ZKI>2QG.
M9G+VHCS]RBGZJ8Z4K*VAWE;NMD::JMJ]?T33*:9F*IS>>RN6B)C'&)[-=HPF
M.35CCQ<F<>*7LWCSPB_$2Y)C0GQ73-N&NVE:2:I/><AY+6..86U.6;N1FKX_
M=,YA<W&>,\80A3IVM2K&$>]"7NPC-"V\YO#V.R6,7,];KJCH6XJN8^'1353X
M>.#7W:KGU\U'9&*J<]MCD,W?IG"*,C;S&?Y4X8^5KREF[9PP^FJN4TX\'*Y6
M$3(1Q7Z./U([%ZVN>7>:^*.,K.MW)ZMGJ]EL7)>P6DD>Y&>G<VM6CH^!A<2]
MLT/Y')5Z?;"'WWJ^I9^?WS:+9QIT[*YB_5'1JFFU3/@3Y>KKTPU8VU[[/NCT
MKEV=A-G=<UC,4XQ%>9KL:?8JGAPFFJ)SE[D\7FLO15U$H_#'H_'11Q]-:W_)
MF1Y+YTRM*-*>O:[%L4--U*>K2CWH36^#T:GB<[)3J3_Z].XS%U)-"$(=G9WN
M]8NI;W=I\YC1D:;&5M].FGEU^FKQIZU$-,-X/?2.<1M3%>6V/M:/LUDJL8IJ
ML6.V\U$3YZ]G)NV9F(XJJ,K;F)QG''#"7+B+I[X,X#Q<</PMQ'Q[QC95+>G;
M7<VFZKA\)?Y2G2\GW)LWE[2UDRV=N.VE+&:K>5Z]6:,L(S31C"#'NHZQJNK7
M.R:GF+U^K'&.77-41Z&)G"GP(B(:*[=;T]Y.\[.]O[PM=U76<Q%<U4]MYF[>
MHMS../8;554VK-/#.%-JBBF,9B(C%W$IJP0                     %+7T
MC3X[G%OR5](^%OG!LON:_5B_[OK]BL/0KWIK^'36OVUSGZ,T= *RTE
M6(_1O_C3<Y_L K?"+I+#N^?\A97W7_PZT4O?;/F6V;_:B/Q#.+D+7! (
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MFI3&P
M
M
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MU3/17RN5VQF[][E<KS6/9+E6/*^FQX^B[!=-:P
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M35551PX\G&(F/9"VV
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
9                             '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379391158432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 13, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GRI BIO, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4369909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2223 Avenida de la Playa<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">#208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">La Jolla<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-1170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GRI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,246,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001824293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379387949360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,488<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">879<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">4,367<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,404<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">988<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,143<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_EmployeeAdvancesCurrent', window );">Advances from employees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Bridge promissory note, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,177<span></span>
</td>
<td class="nump">1,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,177<span></span>
</td>
<td class="nump">2,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, 0.0001 par value; 250,000,000 shares authorized as of September&#160;30, 2023 and December&#160;31, 2022; 2,956,354 and 999,748 shares issued and outstanding as of September&#160;30, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">31,756<span></span>
</td>
<td class="nump">16,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(29,529)<span></span>
</td>
<td class="num">(18,496)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">2,227<span></span>
</td>
<td class="num">(1,625)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
<td class="nump">$ 4,404<span></span>
</td>
<td class="nump">$ 383<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_EmployeeAdvancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Advances, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_EmployeeAdvancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379390862272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">2,956,354<span></span>
</td>
<td class="nump">999,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">2,956,354<span></span>
</td>
<td class="nump">999,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379387953024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,189<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 2,186<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">7,175<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,439<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="nump">9,361<span></span>
</td>
<td class="nump">572<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,439)<span></span>
</td>
<td class="num">(186)<span></span>
</td>
<td class="num">(9,361)<span></span>
</td>
<td class="num">(572)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expense), net</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(165)<span></span>
</td>
<td class="num">(2,089)<span></span>
</td>
<td class="num">(376)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,137)<span></span>
</td>
<td class="num">$ (351)<span></span>
</td>
<td class="num">$ (11,033)<span></span>
</td>
<td class="num">$ (948)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic (in usd per share)</a></td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (3.83)<span></span>
</td>
<td class="num">$ (1.06)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted (in usd per share)</a></td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (3.83)<span></span>
</td>
<td class="num">$ (1.06)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">4,124,478<span></span>
</td>
<td class="nump">896,117<span></span>
</td>
<td class="nump">2,883,537<span></span>
</td>
<td class="nump">894,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">4,124,478<span></span>
</td>
<td class="nump">896,117<span></span>
</td>
<td class="nump">2,883,537<span></span>
</td>
<td class="nump">894,669<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379387080000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional&#160;Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">7,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">7,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="num">(4,848)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,430<span></span>
</td>
<td class="num">$ (15,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(302)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="num">$ (5,150)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,430<span></span>
</td>
<td class="num">(15,580)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">7,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">7,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="num">(4,848)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,430<span></span>
</td>
<td class="num">(15,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(948)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="num">$ (5,706)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,520<span></span>
</td>
<td class="num">(16,226)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">7,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">7,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="num">(5,150)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,430<span></span>
</td>
<td class="num">(15,580)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(295)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="num">$ (5,445)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,430<span></span>
</td>
<td class="num">(15,875)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">7,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Issuance of warrants and non-contingent beneficial ownership feature in connection with convertible promissory note</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant issuance</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(351)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(351)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="num">$ (5,706)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,520<span></span>
</td>
<td class="num">(16,226)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">999,748<span></span>
</td>
<td class="nump">999,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">$ (1,625)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">16,871<span></span>
</td>
<td class="num">(18,496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant issuance</a></td>
<td class="nump">532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,150)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="num">$ (3,230)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">17,416<span></span>
</td>
<td class="num">(20,646)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">999,748<span></span>
</td>
<td class="nump">999,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">$ (1,625)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">16,871<span></span>
</td>
<td class="num">(18,496)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,033)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="nump">2,956,354<span></span>
</td>
<td class="nump">2,956,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">$ 2,227<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">31,756<span></span>
</td>
<td class="num">(29,529)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="num">(3,230)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">17,416<span></span>
</td>
<td class="num">(20,646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise', window );">Warrant exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises', window );">Warrant exercise</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing', window );">Issuance of common stock in pre-closing financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,214,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing', window );">Issuance of common stock in pre-closing financing</a></td>
<td class="nump">11,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt', window );">Issuance of common stock for settlement of bridge note (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt', window );">Issuance of common stock for settlement of bridge note</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses', window );">Issuance of common stock for reverse recapitalization expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses', window );">Issuance of common stock for reverse recapitalization expenses</a></td>
<td class="nump">1,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization', window );">Issuance of common stock to Vallon stockholders in reverse recapitalization (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization', window );">Issuance of common stock to Vallon stockholders in reverse recapitalization</a></td>
<td class="num">(2,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,746)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,956,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">4,038<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">31,430<span></span>
</td>
<td class="num">(27,392)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,137)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="nump">2,956,354<span></span>
</td>
<td class="nump">2,956,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">$ 2,227<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31,756<span></span>
</td>
<td class="num">$ (29,529)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Pre-closing Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Reverse Recapitalization Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Settlement Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrant Exercise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Pre-closing Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Reverse Recapitalization Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Settlement Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValueWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 51<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-51<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379391019984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,033)<span></span>
</td>
<td class="num">$ (948)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discounts and issuance costs</a></td>
<td class="nump">2,104<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Reduction in operating lease right of use assets</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(836)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">4,860<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,106<span></span>
</td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(3,430)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ProceedsFromAdvancesFromEmployees', window );">Advances from employees</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_RepaymentOfAdvancesFromEmployees', window );">Repayment of advances from employees</a></td>
<td class="num">(195)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ProceedsFromNonConvertibleDebt', window );">Proceeds from issuance of non-convertible promissory note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible promissory note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in pre-closing financing</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of bridge promissory note</a></td>
<td class="nump">12,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercise</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization', window );">Net liabilities assumed in connection with reverse recapitalization</a></td>
<td class="num">(2,939)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_PaymentOfReverseRecapitalizationCosts', window );">Payment of reverse recapitalization costs</a></td>
<td class="num">(2,984)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of deferred stock issuance costs</a></td>
<td class="num">(517)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(150)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">6,917<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">3,479<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">3,488<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedForRepaymentOfNotesPayable', window );">Issuance of stock for repayment of bridge promissory note</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants', window );">Recognition of debt discount and additional paid-in-capital for issuance of warrants in connection with the issuance of promissory notes</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts', window );">Issuance of stock for payment of reverse recapitalization costs</a></td>
<td class="nump">1,875<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_WarrantsIssued', window );">Issuance of warrants for payment of stock issuance costs</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_NoncashMergerRelatedCostsFinancingActivities', window );">Merger costs included in accounts payable</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Liabilities Assumed In Connection With Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_NoncashMergerRelatedCostsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Merger Related Costs, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_NoncashMergerRelatedCostsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_PaymentOfReverseRecapitalizationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Reverse Recapitalization Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_PaymentOfReverseRecapitalizationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ProceedsFromAdvancesFromEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Advances From Employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ProceedsFromAdvancesFromEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ProceedsFromNonConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Non Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ProceedsFromNonConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_RepaymentOfAdvancesFromEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment Of Advances From Employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_RepaymentOfAdvancesFromEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued For Payment Of Reverse Recapitalization Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedForRepaymentOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued For Repayment Of Notes Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedForRepaymentOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379395770608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text">ORGANIZATION AND DESCRIPTION OF BUSINESS<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date of inception.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. The Company&#8217;s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. The Company&#8217;s lead product candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T (iNKT I) cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). The Company&#8217;s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 Natural Killer T (NKT II) cells and is being developed for the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease (SLE) or lupus and multiple sclerosis (MS).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reverse Merger with Vallon Pharmaceuticals, Inc.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the Company (formerly Vallon Pharmaceuticals, Inc.(Vallon)) consummated a merger with GRI Bio Operations, Inc. (formerly GRI Bio, Inc.) (Private GRI) pursuant to an Agreement and Plan of Merger, as amended (the Merger Agreement), by and among the Company, Private GRI and Vallon Merger Sub, Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of the Company (Note 4). The Merger Agreement provided for the merger of Merger Sub with and into Private GRI, with Private GRI surviving the merger as a wholly-owned subsidiary of the Company (the Merger). In connection with the closing of the Merger (the Closing), the Company amended its certificate of incorporation and bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221; In addition, prior to the effective time of the Merger (the Effective Time), the Company effected a reverse stock split of the Company&#8217;s common stock at a ratio of 1 for 30 (the Reverse Stock Split). At the Effective Time, each share of Private GRI&#8217;s common stock outstanding immediately prior to the Effective Time automatically converted solely into the right to receive a number of shares of the Company's common stock equal to 0.0374 (the Exchange Ratio).</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise indicated or as the context requires, references herein to &#8220;GRI Bio,&#8221; the &#8220;Company,&#8221; or the &#8220;combined company,&#8221; refer to GRI Bio, Inc. on a post-Merger basis, and references to &#8220;Private GRI&#8221; refer to the business of  GRI Bio, Inc. prior to the completion of the Merger. References to &#8220;Vallon&#8221; refer to Vallon Pharmaceuticals, Inc. prior to the completion of the Merger.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the Merger was accounted for as reverse recapitalization under which the historical financial statements of the Company prior to the Merger are the historical financial statements of the accounting acquirer, Private GRI. All common stock, per share and related information presented in the consolidated financial statements and notes prior to the Merger has been retroactively adjusted to reflect the Exchange Ratio and Reverse Stock Split for all periods presented, to the extent applicable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379393284240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">LIQUIDITY</a></td>
<td class="text">LIQUIDITYThese financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and as a result has incurred $29,529 in accumulated deficit through September&#160;30, 2023. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of September&#160;30, 2023, the Company had cash of approximately $3,488. <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered the Equity SPA pursuant to which the Investor agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI common stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, Private GRI issued 6,787,219 shares of Private GRI common stock (the Initial Shares) to the Investor and 27,148,877 shares of Private GRI common stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $11,704, after deducting offering expenses of $546.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 253,842 shares of the Company&#8217;s common stock and the Additional Shares converted into an aggregate of 1,015,368 shares of the Company&#8217;s common stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and the Investor authorized the escrow agent to, subject to beneficial ownership limitations, disburse to the Investor all of the shares of the Company&#8217;s common stock issued in exchange for the Additional Shares. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2024. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Series T Warrants issued in connection with the Merger are not presently subject to forced exercise by the Company as the equity conditions for their forced exercise, which include (among other things) a requirement that shares of the Company&#8217;s common stock have a value weighted average price of at least $9.21 per share for the periods specified in the Series T Warrants, are not met. The Company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if the Company&#8217;s research and development efforts are successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of one year from the issuance of these financial statements. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379391162000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2022 balance sheet was derived from the Company&#8217;s audited financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited interim financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of September&#160;30, 2023, and the results of operations and stockholders&#8217; equity (deficit) for the three and nine months ended September&#160;30, 2023 and 2022 and cash flows for the three and nine months ended September&#160;30, 2023 and 2022. Results of operations for the three and nine months ended September&#160;30, 2023, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2023. The unaudited interim financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2022, which are included as Exhibit 99.2 of Amendment No. 2 to the Current Report on Form 8-K filed with the SEC on July 6, 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance and subsequent revaluations, </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of September&#160;30, 2023 and December&#160;31, 2022 included investments in money market funds. The Company maintains its cash and cash equivalent balances at domestic financial institutions. Bank deposits with US banks are insured up to $250 by the Federal Deposits Insurance Corporation. The Company had an uninsured cash balances of $2,988 at September&#160;30, 2023. The Company&#8217;s cash balance as of December&#160;31, 2022 was fully insured.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ASC 820) establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, the Company&#8217;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At September&#160;30, 2023, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon issued warrants in connection with a securities purchase agreement. Vallon evaluated the warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As a result, the warrants are recorded as a liability on the balance sheet. Vallon recorded the fair value of the warrants upon issuance using a Black-Scholes valuation model. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to revalue the warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrants liabilities is reflected in the statement of operations for the nine months ended September&#160;30, 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Stock Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred stock issuance costs represent incremental legal costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Discounts</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relative fair values of warrants and common shares issued and call option rights assigned in connection with principal advances under promissory notes, the increases in fair values of embedded conversion options in connection with convertible promissory note modifications, and the intrinsic values of non-contingent beneficial conversion features were recorded as debt discounts that are amortized as additional interest expense over the estimated terms of the notes using the effective interest method.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs represent incremental legal costs and other costs incurred that are directly attributable to issuing debt. The costs are included as a direct reduction of the carrying amount of the respective liability and are amortized as additional interest expense over the estimated term of the debt using the effective interest method.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are recorded as a cumulative adjustment in the period the estimates are revised. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share are calculated by dividing the net loss by the applicable weighted-average number of common shares outstanding during the period. As the Company had a net loss in each of the three and nine months ended September&#160;30, 2023 and 2022, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,546,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock with repurchase rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock subject to put right</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible promissory note</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,864,174&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,837&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended September&#160;30, 2023 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379393296048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MERGER WITH VALLON<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">MERGER WITH VALLON</a></td>
<td class="text">MERGER WITH VALLON<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, pursuant to the Merger Agreement, Merger Sub was merged with and into Private GRI, with Private GRI surviving the Merger as a wholly owned subsidiary of the Company. In connection with the Closing, the Company amended its certificate of incorporation and bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Effective Time:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Each share of Private GRI&#8217;s common stock outstanding immediately prior to the Effective Time, including any shares of Private GRI&#8217;s common stock issued pursuant to the Equity SPA automatically converted solely into the right to receive a number of shares of the Company&#8217;s common stock equal to the Exchange Ratio.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Each option to purchase shares of Private GRI&#8217;s common stock (each, a GRI Option) outstanding and unexercised immediately prior to the Effective Time under the GRI Bio, Inc. 2015 Equity Incentive Plan (the GRI Plan), whether or not vested, converted into and became an option to purchase shares of the Company&#8217;s common stock, and the Company assumed the GRI Plan and each such GRI Option in accordance with the terms of the GRI Plan (the Assumed Options). The number of shares of the Company&#8217;s common stock subject to each Assumed Option was determined by multiplying (i) the number of shares of Private GRI&#8217;s common stock that were subject to such GRI Option, as in effect immediately prior to the Effective Time, by (ii) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of the Company&#8217;s common stock. The per share exercise price for the Company&#8217;s common stock issuable upon exercise of each Assumed Option was determined by dividing (A) the per share exercise price of such Assumed Option, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio and rounding the resulting per share exercise price up to the nearest whole cent. Any restriction on the exercise of any Assumed Option continued in full force and effect and the term, exercisability, vesting schedule, and any other provisions of such Assumed Option otherwise remained unchanged.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Each warrant to purchase shares of Private GRI&#8217;s common stock outstanding immediately prior to the Effective Time other than the Bridge Warrants (as defined below) (the GRI Warrants), was assumed by the Company and converted into a warrant to purchase shares of the Company&#8217;s common stock (the Assumed Warrants) and thereafter (i) each Assumed Warrant became exercisable solely for shares of the Company&#8217;s common stock; (ii) the number of shares of the Company&#8217;s common stock subject to each Assumed Warrant was determined by multiplying (A) the number of shares of Private GRI&#8217;s common stock that were subject to such GRI Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of the Company&#8217;s common stock; (iii) the per share exercise price for shares of the Company&#8217;s common stock issuable upon exercise of each Assumed Warrant was determined by dividing (A) the exercise price per share of Private GRI&#8217;s common stock subject to such GRI Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Bridge Warrants (Note 8) were exchanged for warrants (the Exchange Warrants) to purchase an aggregate of 421,589 shares of the Company&#8217;s common stock. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $14.73 per share.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All rights with respect to Private GRI restricted stock awards were assumed by the Company and converted into Company restricted stock awards with the number of shares subject to each restricted stock award multiplied by the Exchange Ratio and rounding the resulting number down to the nearest whole number of shares of the Company&#8217;s common stock. The term, exercisability, vesting schedule and other provisions of the Private GRI restricted stock awards otherwise remained unchanged.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger is accounted for as a reverse recapitalization under U.S. GAAP because the primary assets of Vallon were cash and cash equivalents. For accounting purposes, GRI has been determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i)  the equity holders of Private GRI immediately prior to the Merger owned, or held rights to acquire, in the aggregate approximately 85% of the outstanding shares of the Company&#8217;s common stock and the Company&#8217;s stockholders immediately prior to the Merger owned approximately 15% of the outstanding shares of the Company&#8217;s common stock (ii) Private GRI holds the majority (4 out of 5) of board seats of the combined company, and (iii) Private GRI&#8217;s management holds the majority of </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">key positions in the management of the combined company. Immediately after the Merger, there were 2,956,354 shares of the Company&#8217;s common stock outstanding.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the net liabilities assumed in the Merger:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 21, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,939)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: Transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,984)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net liabilities assumed plus transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,923)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>In addition to the transaction costs noted above, at the Effective Time, 30,542 shares of the Company&#8217;s common stock were issued to Private GRI&#8217;s financial advisor for services related to the Merger.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379393304896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the guidance in ASC 820 to account for financial assets and liabilities measured on a recurring basis. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The guidance requires that fair value measurements be classified and disclosed in one of the following 3 categories:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities; and</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. There were no transfers between Level 1, 2 and 3 during the nine months ended September&#160;30, 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s liabilities that are measured at fair value on a recurring basis at September&#160;30, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the Level 3 liability:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant Liability </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of September&#160;30, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.7&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.9&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92&#160;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379393304896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $3 and $2 for the nine months ended September&#160;30, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379485489392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379484793952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">PROMISSORY NOTES</a></td>
<td class="text">PROMISSORY NOTES<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bridge Financing</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, Private GRI entered into a Securities Purchase Agreement, dated as of December 13, 2022 (Bridge SPA), with Altium Growth Fund, LP (the Investor), pursuant to which Private GRI issued senior secured promissory notes (Bridge Notes) in the aggregate principal amount of $3,333, in exchange for an aggregate purchase price of $2,500. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bridge Notes were issued in two closings: (i) the first closing for $1,667 in aggregate principal amount (in exchange for an aggregate purchase price of $1,250) closed on December 14, 2022; and (ii) the second closing for $1,667 in aggregate principal amount (in exchange for an aggregate purchase price of $1,250) closed on March 9, 2023. The Bridge Notes were secured by a lien on all of the Company&#8217;s assets. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, upon the funding of each tranche, the Investor received warrants to purchase an aggregate of 1,252,490 shares of the Company&#8217;s common stock (the Bridge Warrants). The Bridge Warrants had an exercise price of $1.33 per share, were exercisable at any time on or after the applicable issuance date and had a term of 60 months from the date all shares underlying the Bridge Warrants were freely tradable. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $1,250 of proceeds from the first closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $679 and $571, respectively. The $1,250 of proceeds from the second closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $718 and $532, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Bridge SPA, and also in connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered into the Equity SPA (Note 9) pursuant to which the Investor agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI&#8217;s common stock immediately prior to the consummation of the Merger. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the Company completed the Merger and the outstanding principal and accrued interest on the Bridge Notes was cancelled and the Bridge Warrants were exchanged for the Exchange Warrants. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $14.73 per share subject to adjustments for splits and recapitalization events.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bridge Notes were accounted for as share-settled debt under the accounting guidance in ASC 835-30 and, as such, the initial net carrying amounts were accreted to the redemption amounts using the effective interest method. The Company incurred debt issuance costs of $205 during the year ended December&#160;31, 2022 and $90 during the nine months ended September&#160;30, 2023 related to its issuance of debt under the Bridge SPA. Unamortized debt discounts and debt issuance costs totaled $1,065 as of December&#160;31, 2022. Interest expense stemming from amortization of debt discounts and issuance costs was $2,104 for the nine months ended September&#160;30, 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TEP Note</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Private GRI and TEP Biotech, LLC (TEP) entered into a convertible note and warrant purchase agreement pursuant to which TEP agreed to fund up to $5,000 to Private GRI in exchange for a convertible promissory note (the TEP Note) and a warrant to purchase up to 25,245 shares of Private GRI&#8217;s common stock at an exercise price of $0.27 per share. The TEP Note was secured by Private GRI&#8217;s assets and accrued simple interest on the outstanding principal balance at a rate of 12% per annum. The total outstanding principal and accrued interest balance was initially due on the earlier of Private GRI&#8217;s next financing, as defined, and May 2, 2020. The initial $2,500 tranche under the TEP Note was funded upon execution of the agreement in November 2018. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Private GRI and TEP amended the TEP Note. In lieu of TEP funding the second $2,500 tranche, TEP made a first additional advance of $500 to Private GRI in exchange for a convertible promissory note, a warrant to purchase up to 17,269 shares of Private GRI&#8217;s common stock at an exercise price of $0.27 per share, and the assignment of Private GRI&#8217;s rights under a certain call option agreement. The call option agreement, which was entered into in 2015, provided Private GRI with the right to repurchase up to 39,720 shares of Private GRI&#8217;s common stock held by the counterparty for $26.74 per share at any time before April 1, 2025. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the TEP Note maturity date was extended to August 31, 2020, and in March 2021, TEP agreed to forbear on its available right to exercise remedies on account of Private GRI&#8217;s failure to pay the past due principal and accrued interest balance until October 31, 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, Private GRI and TEP amended the TEP Note, and TEP agreed to make a second additional advance of $500 to Private GRI in exchange for a convertible promissory note with separate, modified conversion options. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Private GRI and TEP further amended the TEP Note, and TEP agreed to make a third additional advance of $125 to Private GRI in exchange for a convertible promissory note and a warrant to purchase up to 1,169 shares of Private GRI&#8217;s common stock at an exercise price of $0.27 per share.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Private GRI and TEP entered into a conversion agreement pursuant to which, effective upon the full execution of the Merger Agreement (Note 4), $3,500 of outstanding principal under the TEP Note together with $650 of related accrued interest was to </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">automatically convert into 155,210 shares of Private GRI&#8217;s common stock at a conversion price of $26.74 per share. Further, upon the closing of the first tranche of the Bridge Notes, Private GRI was to repay, in cash, the $125 third additional advance under the TEP Note along with the $15 of related accrued interest. Upon issuance of the 155,210 conversion shares and payment of the $140 principal and accrued interest balance, Private GRI would fully satisfy all of its obligations under the TEP Note.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, upon the full execution of the Merger Agreement and the closing of the first tranche of the Bridge Notes Private GRI issued the 155,210 conversion shares and paid the $140 principal and accrued interest balance as per the terms of the conversion agreement. The share numbers and exercise or conversion prices in this section of Note 8 entitled &#8220;TEP Note&#8221; reflect the Exchange Ratio retroactively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the conversion, the $4,150 of converted principal and accrued interest, along with $863 of related forfeited accrued interest through the conversion date, were credited to stockholders&#8217; deficit. Interest expense recognized on the TEP Note was $142 and $352 for the three and nine months ended September&#160;30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379395684272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered the Equity SPA pursuant to which the Investor agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI&#8217;s common stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, Private GRI issued 6,787,219 shares of Private GRI&#8217;s common stock (the Initial Shares) to the Investor and 27,148,877 shares of Private GRI&#8217;s common stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $11,704, after deducting offering expenses of $546.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 253,842 shares of the Company&#8217;s common stock and the Additional Shares converted into an aggregate of 1,015,368 shares of the Company&#8217;s common stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and the Investor authorized the escrow agent to, subject to beneficial ownership limitations, disburse to the Investor all of the shares of the Company&#8217;s common stock issued in exchange for the Additional Shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Common Stock</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Private GRI entered into an agreement with a stockholder pursuant to which the stockholder had the right to require Private GRI to purchase all or a portion of 7,816 shares of Private GRI&#8217;s common stock held by the stockholder for $15.88 per share (the Put Right). The Put Right was exercisable (i) for a period commencing thirty days prior to the day Private GRI completed an equity or debt financing and ending fifteen business days thereafter, or (ii) at any time following a breach of the agreement by Private GRI.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed the Put Right and determined that (i) it was not freestanding and, therefore, was not required to be classified as a liability and (ii) it could be exercised by the stockholder at any time, which was not within Private GRI&#8217;s control. Therefore, the common shares subject to the Put Right were classified in mezzanine equity. In December 2022, the stockholder exercised the Put Right and Private GRI redeemed the 7,816 shares of Private GRI&#8217;s common stock for $124 ($15.88 per share). The redeemed shares were retired by Private GRI. The share numbers and exercise or conversion prices in this section of Note 9 entitled &#8220;Redeemable Common Stock&#8221; reflect the Exchange Ratio retroactively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Equity SPA, on May 8, 2023, the Company issued to the Investor (i) Series A-1 Warrants to purchase 1,269,210 shares of the Company&#8217;s common stock at an exercise price of $13.51, (ii) Series A-2 Warrants to purchase 1,142,289 shares of the Company&#8217;s common stock at an exercise price of $14.74 , and (iii) Series T Warrants to purchase (x) 814,467 shares of the Company&#8217;s common stock at an exercise price of $12.28 and (y) upon exercise of the Series T Warrants, 814,467 additional Series </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-1 Warrants and Series A-2 Warrants, each to purchase 814,467 shares of the Company&#8217;s common stock at an exercise price of $13.51 and $14.74, respectively (collectively, the Equity Warrants). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A-1 Warrants have a term of 60 months from the date all shares underlying the Series A-1 Warrants are freely tradable. The A-2 warrants have a 2-year term and expire in June 2025. Series T Warrants have a term of 24 months from the date all shares underlying Series T Warrants are freely tradable. As noted in Note 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Liquidity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company may force the exercise of the Series T Warrants subject to the satisfaction of certain equity conditions. The Equity Warrants include certain contingent cashless exercise features and contain certain other rights with regard to asset distributions and fundamental transactions. The exercise price of the Series A-1 Warrants is subject to adjustment for certain dilutive issuances, and all of the Equity Warrants are subject to standard antidilution adjustments. All of the Equity Warrants were outstanding as of September&#160;30, 2023. The Equity Warrants were classified as equity and the allocated fair value of $5,675 is included in additional paid in capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Bridge SPA, upon the funding of each tranche of the Bridge Note, the Investor received the Bridge Warrants. The Bridge Warrants had an exercise price of $1.33 per share, were exercisable at any time on or after the applicable issuance date and had a term of 60 months from the date all shares underlying the Bridge Warrants are freely tradable. Upon the completion of the Merger the Bridge Warrants were exchanged for the Exchange Warrants to purchase an aggregate of 421,589 shares of the Company&#8217;s common stock. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $14.73 per share subject to adjustments for splits and recapitalization events. All of the Bridge Warrants were outstanding as of September&#160;30, 2023. The Bridge Warrants were classified as equity and the allocated fair value of $2,860 is included in additional paid in capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Closing, Private GRI granted its financial advisor warrants (the Advisor Warrants) to purchase shares of Private GRI&#8217;s common stock, which, at the Effective Time, became exercisable for an aggregate of 2,402 shares of the Company&#8217;s common stock at an exercise price of $61.39 per share. The Advisor Warrants have a five-year term. All of the Advisor Warrants were outstanding as of September&#160;30, 2023. The Advisor Warrants were classified as equity and the fair value of $18 is included in additional paid in capital. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the fair value of the Equity Warrants, the Exchange Warrants and the Advisor Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.6&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.37&#160;%</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, the Company had the following warrants outstanding to purchase common stock. </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,629</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$34.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$34.76</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,142,289</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$14.74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,758</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$300.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,667</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$28.15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,168</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,402</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$61.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421,590</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$14.73</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 months after registration date</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,269,210</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$13.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 months after registration date</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">814,467</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$12.28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 months after registration date</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379393185136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSET PURCHASE AGREEMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">ASSET PURCHASE AGREEMENT</a></td>
<td class="text">ASSET PURCHASE AGREEMENT<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 22, 2023, the Company entered into Asset Purchase Agreement (the Aardvark Agreement) with Aardvark Therapeutics, Inc. (Aardvark), pursuant to which Aardvark agreed to purchase (i) the Company&#8217;s license agreement with Medice Arzneimittel P&#369;tter GmbH &amp; Co. KG, dated January 6, 2020, (ii) certain patents related to the Company&#8217;s ADAIR product candidate, and (iii) files (of contract manufacturing and FDA correspondence) for a formulation described in IND No. 133072, ADAIR for the Treatment of ADHD and Narcolepsy, filed with the United States FDA. Under the terms of the Aardvark Agreement, the Company received an upfront cash payment of $250, which was recognized as other income. The Company is also eligible to receive potential additional milestone payments contingent upon Aardvark achieving certain future ADAIR regulatory and sales milestones. Other than the upfront payment, the Company does not anticipate the receipt of any milestone payments from Aardvark in the near term, which potential milestone payments may or may not be achieved, paid or received in the future.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Aardvark Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the text of the Aardvark Agreement that is filed as Exhibit 10.2 to this Quarterly Report on Form 10-Q.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379393141456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private GRI adopted the GRI Bio, Inc. 2015 Equity Incentive Plan, as amended (the Private GRI Plan), that provided Private GRI with the ability to grant stock options, restricted stock awards and other equity-based awards to employees, directors, and consultants. Stock options granted under the Private GRI Plan generally had a contractual life of up to 10 years. Upon completion of the Merger, the Company assumed the Private GRI Plan and 89,472 outstanding and unexercised options issued thereunder, and ceased granting awards under the Private GRI Plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated 2018 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the stockholders of the Company approved the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan, formerly the Vallon Pharmaceuticals, Inc. 2018 Equity Incentive Plan (the A&amp;R 2018 Plan). The A&amp;R 2018 Plan had previously been approved by the Company&#8217;s board of directors, subject to stockholder approval. The A&amp;R 2018 Plan became effective on April 21, 2023, with the stockholders approving the amendment to the A&amp;R 2018 Plan to, among other things, (i) to increase the aggregate number of shares by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,905 shares to 216,666 shares of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company&#8217;s common stock </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for issuance as awards under the A&amp;R 2018 Plan, (ii) to extend the term of the A&amp;R 2018 Plan through January 1, 2033, (iii) to prohibit any action that would be treated as a &#8220;repricing&#8221; of an award without further approval by the stockholders of Company, and (iv) to revise the limits on awards to non-employee directors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The A&amp;R 2018 Plan provides the Company with the ability to grant stock options, restricted stock and other equity-based awards to employees, directors and consultants. Stock options granted by the Company under the A&amp;R 2018 Plan generally have a contractual life of up to 10 years. As of September&#160;30, 2023, awards granted under the A&amp;R 2018 Plan representing the right to purchase or contingent right to receive up to an aggregate of 228,542 shares of the Company's common stock were outstanding and 216,666 shares of the Company&#8217;s common stock were reserved for issuance under the A&amp;R 2018 Plan. The number of shares reserved for issuance under the A&amp;R 2018 Plan may be increased pursuant to the A&amp;R 2018 Plan&#8217;s &#8220;evergreen&#8221; provision on the first day of each calendar year beginning January 1, 2024 and ending on and including January 1, 2033, by a number of shares not to exceed 4% of the aggregate number of shares of the Company&#8217;s common stock outstanding on the final day of the immediately preceding calendar year.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to stock options issued under the Private GRI Plan and the A&amp;R 2018 Plan in the following expense categories of its accompanying statements of operations for the three and nine months ended September&#160;30, 2023 and 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period for certain performance-based awards. The Company records expense for performance-based awards if it concludes that it is probable that the performance condition will be achieved.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the nine months ended September&#160;30, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,612</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.71</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,265</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,863)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.92</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2023</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,014</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.92</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.84</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.98</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>As of September&#160;30, 2023, the unrecognized compensation cost related to unvested stock options expected to vest was $424. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of 3.16 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379393117584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation and Release Agreement</span></div>In connection with the resignation of David Baker, the Company&#8217;s Former Chief Executive Officer, pursuant to the Merger, the Company and Mr. Baker entered into a Separation and Release Agreement on April 21, 2023 (the Separation Agreement). Pursuant to the terms of the Separation Agreement and his employment agreement, Mr. Baker will receive continuation of his current salary and certain COBRA benefits for 18 months payable in accordance with the Company&#8217;s payroll practices. Mr. Baker also received a lump sum payment equal to 150% of his target bonus and agreed to reduce amounts payable with respect to certain future milestone payments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379391121824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting</a></td>
<td class="text">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2022 balance sheet was derived from the Company&#8217;s audited financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance and subsequent revaluations, </span></div>valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of September&#160;30, 2023 and December&#160;31, 2022 included investments in money market funds. The Company maintains its cash and cash equivalent balances at domestic financial institutions. Bank deposits with US banks are insured up to $250 by the Federal Deposits Insurance Corporation. The Company had an uninsured cash balances of $2,988 at September&#160;30, 2023. The Company&#8217;s cash balance as of December&#160;31, 2022 was fully insured.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ASC 820) establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, the Company&#8217;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At September&#160;30, 2023, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon issued warrants in connection with a securities purchase agreement. Vallon evaluated the warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As a result, the warrants are recorded as a liability on the balance sheet. Vallon recorded the fair value of the warrants upon issuance using a Black-Scholes valuation model. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to revalue the warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrants liabilities is reflected in the statement of operations for the nine months ended September&#160;30, 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Stock Issuance Costs</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Stock Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred stock issuance costs represent incremental legal costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Discounts and Debt Issuance Costs</a></td>
<td class="text">Debt Discounts<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relative fair values of warrants and common shares issued and call option rights assigned in connection with principal advances under promissory notes, the increases in fair values of embedded conversion options in connection with convertible promissory note modifications, and the intrinsic values of non-contingent beneficial conversion features were recorded as debt discounts that are amortized as additional interest expense over the estimated terms of the notes using the effective interest method.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs represent incremental legal costs and other costs incurred that are directly attributable to issuing debt. The costs are included as a direct reduction of the carrying amount of the respective liability and are amortized as additional interest expense over the estimated term of the debt using the effective interest method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are recorded as a cumulative adjustment in the period the estimates are revised. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share are calculated by dividing the net loss by the applicable weighted-average number of common shares outstanding during the period. As the Company had a net loss in each of the three and nine months ended September&#160;30, 2023 and 2022, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended September&#160;30, 2023 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379393117584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Calculation</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,546,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock with repurchase rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock subject to put right</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible promissory note</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,864,174&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,837&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379393224160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MERGER WITH VALLON (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of the Net Liabilities Assumed in the Merger</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the net liabilities assumed in the Merger:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 21, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,939)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: Transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,984)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net liabilities assumed plus transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,923)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379387016704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s liabilities that are measured at fair value on a recurring basis at September&#160;30, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of the Changes is the Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the Level 3 liability:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant Liability </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of September&#160;30, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of the Fair Value of the Warrants</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.7&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.9&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92&#160;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;%</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the fair value of the Equity Warrants, the Exchange Warrants and the Advisor Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.6&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.37&#160;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379395752768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379395634160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379393284240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of the Fair Value of the Warrants</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.7&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.9&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92&#160;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;%</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the fair value of the Equity Warrants, the Exchange Warrants and the Advisor Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.6&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.37&#160;%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding to Purchase Common Stock</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, the Company had the following warrants outstanding to purchase common stock. </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,629</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$34.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$34.76</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,142,289</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$14.74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,758</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$300.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,667</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$28.15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,168</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,402</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$61.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421,590</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$14.73</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 months after registration date</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,269,210</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$13.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 months after registration date</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">814,467</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$12.28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 months after registration date</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379387784496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to stock options issued under the Private GRI Plan and the A&amp;R 2018 Plan in the following expense categories of its accompanying statements of operations for the three and nine months ended September&#160;30, 2023 and 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Activity of Stock Options</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the nine months ended September&#160;30, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,612</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.71</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,265</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,863)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.92</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2023</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,014</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.92</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.84</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.98</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379393198480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)<br></strong></div></th>
<th class="th"><div>Apr. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">0.0333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CommonStockExchangeRatio', window );">Common stock, exchange ratio</a></td>
<td class="nump">0.0374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_CommonStockExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_CommonStockExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379386918880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 21, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (29,529)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18,496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,956,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">999,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in pre-closing financing</a></td>
<td class="nump">$ 11,704<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="nump">$ 546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesTWarrantsMember', window );">Series T Warrants | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock (in shares)</a></td>
<td class="nump">253,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ConversionOfStockAdditionalSharesConverted', window );">Additional shares converted into common stock (in shares)</a></td>
<td class="nump">1,015,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ck0001824293_GRIBioIncMember', window );">GRI Bio, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CommonStockHeldIntoEscrowAccount', window );">Common stock placed into escrow (in shares)</a></td>
<td class="nump">27,148,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyCommittedCapital', window );">Investment in cash</a></td>
<td class="nump">$ 12,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Private GRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">6,787,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_CommonStockHeldIntoEscrowAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Held Into Escrow Account</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_CommonStockHeldIntoEscrowAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ConversionOfStockAdditionalSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Additional Shares Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ConversionOfStockAdditionalSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyCommittedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funds committed to investment company from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480737/946-205-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyCommittedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesTWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesTWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ck0001824293_GRIBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ck0001824293_GRIBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001824293_PrivateGRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379395695936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">FDIC insured amount</a></td>
<td class="nump">$ 250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Uninsured cash balances</a></td>
<td class="nump">$ 2,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379391177808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in usd per share)</a></td>
<td class="nump">2,864,174<span></span>
</td>
<td class="nump">405,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in usd per share)</a></td>
<td class="nump">318,014<span></span>
</td>
<td class="nump">89,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in usd per share)</a></td>
<td class="nump">2,546,160<span></span>
</td>
<td class="nump">10,067<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock with repurchase rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">147,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ck0001824293_StockSubjectToPutRightMember', window );">Stock subject to put right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ck0001824293_ConvertiblePromissoryNoteMember', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,506<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ck0001824293_StockSubjectToPutRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ck0001824293_StockSubjectToPutRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ck0001824293_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ck0001824293_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379391549472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MERGER WITH VALLON - Narrative (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Apr. 21, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Apr. 20, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CommonStockOwnershipPercentage', window );">Ownership percentage in common stock (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,956,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">999,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses', window );">Issuance of common stock for reverse recapitalization expenses (in shares)</a></td>
<td class="nump">30,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember', window );">Private GRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">17,269<span></span>
</td>
<td class="nump">25,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CommonStockOwnershipPercentage', window );">Ownership percentage in common stock (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember', window );">Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="nump">421,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="nump">$ 14.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_CommonStockOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_CommonStockOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Reverse Recapitalization Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001824293_PrivateGRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379388117008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details) - Private GRI<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Apr. 21, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(4,190)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total net liabilities assumed</a></td>
<td class="num">(2,939)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Plus: Transaction costs</a></td>
<td class="num">(2,984)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts', window );">Total net liabilities assumed plus transaction costs</a></td>
<td class="num">$ (5,923)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001824293_PrivateGRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379384821088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Other Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379391593568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Schedule of Liability Measured at Estimated Fair Value (Details) - Warrant Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of December 31, 2022</a></td>
<td class="nump">$ 185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in valuation</a></td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of September&#160;30, 2023</a></td>
<td class="nump">$ 18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ck0001824293_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ck0001824293_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379386855232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Schedule of Derivative Liability Measurement Inputs (Details) - Weighted Average<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.677<span></span>
</td>
<td class="nump">1.399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="nump">0.000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.0492<span></span>
</td>
<td class="nump">0.0432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379390523328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379391156736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379388422768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent', window );">Research and development</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent', window );">General and administrative</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related</a></td>
<td class="nump">880<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 1,143<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued General and Administrative Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379387561136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTES - Bridge Financing (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 21, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 09, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 14, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 13, 2022 </div>
<div>USD ($) </div>
<div>closing</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 08, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,250<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discounts and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discounts and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,104<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BridgeWarrantsMember', window );">Bridge Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 532<span></span>
</td>
<td class="nump">$ 571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember', window );">Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares) | shares</a></td>
<td class="nump">421,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 14.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ck0001824293_BridgeSecuritiesPurchaseAgreementMember', window );">Bridge SPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtInstrumentAggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtInstrumentNumberOfClosings', window );">Number of closings | closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 718<span></span>
</td>
<td class="nump">$ 679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember', window );">Private GRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">17,269<span></span>
</td>
<td class="nump">25,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyCommittedCapital', window );">Investment in cash</a></td>
<td class="nump">$ 12,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Bridge Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,252,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Private GRI | Bridge SPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtInstrumentAggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtInstrumentAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Aggregate Purchase Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtInstrumentAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtInstrumentNumberOfClosings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Closings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtInstrumentNumberOfClosings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyCommittedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funds committed to investment company from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480737/946-205-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyCommittedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BridgeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BridgeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ck0001824293_BridgeSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ck0001824293_BridgeSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001824293_PrivateGRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379387983952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTES - TEP Note (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of bridge promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,250,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">999,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,956,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember', window );">Private GRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,269<span></span>
</td>
<td class="nump">25,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion', window );">Number of shares to be issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible notes, converted, shares issued (in shares)</a></td>
<td class="nump">155,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember', window );">Private GRI | Call Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CallOptionPrice', window );">Call option price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember', window );">Private GRI | Convertible Notes Payable | TEP Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of bridge promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt', window );">Principal amount of debt to be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest', window );">Amount of accrued interest to be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_LongTermDebtIncludingInterest', window );">Long-term debt, including interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment of notes payable</a></td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible notes to common stock</a></td>
<td class="nump">4,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_AccruedInterestForfeited', window );">Accrued interest forfeited</a></td>
<td class="nump">$ 863,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowings', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 352,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedInterestForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Interest Forfeited</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedInterestForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_CallOptionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Call Option Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_CallOptionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Conversion, Converted Instrument, Amount Of Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Conversion, Converted Instrument, Principal Amount Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Shares Issued Upon Conversion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_LongTermDebtIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Including Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_LongTermDebtIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest expense on all borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.7,8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001824293_PrivateGRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_CallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_CallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ck0001824293_TEPNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ck0001824293_TEPNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379386210960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 21, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>May 08, 2023</div></th>
<th class="th"><div>Mar. 09, 2023</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">999,748<span></span>
</td>
<td class="nump">2,956,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 11,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="nump">$ 546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Outsanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember', window );">Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="nump">421,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="nump">$ 14.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BankerWarrantsMember', window );">Banker Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares that became exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock (in shares)</a></td>
<td class="nump">253,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ConversionOfStockAdditionalSharesConverted', window );">Additional shares converted into common stock (in shares)</a></td>
<td class="nump">1,015,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ck0001824293_GRIBioIncMember', window );">GRI Bio, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CommonStockHeldIntoEscrowAccount', window );">Common stock placed into escrow (in shares)</a></td>
<td class="nump">27,148,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember', window );">Private GRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased during period, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Purchase price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">17,269<span></span>
</td>
<td class="nump">25,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember', window );">Private GRI | Put Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_PutOptionSharePrice', window );">Put right, share price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyCommittedCapital', window );">Investment in cash</a></td>
<td class="nump">$ 12,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Series A-1 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,269,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Series A-2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Series T Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">814,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Bridge Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,589<span></span>
</td>
<td class="nump">1,252,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Common&#160;Stock | Series A-1 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">814,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Common&#160;Stock | Series A-2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">814,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Additional&#160;Paid-in Capital | Equity Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Outsanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Additional&#160;Paid-in Capital | Bridge Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Outsanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Additional&#160;Paid-in Capital | Banker Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Outsanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Private GRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">6,787,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_CommonStockHeldIntoEscrowAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Held Into Escrow Account</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_CommonStockHeldIntoEscrowAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ConversionOfStockAdditionalSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Additional Shares Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ConversionOfStockAdditionalSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_PutOptionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Put Option, Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_PutOptionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyCommittedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funds committed to investment company from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480737/946-205-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyCommittedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BankerWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BankerWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ck0001824293_GRIBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ck0001824293_GRIBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001824293_PrivateGRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_PutOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_PutOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA2WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA2WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesTWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesTWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BridgeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BridgeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_EquityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_EquityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379385951808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Estimate of the Fair Value of the Warrants and Assumptions (Details) - Weighted Average<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.677<span></span>
</td>
<td class="nump">1.399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="nump">0.000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.0492<span></span>
</td>
<td class="nump">0.0432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember', window );">Equity Warrants, Exchange Warrants and Banker Warrants | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember', window );">Equity Warrants, Exchange Warrants and Banker Warrants | Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember', window );">Equity Warrants, Exchange Warrants and Banker Warrants | Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember', window );">Equity Warrants, Exchange Warrants and Banker Warrants | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.0437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379386084912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInNovember2023Member', window );">Warrants Expiring In November 2023</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">8,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 34.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInDecember2023Member', window );">Warrants Expiring In December 2023</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">1,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 34.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJune2025Member', window );">Warrants Expiring In June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">1,142,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 14.74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2026Member', window );">Warrants Expiring In February 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">3,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 300.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMay2027Member', window );">Warrants Expiring In May 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">24,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 28.15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJuly2027Member', window );">Warrants Expiring In July 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">1,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2028Member', window );">Warrants Expiring In April 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">2,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 61.39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember', window );">Warrants Expiring in 60 Months After Registration Date</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">421,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 14.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ClassOfWarrantOrRightExpirationPeriod', window );">Expiration Period (in months)</a></td>
<td class="text">60 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember', window );">Warrants Expiring in 60 Months After Registration Date</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">1,269,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 13.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ClassOfWarrantOrRightExpirationPeriod', window );">Expiration Period (in months)</a></td>
<td class="text">60 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember', window );">Warrants Expiring in 24 Months After Registration Date</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares | shares</a></td>
<td class="nump">814,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 12.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ClassOfWarrantOrRightExpirationPeriod', window );">Expiration Period (in months)</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ClassOfWarrantOrRightExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ClassOfWarrantOrRightExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInNovember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInNovember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInDecember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInDecember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJuly2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJuly2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379391162000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ASSET PURCHASE AGREEMENT (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Aug. 22, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ck0001824293_AardvarkTherapeuticsIncMember', window );">Aardvark Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Upfront cash payment</a></td>
<td class="nump">$ 250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ck0001824293_AardvarkTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ck0001824293_AardvarkTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379390497760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 21, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318,014<span></span>
</td>
<td class="nump">112,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation, weighted average amortization period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_PrivateGRIPlanMember', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding</a></td>
<td class="nump">89,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_PrivateGRIPlanMember', window );">2015 Plan | Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock awards, contractual life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember', window );">A&amp;R 2918 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="nump">168,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="nump">216,666<span></span>
</td>
<td class="nump">228,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember', window );">A&amp;R 2918 Plan | Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock awards, contractual life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ck0001824293_PrivateGRIPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ck0001824293_PrivateGRIPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379384902656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 326<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 326<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379391181104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Activity of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning balance (in shares)</a></td>
<td class="nump">112,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">221,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/Cancelled (in shares)</a></td>
<td class="num">(15,863)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending balance (in shares)</a></td>
<td class="nump">318,014<span></span>
</td>
<td class="nump">112,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Ending balance (in shares)</a></td>
<td class="nump">318,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning balance (in usd per share)</a></td>
<td class="nump">$ 39.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/Cancelled (in usd per share)</a></td>
<td class="nump">128.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending balance (in usd per share)</a></td>
<td class="nump">9.35<span></span>
</td>
<td class="nump">$ 39.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Ending balance (in usd per share)</a></td>
<td class="nump">$ 9.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term&#160;(years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (years)</a></td>
<td class="text">7 years 11 months 1 day<span></span>
</td>
<td class="text">4 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (years)</a></td>
<td class="text">7 years 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379388423024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Estimate Fair Value of Options (Details) - Stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">129.54%<span></span>
</td>
<td class="nump">90.39%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">5 years 10 months 2 days<span></span>
</td>
<td class="text">5 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.34%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of option on grant date (in usd per share)</a></td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="nump">$ 3.86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140379387937456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - Former Chief Executive Officer<br></strong></div></th>
<th class="th"><div>Apr. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_COBRABenefitsPaymentPeriod', window );">COBRA benefits, payment period (in months)</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_PercentageOfTargetBonus', window );">Percentage of target bonus (as a percent)</a></td>
<td class="nump">150.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_COBRABenefitsPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>COBRA Benefits, Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_COBRABenefitsPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_PercentageOfTargetBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Target Bonus</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_PercentageOfTargetBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ck0001824293_FormerChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ck0001824293_FormerChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>ck0001824293-20230930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ck0001824293="http://www.vallon-pharma.com/20230930"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ck0001824293-20230930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-11-13</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ck0001824293:GRIBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesTWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ck0001824293:StockSubjectToPutRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ck0001824293:StockSubjectToPutRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ck0001824293:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ck0001824293:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ExchangeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-20</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-04-20</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-13</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-13</startDate>
            <endDate>2022-12-13</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-13</startDate>
            <endDate>2022-12-13</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-14</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-14</startDate>
            <endDate>2022-12-14</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-09</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-09</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-14</startDate>
            <endDate>2022-12-14</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:TEPNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA1WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA2WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesTWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA2WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA1WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ExchangeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BankerWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BankerWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BankerWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsExchangeWarrantsAndBankerWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsExchangeWarrantsAndBankerWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsExchangeWarrantsAndBankerWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:EquityWarrantsExchangeWarrantsAndBankerWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInNovember2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInDecember2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInMay2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJuly2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn24MonthsAfterRegistrationDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn24MonthsAfterRegistrationDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ck0001824293:AardvarkTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-22</startDate>
            <endDate>2023-08-22</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:PrivateGRIPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:PrivateGRIPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ck0001824293:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="closing">
        <measure>ck0001824293:closing</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-29">0001824293</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-31">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-32">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-33">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-55" decimals="4" id="f-289" unitRef="number">0.0333</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentType contextRef="c-1" id="f-2">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-3">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-5">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-6">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-7">001-40034</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-8">GRI BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-10">82-4369909</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-11">2223 Avenida de la Playa</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-12">#208</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-13">La Jolla</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-14">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-15">92037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-16">619</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-17">400-1170</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, par value $0.0001per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">GRI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-26">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="c-1" id="f-27">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-28" unitRef="shares">3246354</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">3488000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">9000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">879000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">303000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">4367000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">312000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">9000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">4000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">28000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">67000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">4404000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">383000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">988000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">1294000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">1143000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">36000</us-gaap:AccruedLiabilitiesCurrent>
    <ck0001824293:EmployeeAdvancesCurrent contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">0</ck0001824293:EmployeeAdvancesCurrent>
    <ck0001824293:EmployeeAdvancesCurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">5000</ck0001824293:EmployeeAdvancesCurrent>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">18000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:NotesPayableCurrent contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">602000</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">28000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">57000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">2177000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">1994000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">14000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">2177000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">2008000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-64" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-65" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-66"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-67"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-68" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-69" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-70" unitRef="shares">2956354</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-71" unitRef="shares">2956354</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-72" unitRef="shares">999748</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-73" unitRef="shares">999748</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-3" decimals="-3" id="f-74" unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">31756000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">16871000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-78" unitRef="usd">-29529000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">-18496000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-80" unitRef="usd">2227000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">-1625000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-82" unitRef="usd">4404000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-83" unitRef="usd">383000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-84" unitRef="usd">1189000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-85" unitRef="usd">63000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-86" unitRef="usd">2186000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-87" unitRef="usd">181000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-88" unitRef="usd">1250000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-89" unitRef="usd">123000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-90" unitRef="usd">7175000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-91" unitRef="usd">391000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-92" unitRef="usd">2439000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-93" unitRef="usd">186000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-94" unitRef="usd">9361000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-95" unitRef="usd">572000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-96" unitRef="usd">-2439000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-97" unitRef="usd">-186000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-98" unitRef="usd">-9361000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-99" unitRef="usd">-572000</us-gaap:OperatingIncomeLoss>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-5" decimals="-3" id="f-100" unitRef="usd">46000</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-6" decimals="-3" id="f-101" unitRef="usd">0</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-1" decimals="-3" id="f-102" unitRef="usd">167000</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-7" decimals="-3" id="f-103" unitRef="usd">0</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-104" unitRef="usd">250000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-105" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">250000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-107" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-5" decimals="-3" id="f-108" unitRef="usd">6000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-6" decimals="-3" id="f-109" unitRef="usd">-165000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-110" unitRef="usd">-2089000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-7" decimals="-3" id="f-111" unitRef="usd">-376000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-112" unitRef="usd">-2137000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-113" unitRef="usd">-351000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-114" unitRef="usd">-11033000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-115" unitRef="usd">-948000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-116"
      unitRef="usdPerShare">-0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-117"
      unitRef="usdPerShare">-0.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-118"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-119"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-120"
      unitRef="usdPerShare">-3.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-121"
      unitRef="usdPerShare">-3.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-122"
      unitRef="usdPerShare">-1.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-123"
      unitRef="usdPerShare">-1.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-124" unitRef="shares">4124478</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-125" unitRef="shares">4124478</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-126" unitRef="shares">896117</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-127" unitRef="shares">896117</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-128" unitRef="shares">2883537</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-129" unitRef="shares">2883537</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-130" unitRef="shares">894669</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-131" unitRef="shares">894669</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-8" decimals="INF" id="f-132" unitRef="shares">7816</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-8" decimals="-3" id="f-133" unitRef="usd">124000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-9" decimals="INF" id="f-134" unitRef="shares">851419</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-135" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-136" unitRef="usd">10430000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-137" unitRef="usd">-15278000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-138" unitRef="usd">-4848000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-139" unitRef="usd">-302000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-140" unitRef="usd">-302000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-141"
      unitRef="shares">7816</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-14" decimals="-3" id="f-142" unitRef="usd">124000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-15"
      decimals="INF"
      id="f-143"
      unitRef="shares">851419</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-144" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-145" unitRef="usd">10430000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-146" unitRef="usd">-15580000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-147" unitRef="usd">-5150000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-18" decimals="-3" id="f-148" unitRef="usd">-295000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-19" decimals="-3" id="f-149" unitRef="usd">-295000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-20"
      decimals="INF"
      id="f-150"
      unitRef="shares">7816</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-20" decimals="-3" id="f-151" unitRef="usd">124000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-21"
      decimals="INF"
      id="f-152"
      unitRef="shares">851419</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-153" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-154" unitRef="usd">10430000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-155" unitRef="usd">-15875000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-156" unitRef="usd">-5445000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="c-24" decimals="-3" id="f-157" unitRef="usd">60000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="c-6" decimals="-3" id="f-158" unitRef="usd">60000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-24" decimals="-3" id="f-159" unitRef="usd">30000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-6" decimals="-3" id="f-160" unitRef="usd">30000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss contextRef="c-25" decimals="-3" id="f-161" unitRef="usd">-351000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-162" unitRef="usd">-351000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-26"
      decimals="INF"
      id="f-163"
      unitRef="shares">7816</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-26" decimals="-3" id="f-164" unitRef="usd">124000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-27"
      decimals="INF"
      id="f-165"
      unitRef="shares">851419</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-166" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-167" unitRef="usd">10520000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-168" unitRef="usd">-16226000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-169" unitRef="usd">-5706000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-30"
      decimals="INF"
      id="f-170"
      unitRef="shares">999748</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-171" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-172" unitRef="usd">16871000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-173" unitRef="usd">-18496000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-174" unitRef="usd">-1625000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-33" decimals="-3" id="f-175" unitRef="usd">13000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-34" decimals="-3" id="f-176" unitRef="usd">13000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-35"
      decimals="INF"
      id="f-177"
      unitRef="shares">467</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-33" decimals="-3" id="f-178" unitRef="usd">532000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-34" decimals="-3" id="f-179" unitRef="usd">532000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss contextRef="c-36" decimals="-3" id="f-180" unitRef="usd">-2150000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-34" decimals="-3" id="f-181" unitRef="usd">-2150000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-37"
      decimals="INF"
      id="f-182"
      unitRef="shares">1000215</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-183" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-184" unitRef="usd">17416000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-185" unitRef="usd">-20646000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-186" unitRef="usd">-3230000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-41" decimals="-3" id="f-187" unitRef="usd">13000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-42" decimals="-3" id="f-188" unitRef="usd">13000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-43"
      decimals="INF"
      id="f-189"
      unitRef="shares">164038</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise
      contextRef="c-43"
      decimals="INF"
      id="f-190"
      unitRef="shares">43682</ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise>
    <ck0001824293:StockIssuedDuringPeriodValueWarrantExercises contextRef="c-41" decimals="-3" id="f-191" unitRef="usd">12000</ck0001824293:StockIssuedDuringPeriodValueWarrantExercises>
    <ck0001824293:StockIssuedDuringPeriodValueWarrantExercises contextRef="c-42" decimals="-3" id="f-192" unitRef="usd">12000</ck0001824293:StockIssuedDuringPeriodValueWarrantExercises>
    <ck0001824293:StockIssuedDuringPeriodSharesPreClosingFinancing
      contextRef="c-43"
      decimals="INF"
      id="f-193"
      unitRef="shares">1214912</ck0001824293:StockIssuedDuringPeriodSharesPreClosingFinancing>
    <ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing contextRef="c-41" decimals="-3" id="f-194" unitRef="usd">11721000</ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing>
    <ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing contextRef="c-42" decimals="-3" id="f-195" unitRef="usd">11721000</ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing>
    <ck0001824293:StockIssuedDuringPeriodSharesSettlementOfDebt
      contextRef="c-43"
      decimals="INF"
      id="f-196"
      unitRef="shares">54298</ck0001824293:StockIssuedDuringPeriodSharesSettlementOfDebt>
    <ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt contextRef="c-41" decimals="-3" id="f-197" unitRef="usd">3333000</ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt>
    <ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt contextRef="c-42" decimals="-3" id="f-198" unitRef="usd">3333000</ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt>
    <ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses
      contextRef="c-43"
      decimals="INF"
      id="f-199"
      unitRef="shares">30542</ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses>
    <ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses contextRef="c-41" decimals="-3" id="f-200" unitRef="usd">1875000</ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses>
    <ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses contextRef="c-42" decimals="-3" id="f-201" unitRef="usd">1875000</ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses>
    <ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalization
      contextRef="c-43"
      decimals="INF"
      id="f-202"
      unitRef="shares">448667</ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalization>
    <ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization contextRef="c-41" decimals="-3" id="f-203" unitRef="usd">-2940000</ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization>
    <ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization contextRef="c-42" decimals="-3" id="f-204" unitRef="usd">-2940000</ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization>
    <us-gaap:NetIncomeLoss contextRef="c-44" decimals="-3" id="f-205" unitRef="usd">-6746000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-42" decimals="-3" id="f-206" unitRef="usd">-6746000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-45"
      decimals="INF"
      id="f-207"
      unitRef="shares">2956354</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-208" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-209" unitRef="usd">31430000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-210" unitRef="usd">-27392000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-211" unitRef="usd">4038000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-49" decimals="-3" id="f-212" unitRef="usd">326000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-213" unitRef="usd">326000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-50" decimals="-3" id="f-214" unitRef="usd">-2137000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-215" unitRef="usd">-2137000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-51"
      decimals="INF"
      id="f-216"
      unitRef="shares">2956354</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-3" id="f-217" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="-3" id="f-218" unitRef="usd">31756000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-3" id="f-219" unitRef="usd">-29529000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-220" unitRef="usd">2227000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">-11033000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-222" unitRef="usd">-948000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">3000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-7" decimals="-3" id="f-224" unitRef="usd">2000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">2104000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-7" decimals="-3" id="f-226" unitRef="usd">45000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">352000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-228" unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">18000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-7" decimals="-3" id="f-230" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">39000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-7" decimals="-3" id="f-232" unitRef="usd">35000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">836000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-3" id="f-234" unitRef="usd">7000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-235" unitRef="usd">4860000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-7" decimals="-3" id="f-236" unitRef="usd">77000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">1106000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-7" decimals="-3" id="f-238" unitRef="usd">590000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">-43000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-240" unitRef="usd">-35000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-241" unitRef="usd">-3430000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-242" unitRef="usd">-241000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-243" unitRef="usd">8000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-244" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-245" unitRef="usd">-8000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-246" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ck0001824293:ProceedsFromAdvancesFromEmployees contextRef="c-1" decimals="-3" id="f-247" unitRef="usd">190000</ck0001824293:ProceedsFromAdvancesFromEmployees>
    <ck0001824293:ProceedsFromAdvancesFromEmployees contextRef="c-7" decimals="-3" id="f-248" unitRef="usd">35000</ck0001824293:ProceedsFromAdvancesFromEmployees>
    <ck0001824293:RepaymentOfAdvancesFromEmployees contextRef="c-1" decimals="-3" id="f-249" unitRef="usd">195000</ck0001824293:RepaymentOfAdvancesFromEmployees>
    <ck0001824293:RepaymentOfAdvancesFromEmployees contextRef="c-7" decimals="-3" id="f-250" unitRef="usd">30000</ck0001824293:RepaymentOfAdvancesFromEmployees>
    <ck0001824293:ProceedsFromNonConvertibleDebt contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">0</ck0001824293:ProceedsFromNonConvertibleDebt>
    <ck0001824293:ProceedsFromNonConvertibleDebt contextRef="c-7" decimals="-3" id="f-252" unitRef="usd">125000</ck0001824293:ProceedsFromNonConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-1" decimals="-3" id="f-253" unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-7" decimals="-3" id="f-254" unitRef="usd">125000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-255" unitRef="usd">1250000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-7" decimals="-3" id="f-256" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-1" decimals="-3" id="f-257" unitRef="usd">12250000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-7" decimals="-3" id="f-258" unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-1" decimals="-3" id="f-259" unitRef="usd">12000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-7" decimals="-3" id="f-260" unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization contextRef="c-1" decimals="-3" id="f-261" unitRef="usd">2939000</ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization>
    <ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization contextRef="c-7" decimals="-3" id="f-262" unitRef="usd">0</ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization>
    <ck0001824293:PaymentOfReverseRecapitalizationCosts contextRef="c-1" decimals="-3" id="f-263" unitRef="usd">2984000</ck0001824293:PaymentOfReverseRecapitalizationCosts>
    <ck0001824293:PaymentOfReverseRecapitalizationCosts contextRef="c-7" decimals="-3" id="f-264" unitRef="usd">0</ck0001824293:PaymentOfReverseRecapitalizationCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-1" decimals="-3" id="f-265" unitRef="usd">517000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-7" decimals="-3" id="f-266" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-267" unitRef="usd">150000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-7" decimals="-3" id="f-268" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-269" unitRef="usd">6917000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-270" unitRef="usd">255000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-271" unitRef="usd">3479000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-272" unitRef="usd">14000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-273" unitRef="usd">9000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-274" unitRef="usd">90000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-275" unitRef="usd">3488000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-26" decimals="-3" id="f-276" unitRef="usd">104000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <ck0001824293:StockIssuedForRepaymentOfNotesPayable contextRef="c-1" decimals="-3" id="f-277" unitRef="usd">3333000</ck0001824293:StockIssuedForRepaymentOfNotesPayable>
    <ck0001824293:StockIssuedForRepaymentOfNotesPayable contextRef="c-7" decimals="-3" id="f-278" unitRef="usd">0</ck0001824293:StockIssuedForRepaymentOfNotesPayable>
    <ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants contextRef="c-1" decimals="-3" id="f-279" unitRef="usd">532000</ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants>
    <ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants contextRef="c-7" decimals="-3" id="f-280" unitRef="usd">90000</ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants>
    <ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts contextRef="c-1" decimals="-3" id="f-281" unitRef="usd">1875000</ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts>
    <ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts contextRef="c-7" decimals="-3" id="f-282" unitRef="usd">0</ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts>
    <ck0001824293:WarrantsIssued contextRef="c-1" decimals="-3" id="f-283" unitRef="usd">18000</ck0001824293:WarrantsIssued>
    <ck0001824293:WarrantsIssued contextRef="c-7" decimals="-3" id="f-284" unitRef="usd">0</ck0001824293:WarrantsIssued>
    <ck0001824293:NoncashMergerRelatedCostsFinancingActivities contextRef="c-1" decimals="-3" id="f-285" unitRef="usd">72000</ck0001824293:NoncashMergerRelatedCostsFinancingActivities>
    <ck0001824293:NoncashMergerRelatedCostsFinancingActivities contextRef="c-7" decimals="-3" id="f-286" unitRef="usd">0</ck0001824293:NoncashMergerRelatedCostsFinancingActivities>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-287">ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date of inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. The Company&#x2019;s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. The Company&#x2019;s lead product candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T (iNKT I) cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). The Company&#x2019;s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 Natural Killer T (NKT II) cells and is being developed for the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease (SLE) or lupus and multiple sclerosis (MS).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reverse Merger with Vallon Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2023, the Company (formerly Vallon Pharmaceuticals, Inc.(Vallon)) consummated a merger with GRI Bio Operations, Inc. (formerly GRI Bio, Inc.) (Private GRI) pursuant to an Agreement and Plan of Merger, as amended (the Merger Agreement), by and among the Company, Private GRI and Vallon Merger Sub, Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of the Company (Note 4). The Merger Agreement provided for the merger of Merger Sub with and into Private GRI, with Private GRI surviving the merger as a wholly-owned subsidiary of the Company (the Merger). In connection with the closing of the Merger (the Closing), the Company amended its certificate of incorporation and bylaws to change its name from &#x201c;Vallon Pharmaceuticals, Inc.&#x201d; to &#x201c;GRI Bio, Inc.&#x201d; In addition, prior to the effective time of the Merger (the Effective Time), the Company effected a reverse stock split of the Company&#x2019;s common stock at a ratio of 1 for 30 (the Reverse Stock Split). At the Effective Time, each share of Private GRI&#x2019;s common stock outstanding immediately prior to the Effective Time automatically converted solely into the right to receive a number of shares of the Company's common stock equal to 0.0374 (the Exchange Ratio).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except as otherwise indicated or as the context requires, references herein to &#x201c;GRI Bio,&#x201d; the &#x201c;Company,&#x201d; or the &#x201c;combined company,&#x201d; refer to GRI Bio, Inc. on a post-Merger basis, and references to &#x201c;Private GRI&#x201d; refer to the business of  GRI Bio, Inc. prior to the completion of the Merger. References to &#x201c;Vallon&#x201d; refer to Vallon Pharmaceuticals, Inc. prior to the completion of the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 4, the Merger was accounted for as reverse recapitalization under which the historical financial statements of the Company prior to the Merger are the historical financial statements of the accounting acquirer, Private GRI. All common stock, per share and related information presented in the consolidated financial statements and notes prior to the Merger has been retroactively adjusted to reflect the Exchange Ratio and Reverse Stock Split for all periods presented, to the extent applicable.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <ck0001824293:CommonStockExchangeRatio contextRef="c-54" decimals="4" id="f-288" unitRef="number">0.0374</ck0001824293:CommonStockExchangeRatio>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="c-1" id="f-290">LIQUIDITYThese financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and as a result has incurred $29,529 in accumulated deficit through September&#160;30, 2023. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of September&#160;30, 2023, the Company had cash of approximately $3,488. &lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered the Equity SPA pursuant to which the Investor agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI common stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, Private GRI issued 6,787,219 shares of Private GRI common stock (the Initial Shares) to the Investor and 27,148,877 shares of Private GRI common stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $11,704, after deducting offering expenses of $546.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 253,842 shares of the Company&#x2019;s common stock and the Additional Shares converted into an aggregate of 1,015,368 shares of the Company&#x2019;s common stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and the Investor authorized the escrow agent to, subject to beneficial ownership limitations, disburse to the Investor all of the shares of the Company&#x2019;s common stock issued in exchange for the Additional Shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company&#x2019;s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Series T Warrants issued in connection with the Merger are not presently subject to forced exercise by the Company as the equity conditions for their forced exercise, which include (among other things) a requirement that shares of the Company&#x2019;s common stock have a value weighted average price of at least $9.21 per share for the periods specified in the Series T Warrants, are not met. The Company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if the Company&#x2019;s research and development efforts are successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of one year from the issuance of these financial statements. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-291" unitRef="usd">-29529000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-292" unitRef="usd">3488000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentCompanyCommittedCapital contextRef="c-56" decimals="-3" id="f-293" unitRef="usd">12250000</us-gaap:InvestmentCompanyCommittedCapital>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-57"
      decimals="INF"
      id="f-294"
      unitRef="shares">6787219</us-gaap:CommonStockSharesIssued>
    <ck0001824293:CommonStockHeldIntoEscrowAccount
      contextRef="c-58"
      decimals="INF"
      id="f-295"
      unitRef="shares">27148877</ck0001824293:CommonStockHeldIntoEscrowAccount>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-55" decimals="-3" id="f-296" unitRef="usd">11704000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-55" decimals="-3" id="f-297" unitRef="usd">546000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c-59"
      decimals="INF"
      id="f-298"
      unitRef="shares">253842</us-gaap:ConversionOfStockSharesConverted1>
    <ck0001824293:ConversionOfStockAdditionalSharesConverted
      contextRef="c-59"
      decimals="INF"
      id="f-299"
      unitRef="shares">1015368</ck0001824293:ConversionOfStockAdditionalSharesConverted>
    <us-gaap:SharePrice
      contextRef="c-60"
      decimals="2"
      id="f-300"
      unitRef="usdPerShare">9.21</us-gaap:SharePrice>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-301">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#x201c;authoritative guidance&#x201d; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2022 balance sheet was derived from the Company&#x2019;s audited financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the unaudited interim financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of September&#160;30, 2023, and the results of operations and stockholders&#x2019; equity (deficit) for the three and nine months ended September&#160;30, 2023 and 2022 and cash flows for the three and nine months ended September&#160;30, 2023 and 2022. Results of operations for the three and nine months ended September&#160;30, 2023, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2023. The unaudited interim financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2022, which are included as Exhibit 99.2 of Amendment No. 2 to the Current Report on Form 8-K filed with the SEC on July 6, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance and subsequent revaluations, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of September&#160;30, 2023 and December&#160;31, 2022 included investments in money market funds. The Company maintains its cash and cash equivalent balances at domestic financial institutions. Bank deposits with US banks are insured up to $250 by the Federal Deposits Insurance Corporation. The Company had an uninsured cash balances of $2,988 at September&#160;30, 2023. The Company&#x2019;s cash balance as of December&#160;31, 2022 was fully insured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, (ASC 820) establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2023, the Company&#x2019;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At September&#160;30, 2023, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Vallon issued warrants in connection with a securities purchase agreement. Vallon evaluated the warrants in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 815-40), and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As a result, the warrants are recorded as a liability on the balance sheet. Vallon recorded the fair value of the warrants upon issuance using a Black-Scholes valuation model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to revalue the warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrants liabilities is reflected in the statement of operations for the nine months ended September&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Stock Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred stock issuance costs represent incremental legal costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The relative fair values of warrants and common shares issued and call option rights assigned in connection with principal advances under promissory notes, the increases in fair values of embedded conversion options in connection with convertible promissory note modifications, and the intrinsic values of non-contingent beneficial conversion features were recorded as debt discounts that are amortized as additional interest expense over the estimated terms of the notes using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt issuance costs represent incremental legal costs and other costs incurred that are directly attributable to issuing debt. The costs are included as a direct reduction of the carrying amount of the respective liability and are amortized as additional interest expense over the estimated term of the debt using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are recorded as a cumulative adjustment in the period the estimates are revised. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share are calculated by dividing the net loss by the applicable weighted-average number of common shares outstanding during the period. As the Company had a net loss in each of the three and nine months ended September&#160;30, 2023 and 2022, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,546,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock with repurchase rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock subject to put right&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible promissory note&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,864,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the applicability and impact of all ASUs issued during the quarter ended September&#160;30, 2023 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-302">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#x201c;authoritative guidance&#x201d; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2022 balance sheet was derived from the Company&#x2019;s audited financial statements.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-303">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance and subsequent revaluations, &lt;/span&gt;&lt;/div&gt;valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-304">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of September&#160;30, 2023 and December&#160;31, 2022 included investments in money market funds. The Company maintains its cash and cash equivalent balances at domestic financial institutions. Bank deposits with US banks are insured up to $250 by the Federal Deposits Insurance Corporation. The Company had an uninsured cash balances of $2,988 at September&#160;30, 2023. The Company&#x2019;s cash balance as of December&#160;31, 2022 was fully insured.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount contextRef="c-3" decimals="-3" id="f-305" unitRef="usd">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount contextRef="c-3" decimals="-3" id="f-306" unitRef="usd">2988000</us-gaap:CashUninsuredAmount>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-307">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, (ASC 820) establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2023, the Company&#x2019;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At September&#160;30, 2023, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Vallon issued warrants in connection with a securities purchase agreement. Vallon evaluated the warrants in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 815-40), and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As a result, the warrants are recorded as a liability on the balance sheet. Vallon recorded the fair value of the warrants upon issuance using a Black-Scholes valuation model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to revalue the warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrants liabilities is reflected in the statement of operations for the nine months ended September&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="c-1" id="f-308">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Stock Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred stock issuance costs represent incremental legal costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.&lt;/span&gt;&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="c-1" id="f-309">Debt Discounts&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The relative fair values of warrants and common shares issued and call option rights assigned in connection with principal advances under promissory notes, the increases in fair values of embedded conversion options in connection with convertible promissory note modifications, and the intrinsic values of non-contingent beneficial conversion features were recorded as debt discounts that are amortized as additional interest expense over the estimated terms of the notes using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt issuance costs represent incremental legal costs and other costs incurred that are directly attributable to issuing debt. The costs are included as a direct reduction of the carrying amount of the respective liability and are amortized as additional interest expense over the estimated term of the debt using the effective interest method.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-310">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are recorded as a cumulative adjustment in the period the estimates are revised. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-311">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share are calculated by dividing the net loss by the applicable weighted-average number of common shares outstanding during the period. As the Company had a net loss in each of the three and nine months ended September&#160;30, 2023 and 2022, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-312">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,546,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock with repurchase rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock subject to put right&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible promissory note&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,864,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-61" decimals="0" id="f-313" unitRef="shares">318014</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-62" decimals="0" id="f-314" unitRef="shares">89472</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-63" decimals="0" id="f-315" unitRef="shares">2546160</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-64" decimals="0" id="f-316" unitRef="shares">10067</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-65" decimals="0" id="f-317" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-66" decimals="0" id="f-318" unitRef="shares">147976</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-67" decimals="0" id="f-319" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-68" decimals="0" id="f-320" unitRef="shares">7816</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-69" decimals="0" id="f-321" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-70" decimals="0" id="f-322" unitRef="shares">150506</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-323" unitRef="shares">2864174</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="0" id="f-324" unitRef="shares">405837</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-325">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the applicability and impact of all ASUs issued during the quarter ended September&#160;30, 2023 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-326">MERGER WITH VALLON&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2023, pursuant to the Merger Agreement, Merger Sub was merged with and into Private GRI, with Private GRI surviving the Merger as a wholly owned subsidiary of the Company. In connection with the Closing, the Company amended its certificate of incorporation and bylaws to change its name from &#x201c;Vallon Pharmaceuticals, Inc.&#x201d; to &#x201c;GRI Bio, Inc.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Effective Time:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Each share of Private GRI&#x2019;s common stock outstanding immediately prior to the Effective Time, including any shares of Private GRI&#x2019;s common stock issued pursuant to the Equity SPA automatically converted solely into the right to receive a number of shares of the Company&#x2019;s common stock equal to the Exchange Ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Each option to purchase shares of Private GRI&#x2019;s common stock (each, a GRI Option) outstanding and unexercised immediately prior to the Effective Time under the GRI Bio, Inc. 2015 Equity Incentive Plan (the GRI Plan), whether or not vested, converted into and became an option to purchase shares of the Company&#x2019;s common stock, and the Company assumed the GRI Plan and each such GRI Option in accordance with the terms of the GRI Plan (the Assumed Options). The number of shares of the Company&#x2019;s common stock subject to each Assumed Option was determined by multiplying (i) the number of shares of Private GRI&#x2019;s common stock that were subject to such GRI Option, as in effect immediately prior to the Effective Time, by (ii) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of the Company&#x2019;s common stock. The per share exercise price for the Company&#x2019;s common stock issuable upon exercise of each Assumed Option was determined by dividing (A) the per share exercise price of such Assumed Option, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio and rounding the resulting per share exercise price up to the nearest whole cent. Any restriction on the exercise of any Assumed Option continued in full force and effect and the term, exercisability, vesting schedule, and any other provisions of such Assumed Option otherwise remained unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Each warrant to purchase shares of Private GRI&#x2019;s common stock outstanding immediately prior to the Effective Time other than the Bridge Warrants (as defined below) (the GRI Warrants), was assumed by the Company and converted into a warrant to purchase shares of the Company&#x2019;s common stock (the Assumed Warrants) and thereafter (i) each Assumed Warrant became exercisable solely for shares of the Company&#x2019;s common stock; (ii) the number of shares of the Company&#x2019;s common stock subject to each Assumed Warrant was determined by multiplying (A) the number of shares of Private GRI&#x2019;s common stock that were subject to such GRI Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of the Company&#x2019;s common stock; (iii) the per share exercise price for shares of the Company&#x2019;s common stock issuable upon exercise of each Assumed Warrant was determined by dividing (A) the exercise price per share of Private GRI&#x2019;s common stock subject to such GRI Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The Bridge Warrants (Note 8) were exchanged for warrants (the Exchange Warrants) to purchase an aggregate of 421,589 shares of the Company&#x2019;s common stock. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $14.73 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;All rights with respect to Private GRI restricted stock awards were assumed by the Company and converted into Company restricted stock awards with the number of shares subject to each restricted stock award multiplied by the Exchange Ratio and rounding the resulting number down to the nearest whole number of shares of the Company&#x2019;s common stock. The term, exercisability, vesting schedule and other provisions of the Private GRI restricted stock awards otherwise remained unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Merger is accounted for as a reverse recapitalization under U.S. GAAP because the primary assets of Vallon were cash and cash equivalents. For accounting purposes, GRI has been determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i)  the equity holders of Private GRI immediately prior to the Merger owned, or held rights to acquire, in the aggregate approximately 85% of the outstanding shares of the Company&#x2019;s common stock and the Company&#x2019;s stockholders immediately prior to the Merger owned approximately 15% of the outstanding shares of the Company&#x2019;s common stock (ii) Private GRI holds the majority (4 out of 5) of board seats of the combined company, and (iii) Private GRI&#x2019;s management holds the majority of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;key positions in the management of the combined company. Immediately after the Merger, there were 2,956,354 shares of the Company&#x2019;s common stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the net liabilities assumed in the Merger:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 21, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plus: Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net liabilities assumed plus transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;In addition to the transaction costs noted above, at the Effective Time, 30,542 shares of the Company&#x2019;s common stock were issued to Private GRI&#x2019;s financial advisor for services related to the Merger.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-71"
      decimals="INF"
      id="f-327"
      unitRef="shares">421589</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-71"
      decimals="2"
      id="f-328"
      unitRef="usdPerShare">14.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:CommonStockOwnershipPercentage contextRef="c-72" decimals="2" id="f-329" unitRef="number">0.85</ck0001824293:CommonStockOwnershipPercentage>
    <ck0001824293:CommonStockOwnershipPercentage contextRef="c-73" decimals="2" id="f-330" unitRef="number">0.15</ck0001824293:CommonStockOwnershipPercentage>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-331" unitRef="shares">2956354</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-332" unitRef="shares">2956354</us-gaap:CommonStockSharesIssued>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c-1" id="f-333">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the net liabilities assumed in the Merger:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 21, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plus: Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net liabilities assumed plus transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-74" decimals="-3" id="f-334" unitRef="usd">941000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c-74" decimals="-3" id="f-335" unitRef="usd">310000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses contextRef="c-74" decimals="-3" id="f-336" unitRef="usd">4190000</ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-74" decimals="-3" id="f-337" unitRef="usd">-2939000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c-74" decimals="-3" id="f-338" unitRef="usd">2984000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts contextRef="c-74" decimals="-3" id="f-339" unitRef="usd">-5923000</ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts>
    <ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses
      contextRef="c-55"
      decimals="INF"
      id="f-340"
      unitRef="shares">30542</ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-341">FAIR VALUE MEASUREMENTS&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the guidance in ASC 820 to account for financial assets and liabilities measured on a recurring basis. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The guidance requires that fair value measurements be classified and disclosed in one of the following 3 categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. There were no transfers between Level 1, 2 and 3 during the nine months ended September&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#x2019;s liabilities that are measured at fair value on a recurring basis at September&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the Level 3 liability:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrant Liability &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of September&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.7&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.9&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.92&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-342">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#x2019;s liabilities that are measured at fair value on a recurring basis at September&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-75" decimals="-3" id="f-343" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-76" decimals="-3" id="f-344" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-77" decimals="-3" id="f-345" unitRef="usd">18000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-75" decimals="-3" id="f-346" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-76" decimals="-3" id="f-347" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-77" decimals="-3" id="f-348" unitRef="usd">18000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-349">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the Level 3 liability:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrant Liability &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of September&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-78" decimals="-3" id="f-350" unitRef="usd">185000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-79" decimals="-3" id="f-351" unitRef="usd">-167000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-80" decimals="-3" id="f-352" unitRef="usd">18000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-353">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.7&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.9&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.92&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model was used to estimate the fair value of the Equity Warrants, the Exchange Warrants and the Advisor Warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.6&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.69&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.37&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-81" decimals="3" id="f-354" unitRef="number">1.677</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-82" decimals="3" id="f-355" unitRef="number">1.399</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-83" decimals="1" id="f-356" unitRef="number">2.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-84" decimals="1" id="f-357" unitRef="number">2.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-85"
      decimals="INF"
      id="f-358"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-86"
      decimals="INF"
      id="f-359"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-87" decimals="4" id="f-360" unitRef="number">0.0492</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-88" decimals="4" id="f-361" unitRef="number">0.0432</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-362">PROPERTY AND EQUIPMENT&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.512%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was $3 and $2 for the nine months ended September&#160;30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-363">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.512%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-89" decimals="-3" id="f-364" unitRef="usd">21000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-90" decimals="-3" id="f-365" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-91" decimals="-3" id="f-366" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-92" decimals="-3" id="f-367" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-3" id="f-368" unitRef="usd">34000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-369" unitRef="usd">26000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-370" unitRef="usd">25000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-371" unitRef="usd">22000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-372" unitRef="usd">9000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-373" unitRef="usd">4000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-374" unitRef="usd">3000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-7" decimals="-3" id="f-375" unitRef="usd">2000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-376">ACCRUED EXPENSES&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-377">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent contextRef="c-3" decimals="-3" id="f-378" unitRef="usd">75000</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent contextRef="c-4" decimals="-3" id="f-379" unitRef="usd">0</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent contextRef="c-3" decimals="-3" id="f-380" unitRef="usd">188000</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent contextRef="c-4" decimals="-3" id="f-381" unitRef="usd">0</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-382" unitRef="usd">880000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-383" unitRef="usd">36000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-384" unitRef="usd">1143000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-385" unitRef="usd">36000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-386">PROMISSORY NOTES&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bridge Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with signing the Merger Agreement, Private GRI entered into a Securities Purchase Agreement, dated as of December 13, 2022 (Bridge SPA), with Altium Growth Fund, LP (the Investor), pursuant to which Private GRI issued senior secured promissory notes (Bridge Notes) in the aggregate principal amount of $3,333, in exchange for an aggregate purchase price of $2,500. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Bridge Notes were issued in two closings: (i) the first closing for $1,667 in aggregate principal amount (in exchange for an aggregate purchase price of $1,250) closed on December 14, 2022; and (ii) the second closing for $1,667 in aggregate principal amount (in exchange for an aggregate purchase price of $1,250) closed on March 9, 2023. The Bridge Notes were secured by a lien on all of the Company&#x2019;s assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, upon the funding of each tranche, the Investor received warrants to purchase an aggregate of 1,252,490 shares of the Company&#x2019;s common stock (the Bridge Warrants). The Bridge Warrants had an exercise price of $1.33 per share, were exercisable at any time on or after the applicable issuance date and had a term of 60 months from the date all shares underlying the Bridge Warrants were freely tradable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $1,250 of proceeds from the first closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $679 and $571, respectively. The $1,250 of proceeds from the second closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $718 and $532, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the Bridge SPA, and also in connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered into the Equity SPA (Note 9) pursuant to which the Investor agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI&#x2019;s common stock immediately prior to the consummation of the Merger. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2023, the Company completed the Merger and the outstanding principal and accrued interest on the Bridge Notes was cancelled and the Bridge Warrants were exchanged for the Exchange Warrants. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $14.73 per share subject to adjustments for splits and recapitalization events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Bridge Notes were accounted for as share-settled debt under the accounting guidance in ASC 835-30 and, as such, the initial net carrying amounts were accreted to the redemption amounts using the effective interest method. The Company incurred debt issuance costs of $205 during the year ended December&#160;31, 2022 and $90 during the nine months ended September&#160;30, 2023 related to its issuance of debt under the Bridge SPA. Unamortized debt discounts and debt issuance costs totaled $1,065 as of December&#160;31, 2022. Interest expense stemming from amortization of debt discounts and issuance costs was $2,104 for the nine months ended September&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;TEP Note&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, Private GRI and TEP Biotech, LLC (TEP) entered into a convertible note and warrant purchase agreement pursuant to which TEP agreed to fund up to $5,000 to Private GRI in exchange for a convertible promissory note (the TEP Note) and a warrant to purchase up to 25,245 shares of Private GRI&#x2019;s common stock at an exercise price of $0.27 per share. The TEP Note was secured by Private GRI&#x2019;s assets and accrued simple interest on the outstanding principal balance at a rate of 12% per annum. The total outstanding principal and accrued interest balance was initially due on the earlier of Private GRI&#x2019;s next financing, as defined, and May 2, 2020. The initial $2,500 tranche under the TEP Note was funded upon execution of the agreement in November 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, Private GRI and TEP amended the TEP Note. In lieu of TEP funding the second $2,500 tranche, TEP made a first additional advance of $500 to Private GRI in exchange for a convertible promissory note, a warrant to purchase up to 17,269 shares of Private GRI&#x2019;s common stock at an exercise price of $0.27 per share, and the assignment of Private GRI&#x2019;s rights under a certain call option agreement. The call option agreement, which was entered into in 2015, provided Private GRI with the right to repurchase up to 39,720 shares of Private GRI&#x2019;s common stock held by the counterparty for $26.74 per share at any time before April 1, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the TEP Note maturity date was extended to August 31, 2020, and in March 2021, TEP agreed to forbear on its available right to exercise remedies on account of Private GRI&#x2019;s failure to pay the past due principal and accrued interest balance until October 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, Private GRI and TEP amended the TEP Note, and TEP agreed to make a second additional advance of $500 to Private GRI in exchange for a convertible promissory note with separate, modified conversion options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, Private GRI and TEP further amended the TEP Note, and TEP agreed to make a third additional advance of $125 to Private GRI in exchange for a convertible promissory note and a warrant to purchase up to 1,169 shares of Private GRI&#x2019;s common stock at an exercise price of $0.27 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, Private GRI and TEP entered into a conversion agreement pursuant to which, effective upon the full execution of the Merger Agreement (Note 4), $3,500 of outstanding principal under the TEP Note together with $650 of related accrued interest was to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;automatically convert into 155,210 shares of Private GRI&#x2019;s common stock at a conversion price of $26.74 per share. Further, upon the closing of the first tranche of the Bridge Notes, Private GRI was to repay, in cash, the $125 third additional advance under the TEP Note along with the $15 of related accrued interest. Upon issuance of the 155,210 conversion shares and payment of the $140 principal and accrued interest balance, Private GRI would fully satisfy all of its obligations under the TEP Note.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, upon the full execution of the Merger Agreement and the closing of the first tranche of the Bridge Notes Private GRI issued the 155,210 conversion shares and paid the $140 principal and accrued interest balance as per the terms of the conversion agreement. The share numbers and exercise or conversion prices in this section of Note 8 entitled &#x201c;TEP Note&#x201d; reflect the Exchange Ratio retroactively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the conversion, the $4,150 of converted principal and accrued interest, along with $863 of related forfeited accrued interest through the conversion date, were credited to stockholders&#x2019; deficit. Interest expense recognized on the TEP Note was $142 and $352 for the three and nine months ended September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-93" decimals="-3" id="f-387" unitRef="usd">3333000</us-gaap:DebtInstrumentFaceAmount>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-94" decimals="-3" id="f-388" unitRef="usd">2500000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <ck0001824293:DebtInstrumentNumberOfClosings
      contextRef="c-95"
      decimals="INF"
      id="f-389"
      unitRef="closing">2</ck0001824293:DebtInstrumentNumberOfClosings>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-96" decimals="-3" id="f-390" unitRef="usd">1667000</us-gaap:DebtInstrumentFaceAmount>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-97" decimals="-3" id="f-391" unitRef="usd">1250000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-98" decimals="-3" id="f-392" unitRef="usd">1667000</us-gaap:DebtInstrumentFaceAmount>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-99" decimals="-3" id="f-393" unitRef="usd">1250000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-100"
      decimals="INF"
      id="f-394"
      unitRef="shares">1252490</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-100"
      decimals="2"
      id="f-395"
      unitRef="usdPerShare">1.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-100" id="f-396">P60M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-97" decimals="-3" id="f-397" unitRef="usd">1250000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-97" decimals="-3" id="f-398" unitRef="usd">679000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-101" decimals="-3" id="f-399" unitRef="usd">571000</us-gaap:ProceedsFromNotesPayable>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-99" decimals="-3" id="f-400" unitRef="usd">1250000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-99" decimals="-3" id="f-401" unitRef="usd">718000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-102" decimals="-3" id="f-402" unitRef="usd">532000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:InvestmentCompanyCommittedCapital contextRef="c-56" decimals="-3" id="f-403" unitRef="usd">12250000</us-gaap:InvestmentCompanyCommittedCapital>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-71"
      decimals="2"
      id="f-404"
      unitRef="usdPerShare">14.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-103" decimals="-3" id="f-405" unitRef="usd">205000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-104" decimals="-3" id="f-406" unitRef="usd">90000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-4" decimals="-3" id="f-407" unitRef="usd">1065000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-408" unitRef="usd">2104000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-105" decimals="INF" id="f-409" unitRef="usd">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-106"
      decimals="INF"
      id="f-410"
      unitRef="shares">25245</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-106"
      decimals="2"
      id="f-411"
      unitRef="usdPerShare">0.27</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-105"
      decimals="INF"
      id="f-412"
      unitRef="number">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-107" decimals="INF" id="f-413" unitRef="usd">2500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-108" decimals="INF" id="f-414" unitRef="usd">2500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-109" decimals="-3" id="f-415" unitRef="usd">500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-110"
      decimals="INF"
      id="f-416"
      unitRef="shares">17269</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-110"
      decimals="2"
      id="f-417"
      unitRef="usdPerShare">0.27</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-111"
      decimals="INF"
      id="f-418"
      unitRef="shares">39720</us-gaap:CommonStockSharesIssued>
    <ck0001824293:CallOptionPrice
      contextRef="c-111"
      decimals="2"
      id="f-419"
      unitRef="usdPerShare">26.74</ck0001824293:CallOptionPrice>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-112" decimals="-3" id="f-420" unitRef="usd">500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-113" decimals="-3" id="f-421" unitRef="usd">125000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-114"
      decimals="INF"
      id="f-422"
      unitRef="shares">1169</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-114"
      decimals="2"
      id="f-423"
      unitRef="usdPerShare">0.27</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:DebtConversionConvertedInstrumentPrincipalAmountOfDebt contextRef="c-115" decimals="-3" id="f-424" unitRef="usd">3500000</ck0001824293:DebtConversionConvertedInstrumentPrincipalAmountOfDebt>
    <ck0001824293:DebtConversionConvertedInstrumentAmountOfInterest contextRef="c-115" decimals="-3" id="f-425" unitRef="usd">650000</ck0001824293:DebtConversionConvertedInstrumentAmountOfInterest>
    <ck0001824293:DebtInstrumentConvertibleSharesIssuedUponConversion
      contextRef="c-116"
      decimals="INF"
      id="f-426"
      unitRef="shares">155210</ck0001824293:DebtInstrumentConvertibleSharesIssuedUponConversion>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-116"
      decimals="2"
      id="f-427"
      unitRef="usdPerShare">26.74</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-117" decimals="-3" id="f-428" unitRef="usd">125000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="c-117" decimals="-3" id="f-429" unitRef="usd">15000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <ck0001824293:DebtInstrumentConvertibleSharesIssuedUponConversion
      contextRef="c-116"
      decimals="INF"
      id="f-430"
      unitRef="shares">155210</ck0001824293:DebtInstrumentConvertibleSharesIssuedUponConversion>
    <ck0001824293:LongTermDebtIncludingInterest contextRef="c-117" decimals="-3" id="f-431" unitRef="usd">140000</ck0001824293:LongTermDebtIncludingInterest>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="c-118"
      decimals="INF"
      id="f-432"
      unitRef="shares">155210</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-119" decimals="-3" id="f-433" unitRef="usd">140000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c-119" decimals="-3" id="f-434" unitRef="usd">4150000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <ck0001824293:AccruedInterestForfeited contextRef="c-119" decimals="-3" id="f-435" unitRef="usd">863000</ck0001824293:AccruedInterestForfeited>
    <us-gaap:InterestExpenseBorrowings contextRef="c-120" decimals="-3" id="f-436" unitRef="usd">142000</us-gaap:InterestExpenseBorrowings>
    <us-gaap:InterestExpenseBorrowings contextRef="c-121" decimals="-3" id="f-437" unitRef="usd">352000</us-gaap:InterestExpenseBorrowings>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-438">STOCKHOLDERS&#x2019; EQUITY &lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with signing the Merger Agreement, Vallon, Private GRI and the Investor entered the Equity SPA pursuant to which the Investor agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of Private GRI&#x2019;s common stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, Private GRI issued 6,787,219 shares of Private GRI&#x2019;s common stock (the Initial Shares) to the Investor and 27,148,877 shares of Private GRI&#x2019;s common stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $11,704, after deducting offering expenses of $546.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 253,842 shares of the Company&#x2019;s common stock and the Additional Shares converted into an aggregate of 1,015,368 shares of the Company&#x2019;s common stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and the Investor authorized the escrow agent to, subject to beneficial ownership limitations, disburse to the Investor all of the shares of the Company&#x2019;s common stock issued in exchange for the Additional Shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redeemable Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, Private GRI entered into an agreement with a stockholder pursuant to which the stockholder had the right to require Private GRI to purchase all or a portion of 7,816 shares of Private GRI&#x2019;s common stock held by the stockholder for $15.88 per share (the Put Right). The Put Right was exercisable (i) for a period commencing thirty days prior to the day Private GRI completed an equity or debt financing and ending fifteen business days thereafter, or (ii) at any time following a breach of the agreement by Private GRI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management assessed the Put Right and determined that (i) it was not freestanding and, therefore, was not required to be classified as a liability and (ii) it could be exercised by the stockholder at any time, which was not within Private GRI&#x2019;s control. Therefore, the common shares subject to the Put Right were classified in mezzanine equity. In December 2022, the stockholder exercised the Put Right and Private GRI redeemed the 7,816 shares of Private GRI&#x2019;s common stock for $124 ($15.88 per share). The redeemed shares were retired by Private GRI. The share numbers and exercise or conversion prices in this section of Note 9 entitled &#x201c;Redeemable Common Stock&#x201d; reflect the Exchange Ratio retroactively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Equity SPA, on May 8, 2023, the Company issued to the Investor (i) Series A-1 Warrants to purchase 1,269,210 shares of the Company&#x2019;s common stock at an exercise price of $13.51, (ii) Series A-2 Warrants to purchase 1,142,289 shares of the Company&#x2019;s common stock at an exercise price of $14.74 , and (iii) Series T Warrants to purchase (x) 814,467 shares of the Company&#x2019;s common stock at an exercise price of $12.28 and (y) upon exercise of the Series T Warrants, 814,467 additional Series &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A-1 Warrants and Series A-2 Warrants, each to purchase 814,467 shares of the Company&#x2019;s common stock at an exercise price of $13.51 and $14.74, respectively (collectively, the Equity Warrants). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Series A-1 Warrants have a term of 60 months from the date all shares underlying the Series A-1 Warrants are freely tradable. The A-2 warrants have a 2-year term and expire in June 2025. Series T Warrants have a term of 24 months from the date all shares underlying Series T Warrants are freely tradable. As noted in Note 2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Liquidity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company may force the exercise of the Series T Warrants subject to the satisfaction of certain equity conditions. The Equity Warrants include certain contingent cashless exercise features and contain certain other rights with regard to asset distributions and fundamental transactions. The exercise price of the Series A-1 Warrants is subject to adjustment for certain dilutive issuances, and all of the Equity Warrants are subject to standard antidilution adjustments. All of the Equity Warrants were outstanding as of September&#160;30, 2023. The Equity Warrants were classified as equity and the allocated fair value of $5,675 is included in additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Bridge SPA, upon the funding of each tranche of the Bridge Note, the Investor received the Bridge Warrants. The Bridge Warrants had an exercise price of $1.33 per share, were exercisable at any time on or after the applicable issuance date and had a term of 60 months from the date all shares underlying the Bridge Warrants are freely tradable. Upon the completion of the Merger the Bridge Warrants were exchanged for the Exchange Warrants to purchase an aggregate of 421,589 shares of the Company&#x2019;s common stock. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $14.73 per share subject to adjustments for splits and recapitalization events. All of the Bridge Warrants were outstanding as of September&#160;30, 2023. The Bridge Warrants were classified as equity and the allocated fair value of $2,860 is included in additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Closing, Private GRI granted its financial advisor warrants (the Advisor Warrants) to purchase shares of Private GRI&#x2019;s common stock, which, at the Effective Time, became exercisable for an aggregate of 2,402 shares of the Company&#x2019;s common stock at an exercise price of $61.39 per share. The Advisor Warrants have a five-year term. All of the Advisor Warrants were outstanding as of September&#160;30, 2023. The Advisor Warrants were classified as equity and the fair value of $18 is included in additional paid in capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model was used to estimate the fair value of the Equity Warrants, the Exchange Warrants and the Advisor Warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.6&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.69&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.37&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2023, the Company had the following warrants outstanding to purchase common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$34.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,438&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$34.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,142,289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$14.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,758&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$300.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,667&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$28.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,168&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,402&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$61.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;421,590&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$14.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60 months after registration date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,269,210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$13.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60 months after registration date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;814,467&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$12.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24 months after registration date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:InvestmentCompanyCommittedCapital contextRef="c-56" decimals="-3" id="f-439" unitRef="usd">12250000</us-gaap:InvestmentCompanyCommittedCapital>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-57"
      decimals="INF"
      id="f-440"
      unitRef="shares">6787219</us-gaap:CommonStockSharesIssued>
    <ck0001824293:CommonStockHeldIntoEscrowAccount
      contextRef="c-58"
      decimals="INF"
      id="f-441"
      unitRef="shares">27148877</ck0001824293:CommonStockHeldIntoEscrowAccount>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-55" decimals="-3" id="f-442" unitRef="usd">11704000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-55" decimals="-3" id="f-443" unitRef="usd">546000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c-59"
      decimals="INF"
      id="f-444"
      unitRef="shares">253842</us-gaap:ConversionOfStockSharesConverted1>
    <ck0001824293:ConversionOfStockAdditionalSharesConverted
      contextRef="c-59"
      decimals="INF"
      id="f-445"
      unitRef="shares">1015368</ck0001824293:ConversionOfStockAdditionalSharesConverted>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-122"
      decimals="INF"
      id="f-446"
      unitRef="shares">7816</us-gaap:CommonStockSharesIssued>
    <ck0001824293:PutOptionSharePrice
      contextRef="c-122"
      decimals="2"
      id="f-447"
      unitRef="usdPerShare">15.88</ck0001824293:PutOptionSharePrice>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c-118"
      decimals="INF"
      id="f-448"
      unitRef="shares">7816</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-118" decimals="-3" id="f-449" unitRef="usd">124000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-118"
      decimals="2"
      id="f-450"
      unitRef="usdPerShare">15.88</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-123"
      decimals="INF"
      id="f-451"
      unitRef="shares">1269210</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-123"
      decimals="2"
      id="f-452"
      unitRef="usdPerShare">13.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-124"
      decimals="INF"
      id="f-453"
      unitRef="shares">1142289</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-124"
      decimals="2"
      id="f-454"
      unitRef="usdPerShare">14.74</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-125"
      decimals="INF"
      id="f-455"
      unitRef="shares">814467</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-125"
      decimals="2"
      id="f-456"
      unitRef="usdPerShare">12.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-126"
      decimals="INF"
      id="f-457"
      unitRef="shares">814467</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-127"
      decimals="INF"
      id="f-458"
      unitRef="shares">814467</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-127"
      decimals="INF"
      id="f-459"
      unitRef="shares">814467</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-126"
      decimals="INF"
      id="f-460"
      unitRef="shares">814467</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-127"
      decimals="2"
      id="f-461"
      unitRef="usdPerShare">13.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-126"
      decimals="2"
      id="f-462"
      unitRef="usdPerShare">14.74</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-123" id="f-463">P60M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-124" id="f-464">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-125" id="f-465">P24M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-128" decimals="-3" id="f-466" unitRef="usd">5675000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-129"
      decimals="2"
      id="f-467"
      unitRef="usdPerShare">1.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-129" id="f-468">P60M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-129"
      decimals="INF"
      id="f-469"
      unitRef="shares">421589</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-130"
      decimals="2"
      id="f-470"
      unitRef="usdPerShare">14.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-131" decimals="-3" id="f-471" unitRef="usd">2860000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-132"
      decimals="INF"
      id="f-472"
      unitRef="shares">2402</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-132"
      decimals="2"
      id="f-473"
      unitRef="usdPerShare">61.39</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-133" id="f-474">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-134" decimals="-3" id="f-475" unitRef="usd">18000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-135" decimals="3" id="f-476" unitRef="number">1.676</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-136" decimals="2" id="f-477" unitRef="number">1.69</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-137" decimals="3" id="f-478" unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-138" decimals="4" id="f-479" unitRef="number">0.0437</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c-1" id="f-480">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2023, the Company had the following warrants outstanding to purchase common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$34.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,438&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$34.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,142,289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$14.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,758&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$300.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,667&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$28.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,168&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,402&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$61.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;421,590&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$14.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60 months after registration date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,269,210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$13.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60 months after registration date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;814,467&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$12.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24 months after registration date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-139"
      decimals="INF"
      id="f-481"
      unitRef="shares">8629</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-139"
      decimals="2"
      id="f-482"
      unitRef="usdPerShare">34.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-140"
      decimals="INF"
      id="f-483"
      unitRef="shares">1438</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-140"
      decimals="2"
      id="f-484"
      unitRef="usdPerShare">34.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-141"
      decimals="INF"
      id="f-485"
      unitRef="shares">1142289</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-141"
      decimals="2"
      id="f-486"
      unitRef="usdPerShare">14.74</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-142"
      decimals="INF"
      id="f-487"
      unitRef="shares">3758</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-142"
      decimals="2"
      id="f-488"
      unitRef="usdPerShare">300.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-143"
      decimals="INF"
      id="f-489"
      unitRef="shares">24667</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-143"
      decimals="2"
      id="f-490"
      unitRef="usdPerShare">28.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-144"
      decimals="INF"
      id="f-491"
      unitRef="shares">1168</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-144"
      decimals="2"
      id="f-492"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-145"
      decimals="INF"
      id="f-493"
      unitRef="shares">2402</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-145"
      decimals="2"
      id="f-494"
      unitRef="usdPerShare">61.39</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-146"
      decimals="INF"
      id="f-495"
      unitRef="shares">421590</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-146"
      decimals="2"
      id="f-496"
      unitRef="usdPerShare">14.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:ClassOfWarrantOrRightExpirationPeriod contextRef="c-147" id="f-497">P60M</ck0001824293:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-148"
      decimals="INF"
      id="f-498"
      unitRef="shares">1269210</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-148"
      decimals="2"
      id="f-499"
      unitRef="usdPerShare">13.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:ClassOfWarrantOrRightExpirationPeriod contextRef="c-149" id="f-500">P60M</ck0001824293:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-150"
      decimals="INF"
      id="f-501"
      unitRef="shares">814467</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-150"
      decimals="2"
      id="f-502"
      unitRef="usdPerShare">12.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:ClassOfWarrantOrRightExpirationPeriod contextRef="c-151" id="f-503">P24M</ck0001824293:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:AssetAcquisitionTextBlock contextRef="c-1" id="f-504">ASSET PURCHASE AGREEMENT&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On August 22, 2023, the Company entered into Asset Purchase Agreement (the Aardvark Agreement) with Aardvark Therapeutics, Inc. (Aardvark), pursuant to which Aardvark agreed to purchase (i) the Company&#x2019;s license agreement with Medice Arzneimittel P&#x171;tter GmbH &amp;amp; Co. KG, dated January 6, 2020, (ii) certain patents related to the Company&#x2019;s ADAIR product candidate, and (iii) files (of contract manufacturing and FDA correspondence) for a formulation described in IND No. 133072, ADAIR for the Treatment of ADHD and Narcolepsy, filed with the United States FDA. Under the terms of the Aardvark Agreement, the Company received an upfront cash payment of $250, which was recognized as other income. The Company is also eligible to receive potential additional milestone payments contingent upon Aardvark achieving certain future ADAIR regulatory and sales milestones. Other than the upfront payment, the Company does not anticipate the receipt of any milestone payments from Aardvark in the near term, which potential milestone payments may or may not be achieved, paid or received in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The foregoing description of the Aardvark Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the text of the Aardvark Agreement that is filed as Exhibit 10.2 to this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c-152" decimals="-3" id="f-505" unitRef="usd">250000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-506">STOCK-BASED COMPENSATION&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2015 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Private GRI adopted the GRI Bio, Inc. 2015 Equity Incentive Plan, as amended (the Private GRI Plan), that provided Private GRI with the ability to grant stock options, restricted stock awards and other equity-based awards to employees, directors, and consultants. Stock options granted under the Private GRI Plan generally had a contractual life of up to 10 years. Upon completion of the Merger, the Company assumed the Private GRI Plan and 89,472 outstanding and unexercised options issued thereunder, and ceased granting awards under the Private GRI Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amended and Restated 2018 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2023, the stockholders of the Company approved the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan, formerly the Vallon Pharmaceuticals, Inc. 2018 Equity Incentive Plan (the A&amp;amp;R 2018 Plan). The A&amp;amp;R 2018 Plan had previously been approved by the Company&#x2019;s board of directors, subject to stockholder approval. The A&amp;amp;R 2018 Plan became effective on April 21, 2023, with the stockholders approving the amendment to the A&amp;amp;R 2018 Plan to, among other things, (i) to increase the aggregate number of shares by &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,905 shares to 216,666 shares of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company&#x2019;s common stock &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for issuance as awards under the A&amp;amp;R 2018 Plan, (ii) to extend the term of the A&amp;amp;R 2018 Plan through January 1, 2033, (iii) to prohibit any action that would be treated as a &#x201c;repricing&#x201d; of an award without further approval by the stockholders of Company, and (iv) to revise the limits on awards to non-employee directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The A&amp;amp;R 2018 Plan provides the Company with the ability to grant stock options, restricted stock and other equity-based awards to employees, directors and consultants. Stock options granted by the Company under the A&amp;amp;R 2018 Plan generally have a contractual life of up to 10 years. As of September&#160;30, 2023, awards granted under the A&amp;amp;R 2018 Plan representing the right to purchase or contingent right to receive up to an aggregate of 228,542 shares of the Company's common stock were outstanding and 216,666 shares of the Company&#x2019;s common stock were reserved for issuance under the A&amp;amp;R 2018 Plan. The number of shares reserved for issuance under the A&amp;amp;R 2018 Plan may be increased pursuant to the A&amp;amp;R 2018 Plan&#x2019;s &#x201c;evergreen&#x201d; provision on the first day of each calendar year beginning January 1, 2024 and ending on and including January 1, 2033, by a number of shares not to exceed 4% of the aggregate number of shares of the Company&#x2019;s common stock outstanding on the final day of the immediately preceding calendar year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation related to stock options issued under the Private GRI Plan and the A&amp;amp;R 2018 Plan in the following expense categories of its accompanying statements of operations for the three and nine months ended September&#160;30, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures equity-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period for certain performance-based awards. The Company records expense for performance-based awards if it concludes that it is probable that the performance condition will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the nine months ended September&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,612&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.71&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,265&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,863)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;As of September&#160;30, 2023, the unrecognized compensation cost related to unvested stock options expected to vest was $424. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of 3.16 years.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-153" id="f-507">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-154"
      decimals="INF"
      id="f-508"
      unitRef="shares">89472</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-155"
      decimals="INF"
      id="f-509"
      unitRef="shares">168905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-156"
      decimals="INF"
      id="f-510"
      unitRef="shares">216666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-157" id="f-511">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-158"
      decimals="INF"
      id="f-512"
      unitRef="shares">228542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-158"
      decimals="INF"
      id="f-513"
      unitRef="shares">216666</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-514">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation related to stock options issued under the Private GRI Plan and the A&amp;amp;R 2018 Plan in the following expense categories of its accompanying statements of operations for the three and nine months ended September&#160;30, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-159" decimals="-3" id="f-515" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-160" decimals="-3" id="f-516" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-161" decimals="-3" id="f-517" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-162" decimals="-3" id="f-518" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-163" decimals="-3" id="f-519" unitRef="usd">326000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-164" decimals="-3" id="f-520" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-165" decimals="-3" id="f-521" unitRef="usd">351000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-166" decimals="-3" id="f-522" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-523" unitRef="usd">326000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-524" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-525" unitRef="usd">351000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-526" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-527">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the nine months ended September&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,612&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.71&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,265&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,863)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-528" unitRef="shares">112612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-529"
      unitRef="usdPerShare">39.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-167" id="f-530">P4Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-531" unitRef="shares">221265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-532"
      unitRef="usdPerShare">2.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-533" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-534"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-535" unitRef="shares">15863</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-536"
      unitRef="usdPerShare">128.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-537" unitRef="shares">318014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-538"
      unitRef="usdPerShare">9.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-539">P7Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-3" decimals="INF" id="f-540" unitRef="shares">318014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-541"
      unitRef="usdPerShare">9.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-542">P7Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-543">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-168" decimals="4" id="f-544" unitRef="number">1.2954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-169" decimals="4" id="f-545" unitRef="number">0.9039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-168" id="f-546">P5Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-169" id="f-547">P5Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-168" decimals="4" id="f-548" unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-169" decimals="4" id="f-549" unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-168" decimals="4" id="f-550" unitRef="number">0.0434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-169" decimals="4" id="f-551" unitRef="number">0.0200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="c-170"
      decimals="2"
      id="f-552"
      unitRef="usdPerShare">2.13</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c-171"
      decimals="2"
      id="f-553"
      unitRef="usdPerShare">3.86</us-gaap:SharePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-3" decimals="-3" id="f-554" unitRef="usd">424000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-168" id="f-555">P3Y1M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-556">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Separation and Release Agreement&lt;/span&gt;&lt;/div&gt;In connection with the resignation of David Baker, the Company&#x2019;s Former Chief Executive Officer, pursuant to the Merger, the Company and Mr. Baker entered into a Separation and Release Agreement on April 21, 2023 (the Separation Agreement). Pursuant to the terms of the Separation Agreement and his employment agreement, Mr. Baker will receive continuation of his current salary and certain COBRA benefits for 18 months payable in accordance with the Company&#x2019;s payroll practices. Mr. Baker also received a lump sum payment equal to 150% of his target bonus and agreed to reduce amounts payable with respect to certain future milestone payments.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ck0001824293:COBRABenefitsPaymentPeriod contextRef="c-172" id="f-557">P18M</ck0001824293:COBRABenefitsPaymentPeriod>
    <ck0001824293:PercentageOfTargetBonus
      contextRef="c-172"
      decimals="INF"
      id="f-558"
      unitRef="number">1.50</ck0001824293:PercentageOfTargetBonus>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>63
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M5/<[D4]_YPN2Q]D,\H)+R</LZYI1CPF]@]J^Y%P>%O0/%/^$,/X/4$L#!!0
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MO1LN<[WX)Y4WO%1 P5O0\DY68$3N;^SV#UI4S:77M=!:%,UPQRA@-P+P?2N
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M"@1E W!^+:5YZ-@JVUVJZ3]02P,$%     @  X=N5X>+4PVE!   P!(  !@
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6RM6&N/XC84_2M6NJIFI('$>3,%
MI!V@[4K=[FAFM_O90PR))HFI;6#VW_<Z"0%B$]%VOD#BG'NNS_';XSWCKR*E
M5**W(B_%Q$JEW-S;MEBFM"!BR#:TA"\KQ@LBX96O;;'AE"154)';KN.$=D&R
MTIJ.J[)'/AVSK<RSDCYR)+9%0?B/!YJS_<3"UJ'@*5NG4A78T_&&K.DSE=\V
MCQS>[)8ER0I:BHR5B-/5Q/J([Q<X4 $5XJ^,[L7),U)27AA[52^?DHGEJ!K1
MG"ZEHB#PMZ,SFN>*">KQ=T-JM3E5X.GS@?W72CR(>2&"SEC^/4MD.K%B"R5T
M1;:Y?&+[WVDCJ*K@DN6B^D7[&AOZ%EINA61%$PPU*+*R_B=OC1$G <!C#G";
M +<;<"F#UP1XUV;PFP#_V@Q!$U!)MVOME7%S(LETS-D><84&-O50N5]%@U]9
MJ3K*L^3P-8,X.9VQ4K \2XBD"7J6\ >]0 K$5NC+AG*B6E.@ ?KV/$<W'V[1
M!Y25Z&O*MH*4B1C;$NJ@F.QED^^ASN=>R.>ASZR4J4"+,J&)(7[>'S_JB;=!
M>VN >S#@P>TE?*:;(?*<.^0ZKF>HS^SZ<-<DY_]E7_SG[&=F>&UO\"H^[P)?
MT^3E&M$WF(H$%?>F)JY)?#.)FMKNQ88LZ<2"N4M0OJ/6].>?<.C\8O+W/<GF
M[TFV>">RLY;PVY;P^]BG3\!(^#)%,,Q@XMO!C+Y1(]/4'#536#&IA6$WQ3@>
MC>W=J<TZ*/3.(7,=XN(X/ <M#,EBW&+.M :MUJ!7ZV^TA&Z75U)) I-<)J3J
MACMJ4EMS!:<5< .GH]8$ZLK5,1&.@HY<'>2-+L@-6[EAK]RO3()8I@TUD]A0
M2^_Z7K=I=9#6;',=,_)"W!&K@X+(-8N-6K%1K]@_F!!HQ5EQ$ S+B4EHI*4>
M&)0:4+I4 \B@U8"Z*#9NQ<:]8F<I*==4K9 KDG&T(_F6JI5T3S@GI41Y1EZR
M/),_3 [$6H7\CK*9#NGT^[F.P&'44=['<B9[U,H>]<K^(E/*0?62%<81.]([
ML39@=4Q7VA4LBSZ6,VG8.>Z/G%YQGTI)87J7C3YTTPS7VSM44N-TW!">UJ+;
MD ;( (>=N6=N0KE.=V9?F&!>%%X0?K(QQ+W"_X132@ZCUR@1:ZO P,5>U)5I
M@'D![LHTH#!V/*^KTX ;^?$%G>Y1IWN53@3S$Q(IX=60A;8NX!P#^^_EZYTZ
MBF1+= ,#>RN2(_#6Z$V=+CZMIC,,W*XW1EAWQIN;8-XPUKPQP/#0N=0)COM!
MW+O)N<J<),NWZO1PI3W>=?888;H]!IC)'@.LQY[C)@WW[]*^5^=0F@S(#A8W
MF/H/SBCY<(C:2B%A5P.K_&D?JK^:W?'U50"[OA_%77]T8#P*,8ZZ!NDX-XZ]
MH#M6%T9"/PQ'%SPZ;NYP_^[NWWATVI7Z7-)W91=<TH%FEW3<!9=,A :7[),3
M>4'YNKH*$2!]6\KZ.-:6MM<M'ZM+AD[Y [Z?84/Y7%W/5#< 1_KZ;N<SX>L,
MSNPY74$J9QA!97E]75*_2+:I[@->F)2LJ!Y32A+*%0"^KQB3AQ>5H+VTFOX#
M4$L#!!0    (  .';E<]O-RPC L  ,1L   8    >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&ULO9U=;]LX%H;_BN 9S+; NK8H2K([28"IS<5V@5D4[7Q<+/9"
ML9E8J"QY)#EI]]<O)2NF*=)'9'*<FS9.R/=0[Z$H/B(E7ST6Y==JPWGM?=MF
M>74]VM3U[OUD4JTV?)M4[XH=S\5?[HIRF]3B8WD_J78E3]9MI6TV(=-I--DF
M:3ZZN6I_]ZF\N2KV=9;F_%/I5?OM-BF_?^!9\7@]\D=/O_B<WF_JYA>3FZM=
M<L^_\/KWW:=2?)H<5=;IEN=56N1>R>^N1[_X[UD<-Q7:$G^D_+$Z^=EK#N6V
M*+XV'SZNKT?3ID4\XZNZD4C$?P]\P;.L41+M^*L3'1UC-A5/?WY2_T=[\.)@
M;I.*+XKLSW1=;ZY'LY&WYG?)/JL_%X__Y-T!A8W>JLBJ]E_OL2L['7FK?547
MVZZR:,$VS0__)]\Z(TXJ^,&9"J2K0&PK!%V%H%>!Q&<JT*X"[5<X=PQA5Z$]
M],GAV%OCEDF=W%R5Q:-7-J6%6O-#ZWY;6_B5YDU'^5*7XJ^IJ%??+(J\*K)T
MG=1\[7VIQ7^B%]255]QYBTV2W_/*2W/QAV+U=5-D:UY6/_TP(W[\L\?^VJ?U
M=^_-DM^EJ[1^ZXV]W[\LO3<_OO5^;.K\MBGV59*OJZM)+1K:A)NLND9].#2*
MG&G4;T6=9(9J"[C:HMANB_RG'_QH^G/;8H/$$I;X9;U.FPZ<9 >93TFZ'HN#
M622[U-PF-B"X6NVW^ZRUMW-*%9F(A!VS1HY9(ZTJ/:/Z@=^G>9[F]^(DR9)\
MQ;TWHI'5)BEY]=9+:A%J]<X+_+][9$I\4P(.^F&KWPPF#S?QS(^N)@^G=H.-
M:(:P]]4N6?'KD1BC*EX^\-'-P3:3\9AB#$E,,3\XFA\XFF]C^$$S.C'<)[3G
M-QC7U6],,88DIOA-CWY3T&^6KX&>_FM2'HTG)N.I34\'6^#J/*880Q)3G ^/
MSH<NSMNX'5IT<S"HJ]F88@Q)3#$[.IH=77A,!_4=K5A$VFDS"WWJS]5<+C%C
M,B0QQ?[X:']\@5$]UEP:TQF=]3I\K)T4TYZ->@E_2H->*::7&OLAB64XY<AG
MQR.?M?6",T?^,5\)Q*AX,Y4[_/2V/^?[V]-L[S^?BRSSQ!3],2G7_S4Y,L/L
MA)AB2TPQAB2F)&Q^3-@<[*K_%OR8%95Q8CW7.V0P);W^",J[VHHIQ@::K]CE
M3R7C3"\Y@X#57?MTIS8XLJ)&95AJ:@9.*-/'GDETBLIH%_IA;TQ<&(KU!]>N
M2#@PNAJ*B>$UG$W/=#\):_ZE:<VWPC6X&:[G-:H:PU)34R"1S;\$L_DVT 9'
M=G8=%=NPU%37);CY+R&W+WPG[)\"(X 5NL%M</8?%=ZPU%3_);[YKOPV[+D-
MP,%AG2U'13@L-=5R"7'^I2D.#N \V[#D.-2H#$M-38)$.?\2+.?;P9P_3',&
M)>.$PQ 0X#E? IW_FD3GHR(=JMH258UAJ:EIDUCG/Y_K? ,9S?6^B4IVJ&H,
M2TU=,)$,2%["@(/715C=]20@E@R(&I5AJ:D9D Q(7!EPV'43 \93;9UJF &)
MB0%#TA^2#<7&?D1(9!Z2R<F"W0L9<)"'B=V2'>Z:'>ZBW248D$@&),]@P&';
M;1@0CNSL.BH#8JFIKDL&)"]AP'_M\X$1P(H!X38X^X_*@%AJJO^2 8DK PY[
M;L. <%AGRU$9$$M-M5PR('DA PX/.J@,2"P9$#4JPU)3DR 9D#R# 8>--R"9
MX:8S&69 @Y*) 4T!@9O.1#(@>4T&)*@,B*JV1%5C6&IJVB0#DN<S(#$P()F'
M_;Z)RH"H:FSH"-3]6)+M@I>PW>#U#E9W[=R!)=NA1F58:FH&)-L%KFPW[+J)
M[2CM=V=#L?Y0&]BM[QF*B:%V%I_K?I+M ICM7GAK(; ".[@-SIL#4<$.2TWU
M_V0_)@QVS[BQ$%AMQ\3=CXF[(?,25!=(J@OH*\XN DS@6J"J+5'5&)::FC8)
M@P$,@Q^K:M^>(\6=)[)1)LU6_R1?>WF1CU=%7HOSB.>U=\OS=J]ZDGG%8RZ2
MN4EWWAU/ZGW)FSR+HGGWI,=C6F^:SP^\K-/;C'N[LMBF5564WX5JS8WY#K41
M+^I/L>$C<<[B<$2&%5'-C:3& *;&/P_Y\-(N1T;C=)+K7^86<!AGXX8C,JR(
MJG&2] *8]* I<V# JR#T^Y:! 9PMPU1C0T>@FB;Q,  YYL5S%E0>[-2&I\RH
MI(>EIF9 DEX D]YS9BUSJ^400S%MRJR#F&DYQ% ,6@ZADM@H3&Q.VR3,CW7H
MF#6?SV-M2=2RW!)NL/-3&Y? ,2IQC,(X-K@!PFRI@<A$MOM$9BC6[U[40&31
M+.Z-N\Q0;.S/Z/Q<]Y)$1LDK3D\I)BPM4-66J&H,2TU-FP0Y"H-<FY]Q\]SO
M6DPIMSN>5TDSR30F)="[6-#OJ:@ 9Q&18454#3QY4@Y>;/O,J[I,5\W#IE7C
MI?<@?B&& :.!J-!%]74Z&L7]80&5I;#45*\E2U&8I6SFZU3'CC#H/XT!QW'N
MI18A&59(U3J).A1&'6C&3G7@&!-]!0:.X&P:ZLK7X"&HMDG0H3#HV#_&$AB=
MQ>22!36M;TVGXCC[)STJ#F&IJ2F0V$2=L,G*]ID^JPJ(ANV&8MJL2L<D/Z;]
M.\7,4&Q,IA$]-ZN2Q$)A8D&8M.L\89ZTVY5;P@UV[EN7V*$82B8*79G(QM).
M=&C2;BC6[UZA3DJF2;NA&#1I#R6TA/XK3MI#D)!<1SM4M26J&L-24],F62N$
M5[^@BWE75>V<_C3H3]3A$,[VHC(1EIIJKV2BT&EQ"[A19[SZA#JTD'D8!:'V
M4@;+@DNXO<[N7@*80@E,H=/N1"M'J=:G"2%QWTZ]E#;>ZL@4^''8OYP;BC5[
M)LC\S'A[\G(/&&"<MJF9K< DET6HDXMY1HD:EF&IJ5F0+!2Z;A:T<MZ &(9)
M95<,[(6ZDFE2:0H(3"I#"35A_)I7?53&055;HJHQ+#4U;1*$0AB$7&[5A09N
MT68 J%L"+2(RK(BJ@1*F0ABF7&[5P5+.O=JP]A/1:="'*]2H#$M-?;>2A*L(
MAJNGNW7\&R]7::5<ZTR6PW+.+U/2F8D&T:QW6VZ)&I1AJ:F.2YR+X#6HON-&
MEPWK1/W;HW 8UY'!(B+#BJ@:)X$J@H'J=)/.JGVE93="B!XK HY7@K::^<)=
MFHMBS4]#?1EU_2K2MROZQ*?SOHU+U+ ,2TU-BL2P",8PYZ08$V%80?)CTM^.
M C?%N<=;!658055_)8A%,(B=]?>N*+V*UW76OIBV^?-MF:[O>;NY;+#GHZYQ
M13J)A93,^]=-U* ,2TW-BX3$R'['H'U>C+G0\2X(M#M!<'.<^[Y-3(854[7X
MY+V/, &"%I?\01 0%_^O#J\@3O_7SK/%9;69<_-J\!3 ?2ND:3N@. GZIP#N
M:R$OL;\PDH0:P<MN+\N/,2>&M;/3YQ ZKU'ITRHFPXJI6BVI,H*I\JS5=>']
MD639T^?NQD!S\3V;@*'S G4'8Z0#)Z6S2-L!@1J58:FIV9((&\$(BY@M8X:,
M#XO1_CTNN)'.IXE54(855'U5K:39&*99:,TE-JS/13'M;Q*%([C:AJK&!@]!
MM4TB:>STE!KPG*#QIBNL[CIDQ#J)FA=<4,,R+#4U!1)N8Z=GY:QLUX%3OUNU
MB/6E1NTER[I0X!O>LJP7&Y,XF)]Y#6TL&3(.7O%6=XQ)B0M4M26J&L-24],F
MT32&T=3E5G=L6-,CVM"+"8A+FY ,*Z1JH:3(&*9(\'JEOVUD3/R@OZ *1W V
M#74),=8Q4ST$U39)AC%,AB]<^X]U6#.O_=L67,+M=;;M(N_[/WGAO]-V2BM'
M]?=^&-;^#:6T2Y%>Q+3V;RAF7/N?G'P!5//]7K\FY7V:5U[&[T3%Z;NF@Y:'
MK\PZ?*B+7?N=4+=%71?;]L<-3\05J"D@_GY7%/73A^9KIHY?7';S?U!+ P04
M    "  #AVY7%).F=50'  #U(0  &    'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;*U:6W/B-A3^*QJZTVEGRF++YI8FS"1L=YJ';3-)MWT6M@!U;<N59 C]
M]95L@XQU"9GRDH Y.O[.]3N2?;NG[!O?8BS :YX5_&ZP%:*\&8UXLL4YXA]I
MB0OYRYJR' GYE6U&O&08I?6B/!O!()B,<D2*P>*VOO;$%K>T$ADI\!,#O,IS
MQ X/.*/[NT$X.%YX)INM4!=&B]L2;? +%E_+)R:_C4Y:4I+C@A-: (;7=X/[
M\&89UPMJB3\)WO/.9Z!,65'Z37UY3.\&@4*$,YP(I0+)?SN\Q%FF-$D<_[1*
M!Z=[JH7=ST?MGVOCI3$KQ/&29G^15&SO!K,!2/$:59EXIOM?<6O06.E+:,;K
MOV#?R@8#D%1<T+Q=+!'DI&C^H]?6$9T%4H]] 6P7P/Z"V+$@:A=$M:$-LMJL
M3TB@Q2VC>\"4M-2F/M2^J5=+:TBAPO@BF/R5R'5BL:0%IQE)D< I>!'RGXR1
MX("NP1+Q+?@LX\S!$'Q]^01^^/ C^ !( ?[8THJC(N6W(R$Q*$VCI+W?0W,_
MZ+C?''RAA=AR\$N1XO1\_4AB/QD CP8\0*_"%UQ^!%'P$X !C"QXEI<OAQXX
MT<F?4:TO<NC[O<0,"5)LF@0E@F!^8W-3HR:VJU'%>\-+E."[@:Q.CMD.#Q;?
M?Q=.@I]M-EY)V9G%\<GBV*=]\9OL-1GEUEQH5D[JE:JA[!;#, PB&:==%[Y%
M;![/3D)GL,8G6&-O(.[3OV7U-,DLJ.PX"2T2DF%0M'C5U42E>,5EZLNLII>&
M;GS-T%U)V9F/)B<?3;RA^X2ETH2@NJ'B5TD-'-L,;K2,._'I1]"4@/;P34_0
MIEYH]SEE@OS;0)/-*,4K 5+"$UJIB,KF PCG%2H2#!+*A37]IB:J,(A[T$VA
M>&S'/CMAGWFQOPB:?!LJ<DDEMERY]4T7STP7CV$/J2D3V('.3T#G7J#++2HV
M6.7^&A$&=BBKL'+V'C&&"EDF!*U(1L3!AGANH EG/<"FB -P&&BZ"KR0GW%:
M-0/ 6<5F6'H;,,79R@!9T@!QCNUIT=[BS-GS'G2;C",MP@[7AMZ>I/W=Z34U
MS#JAC^YV]9U6^Y4:S[6TG?L":E] ;R"?&"X128\UT7B BBUF<NQA3/9M7P2A
M$9WA+)KT8VB1FCIBJ/D]])+IXCYI6U")#FB568NY57'64V:3H _/E)JZX&DR
M#OUL+.&Q"FNW6N'%9NF&@>$]4VH\=]6O9N702VB=^:@IV4[.6Z&.S1#&??*Q
M"3F+57-CZ"?'Y5NS@16O283#*(Z,T%O$8!PZ(&O.#*?>_O)8[#"_9(()O>3[
M[DYR)6WG5FNV#?UT^U2Q9*MR23;^DJE(B4/=3? _%2G5!&AU@<FFPSY_661<
M!: I-WR#<[MI12P!LX(UF=0$>S';0LVV,/ FU&=2R GK@H2"7M9^;T)=2]NY
MU9JFH9?ZY-9AI^9*#M:,Y@#G948/V!Z85M-9*YWWJ]TBY&I/4/,G]//GLZ3/
M@TINE?;H'8@MI!C.QWW(%JG(E4Z:.Z&?.Y\833!.6YBG^5T:4-!B*#=H.UF[
M1)*JJN-<_D[90?XDK"0+3?HT'&^*A-#E>4VQT$^Q;BO>:X')L(8%%JIV6J!)
M&/I)V&=!GLO9FJL=C&I0LKZ&B=PMJQ:P/C8#JRTF!TN@ACFFE"NI-$]#/T^[
MC5DQDFXNBX3)QR&TP#?%7/ U9T/_1O<<_G'GA5\Q2XA]JPC-'6O8WRI:9%Q(
M-<]"/\_6!SUZ7%/C>94W/"83OVC/9?=$; '#L@[4A@PGJ"0"9>U.WFJ.A8CA
MW-B06<1<%FDNAGXN?M(=U(78?;@ +9P,Y[/^\8)%S($[TK0<^3?!'=PI7F.Y
M6TJ/)?OFF4AD;FR'XW#:0VV1<J'6M!KY:?4,]4I<@M4DSF%H5*5%RH55LVOD
M9]=Z2I.-8T=2Z=O503>_-R:UR"3.R=QTKRD%QXZV'G6.GOWTJ@J4% FK-U:J
M*I41:A"N/ZAI>(<R=2!J!6YR911/^U5HD0IC!VY-J)&?4)<NG  )L,(;4A3*
M\6J\QXS0U K?)$H#NT7$E2B:2B,_E7JQ8W6DX45M\F$4S_J3O46J>XQYCESS
M9C3QSO8O55EF]=,>E-4GJY+F*Z:G,66/+>OM3S.\'/WNQQE7TG;N&4W)D9^2
M'SLS1--6UY0!UAVX+Q\M(I.)H\AX F*1<J6FYNO(S]?/.*&;@EA/T.N416E:
M_RKCKX[BAD1%O2:_VN#N*-7.)=Q&]F*+SV1[3K%W&Y/-QU%_B+$(.0M6<W[D
MYWQ[<,O_,PE$MJ/P:7]+99%R&!/K02#V#P*/MA#U[+ET,(A-RC<.]"TR+AOT
M6!#[QX(OF&W4H:_"I>@KJ])FJ$07G+2VNKN/#J?]-++(]$&/.@_0<X5'O5?
M07W_YE'TZ>KIW87[^HE][_I#>+-LWD#0:IH7(KX@)HF,@PROI<K@XU0ZD37O
M&#1?!"WKQ_0K*@3-ZX];C%+,E(#\?4UE,;5?U U.;WHL_@-02P,$%     @
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M'CU-RY$A!A*B"?,[,2DQ4!@;NOFLNVNY]5UKIU1N&9,4H#3[#U@E72G9>!Y
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MFIPMSI)T=OX:D[^+@(-$5+?#_N\[);LX ,'T+)G-%\GB[.S58J_S7)+' \G
MWS#A,JK5@5M<=Z^880 "(:\Q3(&:&6(?M!S-9LG9=([2MT+T0/V\R4*2F]5*
M6'J@VJ%=M.GH9'Z*=(C%->MPJK] .:*?L$/W*5AK87UDBR$+>0$B%N0HY*<G
MQ\EBG@Y0&"38M]\LTMG9CVX?C2X=#@#Y?[IFR71VDAR?+KY"VYC]KME;OF6+
MK@#$&F9L'J@<8"<AP++J)0Y9-RP8!YG,&U\:*_]NDWDO>-XD&$^7?[5U?(D.
M0>42[IH-FH4K98W&4\DX,Z!OY=(M0[<Y8)Q2G65?@7.; /!7/&8EUX7H,_D
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M,F(V?K2)+][4X4/)TGAOJO!8"IX+2QOP^\I@RFY?2$'_Y>SJ'U!+ P04
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M"VN#T<8A'L+!Z"1( ,-FAPOFVH"",G:1BV(N>1\ID2OT0:B-"VJJ*$LCPH$
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M(UC4FUNQ0EI HP73@I@724()"<%WJ_>VZFX*:%#IDS.5(!D%S"^$FHX(49&
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M;4Y#%[4SH/.%4G8C. ?M&!_^ 5!+ P04    "  #AVY7J'==?H0"  "2!0
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M[X-\'"4NY7T2TW>2Q^P3=>/\X.1XU UR .^YD+W(89=:-8OEO@G=12)=&&2
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M*+P^1_1+9P!N." WL^>>5<QV=@%$HTD0#N,@GDS.)C]-4XX(-#B 721A.L$
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M7*O(4UL?7-ZVB2CJDE\Y8)LBNONAGT%.@ P*)K--XK=<[K!F:$A.>D'KO)=
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M+J]RRJ:5OAT^+ZTI%DOQ#YD5F'T$Q[3?9TE>%(*XU#/M!(/9CRS,?VM3)$
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MRZ62&$EH =[/C7'5#2FHC^$O_@=02P,$%     @  X=N5P[863CQ @  A08
M !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULI55=;]HP%/TK5YFTIXJD
M@79=!TA V<8#%!6V/4Q[,,E-8M6Q4]N!\N]W[4#*I!:IV@OXXYYSS[VV3_H[
MI1]-@6CAN132#(+"VNHV#$U28,E,1U4H:2=3NF26ICH/3:61I1Y4BC".HNNP
M9%P&P[Y?6^IA7]56<(E+#:8N2Z;W8Q1J-P@N@^/" \\+ZQ;"8;]B.:[0_JB6
MFF9ARY+R$J7A2H+&;!",+F_'/1?O WYRW)F3,;A*-DH]NLDL'021$X0"$^L8
M&/UM<8)"."*2\73@#-J4#G@Z/K)_];53+1MF<*+$+Y[:8A#<!)!BQFIA']3N
M.Q[JN7)\B1+&_\*NB;V* TAJ8U5Y )."DLOFGST?^G "N(G> ,0'0.QU-XF\
MRCMFV;"OU0ZTBR8V-_"E>C2)X](=RLIJVN6$L\/)_7P^6\^GB_4*1HL[F-PO
MUK/%M^EB,INN^J&E%"XP3 YTXX8N?H/N,\R5M(6!J4PQ_1<?DK167WS4-X[/
M$JZPZD WNH XBKMG^+IMO5W/UWVK7E66W-*ML@:83&%"<KG,428<#=QQDPAE
M:HWP>[0Q5M.E^?-:%YHDO=>3N(=T:RJ6X""@EV)0;S$8?OQP>1U].5-"KRVA
M=X[]_4?V'W0P+2NA]JY?,,HU8M.Y=8'4N;)B<@\%,T"+J#$%+JT"?($DU%W7
M0T.WVA; ::"RC">H#=B"6:BTVO(4@=P%#&Y1,YF@/YC$'TS-_-M5&6Q08N8(
MN"0H @53 MJ@S/0NVKB3[)N]CSP*=1+(EB!AM4&@A(?]!H&-B%RIE,R&&24[
M,"/72%/NJ"_>D3=3@KR.;A4P2 I&M\N!?2^4N/ L6S3NVCD@-<.2>0(^U=SN
M@>V83@T]\3V53*:5D(%I9C'M +T%IIN$KD,/M$-^]'(NK]VM\,0:2M2Y-T!#
M8FII&Y=H5UN/'376\A+>&/2<Z9Q+ P(S@D:=3U<!Z,;TFHE5E3>:C;)D6WY8
MT'<"M0N@_4PI>YRX!.V79_@74$L#!!0    (  .';E=H.%L)3@X  (XI   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;+5::7/;1A+]*U-**FM741=]
MR9>J*%IV5!7+6E/*UM;6?A@"0Q(1@($Q ]+*K]_7/0< "J(3)_O!%@D,>GKZ
M>/VZP3<;7=^:E5)6?"WRTKS=6UE;O3H\-,E*%=(<Z$J5N+/0=2$MOM;+0U/5
M2J;\4)$?CH^.GA\6,BOW3M_PM:OZ](UN;)Z5ZJH6IBD*6=^=J5QOWNX=[X4+
MG[/ERM*%P],WE5RJF;(WU56-;X=12IH5JC29+D6M%F_W)L>OSH['] "O^#53
M&]/Y+.@H<ZUOZ<M%^G;OB#12N4HLB9#XLU93E><D"7I\\4+WXI[T8/=SD/Z>
M#X_#S*514YW_*TOMZNW>R9Y(U4(VN?VL-S\K?Z!G)"_1N>'_Q<:O/=H326.L
M+OS#T*#(2O=7?O6&^",/C/T#;(A#MQ%K^4Y:>?JFUAM1TVI(HP]\5'X:RF4E
M>65F:]S-\)P]/9O,+F;BTWMQ]?E\=GYY/;F^^'0I)I?OQ.SFX\?)YW_3O=G%
MA\N+]Q?3R>6UF$RGGVXNKR\N/XBK3[]<3"_.9^+1E<ZS)%/F\9M#"Z5(]&'B
M%3AS"HP?4."E^*A+NS+BO$Q5VG_^$(>))QJ'$YV-=PJ<J>I /#D:B?'1^,D.
M>4^BA9ZPO"</R)LDB6Y*FY5+$8XI_C.9&ULCHOX[=& G[^FP/$JS5Z:2B7J[
MASPRJEZKO=.??CA^?O1ZA[9/H[9/=TD_/9,F,T(O1*OVD(J[A5RO%-(ET44E
MRSLZ>%/*)LVL2D566E5GA5ADI2R33.;"6&D5\M0:L9)K)>9*E0(GJV3-ZUE2
MG6*U0FS;%7_W!JWJ#$*J'"9=JE+5,L_OZ+ZJW%["0I.;DG>>T3[N: 542*1X
M]&$RN7HL $T#:E7XKE,C9)F*JJE-(TLKK&:)=9,[2?1EII*FSBRYE=:>?TU6
MLEPJ,=5%D1E&GT>\[GSZ^$!,RCL"(U4K.H_7\'ML!55^^N%D/#YZ+1N[TM!
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M3#_\!(((#G$TR'3?CH$BN]?3DJ8!" K"1>P&[ WS C9#S\X!'X#L2&]0 I:
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MT.BU"=BGODAD&CFPS,YKU_"R=6)ZN,<OEMI]$17<>_M,=.-VKJ)_H-GCA6Z
M]&U+9$X/(PM^^31G(SZ\/#2=/E[GBF=L'4[#Z%%I2BHWP&85*.@[ RIV 1:$
M>SO#;-R&V7AG:'Q6"654]\=%M2[Q.7GXO=9?%-G+RD[MZ@9-2R@#Q"T$]4*3
MV4ULD#H!\J61-7)UMW<Y.-P//BBO^34+ (WJD'O!P.\DVJ@E,A:A0CO,Q5/
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M,Z,_!"H;0.L[23K:@2UP^N>,?P%02P,$%     @  X=N5^DI5B'0 @  %@8
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MF%BLA,Q#B&$>ZWF1W>U6PK>3F=K'5N(UJ/%1(LMLS7GQA<<4L9#]SF&KFQS
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M]8?:.=!^H93=*"Y!=Z$F_P!02P,$%     @  X=N5W\0D4^2 @  E@4  !D
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M#5?TBD;- K2_4,IN)FR@>9>/_@%02P,$%     @  X=N5P!UXV5, @  T00
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MWG$7'M@' A[?='!'8&S=3SZ.XUJ[L5&[CZL5Y5H.^E4Y%T$[!]CQ41,&[O!
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M6@!%:Z>H\>&.V8COOQ=">:(*J@8M*D(->VZX&A]/'R/'];S1Z'"\ G7JH+0
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MN3VL/)$L+_8_W3,I65H<;BB)*-<WJ.]7C,G'$UU O4EO^C]02P,$%     @
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MFNMW!X5)T/L;SM4A,+W0OV3^'U!+ P04    "  #AVY7IC=R<SH$  "Z%
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M*,P4O'-PJ+SQXG1=3"1+\P/JE$EUW,V'"\ 1<+U /9\QU927$WWFK;YQ!'\
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MJY]_J)[DR::\:_]CDN=)5#Y\8MZ2I44#_OHJX</$^DF1H/D1COG?4$L#!!0
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M]/TYY^KE)/F4D'\Z&OX/4$L#!!0    (  .';E?&U8MC,04  ",?   9
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;+U9:V_;-A3]*X0[%"VP6>+#LIS:
M!O(JFJYIO+A=,0S[H$BT+40279**,V _?A2EB"XL,;4AYXNM%^\]Y#WDT1''
M&\;OQ8I2"1[3)!.3WDK*]8GCB'!%TT#TV9IFZLZ"\320ZI0O';'F-(ATHS1Q
MD.MZ3AK$66\ZUM=F?#IFN4SBC,XX$'F:!OS?,YJPS:0'>T\7;N/E2A87G.EX
M'2SIG,JOZQE79TX=)8I3FHF898#3Q:1W"D_.R*!HH)_X,Z8;L74,BJ[<,79?
MG%Q%DYY;(*()#641(E!_#_2<)DD12>'X7@7MU3F+AMO'3]'?Z\ZKSMP%@IZS
MY%L<R=6DY_= 1!=!GLA;MOE JPYI@"%+A/X%F^I9MP?"7$B65HT5@C3.RO_@
ML1J(K088M31 50.D<9>)-,J+0 ;3,6<;P(NG5;3B0'=5MU;@XJRHREQR=3=6
M[>1T_N7F_/</-Y\N+F_GKU_Y" [?@<L_OEY]^0O\!N:* U&>4, 6X%O >9!)
M 6YR*62017&V!)*!6<[#E1H6<,[25 WS7++P'KRYH#*($_%V[$B%LLCEA!6B
MLQ(1:D$T M<LDRL!+K.(1C^V=U3OZBZBIRZ>(6O .5WW 79_!<A%&/P"'"!6
M :>B^K-DP/4@8IV!M&2HQ^;R<1WS8F"N,O"9/=#TCG*=MFD8K#&+V7@BUD%(
M)STUW03E#[0W??T*>NX["V)2(R8Z.FY!?)X$0A1E+<OU]R=U'UQ)FHI_FJ"2
M(T =U% 'UL']G.M1++"69?NOL7 ET#+40(<J%J2'J>^AT=AY: #@U0 \*X#+
M1\K#6#%\QN.0@K4"HY& -W$&<A'I*QK26X7-\*L)7YG)W\*'27_H-0,<U@"'
M^]/O@H9V^EEC'EA3OT;L=TD__PA01S7447?T&^W0#Q+L-U<7NF:)=E^,@%6J
MGV0@W)(1N#\'/^:JK(I_@T8DUH '5A4B QAU2<$J6L=HC<! N\+LQ<(JU@\T
MA 0AOV4AA$8UH'6E[Y:)9(>)4#&1M& T<@'M>M'(Q/?TCN?JK;-@H]>(QAKT
MT/H:B8%>IVRT*M:A:(W>0+O@[,?&X0X;\7#0MB@:!8'65;];*I:IO&V(KMN"
MT @'M"M'(Q&O \W!82,,:[P#JXJ,S""W2PXBJV@=BM8(#K(+SEX<K&)M<Q 1
MSQLVEQ@9$4'69;]3$E:IMM=#Y/?AH 6CD0YT@#GYF"?M/+0'/+2R1F10I]X$
M'<.<(",WJ$-[@G;]"81>RUJ(C'J@EW,H:->BN'T7MD TDH$.\"BG:QXG!0W]
M1B3'<"C(" SJU*.@8Y@49,0&=6A3T*Y/0<1%S37&1D#PR_D4O.M3/-C'+6^P
MV,@&WM>G*&R>^_3-Z70A%<9;NHR%Y('^;G@12-J(\!C^!1OIP9WZ%WP,_X*W
M/I!UZ%_PKG\A" Y&+6]DV"@+?CG[@IOM"V[!:/0$V_5$\[)DWHSRF$4:7*KI
MV?@U]9EXBMME8UL=C=)@N])T.'V.86&PT2,\['3Z'$.+L-$B;#<[^TT??_<E
M WDC!-OFCQ$9;!>93N?/:'?^X/Z@Y46#&!$BSXG0GO/GF7@_,W^(D1]R@/P@
M<L#\L2<Z=/O R _I5'[(,>2'&/DA'<H/V94?'Q+2YA;)UI[+R\D/:9 ?U$<M
M5H(8^2$=R\\S\12WVZ>/L[5OF5*^U+NS H0LSV2YA5E?K7> 3\M]3_-XN7U\
M'?!EG F0T(5JZO:'"A8O=V3+$\G6>A?TCDG)4GVXHD%$>?& NK]@3#Z=% GJ
M??'I_U!+ P04    "  #AVY7^7]35#4"  #-!   &0   'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6RU5$UOVS ,_2N$5@PM4,2.DG1#9AM(VFP-L Y!/K;#
ML(-JT[%06W(E.6G__20Y-3*@R6T72Z3X'A]E4M%>JB==(!IXJ4JA8U(84X^#
M0*<%5DSW9(W"GN125<Q84VT#72MDF0=594##\":H&!<DB;QOH9)(-J;D A<*
M=%-53+U.L93[F/3)FV/)MX5QCB"):K;%%9I-O5#6"CJ6C%<H-)<"%.8QF?3'
MTZ&+]P$_.>[UT1Y<)8]2/CECGL4D=(*PQ-0X!F:7'=YB63HB*^/YP$FZE YX
MO']C_^IKM[4\,HVWLOS%,U/$Y#.!#'/6E&8I]_=XJ&?D^%)9:O^%?1L["@FD
MC3:R.H"M@HJ+=F4OAWLX E!Z D / .IUMXF\RCMF6!(IN0?EHBV;V_A2/=J*
MX\+]E)51]I1;G$DFJ]5L#8O-\O9^LIK!Y-MR-GN8_5C#Y1T:QDM]!1? !:P+
MV6@F,AT%QJ9UX" ]I)BV*>BI%,VV!Y1> PWI #:K.[B\N/J7)K"J.^FTDTX]
M[_ 4+U/9CJDGJPT5J[$Q/-77,!=I[SV19\E<[X]US5*,B6UNC6J')/GXH7\3
M?CDC==!)'7CVP0FITT9;C]8P29\;KKEOR-_?K0_F!BO]YSW!@_\@>-@)'IZ]
MVTV=*RD,I$P74+-7.X;F/8TMRXUG<?._2^@HC(+=<>K@J#O=H#\PM>5"0XFY
M186]3R,"JAV>UC"R]@W[*(UM?[\M['N#R@78\UQ*\V:X&>A>L.0O4$L#!!0
M   (  .';E=QQ5)(_P0  $P>   9    >&PO=V]R:W-H965T<R]S:&5E=#0U
M+GAM;,69;4_C.!#'OXJ56ZU  A*[SVQ;J32<#MT!%86[%Z=[81*WC4CBK.U0
M6.V'7SL)20.IV>Q9@A<T23W_F?DEL6?J\9:R![XA1("G*(SYQ-H(D9S:-O<V
M),+\A"8DEM^L*(NPD*=L;?.$$>QG1E%H(\?IVQ$.8FLZSJXMV'1,4Q$&,5DP
MP-,HPNSYC(1T.[&@]7+A)EAOA+I@3\<)7I,E$7?)@LDSNU3Q@XC$/* Q8&0U
ML6;PU$5(&60C_@[(EN\< Y7*/:4/ZN3"GUB.BHB$Q!-* LN/1S(G8:B49!Q?
M"U&K]*D,=X]?U'_/DI?)W&-.YC3\)_#%9F(-+>"3%4Y#<4.W?Y BH9[2\VC(
ML_]@FX\=C"S@I5S0J#"6$41!G'_BIP+$C@'L[C% A0%Z98#V&70*@\[/>N@6
M!MV,3)Y*QL'% D_'C&X!4Z.EFCK(8&;6,OT@5O=]*9C\-I!V8KJ\O9[_>7PV
M6YZ[8'Y]N3B_6LYN+ZZOP#&XPHQA=5? @4L$#D)^**_>+5UP\.D0? )!#&XW
M-.4X]OG8%C(8)6E[A>-Y[ACM<3P"ES06&P[.8Y_X=7M;)E%F@EXR.4-:P5G"
M3@""1P YJ-,4C]Y\29(3T''VFKMZ<Y=XTCSWCC39=,K[TLGT.OO"V6!&CM43
M[8,%?I9OF@ S>3_B-5''1^#\2;[ZZEN)'\QQ$@@<!M^(?P1F$4WEZ'__DI+@
M0I"(_]>0SUGNO]OL7TTWISS!'IE8<C[AA#T2:_KY-]AWOC2Q-2GF&A*K<>^6
MW+LZ]>E5&MT3!N@*<'4'.)!S)1>2<1"OFRAJU=I2S,5ZF9B:L!^G'3AT8'=L
M/^[R>3L,0M2'J!Q6R[Q79M[39GX7,^+1=:P>(N#12#U>.)N;/<I%4^Y:O;:Y
MYV+]G:2ZZ'7BAAS6\/1+/'TMGJ6@W@.@B2+2--V=:<W;TC IYAH2JV$;E-@&
M'SR/#4QR-RGF&A*K<1^6W(>_]C8?@6U6"RGBCX3)V@[@B#(1?,M?]H2P@/K@
M0*[NSP0S?MC$7.N[+7-](IT\# !!I.H%@(; Q\]-;Z!K**H:[U')>Z0-$SFP
M!Q8ACIMP:4W;XC(IYAH2JR&#3E5[.A\\.10!&$)O5,TUI5:'OU/X0Z.53B&W
M6W8,1]T!JJ_1<[W7UHP,J=49H8H1^KFW&GP'M0) GE_BIR!*HT946M763YU)
M-=>46IUHU=; C^YKH-'&QJB::TJM#K_J;:"^N<D?8;S%S.='LBJ(!<.>2'$(
MPF!%WEGS]=JMN>HCA4X>22-$0X'4(59M$M3W2;//.$J^W  T@L.]*[Y>HS4L
MDVJN*;4ZOZJ/@OV/G@&,MF)&U5Q3:G7X53<&M4W'SJ*/?3]02YE\^8OU'Z=B
M0YDBW0AU\/97A_YPY/1>K_]&6RA3:G5<51,%]<W'FQKI'4;#-XP0[,N_UXP:
MQJ%AK_NJEG+UT?UJ]E5+ _4]S9Q&LN=Z2;WPX(,596"5BI218BG)%HY\5//*
M8;3_*=3>@^R:\EK_,;KJ;9"V?'^[3+0K(?7J;9D957--J=7)5HT+@A^\@""3
M/<S<J)IK2JT.O^J(D+XC^E\EI%Z[-5=]I+H2TE0@.41[9_LM(FR=;6-R"4<^
M:_E.7'FUW"J=91N$=C4\WV>]Q&P=R+DA)"MIZIP,Y#3'\JW+_$30)-O,NZ="
MT"@[W!#L$Z8&R.]7E(J7$^6@W$">_@!02P,$%     @  X=N5Q(Z&*Z! P
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @  X=N5R2,K<$Q!   U"
M  \   !X;"]W;W)K8F]O:RYX;6S%FEUSFS@40/^*AJ?TH6OSD;3-U)TA6'&8
MM8$BG-WL2T<Q<JPI1AZ!DVY__0J()R*Q[^R+PI.#<,3A2MPC7?SU2<B?]T+\
M1+^V15E-K$U=[RY'HVJU85M:_2%VK%1GUD)N::T.Y<.HVDE&\VK#6+TM1LYX
M?#':4EY:W[X>^DKD2#\0-5O57)2JL6FXY>RI>CG?'*)'7O%[7O#ZWXG5_ETP
M"VUYR;?\-\LGUMA"U48\W0C)?XNRI@5925$4$\ON3MPR6?/5FV;20&;TOFI;
M:GJ?4@4RL2[&JL,UEU7=?J/MGRK&1Z:^W!WM:W'-BYK)*:W93(K]CI</33?J
M+D;:;;1Q.'QV0;R4_R>,8KWF*S85J_V6E7471\F*!K"L-GQ76:BD6S:Q O'(
M9',_Z@)AWMU;K:"T2,E+KD[(,&_Q3**4E2AXKJZ>HRM:T'+%4!O"2@-T $!G
M,$!TEE -T@4@W7>$) U$\P\5$FL4[WI#[0&0WF"0P8:6&N0Y 'D^'"2M-AKD
M!0!Y818R3F=^%/[C9V$<(3^:HBDF01HF[7%\K4%^ B _F86<A]^7X33,[C2<
MSP#.9[,X5SX)B0H.2E),<)2]!(\L%PM?@_P"0'XQ"[G Z0RGZ*\PNT&W_GP>
M1WJ6'D-I>FR6[-H/TP9IB=$"^V29XH4*(M'Q0(L8UDB2Q@E.L[MV0+&:>$F#
MI]-!"K$-.\0/@G2)%=C?"8X([D4-LH9M6!LJ:HN0D#B]0U&<];D@4=B&34&R
M./CS)IY/<4I^M,/9RR(VY ?;L"!\0G"&DF4:W/@$(W^68OQZKD%JL V[H8W=
M1Y7MU'P+XD4SX=I4I_-!5K -:T$Q+<*L31[MPQK$419&,QP%87\"0JZPAY3%
M#T?'A&QA&]8%C.GJ"VC('8YA=[RU&CI3NZ*"51]T1,@?CF%_G-#;@5/'!/<B
MAD5R7'-'HPEYQ3'LE=>^.PH("<890#!'(2'3.(9-<RJ3/X/JF)!PG"$W([U<
MZ4#><=YK.X+.IJRFO.@/-&0;9U#;>#HF9!MG4-N<ZY40R#;N^]OF(XJHE+2I
MQB$=$S*.:]@X1S&)ZCC?%PP)'1,RCFO8.*?$^,RJ8X+U+\/& 3%[2<B%O.,:
M]@Z,J2_87,@\KF'SG%AF'.:GC@F9QS5LGI.8W=.N8T+F<0V;Y^UJZ(B 7$A
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M/K\;;Y^_+*\W$>?A!>< 1ZWOOU!+ P04    "  #AVY7G"O3#[T!  !W'0
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M9OG7OP+;>UKKLCGDL^Y_Z_034$L! A0#%     @  X=N5P=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M"  #AVY7T7BQF>X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    "  #AVY7F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  .';E=(
MH-8M] 4  ) @   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    "  #AVY7!;RA2$X%  !#%0  &
M    @($W#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M X=N5R11RV>@ @  8 <  !@              ("!NQ,  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    (  .';E>'BU,-I00  , 2   8
M          " @9$6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    "  #AVY7/;S<L(P+  #$;   &               @(%L&P  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @  X=N5Q23IG54!P  ]2$
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M965T,3 N>&UL4$L! A0#%     @  X=N5ZJ+'73W!0  >@X  !D
M     ("!-5<  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  .';E?F6>G<L@0  "(*   9              "
M@3QX  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @  X=N
M5RR]:72J"   DA<  !D              ("!)7T  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    "  #AVY7#MA9./$"  "%!@  &0
M        @($&A@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   (  .';E=H.%L)3@X  (XI   9              " @2Z)  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @  X=N5S#NN[\T P  ?P8
M !D              ("!LY<  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    "  #AVY7Z2E6(= "   6!@  &0              @($>FP
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (  .';E>#4$_R
M000  /4*   9              " @26>  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @  X=N5_,B\2YY @  7 4  !D
M ("!G:(  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  #
MAVY7?Q"13Y("  "6!0  &0              @(%-I0  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (  .';E?_Z5^C& 0  (L)   9
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M970R.2YX;6Q02P$"% ,4    "  #AVY7IC=R<SH$  "Z%   &0
M    @(&PO   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M  .';E?"H_-<R@0  ' D   9              " @2'!  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @  X=N5[0USAK< @  %P<  !D
M             ("!(L8  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    "  #AVY7*X==I(H#  #O$   &0              @($UR0  >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (  .';E?'P?D&QP(
M %,&   9              " @?;,  !X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @  X=N5VY7G'58 P  L@X  !D              ("!
M],\  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  #AVY7
MGB*8XPL#  #""P  &0              @(&#TP  >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    (  .';E<(FLU/< (  +8%   9
M      " @<76  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @  X=N5_5TYKJ; @  W@8  !D              ("!;-D  'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  #AVY7E5(LG( *  "FC0
M&0              @($^W   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    (  .';E><)#>F[ @  )!C   9              " @?7F  !X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @  X=N5]YQ (_N
M#P  7?0  !D              ("!&/   'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    "  #AVY7L8AVA4H$  !&&@  &0
M@($]  $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (  .'
M;E?&U8MC,04  ",?   9              " @;X$ 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @  X=N5_E_4U0U @  S00  !D
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M=#0X+GAM;%!+ 0(4 Q0    (  .';E<>&LNI60(  .T$   9
M  " @7<= 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
M X=N5T9!#LM, P  E!4   T              ( !!R ! 'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    "  #AVY7EXJ[',     3 @  "P              @ %^
M(P$ 7W)E;',O+G)E;'-02P$"% ,4    "  #AVY7)(RMP3$$  #4(   #P
M            @ %G) $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @  X=N
M5XYA./J] 0  >AT  !H              ( !Q2@! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @  X=N5YPKTP^] 0  =QT  !,
M         ( !NBH! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #D .0"&
)#P  J"P!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>172</ContextCount>
  <ElementCount>228</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>53</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Changes in Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITY</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - MERGER WITH VALLON</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MERGERWITHVALLON</Role>
      <ShortName>MERGER WITH VALLON</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - PROMISSORY NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROMISSORYNOTES</Role>
      <ShortName>PROMISSORY NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - ASSET PURCHASE AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENT</Role>
      <ShortName>ASSET PURCHASE AGREEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - MERGER WITH VALLON (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MERGERWITHVALLONTables</Role>
      <ShortName>MERGER WITH VALLON (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/MERGERWITHVALLON</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - LIQUIDITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITYDetails</Role>
      <ShortName>LIQUIDITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/LIQUIDITY</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - MERGER WITH VALLON - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails</Role>
      <ShortName>MERGER WITH VALLON - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails</Role>
      <ShortName>MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Liability Measured at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofLiabilityMeasuredatEstimatedFairValueDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Schedule of Liability Measured at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Derivative Liability Measurement Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Schedule of Derivative Liability Measurement Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - PROMISSORY NOTES - Bridge Financing (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails</Role>
      <ShortName>PROMISSORY NOTES - Bridge Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - PROMISSORY NOTES - TEP Note (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails</Role>
      <ShortName>PROMISSORY NOTES - TEP Note (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - STOCKHOLDERS??? EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Estimate of the Fair Value of the Warrants and Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Estimate of the Fair Value of the Warrants and Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - ASSET PURCHASE AGREEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails</Role>
      <ShortName>ASSET PURCHASE AGREEMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENT</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Activity of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Activity of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Estimate Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Estimate Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ck0001824293-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ck0001824293-20230930.htm">ck0001824293-20230930.htm</File>
    <File>ck0001824293-20230930.xsd</File>
    <File>ck0001824293-20230930_cal.xml</File>
    <File>ck0001824293-20230930_def.xml</File>
    <File>ck0001824293-20230930_lab.xml</File>
    <File>ck0001824293-20230930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ck0001824293-20230930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="449">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="33">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>69
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ck0001824293-20230930.htm": {
   "nsprefix": "ck0001824293",
   "nsuri": "http://www.vallon-pharma.com/20230930",
   "dts": {
    "inline": {
     "local": [
      "ck0001824293-20230930.htm"
     ]
    },
    "schema": {
     "local": [
      "ck0001824293-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ck0001824293-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ck0001824293-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ck0001824293-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ck0001824293-20230930_pre.xml"
     ]
    }
   },
   "keyStandard": 185,
   "keyCustom": 43,
   "axisStandard": 18,
   "axisCustom": 0,
   "memberStandard": 23,
   "memberCustom": 29,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://fasb.org/us-gaap/2023": 1
   },
   "contextCount": 172,
   "entityCount": 1,
   "segmentCount": 53,
   "elementCount": 374,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 33,
    "http://fasb.org/us-gaap/2023": 449
   },
   "report": {
    "R1": {
     "role": "http://www.vallon-pharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
     "longName": "0000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations",
     "longName": "0000004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
     "longName": "0000005 - Statement - Consolidated Statements of Changes in Stockholders\u2019 Equity (Deficit)",
     "shortName": "Consolidated Statements of Changes in Stockholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS",
     "longName": "0000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.vallon-pharma.com/role/LIQUIDITY",
     "longName": "0000008 - Disclosure - LIQUIDITY",
     "shortName": "LIQUIDITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "0000009 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.vallon-pharma.com/role/MERGERWITHVALLON",
     "longName": "0000010 - Disclosure - MERGER WITH VALLON",
     "shortName": "MERGER WITH VALLON",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS",
     "longName": "0000011 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT",
     "longName": "0000012 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES",
     "longName": "0000013 - Disclosure - ACCRUED EXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.vallon-pharma.com/role/PROMISSORYNOTES",
     "longName": "0000014 - Disclosure - PROMISSORY NOTES",
     "shortName": "PROMISSORY NOTES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY",
     "longName": "0000015 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENT",
     "longName": "0000016 - Disclosure - ASSET PURCHASE AGREEMENT",
     "shortName": "ASSET PURCHASE AGREEMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION",
     "longName": "0000017 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "0000018 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9954471 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9954472 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.vallon-pharma.com/role/MERGERWITHVALLONTables",
     "longName": "9954473 - Disclosure - MERGER WITH VALLON (Tables)",
     "shortName": "MERGER WITH VALLON (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables",
     "longName": "9954474 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables",
     "longName": "9954475 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables",
     "longName": "9954476 - Disclosure - ACCRUED EXPENSES (Tables)",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables",
     "longName": "9954477 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables",
     "longName": "9954478 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
     "longName": "9954479 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-54",
      "name": "ck0001824293:CommonStockExchangeRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-54",
      "name": "ck0001824293:CommonStockExchangeRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
     "longName": "9954480 - Disclosure - LIQUIDITY (Details)",
     "shortName": "LIQUIDITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-60",
      "name": "us-gaap:SharePrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "longName": "9954481 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails",
     "longName": "9954482 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
     "longName": "9954483 - Disclosure - MERGER WITH VALLON - Narrative (Details)",
     "shortName": "MERGER WITH VALLON - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-73",
      "name": "ck0001824293:CommonStockOwnershipPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-73",
      "name": "ck0001824293:CommonStockOwnershipPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails",
     "longName": "9954484 - Disclosure - MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)",
     "shortName": "MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails",
     "longName": "9954485 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-75",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofLiabilityMeasuredatEstimatedFairValueDetails",
     "longName": "9954486 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Liability Measured at Estimated Fair Value (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Liability Measured at Estimated Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-78",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-78",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails",
     "longName": "9954487 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Derivative Liability Measurement Inputs (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Derivative Liability Measurement Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-81",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
     "longName": "9954488 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)",
     "shortName": "PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails",
     "longName": "9954489 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)",
     "shortName": "PROPERTY AND EQUIPMENT - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
     "longName": "9954490 - Disclosure - ACCRUED EXPENSES (Details)",
     "shortName": "ACCRUED EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
     "longName": "9954491 - Disclosure - PROMISSORY NOTES - Bridge Financing (Details)",
     "shortName": "PROMISSORY NOTES - Bridge Financing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromNotesPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails",
     "longName": "9954492 - Disclosure - PROMISSORY NOTES - TEP Note (Details)",
     "shortName": "PROMISSORY NOTES - TEP Note (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromNotesPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-116",
      "name": "ck0001824293:DebtInstrumentConvertibleSharesIssuedUponConversion",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
     "longName": "9954493 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-132",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
     "longName": "9954494 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Estimate of the Fair Value of the Warrants and Assumptions (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Estimate of the Fair Value of the Warrants and Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-81",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-135",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails",
     "longName": "9954495 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-139",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-139",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails",
     "longName": "9954496 - Disclosure - ASSET PURCHASE AGREEMENT (Details)",
     "shortName": "ASSET PURCHASE AGREEMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-152",
      "name": "us-gaap:ProceedsFromSaleOfProductiveAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-152",
      "name": "us-gaap:ProceedsFromSaleOfProductiveAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "longName": "9954497 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails",
     "longName": "9954498 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails",
     "longName": "9954499 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Activity of Stock Options (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Activity of Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails",
     "longName": "9954500 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Estimate Fair Value of Options (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Estimate Fair Value of Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-168",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-168",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "longName": "9954501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-172",
      "name": "ck0001824293:COBRABenefitsPaymentPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-172",
      "name": "ck0001824293:COBRABenefitsPaymentPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20230930.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r371",
      "r378",
      "r486"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding, measurement input",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Calculation",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r119",
      "r120",
      "r122",
      "r123"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class [Axis]",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r111"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r336"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value as of December 31, 2022",
        "periodEndLabel": "Fair value as of September\u00a030, 2023",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock price (in usd per share)",
        "terseLabel": "Fair value of option on grant date (in usd per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Discounts and Debt Issuance Costs",
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Fair Value of the Warrants",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      },
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r95",
      "r116",
      "r128",
      "r140",
      "r141",
      "r144",
      "r150",
      "r157",
      "r159",
      "r160",
      "r161",
      "r162",
      "r165",
      "r166",
      "r170",
      "r178",
      "r179",
      "r181",
      "r183",
      "r184",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r329",
      "r337",
      "r379",
      "r426",
      "r444",
      "r445",
      "r471",
      "r496",
      "r524"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r332",
      "r352",
      "r353",
      "r354",
      "r474",
      "r475",
      "r479",
      "r480",
      "r481"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price (in usd per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r209"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of stock (in shares)",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible notes to common stock",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r210",
      "r238",
      "r351",
      "r466",
      "r468"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes, converted, shares issued (in shares)",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r131",
      "r465"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchased during period, value",
        "label": "Stock Repurchased During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r80",
      "r81",
      "r106",
      "r393",
      "r446",
      "r460",
      "r497"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r349",
      "r350",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r423",
      "r425",
      "r451"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payroll and related",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentCompanyCommittedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentCompanyCommittedCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in cash",
        "label": "Investment Company, Committed Capital",
        "documentation": "Amount of funds committed to investment company from investors."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchased during period (in shares)",
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r80",
      "r81",
      "r106",
      "r391",
      "r446",
      "r460"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in fair value of warrant liability",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r4"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of convertible promissory note",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r93"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r93",
      "r147"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r352",
      "r353",
      "r354",
      "r474",
      "r475",
      "r479",
      "r480",
      "r481"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of common stock, diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r169",
      "r171",
      "r172",
      "r173",
      "r175",
      "r328",
      "r329",
      "r370",
      "r380",
      "r469"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r429",
      "r430",
      "r431"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r431"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock in pre-closing financing",
        "verboseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of notes payable",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities (in usd per share)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedForRepaymentOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "StockIssuedForRepaymentOfNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock for repayment of bridge promissory note",
        "label": "Stock Issued For Repayment Of Notes Payable",
        "documentation": "Stock Issued For Repayment Of Notes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Interest Payable",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r572"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r189",
      "r190",
      "r462",
      "r521"
     ]
    },
    "ck0001824293_ConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "ConvertiblePromissoryNoteMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible promissory note",
        "label": "Convertible Promissory Note [Member]",
        "documentation": "Convertible Promissory Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r314"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge promissory note, net",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ck0001824293_SeriesA2WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "SeriesA2WarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-2 Warrants",
        "label": "Series A-2 Warrants [Member]",
        "documentation": "Series A-2 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ck0001824293_StockIssuedDuringPeriodValueWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "StockIssuedDuringPeriodValueWarrantExercises",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise",
        "label": "Stock Issued During Period, Value, Warrant Exercises",
        "documentation": "Stock Issued During Period, Value, Warrant Exercises"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_DebtConversionConvertedInstrumentAmountOfInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "DebtConversionConvertedInstrumentAmountOfInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of accrued interest to be converted",
        "label": "Debt Conversion, Converted Instrument, Amount Of Interest",
        "documentation": "Debt Conversion, Converted Instrument, Amount Of Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_ProceedsFromNonConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "ProceedsFromNonConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of non-convertible promissory note",
        "label": "Proceeds From Non Convertible Debt",
        "documentation": "Proceeds From Non Convertible Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r121",
      "r124",
      "r125"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "ck0001824293_PrivateGRIPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "PrivateGRIPlanMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 Plan",
        "label": "Private GRI Plan [Member]",
        "documentation": "Private GRI Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term\u00a0(years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited/Cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ck0001824293_WarrantsExpiringInNovember2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "WarrantsExpiringInNovember2023Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In November 2023",
        "label": "Warrants Expiring In November 2023 [Member]",
        "documentation": "Warrants Expiring In November 2023"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "StockIssuedDuringPeriodSharesReverseRecapitalization",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to Vallon stockholders in reverse recapitalization (in shares)",
        "label": "Stock Issued During Period, Shares, Reverse Recapitalization",
        "documentation": "Stock Issued During Period, Shares, Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_ClassOfWarrantOrRightExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "ClassOfWarrantOrRightExpirationPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Period (in months)",
        "label": "Class Of Warrant Or Right, Expiration Period",
        "documentation": "Class Of Warrant Or Right, Expiration Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ck0001824293_ChangeInFairValueOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "ChangeInFairValueOfWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of warrant liability",
        "label": "Change In Fair Value Of Warrant Liability",
        "documentation": "Change In Fair Value Of Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r486"
     ]
    },
    "ck0001824293_SeriesA1WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "SeriesA1WarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-1 Warrants",
        "label": "Series A-1 Warrants [Member]",
        "documentation": "Series A-1 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares outstanding",
        "periodStartLabel": "Outstanding, Beginning balance (in shares)",
        "periodEndLabel": "Outstanding, Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from warrant exercise",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, Beginning balance (in usd per share)",
        "periodEndLabel": "Outstanding, Ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "StockIssuedDuringPeriodValuePreClosingFinancing",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in pre-closing financing",
        "label": "Stock Issued During Period, Value, Pre-closing Financing",
        "documentation": "Stock Issued During Period, Value, Pre-closing Financing"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of debt discount and additional paid-in-capital for issuance of warrants in connection with the issuance of promissory notes",
        "label": "Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants",
        "documentation": "Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable, Ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r133",
      "r377"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ck0001824293_StockIssuanceCostsOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "StockIssuanceCostsOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering expenses",
        "label": "Stock Issuance Costs, Offering Expenses",
        "documentation": "Stock Issuance Costs, Offering Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_DebtInstrumentAggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "DebtInstrumentAggregatePurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase price",
        "label": "Debt Instrument Aggregate Purchase Price",
        "documentation": "Debt Instrument Aggregate Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "StockIssuedDuringPeriodSharesWarrantExercise",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise (in shares)",
        "label": "Stock Issued During Period, Shares, Warrant Exercise",
        "documentation": "Stock Issued During Period, Shares, Warrant Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "StockIssuedDuringPeriodSharesPreClosingFinancing",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in pre-closing financing (in shares)",
        "label": "Stock Issued During Period, Shares, Pre-closing Financing",
        "documentation": "Stock Issued During Period, Shares, Pre-closing Financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "ck0001824293_DebtInstrumentNumberOfClosings": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "DebtInstrumentNumberOfClosings",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of closings",
        "label": "Debt Instrument, Number Of Closings",
        "documentation": "Debt Instrument, Number Of Closings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "StockIssuedDuringPeriodValueReverseRecapitalizationExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for reverse recapitalization expenses",
        "label": "Stock Issued During Period, Value, Reverse Recapitalization Expenses",
        "documentation": "Stock Issued During Period, Value, Reverse Recapitalization Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "StockIssuedDuringPeriodSharesSettlementOfDebt",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for settlement of bridge note (in shares)",
        "label": "Stock Issued During Period, Shares, Settlement Of Debt",
        "documentation": "Stock Issued During Period, Shares, Settlement Of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInApril2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "WarrantsExpiringInApril2028Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In April 2028",
        "label": "Warrants Expiring In April 2028 [Member]",
        "documentation": "Warrants Expiring In April 2028"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Award Types",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295"
     ]
    },
    "ck0001824293_LongTermDebtIncludingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "LongTermDebtIncludingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, including interest",
        "label": "Long-Term Debt, Including Interest",
        "documentation": "Long-Term Debt, Including Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r265",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r406"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r81",
      "r406",
      "r424",
      "r574",
      "r575"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r265",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295"
     ]
    },
    "ck0001824293_WarrantsExpiringInFebruary2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "WarrantsExpiringInFebruary2026Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In February 2026",
        "label": "Warrants Expiring In February 2026 [Member]",
        "documentation": "Warrants Expiring In February 2026"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_BridgeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "BridgeWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge Warrants",
        "label": "Bridge Warrants [Member]",
        "documentation": "Bridge Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIQUIDITY",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r310",
      "r571"
     ]
    },
    "ck0001824293_CommonStockHeldIntoEscrowAccount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "CommonStockHeldIntoEscrowAccount",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock placed into escrow (in shares)",
        "label": "Common Stock Held Into Escrow Account",
        "documentation": "Common Stock Held Into Escrow Account"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_CommonStockExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "CommonStockExchangeRatio",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, exchange ratio",
        "label": "Common Stock Exchange Ratio",
        "documentation": "Common Stock Exchange Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInDecember2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "WarrantsExpiringInDecember2023Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In December 2023",
        "label": "Warrants Expiring In December 2023 [Member]",
        "documentation": "Warrants Expiring In December 2023"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_PrivateGRIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "PrivateGRIMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private GRI",
        "label": "Private GRI [Member]",
        "documentation": "Private GRI"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r270",
      "r289",
      "r290",
      "r291",
      "r292",
      "r295",
      "r304",
      "r305",
      "r306",
      "r307"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r431"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Stock Issuance Costs",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of deferred stock issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r431"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r106",
      "r375",
      "r385",
      "r386",
      "r392",
      "r407",
      "r486"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation, weighted average amortization period (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend rate",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term in years",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of common stock, basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r167",
      "r169",
      "r171",
      "r172",
      "r173",
      "r175",
      "r328",
      "r329",
      "r370",
      "r380",
      "r469"
     ]
    },
    "us-gaap_CommonStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValueOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, 0.0001 par value; 250,000,000 shares authorized as of September\u00a030, 2023 and December\u00a031, 2022; 2,956,354 and 999,748 shares issued and outstanding as of September\u00a030, 2023 and December\u00a031, 2022, respectively",
        "label": "Common Stock, Value, Outstanding",
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r406"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares that became exercisable (in shares)",
        "terseLabel": "Number of Shares",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r132",
      "r378"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity (deficit):",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional shares authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants granted (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r176",
      "r357",
      "r387",
      "r395",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r427",
      "r428",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r446",
      "r491"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r149",
      "r235",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r252",
      "r326",
      "r449",
      "r450",
      "r461"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares reserved for future awards (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_RepaymentOfAdvancesFromEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "RepaymentOfAdvancesFromEmployees",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of advances from employees",
        "label": "Repayment Of Advances From Employees",
        "documentation": "Repayment Of Advances From Employees"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for reverse recapitalization expenses (in shares)",
        "label": "Stock Issued During Period, Shares, Reverse Recapitalization Expenses",
        "documentation": "Stock Issued During Period, Shares, Reverse Recapitalization Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_ProceedsFromAdvancesFromEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "ProceedsFromAdvancesFromEmployees",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Advances from employees",
        "label": "Proceeds From Advances From Employees",
        "documentation": "Proceeds From Advances From Employees"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_FormerChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "FormerChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Former Chief Executive Officer",
        "label": "Former Chief Executive Officer [Member]",
        "documentation": "Former Chief Executive Officer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLON"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MERGER WITH VALLON",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r315"
     ]
    },
    "ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "WarrantsExpiringIn60MonthsAfterRegistrationDateTwoMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring in 60 Months After Registration Date",
        "label": "Warrants Expiring In 60 Months After Registration Date Two [Member]",
        "documentation": "Warrants Expiring In 60 Months After Registration Date Two"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_CallOptionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "CallOptionPrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Call option price (in usd per share)",
        "label": "Call Option Price",
        "documentation": "Call Option Price"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts payable and accrued expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "WarrantLiabilityMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Liability",
        "label": "Warrant Liability [Member]",
        "documentation": "Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesTWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "SeriesTWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series T Warrants",
        "label": "Series T Warrants [Member]",
        "documentation": "Series T Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "AmendedAndRestated2018EquityIncentivePlanMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "A&amp;R 2918 Plan",
        "label": "Amended and Restated 2018 Equity Incentive Plan [Member]",
        "documentation": "Amended and Restated 2018 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_PutOptionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "PutOptionSharePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Put right, share price (in usd per share)",
        "label": "Put Option, Share Price",
        "documentation": "Put Option, Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInJune2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "WarrantsExpiringInJune2025Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In June 2025",
        "label": "Warrants Expiring In June 2025 [Member]",
        "documentation": "Warrants Expiring In June 2025"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total net liabilities assumed plus transaction costs",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_BridgeSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "BridgeSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge SPA",
        "label": "Bridge Securities Purchase Agreement [Member]",
        "documentation": "Bridge Securities Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "WarrantsIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of warrants for payment of stock issuance costs",
        "label": "Warrants Issued",
        "documentation": "Warrants Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringIn24MonthsAfterRegistrationDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "WarrantsExpiringIn24MonthsAfterRegistrationDateMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring in 24 Months After Registration Date",
        "label": "Warrants Expiring In 24 Months After Registration Date [Member]",
        "documentation": "Warrants Expiring In 24 Months After Registration Date"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "WarrantsExpiringIn60MonthsAfterRegistrationDateOneMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring in 60 Months After Registration Date",
        "label": "Warrants Expiring In 60 Months After Registration Date One [Member]",
        "documentation": "Warrants Expiring In 60 Months After Registration Date One"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_DebtConversionConvertedInstrumentPrincipalAmountOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "DebtConversionConvertedInstrumentPrincipalAmountOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount of debt to be converted",
        "label": "Debt Conversion, Converted Instrument, Principal Amount Of Debt",
        "documentation": "Debt Conversion, Converted Instrument, Principal Amount Of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "StockIssuedDuringPeriodValueReverseRecapitalization",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to Vallon stockholders in reverse recapitalization",
        "label": "Stock Issued During Period, Value, Reverse Recapitalization",
        "documentation": "Stock Issued During Period, Value, Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_COBRABenefitsPaymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "COBRABenefitsPaymentPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COBRA benefits, payment period (in months)",
        "label": "COBRA Benefits, Payment Period",
        "documentation": "COBRA Benefits, Payment Period"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInMay2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "WarrantsExpiringInMay2027Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In May 2027",
        "label": "Warrants Expiring In May 2027 [Member]",
        "documentation": "Warrants Expiring In May 2027"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r264"
     ]
    },
    "ck0001824293_ConversionOfStockAdditionalSharesConverted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "ConversionOfStockAdditionalSharesConverted",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares converted into common stock (in shares)",
        "label": "Conversion of Stock, Additional Shares Converted",
        "documentation": "Conversion of Stock, Additional Shares Converted"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_EquityWarrantsExchangeWarrantsAndBankerWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "EquityWarrantsExchangeWarrantsAndBankerWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Warrants, Exchange Warrants and Banker Warrants",
        "label": "Equity Warrants, Exchange Warrants And Banker Warrants [Member]",
        "documentation": "Equity Warrants, Exchange Warrants And Banker Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "StockIssuedForPaymentOfReverseRecapitalizationCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock for payment of reverse recapitalization costs",
        "label": "Stock Issued For Payment Of Reverse Recapitalization Costs",
        "documentation": "Stock Issued For Payment Of Reverse Recapitalization Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_CommonStockOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "CommonStockOwnershipPercentage",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage in common stock (as a percent)",
        "label": "Common Stock, Ownership Percentage",
        "documentation": "Common Stock, Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r349",
      "r350",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r423",
      "r425",
      "r451",
      "r562"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r489",
      "r492",
      "r493",
      "r494",
      "r495"
     ]
    },
    "ck0001824293_GRIBioIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "GRIBioIncMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GRI Bio, Inc",
        "label": "GRI Bio, Inc [Member]",
        "documentation": "GRI Bio, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockSubjectToPutRightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "StockSubjectToPutRightMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock subject to put right",
        "label": "Stock Subject To Put Right [Member]",
        "documentation": "Stock Subject To Put Right"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_AardvarkTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "AardvarkTherapeuticsIncMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aardvark Therapeutics, Inc.",
        "label": "Aardvark Therapeutics, Inc. [Member]",
        "documentation": "Aardvark Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r104",
      "r105",
      "r106",
      "r136",
      "r137",
      "r138",
      "r177",
      "r236",
      "r237",
      "r238",
      "r240",
      "r243",
      "r248",
      "r250",
      "r388",
      "r389",
      "r390",
      "r391",
      "r478",
      "r506",
      "r512"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r177",
      "r236",
      "r237",
      "r238",
      "r240",
      "r243",
      "r248",
      "r250",
      "r388",
      "r389",
      "r390",
      "r391",
      "r478",
      "r506",
      "r512"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r266",
      "r297",
      "r298",
      "r300",
      "r483"
     ]
    },
    "ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "StockIssuedDuringPeriodValueSettlementOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for settlement of bridge note",
        "label": "Stock Issued During Period, Value, Settlement Of Debt",
        "documentation": "Stock Issued During Period, Value, Settlement Of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_EquityWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "EquityWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Warrants",
        "label": "Equity Warrants [Member]",
        "documentation": "Equity Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_NoncashMergerRelatedCostsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "NoncashMergerRelatedCostsFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger costs included in accounts payable",
        "label": "Noncash Merger Related Costs, Financing Activities",
        "documentation": "Noncash Merger Related Costs, Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61"
     ]
    },
    "ck0001824293_DebtInstrumentConvertibleSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "DebtInstrumentConvertibleSharesIssuedUponConversion",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares to be issued upon conversion",
        "label": "Debt Instrument, Convertible, Shares Issued Upon Conversion",
        "documentation": "Debt Instrument, Convertible, Shares Issued Upon Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_PaymentOfReverseRecapitalizationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "PaymentOfReverseRecapitalizationCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of reverse recapitalization costs",
        "label": "Payment Of Reverse Recapitalization Costs",
        "documentation": "Payment Of Reverse Recapitalization Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_BankerWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "BankerWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Banker Warrants",
        "label": "Banker Warrants [Member]",
        "documentation": "Banker Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, outstanding term (in months)",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability",
        "verboseLabel": "Outsanding warrants",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_PercentageOfTargetBonus": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "PercentageOfTargetBonus",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of target bonus (as a percent)",
        "label": "Percentage Of Target Bonus",
        "documentation": "Percentage Of Target Bonus"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "NetLiabilitiesAssumedInConnectionWithReverseRecapitalization",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net liabilities assumed in connection with reverse recapitalization",
        "label": "Net Liabilities Assumed In Connection With Reverse Recapitalization",
        "documentation": "Net Liabilities Assumed In Connection With Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r181",
      "r183",
      "r471"
     ]
    },
    "ck0001824293_TEPNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "TEPNoteMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TEP Note",
        "label": "TEP Note [Member]",
        "documentation": "TEP Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestorMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor",
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r560"
     ]
    },
    "ck0001824293_ExchangeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "ExchangeWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange Warrants",
        "label": "Exchange Warrants [Member]",
        "documentation": "Exchange Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_AccruedInterestForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "AccruedInterestForfeited",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest forfeited",
        "label": "Accrued Interest Forfeited",
        "documentation": "Accrued Interest Forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common\u00a0Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r489",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r515",
      "r516",
      "r555",
      "r573",
      "r574"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock awards, contractual life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Net Liabilities Assumed in the Merger",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59"
     ]
    },
    "ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "AccruedGeneralAndAdministrativeExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "Accrued General and Administrative Expenses, Current",
        "documentation": "Accrued General and Administrative Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInJuly2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "WarrantsExpiringInJuly2027Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In July 2027",
        "label": "Warrants Expiring In July 2027 [Member]",
        "documentation": "Warrants Expiring In July 2027"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_AccruedResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Accrued Research and Development Costs, Current",
        "documentation": "Accrued Research and Development Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash financing activities:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_EmployeeAdvancesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20230930",
     "localname": "EmployeeAdvancesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Advances from employees",
        "label": "Employee Advances, Current",
        "documentation": "Employee Advances, Current"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r127",
      "r142",
      "r143",
      "r144",
      "r154",
      "r155",
      "r156",
      "r158",
      "r164",
      "r166",
      "r176",
      "r185",
      "r186",
      "r252",
      "r301",
      "r302",
      "r303",
      "r312",
      "r313",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r348",
      "r382",
      "r383",
      "r384",
      "r393",
      "r446"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r39"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional\u00a0Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r393",
      "r515",
      "r516",
      "r517",
      "r555",
      "r574"
     ]
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSET PURCHASE AGREEMENT",
        "label": "Asset Acquisition [Text Block]",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r69",
      "r207",
      "r345",
      "r474",
      "r475"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r336"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in-capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant issuance",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r42",
      "r106"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in operating lease right of use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r173"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term in years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discounts and issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r344",
      "r476",
      "r477",
      "r511"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Activity of Stock Options",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r54"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r173"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r130",
      "r150",
      "r184",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r317",
      "r318",
      "r319",
      "r337",
      "r486",
      "r524",
      "r563",
      "r564"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes interest rate (as a percent)",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r208"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r428"
     ]
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r254",
      "r259",
      "r332",
      "r353",
      "r474",
      "r475",
      "r479",
      "r480",
      "r481"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCRUED EXPENSES",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted Prices in Active Markets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r254",
      "r259",
      "r332",
      "r352",
      "r479",
      "r480",
      "r481"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r135",
      "r150",
      "r178",
      "r180",
      "r182",
      "r184",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r316",
      "r318",
      "r337",
      "r372",
      "r418",
      "r486",
      "r498",
      "r524",
      "r525",
      "r563"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r24",
      "r127",
      "r142",
      "r143",
      "r144",
      "r154",
      "r155",
      "r156",
      "r158",
      "r164",
      "r166",
      "r176",
      "r185",
      "r186",
      "r252",
      "r301",
      "r302",
      "r303",
      "r312",
      "r313",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r348",
      "r382",
      "r383",
      "r384",
      "r393",
      "r446"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock with repurchase rights",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Unobservable Inputs (Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r332",
      "r354",
      "r474",
      "r475",
      "r479",
      "r480",
      "r481"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and other assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Domain]",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r154",
      "r155",
      "r156",
      "r158",
      "r164",
      "r166",
      "r185",
      "r186",
      "r301",
      "r302",
      "r303",
      "r312",
      "r313",
      "r320",
      "r322",
      "r323",
      "r325",
      "r327",
      "r382",
      "r384",
      "r393",
      "r574"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r153",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r345",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r513"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FDIC insured amount",
        "label": "Cash, FDIC Insured Amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r41"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity (deficit)",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r84",
      "r85",
      "r97",
      "r408",
      "r424",
      "r447",
      "r448",
      "r486",
      "r498",
      "r514",
      "r519",
      "r558",
      "r574"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price (in usd per share)",
        "verboseLabel": "Exercise Price per Share (in usd per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uninsured cash balances",
        "label": "Cash, Uninsured Amount",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Borrowings",
        "documentation": "Aggregate amount of interest expense on all borrowings."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROMISSORY NOTES",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r148",
      "r206",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r222",
      "r229",
      "r230",
      "r232"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income (expense), net",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r231",
      "r345",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r513"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r77",
      "r78",
      "r113",
      "r114",
      "r153",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r345",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r513"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Accounting",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r47",
      "r50",
      "r66",
      "r67",
      "r69",
      "r74",
      "r104",
      "r105",
      "r153",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r231",
      "r345",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r513"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Plus: Transaction costs",
        "label": "Business Acquisition, Transaction Costs",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, gross",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r114",
      "r233"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of bridge promissory note",
        "verboseLabel": "Proceeds from issuance of notes",
        "label": "Proceeds from Notes Payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r126"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Changes is the Fair Value",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r65"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r510"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r65"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants Outstanding to Purchase Common Stock",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of warrants and non-contingent beneficial ownership feature in connection with convertible promissory note",
        "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature",
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r106",
      "r311"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r80",
      "r81",
      "r106",
      "r276"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock vesting",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r80",
      "r81",
      "r106"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r518",
      "r561"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r210",
      "r238",
      "r351",
      "r467",
      "r468"
     ]
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront cash payment",
        "label": "Proceeds from Sale of Productive Assets",
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]"
       }
      }
     },
     "auth_ref": [
      "r463",
      "r464",
      "r565",
      "r567",
      "r570"
     ]
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes Payable",
        "label": "Convertible Notes Payable [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r113"
     ]
    },
    "us-gaap_CallOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CallOptionMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Call Option",
        "label": "Call Option [Member]",
        "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 12)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r73",
      "r373",
      "r405"
     ]
    },
    "us-gaap_PutOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PutOptionMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Put Option",
        "label": "Put Option [Member]",
        "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r458"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r139",
      "r150",
      "r184",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r316",
      "r318",
      "r337",
      "r486",
      "r524",
      "r525",
      "r563"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r308",
      "r374"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESTEPNoteDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Indexed to Issuer's Equity [Axis]",
        "label": "Option Indexed to Issuer's Equity [Axis]",
        "documentation": "Information by type of options indexed to an issuer's equity."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r62",
      "r63",
      "r110"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r196",
      "r522",
      "r523"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r176",
      "r357",
      "r387",
      "r395",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r427",
      "r428",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r446",
      "r491"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r196",
      "r522",
      "r523"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r253",
      "r261",
      "r292",
      "r293",
      "r294",
      "r355",
      "r356",
      "r381",
      "r396",
      "r397",
      "r452",
      "r453",
      "r454",
      "r455",
      "r459",
      "r463",
      "r464",
      "r472",
      "r478",
      "r482",
      "r487",
      "r490",
      "r520",
      "r526",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized debt discounts and debt issuance costs",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r218",
      "r234",
      "r474",
      "r475"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r150",
      "r184",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r317",
      "r318",
      "r319",
      "r337",
      "r404",
      "r470",
      "r498",
      "r524",
      "r563",
      "r564"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r309"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r261",
      "r356",
      "r381",
      "r396",
      "r397",
      "r452",
      "r453",
      "r454",
      "r455",
      "r459",
      "r463",
      "r464",
      "r472",
      "r478",
      "r482",
      "r487",
      "r526",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r253",
      "r261",
      "r292",
      "r293",
      "r294",
      "r355",
      "r356",
      "r381",
      "r396",
      "r397",
      "r452",
      "r453",
      "r454",
      "r455",
      "r459",
      "r463",
      "r464",
      "r472",
      "r478",
      "r482",
      "r487",
      "r490",
      "r520",
      "r526",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited/Cancelled (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price (in usd per share)",
        "label": "Shares Acquired, Average Cost Per Share",
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders' equity (deficit)",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity (deficit)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r115",
      "r376",
      "r486",
      "r514",
      "r519",
      "r558"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481620/480-10-55-63"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-4"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-40/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-3"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.7,8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "51",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-51"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-25"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>70
<FILENAME>0001824293-23-000170-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001824293-23-000170-xbrl.zip
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M#S(M*;;U>VE0T3JE[FR+OWV:6W6+EUQ/?!_>\,T.3,/Y;V+X-Z[U%218]![
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M4[*+_@7RR0^1DRAI5VHJ_'_TN]EW\3:MQ*.="LJ:^6^B?T<O^31W[FPP: *
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M/PV/MX2-A6T:Y@0:&&)8<L,XIS 9@)9PX2G!,EJYQ'I;(DR+/M#1A(N."$9
M^;"IL(&*;X;M_Y?A3$"YQ7_]*ZQH^.9P^IV\$F?>(8T?NG5!40;T";4H.9N6
ML,&$/-"@%08-PCK\>:!!+PP:A'7$$VCX;AM]V\$2 K3D,I0!M]CBYXHR,Z<E
MK%\L%O0%<&C;PCJT8J'J,&*J+:QS^8/5Z^*OJ/S'^Y7G]</B$V"YFN2_/,<(
M-T'!VHV<3S5-6S@_5B(Y=Y77%K;(8GLDW[R/":;EGHD_*CB&\V1CX:()$L,Y
M\["PD8S=,?R57AOL6H_&VOB\Z)C.DY>%#99(3.?,T\+&8[;']*,=_/KF$W*+
MS1XD",\ TWGRM+ A'XGIG'E:V/#2@^_!0<+I@P-GZ[D6=@B-<8TOTS3263Z>
M^/%#1>&TCK Q(X'AGR/]=X2-&FT%_V\3W[5#$'OPX#?['?]6F&[^CK Q';%1
MD"<7"!MQ.9.FZXW/^Y7TP6P)0G^"@,IXY1??MEX2164/$]\<&@'IO8"-<QS)
MJ^JYT)RP,2!)<Z>GN85JQ3FJ6UVM./?H/NF\CK A+(DPODX\.\=TO,!V7U+#
M<^:@PA^*UMI\C$Y'V!"7B)204A?U7-2%L,$G$7&0P8WUS;FQGHOX%#:&)"+"
M%B\+J'5R81IAHSLBXF"QA"B)A34E1,E']V$:M29L/.B45O&V;1J,>([5I)$7
MMZHU88-1H@!> +VFUH2-5PF)I5,)4F%#6B*JOL.$%=6:L#$>P9&08WA=K0D7
MQQ RR/5\\[!!X^W&[_ONN2\A\4?XWJQ\6=SWBR\-'HRI 7\_)$VI[8JJYD93
MPD5$1&D'S!?,P@4]).L>C7635A2CJHTZ6A8)<#\K2K@@CB3 4^B.3IY&H7!!
M*4E3IQ%JE*HV$VH+!+B74%.%B[$)8[SDR>>J<-&L4_ Y&X9[ZUKDG5C/WFT0
M3(@?L''G[,\%3C0<YU #=!.(;N2):.$"8E*@GT2@:V"B-C;LNZ:/YB70A8OU
M20(\#0%JFU]^1Q_-BP"%BW.*8E$L@GD_12,CF9+/HWQ>;6,^AT?SXG,9]ER1
M-JKEQN<R['FY?'XHFCKG2&8.XG3#0,QB>G@_<2HC@9?+YR(0H';.D4!)@ =S
M'/.:&*=J,D8J"?"$$]E53<9N=PC2/TS"(\3H\ZPDT80+D1:QKIS=<MI3CU59
MWJC4VOF@7[@ Y8Z@U_*Z85;,"]@/A7[A J?%Y?Y-[S@6"/O"12TO@/DWWL.3
M %>@'XKPA(OCBH3X QD=DO" \(0+]HI$>!LBOF=9-N[-<!X,V[IUKXVQ'1K.
ML<F?;?)82C>WKAM-N-BV2"0H2J?B@>2/+EQ<N8C(/_9E>_FA7[BHKDCH+Y;Z
M.:X$RDW]Z,+%=;<&O.'^(G[Q "]LH%5,P.<G=(4-<4JA*S8)YL?[PH99BW\[
MT8']RD5;L^=:125"8:.]!;];1U+@IA0H;-CW3&Z$D92X*24*&P<^DWM,)"5N
M2HG"AH,WQ<P,)V/;M]V76_?.>Z6K(J@*@XBZL*'9W1'QE9@%1(2P0=+=$?&W
MB4L 3(WB(*'P8<(T$KZ1OC\Q_"F JED<1!0^;)A&Q \#<= J#@Z$C2#N(Y&<
M@B%!V!C:[DCHC7W; 3BUBX,%88-(NV.A6?L!AQP&O0$X4(_DQ0Y"W\!@-W9/
MW+N%N9Q3K0L;7RD2<A:'5&_:?:/GV'U3%S8^<2!,/K]YQ6&S,W39CX\<$=BL
M<88^OU9?@<G"\%CC#(, 1\:,$ PF7!@!0]G7W@1CY6.LKK@S1B0#>SW#MUX-
M_]?SD/C&F$Q"VPQN7?/P6&I7-&U#+"4?W0]+PL88>F^ AW0*Y&8T=KPI(;3Y
M8*.&VXW?B%?Z+J&)67LQ/G2 %,L/X]T>3=8EM(LJ"H0-HN2%\KVU9[VBY3/3
MJ"%LK&0%K'OPL$6LGFL]D@"KTBQL=6=Y/Q"]^.Y7<A@T+/)'$A%K^"/YZ'[\
M(6QD14R<'8IUA(VA'$\7[JR:"DY20JA)82,_8N+L4/ZGL#$>@*<W(G'9]G?/
MI#[DO%  -!##-X> D:_DE3C>F)9XOX]AM2.XFIM.S,J3<9K"QG*$Q]B)9IPU
MA8WQ"(^Q$RFGIG#AG,)@[$1CW)K"AG8VPM@?Q"6^X0#">M;(=GG$])6<MR83
M-E)2 )R=2I<)&W$I ,Y.I<V$C;@4 &>GTF<'#\\<%!#Y3:AN"ALGR"U.552Q
M(FSH0!C,G$AXM(0-$9P2,P>*H+6$]>X% ;:6)["%<\PQ:?!LAPZY']RZ%C;)
M3L!628>.OWG^B/C70YL,;MZ).4$+YGXPL$UR@"FZ1\[S?;+?KWP2>!/?) '[
MYY 8%MT\@*3[&_Q!,6AW&G7=,FJ&J=7UND9:'9.T!O56LT_:9F.@:W]'9IK]
M)@BG#F 2K+[*D+9E7C7;U4YG''Y^LZUP>*76:O^S-/^HX;_ TWTO#+W157L<
MPM?!V'"C[TW/\?RKOP!B:H/!YP&<H#(P1K8SO?KW9T!JH-R1-^71&QGNOY<#
MPPTJ 9R9/QC8_R+P2G@[_><;VU&]5OOLV"Z)=JAJM?_Y&>%2L8CIL<*GJXD+
MT,"G8#N&,'M1ACX9_%[ZRWJT@#7ZC'< *-Y N4:TNV'PVR<#<(7 C5 6(Z[[
M6TB?Y@?M>SZ\L@+G=8QQ0*ZBOWRV[&#L&%.0"737]$>?YU'8@"/2VPA,PZD8
MCOWB7M$#L:]G=%"M,5H(@>A"*WHS_[I*O_H46NGO.D!0M>5?UZIJ_-TGNK8?
M/<!AW* T!K^#4R$P?B_II86#\Z.HXU )/,>V%,3Y9_YEZ(VOM&IC_KNQ85FV
M^W)54U2Z_.S]GRB0LIB$@0V70YA1(#%X85Z*^,L9 =ZW _%U%FBOE4%[I>[/
MN]OGFZ_*TW/O^>9IGEH2>Q=DLT\WUS\?;Y]O;YZ4WMU7Y>;_7/^U=_?'C7)]
M_^/'[=/3[?V=Z"?XL_?TU]N[/Y[O[\K*UVM%JS7JG:5[3LG*PQ-->P.!5>K^
M?8/_6W<JY -='#[X=O_XXW_]16W6/O\&VM'UW+L)F .VJ7 E^HB"& R<DN(:
M:+S@)2!?/7."*A]-N!+5GX,*ZL>]%@ #2JU5_I,JZ=DJW?2_)=&<G&@^_##\
M7\J]2SYNCHY2@72O5FTV-E.]6VGT1E7=<%FNT9>I[T@+:^-WU,-)LG#(( 4;
M!I;-2:7GVX:C_'1MT[.(\N-I9RN/07]KL?"?$_ $P!2</I*QYX<E90 ^BA&"
MF0['!)<)#N0Y?<-QO+#OO4<"1"]U_]=?.JUZ\_-2F<'!GB-$*=F?@ /_\V?O
M\?GF\?M_*X\W#_>/S\K#S\>GG[V[9^7Y7@%SX1EL B;655VY?U34Q@?K(_O@
M_IOR_-<;)6%3Q/9$[_I9@:_5CEY?,*"+:N:!=ZN$0Z+\,R(IA?F*"JV74D0W
MF[;GG0=ZO!OF(,]QSI4%GU1&V &#/ZM8QK0R)89?(6[$0O6CO[$!QBT9ARQZ
MH=?*"CK[.=H &^A/J97.6RNE.&M'K40'Q-(9K!EJZ6I@OQ,+]NH$L47;Y JI
M?F2%E"&1FZOB38<48,^/O;NG6]1&HBFJ8SH*V^FJ,":T2%D-?&\4^PJAMY7;
MT!'G@'AAC1U@>%KY9H/,!78 L7^UK?MY0P/,N );(.*W%H;0U0I8H4@5&ZJ,
M,W(2L]7>,@*W1R]*X)MPPD0VH(+JM];1:W]_4:O_&+^4%,,! ??'X^W?E>_W
M?R#'?@>>_?LU0N5O#W^P9^;CCFI-';_OHAHU_&'ITRF0I#9S-L<8C48]QFZ(
M=?L1G;9+70"H\N7VOJS<WEU7#VO>G"(\</-NF*&"9\:X_ P*BA$H3V-B8DK+
M4FQ7L<- N1Y2TWQM*.%HGL6I.;99=$.UWJXV-6TG2W7U=WJCD;O]2S>K']C^
M93A, =T;'YU!MS1^F1S#<CA_S/-TM"J.=O#[TVLPQ=/A&=J!-/:]5UQGYNMU
M2MVOQ#'>#)_L81#/99XN#1'/QOLMKPE@%8GS%I!:*W7;6J6N-SN=6F<ED//U
MY1@ Q8N??*#$JH!A[8%E[2O_F/AV8-GTE@]03:*'?^PDW]%3^"^&:_^+_OMC
MAN=S2-8I%-YOJX_5IZK"2XI\T1$]S]3*G5?E/O R[S:5[==79/MWP/^NCV:*
ME<ZYD=>V8KMG63X) OZ?[[">&HMLM=35-$U7>J_$M2U#L8CB&,H#F'#&H@ O
M*_N_6(M?K)6Z?]'PBB=1/.7-8+];M(!#X!K^>N\_>V^Q4:+JI>YW0_D;FL^Y
MP9MJG7O_ 4P@$.&S''F]U+WN+;Y%V?4M#QX86L[_M<?,"N/O:)2Z':VFMU;C
M=4]F/9D9E9UB_, A@M[FV >0VV/#44A4S@@?8SUC4 :7TW0F>"CE7_98P4#R
MQ[15M#1R* @'*!\V)Q@D^)Y/C#D2:9:Z335E'G[<@@ZQ(<9Y&'KN0@A.;96Z
M@"*0:JV:R)4;:\F*61&SR,7_^DM;4UN? R4D#AGCP167GCQ)4^#8& M$M2D)
M=7_K^Y^V -%I /($#.7;H0T+^A0TQ">6,I[XP02C.Z&GP!/4@E&U#_V/R(X8
MT.Z9X=7.0:TB!3[T1K6NM0H2^-!:.^<3C[]97:LVU--$:;;-4^89'Z %_,A&
MQ#"'BHF3+T\<*CDI-'R#RMFGZ:CO.1^"CQ<,BRBX3@F#\-N8%)"\;T,;/IF)
MYVVB/HG*;S6[[GMCV(QLRW+(:<S!S>T8KM"FJM:GK!;;,6V6K01XTFZDLC(V
M?.75<"9$^3>J'E2JL,?8UC,\>$#SXO#".9TQ>HR4#DV<"0CJK-A%#.A3.A!Y
M\4=TW1M+8R[&^U'\S(?ZM1I(:[#\[HS ,OZ9\GCYY<4*EA&3,(<*CN79LW],
M@M >3-E'MHMQMBO]".4PV08T=N*9&)'N3Q5S2,Q?R@@KJ=^&A(:GT5CV9]G2
M#RJ/ @Z-0!G8#MC:AN/ $UA^A";X/R<V&N!@=_<)?P 6YC9X7%7C^<FJ&FZ3
M)TSY"+EHIZ-*P:H:Q9K@S&SZZ-@G)J&*5]78&K2D+U ^P,I "THP 8T3##U,
MXT8E*^'0"!?/\V;,;QIWS'[,C_2QK!BNI7S0$N?N UG!0_U_P*GP1_1Y^"7N
MAR^&U5D!W0G=KA&$2J?&5K",:5#=.L!R/?%]6)/5>:$<"HUP$L3$K9:Z_TV"
M1:J>#]AN2%Q_PNH(VF OLGK?\JUYDC0[-OOSSCLA$+Q<LNU%EA?(+L I(SL,
M@<&( QSC>R[J)&>J$-!/4X7>48JWW+\2Y:L1&JP0:T&2S-9(NO:/$X<P]-9K
M#5[7,7%8PN*I\JQ\P"];GS5PU?@#X= .8-O&&,L[CB)1V,YC&4&"C]LS?P)$
M""$N"V+FUR3S%XKY^6-UC/V,/597>>43AX[J6=JNS65%;?83HP^VX"1<_I-E
M,;JLT%[RSZ$_,U-?2*7O$^-7Q< K*JX,YPWT%Y;$R:;SXC:=7YH: J%O* X<
MC2B&:8(:\G$@,97'/AIXF9\J($PK&5\$(]!>\ X_LL5 @(\  M,RVK6P&%A_
M",07Y<7WWL)A]'45+%Q"=V:1@>U2'J;Y(8SD:W#()?NC7ZN?H\?6/K!\?]&#
M:-'RAY?L-7K2=A-*5M7Z%2V*H"=-].K.=DZA0NGM:JNY6P1ZU;*MJJ9O%D;>
MJH90J^JMW0H>UVVV?H+.G)/E<;]G,V7^[3*IPI)=>V4.8KWD?<X38+)W23BL
M+</AF;#E+JTY_C7@_L7SIQGA0OH0I0J3/Y2('.JE[EV6*7#X'KHU!)5AGAU;
M3KR?G9QX6F8^72)ZM^4S"KPODP 6"H*L=M30G\SFJ]0I_>Q6%%8\PKK)-K4E
M6:TGJPAT?U#(73/ K26OQF;D=<"RXW/,%PU6N+A8>I;IE]N#K,@PC0>#-G4]
M&LZ=!,P]AG.R61@9;<?@8>.[G"F^_,V&5\-K%1>.YJ'(?K4#JIU=PS6Q-Q]T
M-K8%X<,X2M,R?"M0L _(MK++Q*(4U0=C/CDUY^[N%%7<<%A !^?;'8*%WF?3
M MA\C+73 K0-Q@6<$6%O'U$*AL1Q(MI7/@!%T\@.:R3=(&[RL:K\-PE$H*88
MS3)NO[7)@T2P0B7-LU1KK4XZ"V;JT<#FG??*QNBH.ANC$[<O?*/I+)#K$]=F
ML*4U2V RSL-;*P%+F398E<'OI=N[;QF)<5H314NBGN@2]Y.0BGH@A'ETN)-1
MQ?)HJ!T7!/4-)A.L58N1TRYU];)6;Y;U1CRN(=IIEU55!1$?9Q1BFZP\*\"]
M*&_$)XHWV\N.,=*"E1L?<42LMG1$[)(JJ2W,,^$S=)M/B<;+,616[\*S>H>?
M5K)VQ!6;O90^S04DCMK56K.9?RIF]Y$6JY95X9CJ9LMN&)<Y3(_OB4OB-YSI
M]@"2-JO<?4'1J/6C]TKOHB\/-YSAX-UD&PJH3#5QP#>FU 18G-MH".P5?N@]
M/C-_Z;:J9*B'@\<5)=9VP-JWV[O>W?5M[[L";LW]XX_>,YV9?SCL9<UC/+Y=
ML"2==T $9KTQ#P3J2Y!U=I)R29CDF"C+@^>:I>YM2$8\)%<]<T%Y/DC[%@?S
MX\LOLYP@*2=%E)/-O>7D 2=$G88'P?6EQC:M(RD<0W9*W2^& PQ)E*<A(6&
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MZ*OM<(;]9JMQEJ?N$%U@]$8>[(7=F8D1:HOT0\6R Q/.!_K$<$%A!,$$6WT
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MV_7Y0?P7XC/%@$7QSL1BT\\,D[J> 6H3C*]*)^=R;<"-QKAY+F:M&3T]$L?
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MS//."H]M4R#]E^$X(+T>YN1;L,2N/(U8OG>5'M"KHR#[:C6-$R1G!^4#1I[
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M7F\2@A'G4FL(] 2QT(8"1IX#S_P[J$X!^8 (@"?YK>%(9:#]X -*MO@SF@'
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M&S2>^$"+ >WNL%:[]_2))<&?Q-#BV<:!NN&5! TG_Q<):<)FH<EDA#%]^%_
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M/IS.U2RBG6$\;U[JK%.0E*QB :N ;(W)/0^ S![E7((*%)Y5Z UR"I[L<Z%
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MWNNE;KW6*+?UO*+@IZ1V*N8_T?K 7&I#@4P2MS7ZGNOAE::CV5#^9>7=6J.
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MZ&=BQ?P+ZN54T%!@2S7W-0-[!I<IJ)@;^2W=JE*\"G1.P\7["Q4RV;+N49I
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M6N>+7$9Z'PNZV2AEA:9VI&*Q!Z(YE]Z@1GO,K#F5;<!N@;#]P"9NE^#-(E[
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M+WZD1<I)NK?ZLC"G,_EEFEB5,';,*" 7/1"XIS-Z?NEWK-V"307_\00F?41
M.3?_]7]:W<%GU!V-WZ:COQK_94UGR"QKQM]^4_FJ_V-YU"2+>TO59;* 8A\S
MB_Q/BS&$X=?AY6V1E9R&]K%L*32.29UGYES@S?CV=<@EN=A&P\8:[A/F.YGN
M"IE&05@&A:VU&JU6O0=7QUM1F2<_]&++X=>_?J777('Y"KQE%E(_CDQ[K6QM
M'NRG!A^IYDR9I!TM)^]):*U*/>!JP$"QX USW52_4LQ3J.MYLWS%&(_6>(=6
MT(QDDQ244JZ@<)U[!SV!4=(:U9AA%3IE6FCZ6[X_J$QSIT0A8KHI:HT?',$)
M[-DFHPQ(64SNRVZTH86WF*R/O4IHNR"QF)&IL\L79_PDL .,UD=""BTXP8RK
M8+UYT9Y)#"4;E9P22SSI(A0$4P@4+(%]IOV _@>W0"VG\;S88&EF.;:AY[2J
M$CDZ?_6-*Q)I/ER03S**B&*F:P%YCJ0UA),]I6Q?A 0:8"SL#*1Z<YF#P5(/
MA",VVW4F#@,):P<0Y($ <3N:I\VBTH[)?T8K-J%ZF.2:YC7JM692QKBRXU@E
M;J>D/%0CW*1(-(ZE(P=;+XBH@O)^C94B3R-MR;2\%PE:']:!1<=B%+'',V9C
M&/].]#[=JEU8=$'1_7%Q(_-X%C)WZ$-,;9>_9_:9V5.ZMA5XG!A/+NXT(1G^
M@?HL*'7$.QZ$J[J:>"&8$+'DKB/+^WDH55T7@VSLHKORH'WHKGP(7%8B5>V9
MK9"K:J11#F+@A*G6\.,!)R%_]ZFE_P65&"X9D,7U!%@H4D$X;* ZJ7[0-&3-
MH H/S*T/I7J:=BT&,:&9[,JV8)L]3'MV4L461AMA:W9X4B8+*@<5N2<E&; Q
M# Z9<ZU9*#ZI?WP&D3ISK?DGQZ,STH\^9U?OS'*#YHBX^>N4)];JS!?ES%3Y
M9OEUC;Y:&'_'WP%S[3:;2[^NUQI+OUNU;*-5ZW67_W35LJN_:W4Z+[/9S6"P
M9B[MV@G,@]RC!<,J6?*_SDC'_CKN66>"6\Y4L.%@F=F]:V&DS0EEPD&RPCF,
MY(\S\+"KYOQ6#WK(;#>8Z[T+P.PC;)IEL$>Q3,\GQ6H%C%[KR8\PJEJJ3%H
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M95DJ_3&%: UQ)8%%%DSF\@7/04.F(DH=^KAK.&O7[/5[9K,Q*+/U8[X 0%^
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MS(2*E:5'GZOY_+%Z_>=:-31]Z3%+UYJ6]:&:K>5JMB!,O)*\,\T/U^VN A2
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M19P5(@PC&IWZ)8,%0;.K1O0!T SFL%\M.'W/-0J:Q@1M.J:X?<!)D'6W[E%
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M[P9B\C.T7!2QWCV"PO:F8X^0X1*"[?DUI)B6F5]>0;S2A6*UT+12]:8?"5V
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M=:B\$<PV^;SV9&A@@&9\^)-"<ZA!>IP/JS*[5Z>SFO_7HFI@F.+9&@176'7
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M:2KW+MJ'/03PE)-_E[DCFRV5FNEB3+7D:4L,9+5);WW1JD=2[#LAUI)W%VW
MENYM-P$&SF6V68&;1Y.](_L]*. V2A\4CS8W+TUZ!-,^D**IW+MH#O8N?<1\
M<8:+5;_X.D,\S\TUL3@57"1LRM06F!F\-@%$,-HD%71QS>];[H?35P.8#ESH
M1C+>=1N8R_6<X-EL<% 83[^^)UY/0JJ*F+SX>O,GLXQ**[(/!1G([&KONQS)
MZL8 -G-MC7 F-)]AN#JZ7>7!-^/#G0Z$G>BE@S34FW@NDRU70-11_OM=-+O)
M=>]*?P_09 OA]T,+K4QF5B $'FIE<&;@%+UF47"9(M>&N?9M2ONAPR,YZ[MC
MPSHR[X %\]3'T7B1.*V"J.:QA8B)=D0T#GRPBI9I(D:G9=&E,0.^1="_';JM
M3I;FDFXDT(:)H\O:-RD9R3%2"DI)#%0R9 ?SD* XZXT/VCCWD!OZ;)K(M3[Q
MMY5EPU3 .TV=5L&QA\WDUA+_?9W(-I%=E\WD"F:E(C%21R'(.V4"?-2U_261
M$X/PV3\45'T*.ERCF5P3%:XCLMZ:R7$?HN8B ;)0!P"66 <"<RBT+EJT]PG-
M9DDR3Z>9W%J"7ZF9W#I2:WA03L;3TY<UNQO'GZH%4.OHYV:>=)S."@VFZ!K"
M"@RBD[4[0K9D^9DZYG$52X@><,,*HJ^NW\G[GKTO!V<3V3;,EJYXKI,K#CZ,
M$><U/]]"O'335@"YCH_\"!%6!M;OZ=M&AZ.^%-!PDU\/K'/%Y(((VI'?H+20
M$'6B]X.[Q ,OGL65,J*>-DON.=]W2))UY-Z5!4"'V(O!Z&B8%D=9$<KX$AQ$
M8R4=B4S37HD9>)$VR(1"*;:1 7#K0?V=_QWJ9)EQL(U .ZB^?#<E2Z6N=UZT
M7FM$1\,Z>V;.<<V+XLD2O66M-<^*?'VO(*D4DA-<XNW!8 UR(1\ M"_60WOI
M=U!J<PO3Y<FU JB.KM>7 MK-#7M#Q8VZDGH'-ZK+P07!N8B*USD6G,!9>@.8
M\B 2+YQKVMU$ZWS8'JGPR.UZWTQ81]B=]*6]*@R]/,#(T"F"/&4A2JZ=TLE=
M1AVA).^S4[FPYO/?[H#H_V:]@7+NK]#?0+(=F ;7)5QOPR ?#1?](A;@'&:N
MBBA0D E04==^N$5 $<@,U\QGV3KQZT% ^T"!=A+ON5_8S=97P>F$ND N-H*2
MVD(03H!.'J5AS)7FY;=/NUEA5[9C!_IH6)2["LJ;/?%60/EGT\(F.MZP:>$&
M"MI=TT)&;C0//H- AW43%N"<T2"MLCDYFP(/>T2C1DT+NV?1.GKI@#U7U<J+
M$Y59M)PL<W!:.E "Z42U-:W:)QD00[;-<X)N07BR+0O7TM3MEC);B+F+!F/+
M4J=GC"].*,N=A&P,650N2_#%(_!0#);LN!/-6XS=!V;?S),V4F_8 .)!8)>A
MWQ6@=62&/ !K-[9'(P6N0HLMI-_%%<<#$ -WT<CB0,Y*U!,CB)CH#Q]5*CYD
M'GLIV=VA-=$_+]81>E=QL/D!>5F:M3C8C(U2AZQ UBG;JC:TJ"84&!&<($6Z
M*#;+AEGVM)U5,6VODV5QL*T%VM!2^+8'&HX'.#G@MZ!%$VS@T0"7P1(T36L-
M,D#D)7B7A2ANLQZ4RY_7G[8;:V5I6[GM1=K5>[V )FY!HX5%YE0&K@4'A;8&
M]YD'^C[J:),QMULSK*=ML?_:WD:D#=.*ET![?PL9,BU-3?A37GI0,5KB80WQ
MBY"+3]%RZ[=0]ON]WL>W%VE7K_:+\2!_P%O G"Z>Z)Q :I5 &9X@YBR@6,51
M!NF,V>S(7O:T/5/UU@+MZK4^_)(^AN%=:!B*UY%#D$J#TE[4#"TZ:007:+0P
M)6[6$7;Y\_9,VPV$VE4WX!=A^#N.;P'3F)V@30:2#A%4K6+S,C'(S%MA*N3;
MEWFKOME+GK9GNMY:H/>F'_4Q:.3R"FM4#B?3P7F8TM^F'_%U&(QGC>5F7UTN
M+@SSP61R<3Z[H)QT,IJD 9[NAIFT%E:GXT\2#TQD%D'.LBV+4.!%XN"B3C8Y
MAD6TCN-T,O[DH98NO\ZZW<U2B(Z&GRZFIV1^"T'')O#::EU9>N^BDAF<3%);
M)32[/=2QTY8ZM_$]E6XJZW!CG18[6^FCBPS=!R[H8XW.:&^ V=KT)9M8MV@R
MOF)*@IPKJU<KY-F'QBK;\*&5C)]*8Y7[[VC):&-1: 3TW-0[EP(^VPC&9!Z"
M2-*Q7BZPGVK(:RUMKQSR6D?J/4<T5H'V9\AK+06N$=K81/H]$T19Z^K\0G#"
M!'+P<Z(M510@>UC$+!@ST3QW8FP<\NJ*%^L(O9^0U^WK #*=EGN-=6I<3@7(
M-")KR1D'D5L)J5[R6ZX\FKRJ:[4]G*?EIZ^EU<>#9EVHI ,#]K9!7;.,9B\/
MLT)[$0-H61N;JB@@ZJ @6LX%*]&IF!OO+/=AV3=3I(G,.YCSM@S79<;9"L@Z
M,D3N1[4;.Z2-]E:@Q!:B[\ *>0"A*VB]+1:XJ#><,C,(Y'V3FQ<R8BZ:?+]G
M3HI';)"^.;&.Q'O@PJQM^C]&9V$Z.*,C\+)"2MI:A.\@"Y=!V>3!R5 @L>P=
M=S%*WS4ME@+KW^QHI<E'"+*]&GHP,.JLPC3%7+NG+Q#:9*2F%P(TF9>+H0W1
M(EA%D'6*T9;6=ZJ/H]I;EFRI@!ZVDTN$KP:?!QF'^21,<8%4))62DK2?)IEK
MW2Z9ZPD%G=IDA&N6%+-]4>4NNKVGS)8*Z<%D/1E,?G\]1CRJ[4%P,KV!-"BC
M9'%DHF,B@9@:@@W)@%;&&2S:1FQ]N;HZNKVE3B.%M&[&53WSF8&6,/!81S;P
MVDI7Z>3 <>1 QR3M>JPXGUMT6[MZX+[XLIM+L0M5+ABU"HR6G=.N']U_;[0-
MA7];?5M(KG7+LQMPT(IH'!=@K7&T-:"J ^\#I!"T4BS*8OES4. #;<O:ZF\=
M@376VS^Q7J)>#0&\-"FM\4YJ!LCK;:J6Y/@:;L#G0)"8T$:O5+WWB :7/KSG
M]F2;JF'44H;W>F[]YGA=34Z[3MF8CMXNVK?=:*+2<6K7NC#ZR.C:2C2=)G(%
MHP.W9.HE[XBUF2EPOG@(AK8>+KUVJG6+J$X2N1X=PV1]2=(@&3I>D#EKR'3R
MZ*K%B;S0#YW,K=N?/)?Q5^MP8.WQ5^O(O:\:\T='/I) I&'&@*MSW!0) &*L
M6WN=D\Y\RG*UQJK;DN6Y#.5LSJ"F&NHJ#G\/\D^#<:A*F$_0/K7H@K:6D2&@
M(B@5)$1K:G?2K)B1,F+:K(AII<<_9X9T+.P.KJ0>]+2YLTDE#9DA R5$K ,B
M#4B=O,A)!JU;AT2>;$KH-OM%*QD__910E<DYS*;.[7&6_K 90I ,C"I1EY(-
M^8??=4KH.MI>.25T':GWG?&W K0_4T+74N ZJ7\;2+]G@M!YZ24&#RXK@AB9
M 5^O\)72D7NN7)*]S/A]DBFA7?%B':%W98I>9QZ2041NU]'PS>CSS%"K"KL<
M"V=$\(ES"%H%.G5% !>5AB1"TL%BX6&SW@FK//UI)7RNI;-EYFAS@7?5->4N
MT%>8;@,M+N1@HX42$@>5%+T:UI%YAM:BSB;IO%EN\"I/WWMF;"GP_O:,__=B
MB 127]*7'"FC' .6I #RGQ""4^1,&5(WYR@*"XU8\>V3]YX16PBZJU8-=T&^
MQCB^"..O!-1<)JPG[ETP'CS+)(H0#/EM,8"T&DO,-AC;:I^X^_2]9\66 N^J
MJ<-=H+^&BM$N,$HLFLXV"9EVK]H[5 %M;@RT\87QE#SCFS7@>N3!>\^'S<7<
M<.C,HSO9V4V0IAA:,"O@/8HZ>ZM S/5BQQ?KDI%.R\VZ^#SVY+TGPQ:";M@]
M_A&0!Y_&@[/:BFR!T@=BIO:YFCF>#& =P)<4P1KAA8LE2>D:T>'6H_>>#]N(
MNF'SWD=0&O;K:#C].#DH4QR?X(?!9#J_KW\5IG@\O,HD9=D)1AP.NG8ETU[5
MWD4(W&<RBQ(S3&[6$&I31'M/GPX4<Y=5=A>L>O_'Z,K]MMQ*LJB9YXG$5EN#
MI$*R<SH&QF3"V_U:NF'5%:+OFU6;*>8NJUQ'K!+J ?"7QZ[2* 6/$'D(H*3B
M9(0)#O6[QC@1>&CE *T 9^_YU%HE=\GDN\J4.WCW[O#]V]].7O[]X-WAP<\G
MAX>_'KYYWR#W[>$/;I7-M@;\1OEI+RXF@R%.)@?IWQ>#R27NRQY")E9KUX'A
M=>![+15PEA?(AMG$!6?6M$Y3>PC/UO-.QJ.$F">OZ05[%VITD[Z3+])T\!D/
M)A.<3DZ-C])PE4 4YFO>5&WGR!CP'%.*1C!]NQ_J]B-0'D75_X;3C!5W9J&T
M54&G_<66"&'RXNN-K^;Q<%>T"<$EX+SF1&5?)Q8K R9*X9/(B*)UVX9U,?:5
M=M(9;3I5RJY34NX=J5ZD3D+E##4R08NHIZU.!6Q4P1OOBTXK)<\^DM&_[-F[
M3SSI0M&CA@)O78NS\LCU54"V++E:%5C_!5G;ZW#4EP)VQA;$HE!&<@^T)CO=
M8ZCWUQ:2X,:Z6%#@2BUCGS9+'JCZVA%)UI%[5Z'F@S#.G\/X]_<?<1P^X<5T
MD"9'PW39N9Q,*:>L X*)H)QWX)@*P%5Q6H7 F-K,J7[PL3U7BG6CKV5N=#MA
M]UU8]H)\S5<OCW]]>_CFW<'[H^,W;^J-0+7(6]6,/?Z$IN5@:RZHD2=]2&(9
M?45\A^//@X3O"!F^(.;E.A*;-JK9#<K!V>R#Z&_'Y033Z,-P\#^8YVGT+T>3
MZ>3:7K8E>*Z1[&6!M1. (49Z+L&X)%WQ)I72>AIGXR5L[8K5Y\<[SZ_751]F
M[_*+K]>_\C9\K=\Z^(/>PSL%"@F%+M(+<'4.@'*H@![G01N'3!KTG+6^R&@&
M?@>3W'?(Y#N>WTXXT,6]PG(IWEG(B]L+F<^.O5G$^N9BGIK C<\R!<C*Y#J@
M.$ =4 $\V**]TE&JUN-:FR_B3W+OCA,=9,EOO* Y_.-RD/-,_^%L]GN3@XOI
MQ]&X"O^4(2,SS%LH)=/[:U6D-UDK,N$+.N=UMLVG$W>XG#^)_Q1XTD4QXK9+
MN[.@9!5#J1!X9 Y4TG7PD",'HAAZIXLUKMBG1OP_Z?YT.-$P0_4J('W=/.-E
M^#287KZ&)S@A<6-^/1J_OIA>C/%H,KD(PX2GTF@FLO$0@J:W4D@+,1)J[A@7
MAC&2K&],XK5!?M\D[5:G#7-CUQ+>F]'P,TYJHY_Z/DW>CVA=-W]>!?AF-/T7
M3J]%.Y/!PL0ZY2KGP&JGSH21+*H4:U9XG=C*Z:#A(7!4NW##MUW8]TWVI\>=
MANG"G2]RK@[:$!;?JK_'3RW:9*T2P$TIM:N:!*^Y 58X;0?"D2G6NM5"ORO\
M\Y5YHFQJF%E]-Q#=1@?S:#6YXJJH$J"DVE\N&PLNQ@0Y8#1,)8.N]6'2R4+Z
M2BAY2OS?/2-VG:ARE<1U%H97H50? _>,8)M2Z_MK/QE?HH#BZ)#S(2:+*S4.
M72=C[L;S=Y^HLC,VW$ZMVU0K'=P#7F)9!%=70=-1!Y5OD>RF:<KFFKE'Q5N(
MM7ME\Z)+UH$#2F5 !:TA2JP<-B9BELJQUIY^'TI^I %*5SI>1YI=Y9&\'0\^
MARG^?')4P5VVRA48.<,,SDD%RKG:)5=RB%IQ0;ARR;>NXU=,'UGVM/XM[VW4
ML"P]9&L9=M6IY.!\EOQ01S^3X4X0LZ"?S2?K'0T3F0N#SW@#<PJ<S"9>R)-5
MLK9(9A"T2>"=L$QQ[0M3&^E]32#/GQ)=2KZ#;7[FT5V-V7+"*YZ3 Q39@V(<
M:[&BJZ,DC%=26=N\L>\W /ZT^[;7RRZB7Y/[0AW7RQCF6V_:*FOJR'SL8CV[
M,4*WH,FZT:R^=+R+!(9-UL:<3W46 3 F:F%F+=9,J<XH*"QI'IRWG62?/0O>
M/F)7/W':KJ/:#NAZ=09=1QVNZG-M22Y%0%T;P#L?H Z9 F:40:L\YN:SM^X%
MT[^IMGM=WW=YOI6B&OH WP[$"3K+F%% ".2-J'K/[G(L$-&1E2N-<*;%[)@G
M-)-KU];;YO+O<)K7*C#V;YK76L*_9QK4)I+K<)J72:P48V.-EB$HSS/0P5EH
MCR%\3FK.W4IE[+M6X$K3O%KH;QV!-=;;K^'+X/SB<C!L0"DS,[I.V(B@A$'P
M7ALPUHNDBC;6KA1$?T1SWSQT=].[UA+[J(7,=EY<=3V>:F8+W"EMJ)-?AY/N
M2J_6?'ZWA5G;"..)EFUQ)JR*A4Y_8T,E8P:G$<'QXF.TR6>QDWRQ_LJV%D_"
MO!S(0J>G7"8G$U.@;9&@.+EQ+K%:$BDBTZC0Y]9=\U=#]OS3?-;AX)WKQ/;:
MZ[1+2TM#7AK4-B4'Y(IQ\O#H('&69= .1<D^R="^Q.3/])PVO-T](YY*>L[1
MD$Y=?%<C2O7C?EFL<V8KZQRUT\D"C\Z#HG\,CF0+6DE62.K&-"\J?@#.?ET#
MK,6543<ZZ^".\1YHBTNQ5<!U%)MY$-AN@BS-U+@:/;;00>]$D3GQ$)FMPS9,
M;1AI(2A7P"%B\:Y()EL'C'= D$>B&;OAQSJB[X 7M8"(/O#CP3"_PL]X-OI4
M,2X,R<N)"S)Y%2U!E)S,210*7)8)# ;NC7=&J-9]%U> U;\GT%"1HVZUT(%1
M_S,.<1S.".%!/B=1S]O.?L9O04:)UD;+:LOU3""=@5 [13I1O+4NJ^!;&^DK
M =LGLK37Q+W[2O_W;@>3R<7YO$+K-[+TIJ/#R71P3D)\'0;C?X2S"_J=1057
M#[=P&Z#IZTYN6T$UNJ';N'KZVK$47F7D1H L(A%3D4'P*(%[\C:M$T*V[]&Z
M->J==2*X4N\- M0W/TTQ_V-T1A]S-IA^/2$BG$;,28GH@"=&)T8=LT?6BP3C
MI<RHDE/]I[9LOZPGF+#0EN/-&A1T1)6N^B]MTDCJH26^Q_$Y/_6(/"@>2=ZT
M/.5H>9[)0 N5@;' LPNMC=?N5O-]<G_WQ'A*W9@>6MFKP>=!IF-]]DXGQ;#(
M.CB189TH+S209>D@6R>%$!:-:)UEUOFBOL\7X,G0Y"FU9%JVP)/!Y/?78\2C
MVD46)]/9 IU+&%D4P'AM[\HC>4)VUNTA"&N$SD&UOMSJ?%%_O@<[I4D'79MF
MZ-^.!PE/@TDH<@S@DZ0W,AA>Q]YZ"+D0$&%4Q-;!]^NG?Y_,6E_P'?1,NHY\
M;9XB/8]VZ5"D<,6#-9ZX'%@$IUT -,9KE%GK]D=_*_!]Q<=W3;N=*/NIA,&_
MK1R)3B"+>E9@6\@$J3-<,4B(/L<4E12Z-,\V>EKUBKURX,$:Q75T\5QJO%99
MTY\UBFO5**Y%DSZ*O3;1\;/A+XN>2Z7KC'M!IFE@M#9:)3I5"G?DH?G>/9@G
MP]NU:A2?'FW74&VO-8I*&,F++760>JK7 @F"MG2V,(O:NBAU:1W)W?<:Q;5T
MO7*-XCJ*ZK' XN7QK[\>O:\34M\=O'GU\OC-^Z,W/Q^^>7ET^*Y!X':%3V\5
MB%UW(8T"J[^,)I.79'P/B'##-, ;F;C9YQ1$;2@=N %5DH:8M -)7W/!D]2L
M=<_Q^]$TZ7/S\OC%R<$+')*>II/%V[28#!*5,M(F"[H812]-]<F9<" \%UK'
MX)A>F34K/K/_[::1LI=VLFDDVZY:'!&4VDTG?" OZ'T8?\#IB]'P8G(J:6L4
M-C,0F=&Z%2=L* (8H65)(=EPN[7SJBVLEC]POY3>0JH=F!MWECSW7I/3,FI7
M$Z$2!V5J4,Y%!3)&R;-T,?O6B>_+D?1U]]18]0W%N^L+HEI ^GXPK7<B1\-<
MXU07X6QFNDM5;#".K!LF/6U614$,W@/RH%GV+I3H&A3?+GWXKBZ(6BATU%*P
MC<NK[P#ZYV#Z\03/9M;VY./@T_O1(:U^^O4R;7(%J U[(*P)K_\^"0T4^A ]
M.M#&C@G$;/8Z"7+X4ZAY3E:1"R8X6!,U-^@QBA83=Y\$<1[HS[!;WJRCA*[:
MIKX>C<]Q_/+C ,OA%TP7-8'ZN)1!PO'E5-C('1<N@PRB>NLU#DA&$K!0&)E)
MV87;PYE7-$ ??72_+1\ZU=XRV[2MZ->]TEA\N_Y1D\;^ZS_^?U!+ P04
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MEF4238P)53$/AMD)#7>8("&-;FE@>KYVFE' 0#H7D@")"COF&PX7Q+0:\QL
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M%2*:L!?N=+4@62\G*IV>C9)XW%;Q0KV!^40%JN!R-%>,#[[T#R)9,BF396_
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M$*#1@7A%PQ$HG8<RL218H6L#?TAJ'EA BBTW2-J A)N(CT?* 05)MFG4,'-
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MNY:I5U!3(!V5"!>K1;%8R62<R1=5@$N4X*ROU&990G33U6HWVNVE #CG1@:
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M$UT5+"7KMF.GB?H/VNG:'VR['F&2>"O%9AWGR\MHT$T&A,%!4-/P0BW:C/D
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MTW4LAJD! P>;3C9*-;<2+-245JS0"I2=1#OCS#:>$'G2G0J3 $-'&G@=;DL
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M$.MLAU:1OVBD[A+R#WJ9Q1K_LOO_GW8'2#D*U%\UT/!$Z-N';/1O$CQ,*(6
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M7T)X=0^Y978D 7IM>*SXO'9*O16BB^43.7BFLDK[8Y8OU63!&&2O]KD2G^D
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M.SK[X'''/%\K#5P2*3A@F_ 4#<G"*OB(A2X29YQ=\A_@@H,2RE<=BB23<OR
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MJETWT\%=0;$='_JC#2X<4S(*@>_'IWPEF*5U%#0$5-QUL^?IZ%!MZN RI3M
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M73/X;D+YEXV50<F@7(:K<A%#=:;<6S\.]T:3CAP)%GC13SMTA><(:=[!>^S
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M\<^GLH,E6 [5L;HEP_BS2GA>4N?58G2-<?WEEG#E_>L )]^!W:46,\V])GN
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M?QR?J6&6N:](U/LB]_.*"OJ%_GFJM'X52O&W%%J-C9.STC1J&L)(/9Q*Y,Z
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M<98AV?J'->:?'*GV]JNS-/\XT\ISMB:3"/;6X'RO7O*-U\.*,]>6S>OOE7C
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M/V===<E-03WVF':WHBU-!5PAA3;@)-B3?%-4,W8KMXRG$Y&KS#@<1R-"GU;
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M\\1/R@0(W8DH7*NY%J'GF!D];DT1Z@OH>HAX-WCH,&#HJK9!3D]N+)3/&3Z
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M9"R:?87QP4_6F\I@R0UV!R',I"W>A?[VI/T/X1<!28%[D"RR7(<UO2)<>_!
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MEY+QOU.JKS:4"] E\X2<#!C]T&P%J.(<W%&=477$QLZZ^ [6!S]BHPQO:IU
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M6=[5*]OZ3%OW@L$(%ERE<&+C*O#$18X-ULAB'LJYQAEZZ%XVZJ7$*+AP$ R
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MT\JR2,WJ,15KW*&:U'KS/(7B&,I/@Q(3\Y"[V[AE<0>\4S[/>K]9&7HDW=5
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MV4"A,X_B6*AVK##%EM#O5F_I[B!I)Y&*:>MY[_)/*]>!7:<<C%K$?L%#';(
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M-,N^JN1<,8WHSKPM?%/3/Y1G.8J$8'"NH6GAQU+W,R _[!>L/]A)*X2L52T
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M)\4$+/;]NZGNT/V_TH'&V1 >T3CRE21A?:*WI7[E$,M#[EX-,Q41J_SXH&X
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M8PN/<X)-I:?KUC4GUF:F"G%# 8<*49+"/%C;%3L'"'W*GK[=VN0>+3LYLC%
MO&X1ZA%7N@(+/$DJ<O6?B,D)KM[9)0_Q&SYO:P?*) G:33I7B8@U716FX283
ME6X3/3,U/'I]&(W[6Y_B\<7SJO[(Y*+R7+GB$#A!TD7W->UV^?=,V=D@TTJ5
M!H?LBK:1_2'_9'&;6=73HZXG[BFY!]D,(][9/;%\FF!P<6+N&'RYC7:+$]HH
MZ7KUS=29,8#?0PVU\2.M8ZS<A.F#3AMM<]055VI]''L:Q@R3( V$.4PI%EHG
M$T(1C7FX\OF3]( V "BWEW^A^O3>6E5.?,E%^A143FUWC^EL1K-<V9S4$$]3
M)1W1TV55']1WBV2O[2>BT.RW:6K>9M*F?:Z_6&$CQ]T2&62MH$8)8;"9DMM
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MS'H57F&1_GWGI:=O?,&->I%/WJ9$_BARV8$U<O :6WC9#Z05Z81/TLPN.$-
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M0Y[$0!&Q*HV[[*-0_(JN0DB=_\;M2X0:[7B1F32 @]TB9QWOF[M0R#(7#3,
MY#[89.!5BELPL+&!@/J>%08 .< ^M.FZ8?TX?\MSR@$PXE<_#F]9I+T-8_KY
MU#,,U_>>@(+DPPD&;.4AW(@!@MX+Q8( NB;4N@P3*I&.O(%;'P_DG4<"UM.B
MM6\>%/0]]J6Q*E2\RQ^9#=?[A\'>(E][C*NR-&-\Z0>LXGXN%CE]UCOVL=H*
MMG?.8Y_BJ3]*+#BZ/I)6OHG9A0TNXE1B1$WQ#A\*A;7M"0-7M_N#5/,H_.\R
MOL5A:"87D M'4-<]/TWI13#_I!9^<"N+KO.2DN<Z+[8_J" K9>8XC$P<5R#_
M*:U]QQ[AG>M4:B9@?M%2B"9TX&'8W-*4H['?8L"Q^<!V19=<3SD)EV3&;&I+
M06 ;$NVK3BF>,EGCW"N:L5")JY[3SJH]R0AIB'2ES--++SICU(67!W_&FCMO
M=3E2_ [1")2!1O_EVG::E:-!D.SE(5;(-$QU7L6+MYLF$C?=O?]>MP5CW+SO
M6J0M46@1J;X8:VY7N;X4=\YC2_3E7/MS-4PCRC7+B;BA>U]3R[M22V.^MPL[
M>!:E9/R<SS[:IHW[*K.ZXI+4Y:''#3='Y75-C^/W82"%J*?7%&1O*V&%O>YO
M(^+<QN+>I^V[O#A:++08L#WI2H5@1H MYSPE906(L]^=*&XZ D%@W)1AF"=!
M<4.9F9SQ%7-2LMRU-[QF)+V<J?CG(I33AD>08E>7\TV" CC$Y)SG@JKO=N'-
M>1&!T>>GZS4TVQM>9Y4P[?T(YDL\[UBW&UI#A]X+VXI<*7\_U_6F605UW-(Q
MC4-MK+MA<]&>*(>?!\;Z/G/%ICML1)6<[)%3 29G,$7";;I9,KV9:Q:VYI>U
M19:FR?@/*Y!X'U$[W!TR5:7N9])E_K &MDP2S9 95QDZ6H2%G'9;J\1S(N2;
M65E]%D8;X]7+G/:NLV+0P(>M@CS(\8K8&+=QA8PW_K"\JP>K'#$NS#:<1?1K
MBG4&4C 2%U%=@M9B#+Z+(7G/35R:5!68 <<59^#:ZAJ4;Y"RR")5[?074F(U
MHAH?_'99L#Y67#2R4SR3B9R[L8CP&%?YO&Z$+:C1O$GWI611-#J\0Q TMEJR
M%Q@"VWKKW]FQ6[W(:KI4-MT7@'H.5PX!E#&/MS-;'6P+A<=HT\C&T ZQ-\M=
MWS1YN27%@+D$H@^33"'C;9,ZFJ/A@U4&S<+S5@2189P!.!LWA+W_)3B\2!,*
M-V&ZO +8&=GUJ]!^)KB2HUGJE4S+<#_T9_<&D9;[]QFO)7N.CO_F3R[ MR[H
M[V L8K$$^"W>=;)(_U+E5#@#R\OU=_.[!88E))*:LT39LH-]?I04E5FKQ8G7
MGY=$!3,XD&!5;"K;V/+JY>A#P97&''XW<,/6"BK);L#@S;)UDD9[GY7>]+.U
M??G8&,&B,?&6GL&B\1.V&.#=K?M3+U!=^;2I]Q#F,5!CDB(.AJ40F*Z"[K3?
MK*B?:,0-\;II55B]H\2CWVWKNG:JA"WCUHJ(.25XA9^ 58]H0')##XPRXSS@
M+)IP'V55^1*%V,Y=3(H.@=F/K*-CO%5E>V<ZFXHCZ?@&#T'&O(.UH-V>AK1.
M9?M WAG\9$*MJ]!XQF6\&5980,BA@T#1@:7="Y/T,00 _02))1?4]J; ;T*B
M[ :DV0 UHC.Q*HQ@3_J%Y^_*97)D\9%9B0F?8^$YC^G,NXB5K*,K3S_4NC,V
MYY3WHCX!CX+0L_6;S@E&"3^*#E2V?A=_B]N:L)43I+!P@@DOB:$HKFUX%2SU
M;FSN4,/./#<2_%FM)C]S> =ZUM7QI QOSJ3&#D6G4EO,(UVH7PBK20"2JBQ1
M)O)7-:(<@SMU94T.)G7.>=;@9T]:/]7UEM#:SGGR$X9:#V3<J0D;K2/G/+UQ
MM0-G9/VE*^<\J28[6^<\BY)[5:?=&S/'5=S6G1+_W<^,9^#P_3G/W.!)D_[A
M\U/Y<YX0;?+9VFG0">;?/3M!B>_,XYS'[)QG*IUSSM-XSN-\SB.[/Z!_-'7.
M4Z1TIB#Y;WU+_;_JNB5=GJ'1;D_-M9AY;F\NZ3&%4G:9:R22^ECO*V^?%&6.
MN^ZQ?RU7R>HZ]6T.OD@[2X8$NV]&SJ"G-0,(9=2&;1#:DG\4<0H_JWK.-S8R
M7^[W><!$FWU:Y&B?3-3A[S_KARGF[7!']%2\F^?=#_(VPU>XE+5SGA__?0V9
M_Z="%C7T:(I[SO/;L7>3WZ) T\G'!Y*-68?1:Y(B#Z>WJXY[6(UQ@=&?26]<
MS;3J[J7I^"="?"S3D^:PC#3AH,C1TX4-EAY9-V%9;SQ(Y#!Q4U_CZH6-UV=N
MC5V="'*3W]E.1&"),ZIU3]*?G!;[/J*DZ+NO#VP3E%R]YHV=IU7/>:*TR=:$
M ?<COGKGSA8/[8'^K[\ZQNKG$:NWRQ4V1<YYFHHG,2-+5:<7)A7FW1\4+RU]
M]<OI< EMU/'38.Y!6L*T%8>Q!A\]>\K)W:[*M]K=_>7W^%5K]EIEK \MIK-U
M4^9_M/^_7WO)L@&&W%S!!F&A._1VM_T($)1YR^%F[!IAQM6F5+B4+><\/C+O
M$B:*K*&MTNXR5PQ\CEXA)<.VX<T<HI& 6GV)+*A/XTZ(@VPRJK+3$_MB=0?Z
MNS;)Q'AJ]N,YSZ/\T^II9!.=0MLY^/&<YPGFG$>)4/VI#1WW>>YG'FTPJS0=
MW/CJM1D.!63->+=E_0T^-K=>7RATH,%]QXH#WLT)^WCLU:P:50C/8V\\/?MX
MYN[LM?W<XCCIG.?N_[3^G];_W-9BT]86VF5"M/O0E><X+!3Q%K'38_YB*=>)
M>GLZL;;K%;8SRD.2(D3CG3GG^1X(;?[L0XHB50E\?!=43UE<%EXBI+5TH75T
M\MIR CT#U[HO9G3<$Y^@=+IP%OWAZ+!J8RG</ZKW['EFW-OIYR=C1_AS'H]V
M]Z:LPX1-F=V1YZ/TA CM6J]^ASV=+,ZS/?W%+J;[,>^=TX42VN?IK(^JTVOQ
M.Z:P"O_22XF_>NDYCYH>[IQG+/C6YMTS]^.>$VXI=]>=U;\^MIMSRG?WV*.9
M[[":ZW#6]J(U2F;GG&?:>HG 5X4\VXB =!55+4?)_(>!ZN>=[23H^L3%CA[
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MTNR]R[=RZTIQ,>_')NJ];#A%%<I3_AU M:6,:F:7&CJZ*-1BBZXCU,>P:_H
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M<UWTYP);@,05?)$B]XJ=?Y\#3Q*YWSMP#QJ1WCWA[#Z_R<&/NSM.?Z@(@\9
MP\RB;ZGEA3,7L :+$XM)IJ^Q5E%>=W>,'R"D+O[GPX@52LTAHA,(, Z2=0VO
MM<>C&^7+L)\+M*?OE[0'OKB"%TA8<G+RB_PB4/?VQ:T_#!Y*/(/F- +J.[9'
MSGG&HS+[GG1T1#IM+\ZZ^0S =4+QN-U#1?U^>Y3OZ\Q^P,D%A_JB3/.,7--5
MNS[J[6;_$3/?[H#[S!C9=_PQZ6QQ/B5)CNSJ8<-L 7O+T%Q=-?TP?G ]IZ^E
M'?XK<9]0<V;+(H"145'KE4^ XF1+0'IXG[& NJ=V2(D2"(A$8M$I64%:BDN=
M,9 (PP4%=TUT()A^ZA(8 Q[;'M6H[%3<SWL,*0^#AED5.WGH9!E$P]_S9Q(T
M*U _T>]^0(3SR2-IT)H]R$Z$+#67"/AR_U-:*TOR4[JL53B=HSC >?8\=\(U
MM]^;=*VD'YR:"[^I" QA]LJ46X;VM<]J='QV.#8J3'X["Y,;</R7!8WG7WHD
MOCZ[#=R>GGE4MN'4'Q%J>2SOMID(%]9N>)^.:5V 68*/#9/ IS5_>K])FA>I
M5YG5U?QA\7C(_"[WH;*E]*WI^JY.N)*V.89QSJ,.*5)J-RDDBSGH"K;(-88^
MF><WN6I\T*>)9Y"BK[G,JHDJI ^MA-\I=F,V1L(UY:0N*S< VT#K.7KV7*"@
MI9.%' [GTVL("NJD_N'OIR_X;^,N7XWI6'<<D]5V(B2?'(AZ^*W'_KE7-)=2
MZMN@'3]FU[->: \>O?:B'HEY[$TN564OO,+;!_:&^AKX+B'NY0*2Y%U'ZEB%
M@_"8'RM=4K7LS95"3E>75@(FT'ZXZ-I$*WXQ90W#)[35%#GBFS*4"/K)LVYQ
M@3T2>@\XE/?M'J6,9A"KQ+?LV!Q](&. \'GD/1D((2!GU.6&(5Q?UXV8%N#M
M'+P,]GZ.XOS]MXEO$V\O#40>![P)$@T,TR4-;R,Z2Y&X!:!RAA=)R,9SV-KX
M_C@Z-5A7"",\ZU:O /2DJV'GT/KG/-"V/.Q-\W^8E.F?E#CB7T62SWLDC#7@
MWK<:$WY%H'9-]*;6&C]JM';LV(4HJIS:4J%ZI2_>6C3.C%3!*:8+S]_?6S55
MJ370JQ2K5YJFN7UF/42<TJ"=I2I06="PZT9[UU4+.;!>-=[_#)LWJG*??H*J
MS:9:3JJOCX*H]40;C4%7:K8%R"BTSTL0" #(/?F$^:0*:0S/\UCE0U\-!$(_
MI@0WTC8:K]:">OR+-'TO K'N][S I.AQ\9*,-\.H* Q>&-K<]B%1FI+F%R7'
M8HR=/ITV(D!?O?;+ 0:!/J8H!@.CHX$?T$O OE$]Z*5\-'2IP#WV:ZOI)G:$
M<XOS2$@,#659B8[X==H=A'\F2W8Q @0IH;YL-PF1D$3(_0XJR<:S\:AFU?:7
M+_!\PXD4X;+TK4Z6>(LI7RNOQ8LMK3.+47+-'*=2+W0()]HN&+GAYH0NZ9GP
M.@"'OO'81&]T2KC=%(0BBT6C:TT$-\V]O1R'J-79&'%S68N^V2Y7E%8Y7N7)
MJ#4PCQ_1)V7=8D1'%Z\%3K+=O6M.FEO'8YO#IE*D:(M[#064^!$A+U"4*7+7
MWDL2H(F415/S?%Y0@8ZHL%_^^O9L1X=4/FT$!_6X__3)>>D[VH8?U_.<A[JV
M+\]GT+Q2-<L GY+ZXQ&#'R[33/_X99YYZAN?\\Q;]B>\O3QSL=&<=[-DYZ8#
M*V%KS4@IKG;1&7+. Y/:OCJWH/#DCW_X:Q<7A[>MUGX=*%-$/CS^[O+.Y!ZM
MQZ9E*!(N#.P!81^IVHZ8UA:28IR6$IF :.F'J\[Y]"FL66R:GWSTR\0\?N2M
M^G?KS<XV! 9DW1KN[^&Z<D;4LT=$1T@_6+:6ELN??3:]>W]Q/J$(\NF^;W1.
MXYGU7KIQ$(@BU Z"R:':LM%OTJ\4T++I30#TFVIC3XY +XE?\]/,S(RW4M7#
M*&U:9;JY5%APPLMN]RE[:DM+"Y6@V\%BLUGM7'F6JZL#5H4K9ZW"&- 9_$NV
MI0#F#6!@?MF+%!_T@Q?I%U^D__!BV5#W)W;-N'\N>-I:)C#5R=P.:'3#QN)S
M >2W5+&Q!-Q@6*JT&ZFT&WX68[[N4_@7Z+]NC?9;*<G7JF9;2/(_::F"OUV/
M@F7:]SR6P;CE4M_\7%%EEG;&;(#(?J@ROU3E%5O7?%3['I:#H]^[?-V>@C=.
M,[,B$58F]5]6V0QO&-WTG<M $XE)-TP8(%W%1"]E@(5%YX/I_4]J?,''@@63
MS1^7?'I7U.YXLOA5Z"?,=6D?FG> !4.]:NK]$[2T+#H?QYD@3)2Q>X.<9X]G
M:]^?7O -,;D0$-2X:_\NC4R>.8R0A=ZE:(]U7@<UC)*NP*KQIX(,7]>VYBO1
M0..Y?=^[V"C[NN%EF@FHGAH0IHOO.PV'C!08N3O7"KP3E\.7H*MX$5O MAOM
M7AJ'^"73_K5(E\7P9UZV1()V1($S$Y0YQ!G534_70)_!WK35P^'6%Q3?K(>7
MP= =-^>H62'&N7[ /_X'I_--1-CA;.O[YL@5X. 8YXUO;-NOU03S1^P38[TT
MEW[%2'/;:"%+U(0389[DRR1"-NUJ\;9F(]L(QL1(J0Y7IV*^QMD7NX[V$U56
M#UU=6LN%1,H<#0_PW6G2 KS3 1EV"@4$J?&&3[8M#M39P$V)!).?:]4]X8VN
M$XL*+ND7<?MNE7(<_V&@D-&$+]+O14J0,\529<>G>'C 0JQKR$0.HI&*)*7D
M7\N0Y'/SW+G)U8TA<B9.8=PW\_O%UH#[F;:]'W?T# +76=EKD\S<Z%LJ;Z:&
M\,:6V$%5NKI/R(U5+>]8JO([@(Z@C8,Q<K[4+@RMX5N ]H0.U2^1>]YJ[XU5
MMK V=C6%"=*;V10CF^[6G%9^ 3=G93_AP@C"O%"GLE$H73W (809ZH(?P%%E
MOT#V]=ZXV[17D,)#C35JX=6D)/J52=$U.6Y T/TJ!5B/V\3&T&+BWIKSU.0(
MYB\N6CK3Q^ SP;O MF.X*AL%"QAV"@BT"0AT"8@+Y?%Z*>71V6N]D.6R#7N.
MH(VK(.-+8=AAQ[1H_UP( $#* @(" ,#3/TI>#J0$1$^LX 4SQW9N[NX&W>Q)
M&SI\]IX?<Z_3Y/8]DFD8YZRX66_A;LU,\(CR*):5F2,797:KSK?GLMUCQ$0&
M>5+!OL\OS 8B0XG8)O;ME4LJ!+TC*S\WAA2@H<^\V9.H&;6U$U9$<X+LZPF<
M>AC!LF\ZS_TJ(S 9IZUG!BL*KKH7TE!6!,'A:*-Y%%>7QM47617IC)=_=^'\
M;V,O\"##T;;<ENT>:L:++FF/A'.>S+F4@G3 RL;TV80I=O%063F56_6'H/"W
M>)W:(X;1\,[+#O!PDE9VH%*M.B S2GX>DNA%*[$_D&6$^K<L[_F5[!XNERNC
MD- ^[V6\Z$TH;]I:W3ZX7 CI0S(&J$PG!?U$"\$7T=T@&E+OE@>2YKFW-HUP
ML_]XI/]<;L&3H#7LZV*+-VB6"WMCC]$5&?8S53 #8>UR']I5V!=M(;_<EE+Q
M4*E.]! RJ5$:*TCNU)"6M'-PQ<UQL,C S_P H&%A\:3]"ZFPOFH1+#LS?VU6
MQCI1#JJ%6<ESPZM_[^XVW,*6>-@V/HSGE:-2T\R8^RS8Q+1I4XG(U%1TGOUG
MLO8KP=;Q,WG^W9I5/4:?VOPN[*?R'T?ESWF. $)@JO*^8\9K7%R(EL#>=A?[
M9.H3_.(2W7X;2PMTB-7$)0SD<CI$PDO#WZ2O *WXK1P (&#;&Z#UV$;"8380
MX'["U%CT0_4E>WW1]<(QQC8:V&.?O<OX'%_!@%@KGQY=S06$=&:43.X#I!,;
M*?X6H>MHF)^,D$G>!:F,6@RZ& X"$MNWVMNWV[N,[_VFE#@ =N^$FC6>.4![
MHG?S&W!^5MKL?'OL3%/O0J4_N]!E&A:Q.DRPMYRY8 8^$(0D:4)H-BT8*T=@
MQ7VO-\>_CU?M3+>Z4F_,8B  BE\%OS+[S3F/ ?%BAJ9*WQ:-AM%3#'*G[A\K
M.RE(#'B-B0?*#?CF&]]P)KLFN/=T?6-H9;5'OP$4L.L$-Y% UG*4%UD=",9?
M X7_[^\9Z>NR6(0D IW+I3?GI.4T^U%IM,9A#B% (0!+!\\M+L[5#=F4!AD@
M7J&BOI!^1V, XO8%SM_R"=G]-9_0A^<*J;=V'99IWF^(BQ!VL.5G=4 @D-VL
MI0I#B X"*?/S\RLK:SS2U1?HKU4Z&EXM#&1MD[FKV_8YMO,&LWVQL17:4:%3
M1FP?NW%(/0ILDR5%79AWN&</RS1HUHZNWV=T^@:\7I^Z]FR\40WZ(SF'*$7>
M. W9.^=Q\^J;'RI[@-82:F=*P-RPFH6[\31XU%2]"50Y'(L)( EAM'&C[U3#
M61-25UOE )W35C,R2A9 G10\FK/J*<W]:=/M6N5?[.BW:,^5\NRC^D4%KZ3(
M#+Y/)EYC<G3WV]G4W#E4ZYNU^EK@B5)]@/K^GJ)4VCM/7[N\9OUP6,[:@-DT
M(D=1WK9"5\IE9$=4%STUS+W\MM;DAK$8;A4E)YN>!MR3$BZZ(^UU*R@C5E2P
M@?[G_B"^P%KQ5-->1M+-E87/S.*H>MW)GR1HJ9O)'4]^#TCQ*9.GAN 4G(F-
M0;N#DH:Q)A\&^">"6T4G'LF\?3SK^W(AWJ0;;%->$\+;8XP8,CXZ>F@)UEB7
MT%+% 3N]9(=126F7%H]7R8*!BO*K5@R.7CE)"[$$K^VIM0($3EGGD*W-M,*L
M&: NN[VR.U*T&8W^X,*P?O- _ 2+4/5VQ3[*[O'#&R#EO&[VHF?4#2_^<267
M]\A:X11LRJ8#_SLCG *8O%Y1/_J_>QX)U35XF9[46N&+C4\SF0JW$6. E]3N
MX"ZI><X/(^,:QX\)QDZWX[R$%\O%TOFD1%16%K9SY$P-CA(S3[GR*?8'-Q0M
M\R?B3+Q)0OT+F!Q(Y1TVI40^!)6]A\NHP*<7K+3W6?T.AR\)DUTFPU?3".-R
MQVHY,5G&";==@<*Q^V[2T%=N_+KIW"887BD?74"DPW4$)X@<?/:5U52TA,.*
M0+Z:Q*W%JSKYG.=\4\T=;'\T-KB*<T1G^:5$II$=6[%6V4%O"QR=K2_%#/6
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M7+OT#119-CAHFC?Z^F/_ GJO,EAYF)(> TOVT#AO%?_[OY+AJ-F\Y>T/\&-
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M<X-$N/BX+T90@5+"C#U:+1DLTCJ[BVN(-O;:&5#?!^K_("LG\;G^-R^Y@L>
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MI'FZ31V2*14G@3>(EQ97ZM73>AVEZ5C1"PU\<(6F;#3.TYOA/U@:"HR(JW1
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M.?D0ZY*PJ.O.\D\";WBBPZ12CI#4,^!5]2[OB%>N"7J&BH6=$?T\ST'Q>C'
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M*G%[8K(+C\P-AE2$QO95G@,ZRJJ6(YOM$S!AG98_O^JPC=/@FRGH9!CX+1@
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MO)8MLP@QQ7N;[>2[NP48[<@KY97G:VE4P?N>#SR2-E0J-X\+?1<G+L(TN=_
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MI9AF=?4E#X7FIN;+Y^9DB$E!FI<"#C%12MDYN>BY>H34I69CE@%1ZIE$DE'
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M7?]WU0._)4NED-:L%C!+%DFWAU>I,<-,TZ .2)-7M(*U5Y?WJ+(A,B6X4,,
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M>T%YN&QGDZ'5R0&L8F$Y7-FE_6O3T\*IV\PD(.->4/A=$0SA%BMA&\T!-S=
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MG,+=#J\Q,!F.'(SPQ$FF?BZX_W0S>PS&1:(\ASBE.K\R&VN/WK:\G1BZPYG
MZ&?&FK!INL6KGA(@Z *I8:GK 57IYW%>I#JM*G1?+37WA&F\T/)D%VH'UM$>
MCSM)S><%+71D3]5B!_3'_>('&(_6[?@SNQB3\*%@ I9<-1W "T]Y#RS*EL44
M_#:WD>?\:+7GKD8JI]0K_8>8; 'ES)=3I6+X)_>,2OW6%_'I#2M+,@'"$3:V
MK(6J#:?ZTU-*7D* E@+==_D>M=T0,8BI7K>1>-GQGZ8??3G5EOU/;0V1:W"\
MTDZJ@)[7M?E0*:FI/T+!96#CP$/!1]+_QR?7_?!UME?=Z5ZE\ )%9;IM147;
M<7/LS5BEX6?;%;WKCA[OOISJ;K#N73HHNN0O$L1,N*^Z#%F+F[*CP.DCMY.Y
MM!"(;E_>MV[E',E=8QI)8]%GMU2]EM9/=D^W#2\;)"N[0U".6K80E$NNN(#B
M\.I96K: ^$/+[30E:6NQU5_DA" 7H9Y07-)R2M<T1#MR^_'_! ;CZQ2ODBA>
MJ;;L*(N9>Z>O WU84?@H"!%P+AP'MWX\9YLU!=3"]KS:+N7T^M%G-UU\\:A;
M_7G-[AQ;Z#95F%51[#^\&N_,)*&V-RO'B$9;>@(%= /Y)4BWU4QF.JD@/[F3
M\,]Q_??KS*!-V8;WL?)Y;CUCFT)AFCOO/0E1@\1)6CK>X./]<CS:0!!'E?&&
M +:G!(3H"#T&ASJZCLW4X>)5/"-#91JJWR_CQSGMMON/KCN\IL$_?O?BEX1-
MIZ?E56$!(*![DT/A7EY.@"?D:4ZEL^Z8//%=*-RH=+1_4U>D-D6ES-!96Q"A
MD)@0=N-&_H>D&.H84E1G$PQGOEV;1RQT:.22\^)U(;I2N +JM(D^>E?<W&NV
MS4IODYH*I3"1R;/PTKD<5-YO7Q,T\H7-+Z]B"E9'XY9E,>TM@>;/K(_2ZO$&
M82;>(?5S@:M+Z[)F:8*6^[,9S>6>@O9^FL[C'/\Y[=D==7A'S9GUI_X^@]#!
M'M^E0]%P*C-XZWGO<](C2:>N_)D,*T#[K:CU\J#^=(!?&/^-/^QU[Q+0J0P=
MAV_L@0K#K1UUO*3;=N/:@4AU4C"5**R"732(PM0-M4G_X]_#_OX5^R8A]('\
M4ARK@\V4"G(=OG,8^5?T087-PPZ^C"]Q1HSXNC*C,9V#>D749]:BAM+M8C9;
MFRT:JUVR;N-=K>7+,W"Z9#\MOVI&*$X?"_8$"$DA:3$A@HRT8&VSS!$.SCN"
MYC!JAN?H X]U3/R >94O0:/ ]K#-$FF1$T .OT \MX OHTD7/,%Z.H=MU6_3
M>CV>O9%MJZ+D]0&$@>75U>\H%H*'0SIJ@K<!)F8)#,71\Z:?+RTE=BNOXO7\
MB&BP3;.#_[VP,"V$5B5*/]RC\OU:7UJ'-;[D9ZH?#>2D*YR9SJ/+\]9A_S&)
M7*E-%ZW,3CT;V*SRC-A(/AGH CQ )N;C8:P!A3[6>UK]AD:FAHO]P3'4]_>I
M@!^:GYY.,M]Y!].Q(Y1HWT-.%?5/<SMR]]<2W1]]RC6? *)&,-<&M-'.C-HQ
M!@NK2IP .#KDK$KW!KBCE"G*Z*L1PRM/8 %Z:^V&3A3W9 +,&-Q'*C=$IKR>
MFL'[G2N14U$%'XSB7(?IN-C3QN&=C.R)2R] X8L%2\7!3$]7D%M<AXH*M;H@
MP]XJ1 P"I<U.,$%@$'3M0782*S*#-9G!P,*FT\GR]0NQ&<;VN>(&Z43_3N<?
M^$ -@L8HNKHS/(TWH_V*.+'9,VT;>94I,5\*O>^7>_L)"6T<@;/M\1#LG ^'
M\T=IYR@O7NJ:@L7EOAX[F]#V84N,&7N60:@=Z5YKPS39KMU#54LAQY<-E)ZH
M9N 7J+HD$>UY-PR]*@YAYRZ1&M3Q2.5A[:R^_QE9?[FPW[Q/11QZ#U9S3#ZJ
MM&*B![""C'0Z_P47EN@?3&(]KTGSCC=K/\NN9<EJH;S<JG+'F\#7K:,>0!,X
M=5D>OH_& R5C1(?AZ>[)Z=?&707V7T[545535T/,T8_Q<>6/]*^@N@$%U@%Q
M^/;TY2 3#4^.X"%]LWI7&_PT?'V4UFT%:#4Z#['D^LS)$7;:1!5\UP=4H1KM
M?[D85_!?BW%/*_Z_+,:=^I9G>NKP#JU=3K=PB1;9;CT:,1]K'%7Q7?IJ[4#0
MZT:;U+?6M3JSB6ZHP=)+%KUN@L8$I3.=\.O>"*_"OMS:V'!V;*S=M2>EUC_E
MT.3HSB&LA(^0&$3JEU-,^ZD!*G4ZBA@?NV#ZH6STT0<14[4F[R#6I,9 92["
MGW9->RGR5NLS0X3XB#Z:X!&B-\DI8'H@L+=?MUXN_D-A_/O9JL%U.[^GNQB=
M-IRU*)9G5[!S";4X[_#B3WGXM/YAT.N-B2!OX6Y%3+H_3Y,1%")]^#YUY%T"
M8HR<6[)TR/DU;\W'^+.CT_A5OWM,EXC/131/D2#S,J+9BIU+MP^[02U>%1,0
M(%I%/LED@.2QEDO'"1JWJ;\;S[EY^EW;=&C!"AUP.J%C0K1E5)Z8JRJ6T@&'
M-+Y]N%D@BX^(D#XZ;Q*M#FO@<-@5RL8NL[FH>:*_W1EKW5^>'!\9P27G<$!!
MD XV^3\+SO*Y5&K!AZ2DY(*3^]3C-OL>,>[(T](UG>8IA8+#B*FX\FWJ[/[3
MG_>S4S<A6DL#E1:EGW_Z9\!AZ>QV@+ R',I06],%6+O-T9Q1+X>E^7J/7 \&
M1CW1@_V8W(I:Z V?GG@P'XGBWB:"CO:TN;IB8N*)'JXV/YV?$(ICA7J.\GIM
MX2\AE?;8+5PV22%C8_?.T+'"V%;/8G0M2%.;@[G8TY'I5U)LYXY227RNP4]X
MN_+805(YW95W]E.AMZ;Z[MI>[-I$D0FJ5@H[-8X.8^L&I2JT0CX%>?>UYCD\
MD#,TK)J:I1@/:50Y7;?K(C;)*9C<U:-4O+O6$W7*"PN;N/SH>^B$J%(;ZW!W
M+'#%&W>^S"6#D"%JLNC8Z.YOV40M'9S=WQV5NN:4$/<<9?U ^0QXS>)[< ]Q
MHB@@_LC.H>!I@ -Z0/CD.I*FX5/>(?6=&1&+Z.N0BPKQ/(S4J*W8K/](K ,\
M?6=O]Z!HR'+G?FSG^XF"F-2W'W/4=PX(U]^8LF/;PK10?/<YIJK[QN?6!W\K
M#;*UBV4M#5$8X-J$K)8<5[Z>]YG[!F/IO57ZV_!1OU=N(_>3AD=V3,N1I*@;
M=P2/QQX4%"+.K'B41R'>/)6?\'"G8@Z:[*<^3/W6'J\6GM74^3 (!Y,:*DCE
M+;/+&1/.C':N[;)R2(ASQ0[7FC,F&(<U58:;;D&)KQ#.Z&=IR#2$-$=RN)A/
MTX/SVO5$BZ0;^:0;:BD^MTEJ21].WI*2/K0F/W0P_+C!0&Y'5G]B%7Q\LJB_
MG(\HI#U_F3*QT6 UP8-.DY#KR1MQF8SW(>5;O.B;>2ZO!T\"4C;05&4U*T[K
MO-$"5T^U5$)^JZ;JGZ*]/7I?S7&*)C\"S;DZ;22&I^F@3WSYER$#%32[+U7H
MD=)8Z\(.&Z:'AH7N[P=_U/WP.:,X\-KT^O_(P\:C>=&1&?5*&75$F.@169[L
M'Q-A')<;9)!%]+_O\,/O"QP::.?>\&S>[!HY:Z*G9\(V3PHF>;/4]CX9_WUF
MI(.@!D\/G7A!'J7.846N8/M',@7324E3!<0S:4B_;\=?$T[0@C?2G=L6:&V[
M%H^JV?,9)^C///'+H"Y3@TGCM+"VH8A5'(@=L4AM6$KQ\?W;EU-7+G_/6:_T
M\B#H.'MD5+4T>/)%Y"L;_':T+B6CIE+KFA0!VBM[GU3'&8LPA/.<F0^%*,2"
M-=Q6O/>L.JQ^5"OU_2=2Y^)QAI$!T*1*/&(VS.^EE>''=HEM0Q)E4R"69AD3
M-O>,#T>RJ@,U'ZH1W/A32Q).4/(+DNJYI9/!K'N0(RKK>B^R!Z>!(8<'L#6P
MO="*YO2VD8#\ZK)+;=,.6F/1[.PP[,V9E8<'CWB_UGD@*_]1_31&@A.=59_[
M'+NNWJGYF<%%E$6N86E<^:ZK U070K4;0LKQQUY1;6/Z^#TCF*H6,IE*6;*Q
M,,:9.LG+Y"=2F'#4/['+"(96PPBA#^&W75[4W7ZXKSL+)RN Q !RM#SUEO$&
MI2?L'+!E<+=>^B+Y']MK^88:Z5%*5EFZ0_OK\+JVF,^EZF'8K6'\COIL!(B@
MZ)"W&3H;X?GSYMQA8_7Q;(X&UTWQK**F8NGA1$7!4#C\D!ZP,D3KN)2HVP[2
M'2#EIR!^BU:8^+S%.-Y<UW"=\.KO_7)J0(@+]YRU[!8@!RSA/-%"P=1*=*P$
MO,:R]X+ $N0J!&AO.>>__[=QT'_!8%L=V2\I!\PG*PTE,RN66!;@IPT#"0.X
MW7F4*F>D/B8 GW=P;D<EUW6P$M<A)5Q^2+$;/>O;,3:KDAD3C;+E$<I&\@5
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MCK%XMI;I, :@&U-&J-)S7YCIF++)/KYXVW F4Z]':6;U>LK^\C=^-'^Y($K
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M[T0ERDQ30X=_R!>Y=3EY6$[MVNV 0:,"$09>(YO:Q_S=37\>\<J<OP=8SK_
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MHJ@BX^YU1(!##J,HIXBAANHO=7!#"<B:RKE?&WO18)Z1 80\%33+I;N[>P8
M: 4 3+^^[FRY%?8@=RZ,CWU^O,H[6-[[?::<2A?Q<H1 F&>X$  )'_J*F%\O
M  !PY[@RS^,_$_R__<RY4VI6BU91[+4QOV<O6G%D$'7=E>?'D)6;A,@2SRWI
MLT:,YT3>RFLU+?7+2P!>]%-R=8"!Q";[+]M'V>/3U5>A6<)T3OOQM2Q@-RT8
MCZWQ$\4'E(-CVLO;75!U 6G^A%QJRUPHU>_GIHY0%6%2H0^AUH.ERRL6.MT3
MXG+ 9C1T<*%I[;[9957*5!DV6]CTS?;PA!>B4BM4^HA&D#V2Q?]^O/;2R(3;
MA+LPE_-U[>OLJXH@7)#[?;^L:)6$?M 9:[&$O^^SL./+X>YL>PBZ+#\_/SDY
M.4U%1?5G'\3//E$JUQL];O=/]C$WD,,QFQ^*,LG81^^I\X<%BTRQY IYMAH.
MR,7EU3_>G)8NU)_/KS U+=T=)3^<L1$G-+RHBWWK@5A;ZH4N+<WYWR.;'+<_
MW/.NW8U@^E985:0/:D/D4_);TNAHI1Q/O-(BQI,L6X?*.&=D@!&<$*WO6=O=
MLW-:?'9V^DB,F>'BON?ULT@H03UI?>/A4N;?%UI;R=2U$L:Y)L:X'M:0G-17
M;>Z GOQICVX[_%K.K=2O,:V69M'\X2(YHI:SYJB3_>)MI%]:M37J96ZD5)41
M:#HHZ-[P10LC]P@_HRZ.HY1VC]=X-&$ D>;-8R"INAG2(H1TS_?+?MK\-$8D
M:LM)3N'"1YN4CDFE9V^1=Z0. AG'<V"-YXT-;V<WHV6I>\,7,BP.&_<,F'M[
M3("0Q6YDLVA?EX1 >CNJ>,#7YS_E<> P(X\!2I406*6H_5%NA?_:\2FIY<97
M\ODAZ4,B 0 P[)7=,'J0&AUS8]PUZ%H\-([1=[SF?+B7:I2=!O H2GHS0',^
M$9]=<2&1OY3*#9JGWR^QDW=\V+<)JSN0H;2(>[ITS$S=#;QE-_Q2[EA?%C2@
M+Z[(W%T@%04Y]O3E4AMOXS>'D^C1DH[RGAD[>A"L:G=[9/"6<_G"'I6T/7QH
M6W+]TMT2KC\R>8?[\OHKX,P+H5>R\/%.G\$/<:5Y4_+B3[1>&SX&S9J;5Z@
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MYV+,MTF;!7$5>,T14I0N[1E6+9E>KDMOJ**S-H4GZ*']_0K]C_*%TPNUM2<
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M</)KMP8H?@; #7Y<7FCCIJ#4S-2SK@.NY'Z_Q%1I5%GMY5EOF9)A327IB(K
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MBEVRPIG&&DE^#]N"S_.#CW8'LO3-*[KG;UYLK0$%;I]#,"['4%.I:KE6]WS
MD3-@IT[[OE!.@WNIU(P3(>?HH%Q9TC:IZM4_$Q5T- +5-T*>/,.8VL"/T;M,
M0"$:)1DO7>&O/&'9R0K^=(]86.,F__B5/"!8/MI2EN">%PQ/V#ZOPS74IFIF
M'?4_MJ][F$N9WZ9#=,J6MKKPGR:\QXLB^[H AKJBLTYR+E.R<E G^;Z7-DKK
MEU$5F4]3OLUV-&NI;Q06NJH7NKE\*'I<8O[7WF/<L[,9R-AB(T<SKU&9K:%>
MB2KL1@KUE6QS:SVQDRD]&)FD8I7-I0G10NC9_I3'%/68!<@K+V77CD_]LL./
MR$_LZ,##WW!_,0H,J\I\OI#!"(!DQSC]'C8A(WXF<'0[2RD_)C5M8]KT.&=;
M. =P8^Z.I?BJ$SX?B7WG.BXSXD[2)I6W6X57[1=JK5](R)^H6S"NA'?SQT=)
M!!] QJ?MY;(' -XA0J. I!Y?'>J3I61EX3I_>F7HIQD[DRC?&8M\%CVM8<@E
M+^/^2N+OZ">+ Q?#\1>%P:!/ZGN@OFQH80#?]MR2-=HOZ9+S/;[D:H0VVWW[
M"_DQ)S/O)#J/0P\N4EDIOR9].-5;CUS,>-X'!R.\&F-#G%,+N"2R[6$("D#R
MUFJ/N]I-)-R@!M".$[G$SA,M"CU?$H>;8GP^+#Z*&KHKZPK-#G";?(,AF@O0
MS,( WKOY5U)V7*OW3'?OZ'A2:%TGJQ&(*Y&W1-1?8A\4]O9!26QB'W3P$?4:
M)5[KLM;G(\AZTPL3M/F]OPNM#JH',/MKWAJ]3LB/>'LFTH&7RW3P)L6$?3Y2
M1#YUH_,X,3TD8 5.4RDI;V;-6_S=&!C5Y8$[B*"[!^&,B@TJGA#4;J%R:PZ/
M#U?M<BZ=::U+J3IV>^TO]Y>*@/7[%N?0;+OS#)MS[@6%!^;W1(?UD;@X_DS8
M1RHUG?.'NGV+XF)6B@8 G!8R7R:CM\<YR =:*(\NO6]I8P"O_7-5OK7ZI=B]
MSKOW=7CM:IZKESQ??S#+]]*QVT*"C^P>\"P7^.('UM-?<4FM'CHYWPCS(?LM
MFAO0V&C73/D9L_&6US4\@^TK9.;I%2Q7E/=#1>NXH,HAWB_7->Z-;6(O+$_A
M^&QVIX?AXY9C QL[B;?9GX]<E>]::?A\I.&P7&XE;$MH4S2=I4D0??LE'[$W
MG!IS42Q5=LN:Z25[$08V?%WXXBE5_7(U&38;-EM54-#G00GM=QR1#@0*H*ZT
M:S>HE__\W[!F\1_#=Y&?W,R4I?CV?<?A2;N"N'@<H!L;09SUT.:*!25>O5#-
M1#U\[<J/$'*N$DZ-;RW'#\,>5[,SO^6[OH$;)&/&NCG2&6CYAKYY=%6QH7PZ
M#A43'%E%J\"6FT7O-^")/\\;#DSOK,4Y1G 6^J"XGU'48-\H[5Q[$>7.NI,/
M "AG>%/6R(I3L%'G-.>?FS?+]2##=RZ\X:STH1SZ5Y2S>4CW>[Z W9UMNEXU
MEJ[MB,7YX]%A5TUV6##F$O^J;43O]0W'ZU[REC<(B@I6D6,4[5)OJA;!V^>A
MND::=RQ <ZT7%3XZQFR9=YB[$)X?0&G6+JVDIBU2+U,QI504FEI855 8^*C@
M"TBJC_<7_GTK?9OU 1<3&L[R(/URI6D?WISX?> H(E")V".D+^V=O(8WUM,0
M1ITP].Q>P+DG/QO:]<USR_NP'.7;Q"%<)2=KIP.#H@<<1\TJ\COFJ\*)J[#F
M^S+0&'SAY7@3BKKF-#'C[@*B7^)M7+?:T!](PQ_,^@=!84\I79",>* ]*@+B
M>)I4?LZ'T"= [E=1A0144:ZX#7=L/4LA4LIU:__AO4R-7U6 ./>)#J!)\E?<
MFBY#X^/'5:[W?H*$U(C3B5"@C8^+"@.%*V %2M98$LC&10@4]\?.EU6.%1%I
M.82^+1,GV:ZS+T._T//;?6WO<>F-IB*)TMJX=")Z/@X-%!G#=:$OP/J\[\[3
MG51@PB*7*2N:RQV(%4!6E@<4+\>^^A=#_=<?3OZ"5S/<CQ32.SN/:\7N2WA3
M14Z0REX/XGN317CNDDNV0+,\(L1ZY;?J]N]@5;NB/),U3U#<K^2:H,'M$:V&
M'+#^$%A^0,-@O+8WN'$N4MF:[]+OKYU==C7A<@RZ-8=RW5'+Y)Q[:9K>';RD
MH>_.G8Z! ;<BU^8ELB;)YW>RZJ+52>/FGX_4&Y8^%3C@\EOL=?9ZSH/4*%L5
M7$7&5%[/<+ES.<%0QE%4[PZFK CXU]4<[//LSM7YWX0=.BM/S)^O?DW0LE,#
ML]>EF8@_C\VNBK1,2QC^06(**9[EW>M>!HI>**'0HH.%*=;;@*Z;5+0!I47D
MN^]VV;^3?.S]/E_O]73SD=N>J?Z_V/S%0RWN=(+-[+B=[_1$"+LD&/O;?.;9
M5]-1P2Q4N8]U;FN&^<J%_!>K)IE+SN*19%,\5@_POO<NVK:XU;0G$BW(!B>-
MWS*F+X:D:UZTSDCHQZ&6B(7AQ)Y 3N"8T$CX)I#"P07- $'AUVIJP1 0GTU%
M^9<37_EM GNHZKJ1,[RE,DSR?=F$!_KF'0+?N3:/A8G(#A_&TMC@ZYJ;)B+E
M%>/ <,?K@W6C-<SK]KB3O;;9'3>*UJ,A<G#AYR.>]<.9/XLM$HH&A?K[=;$R
MM^T$0) @:3(MQ)/M"!LW#%QUNA7$BC;)I%^T\"!RFZE4$W</C1,#8SY<)7R'
M^&A55SR8@FG!\TP,+C_\WED LO=K5/W#+UT(+GZNL;:6F6T;SG=K=5V!51G&
MTKMB<X0T_6T-<LQ2-),>*+&B3HI 8UVK$S5$-FB\-;J*T;Q,SH ZVMY(S=1"
MIU(*4E.386F:I06EJ:D4$YEHBL7?CARU.00<7B'].FT^HG%I;=?4VI;UQT5%
M=9SMDL"J['[8:9_O>1_BD]VC&%..YW30JV6LC3N-X7/AK-IDVTU\X-==U_)B
MNDE$%W\S\B)L$9?X1!!0?R?8.I!_H7Z74K":.\DHH :'/^?5^KTO@E6^K7A
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M8#<[9V%?\0-1%\:"6:U?8[?BO;';,T:NU2Z 4S1GA>;5L[\WUN3W<K')Z]]
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MJ8)!*H4QI06DH;:L19B$ HDX%@H[GR(>##&UY50+!XQT'8Z:#J%S.,KK#,C
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MWW^*O%6Y]R!*M]74R+G5?&^R+8O.EO6F,4P8%81"QE@ $8YC2&46P%12HK)
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M41B%D&49@B*1/%!")%EL9:^>>OC4/M9"/E ("$H)[;_4(^ N?Z9]X!CX&W5
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MM-/S->63WN31<T:YUOX&[/0'#0 NQ#E/X(6Y\M;.UXOSF]C5^7^!KK^ALYG
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MC9Y^N/^OG^[?WG_YJZ.SV1YK2Q?S( @.[5C>"PT*J0$U8H-";E )/E ' W?
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M3>Z O&:J#D_H1ER[9-=&W%<UN'@P=1ZVZ[5>]$U26_[3<L5RN?YF.+242AI
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M*!;5;+Q;7F@3-N)<U+(,-Q/ORM/_D:;!;E4=%-B!%\V=[%4#C!M0BU]E[MR
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MZ$9)'>;!CJ&&17=H<U9NRA3H6GP3T/"=T4!O'WX/]KCOM1@D!:([B)Y(K8,
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M<).C\)VTT:(Z*%\T\LYU# VK9;8SP2_ ;692^P,Q,(<?\*LDO8GVLMY$[R_
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M/B_FVWKTC7K;ONAW+IF) HL42>7JI+ER=:@B;IP7)4!(I$DA"!&LM.JA:BG
MU)C\B]#BB3I()-IHD2V[F]K.@)FQ&Q+7P,S>%OU_1LVVS^<J,+AN_%8I<!,=
M5(@J'3RV'W4$SU>#4=OAQVTAZ@C.29-0U^<,;T_P-[$4:[)0EO M_S%?SG5I
M!AT M6M.MPLASWA!$,$8$*PH#B*9 4Q1J>Q57/ <IUG)C0(]!L@P-;YKQ*Y\
M2_)&</>R_*;386''A@,Y,/GM2O:W<7XK^[Z]Y>5\ &_(N[=)"# #(S=/\#(3
M@]HJ6&+HTFS!=(BKM6"PQ*"O,8/MHP:L-[KNW(?YILHXK<;C<_W2DL4CF?/[
MY7OR/-^2A2XM]&VI@X9U0^Q=V]0'N3OAF&&"TUSF$B12-\_)"@I*RB&@<<IP
M5J9)R;'U.N1'MJFM3XV\NV;UND9EQ!LMFT5KIV?TK!0%\R5@M:JZ*T\57ETU
M%58W_[$[5YPO(_7*+G64M'KL'_/M]VC[7;RY]F@7Q^60WM/+8K%*CO\*!%X]
MM4+13J/J./B@4Z25 O=+T*@5'?2*M&*'?M(/<DBLA:=I=%ARQY_.D9;B\:;5
M;9WV"[S5^NUIZ/'7=;^8=:[WGH?P4P-"6QGZY$57!6[VE*&,J4A+"&*48@ +
M5 "*,P8R%G.42906TJIBW^4AI[9J[R2,JL+2:KE]%61M6=7& &BSK3._\ 5>
M\4Z*1-Q$>S"KPM,7ST(&%XPXCT^@TA$= UZUB,1Y "Z5D^BY<W F9YWY>U^E
M"\YP04B"& $,P@+ E":@C&4*!$48$I[B1%CU>3LSSM1XY6T&Y]L,2IU;7O^+
M95+Y.8P-HU"&(Q?\9+6=[E@+>1/58@9)=>S"P7^:XYM1KI7BV*5J3WICY^5N
MS/#PK&V?^R47?RJ^657/W&V\ZZHV388+9DSF&9<Z.C\%$,4,E!QCP!#,><IA
MPK"5+6(V[-1XHY8Z:L36!<9KP?_GICF/NFEJ,5EE'%E.A1F?^ <X,+UXP]::
M<NR@\L1 AH..2DAV0!SSD^7=CH$)[+O@+SK!J>+ =V0C^"-YK?J5_T'6O*+'
M6I*-3@*O=B!NE2@_ZG][TD5\#A4LLY+D60HS0..< )@QW><V(2 O!1$9A9F,
M<ZNP!:_B38W^=MKIC<V]]%%+?,L0![]S:1@ <;49"AT>T9J<2C50Z18URD65
M=KM0B4;!F^YIC'ZOM Q3T#3,!/@*L? KW+@!&$& /0G/"#.*AR9+9_;Q6H%R
M>N-/9\,>0D@^"K)5CO=,X)0D,$U!*?,20 XAH#2'@&0BAT2BE"&K:D:^!)O:
M"K#?-&\?@^GCL^5J"=1[JNOG:K*A8BGDG,W)(EK]L52"?9\_1[+6J>O8C T-
M?/;^1IBM)M>8Y]"1)F\;+!V=J.C):_3:1=K5LU:=Q51SV8J_:[0+U$O) ]XA
M^B<-$>MZ/9,\@-G;)\G'\^U[DW_5S="5_['+%M7E6698,I8QGH.$P%BG93)
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M+0"!A.OMT#)/,RG5(CI;BF]ZI">+> !/\AEQ8UESXXF4 8\P#NI%O*6?9<"
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MX/GR:X8),ZZWXP6X$Q_(SU-=HPJ>R)_W7#VQZD:AQZVK6<XHAJAD*0$93S,
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M;8MFE*(\3DOD(1#E[:A3(XK.,W,M<J1E]A*[< 2[A3'I$\S #-*/H]]@D"-
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MEF69Q[G1WG??(%.C@2J$NCZV'%BON!=:&^/.';#09EPKW+R_T+ Y,"Y6F3M
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M*R KAQQW_='0:K\R![U4JGT:#?^![#^YV+_O+*0ES4ZJ0$(T#$/0J(BWW!$
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MK?.6-/X9!MMO@\?-^LY7TFF/_L9CRS=O2KATIDZ^Q<]^] GFW RBS\;17&:
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M.B ^89A/5<0H+'.AJ\<H/R2JWL#<5U^UV,X"3T($QH@RWA!IM<#M+#K"LF?
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MZ,JF:*W)$'RJ[9_M1&A+7G^'\*RJKP9 N:XG<9G,,6 F:6^#(TZ4MF("! F
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MUJ3TV4P[//KV4DE/P+MCZ5YQV/W;_N]?;@1017%1I$ E@P4RLSJHG$+>B'5
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MWN34'F6#**4#L#WZBOGVJKXWDOPPD3$M)^0;ALM+S*]N2[%N-K5?*&,4,89
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M;R(#;7QA/"7/^&[3C5_X<!>S0P^%I=U%WB^,_NOJ\CY3IA@2$"O@/=*)BZ%
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MP$0I?!(94;0>$K,MC>,Z;@,B[.GZU0&4-W+OV>NZ1A3G)//EM[?A\W7_7:&
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MZVRU1,'$/V844TPN)\MO[RFVN(B8DQ+1 4_U-:;6"T3G)1@O94:5G&H>[QZ
MK<[/_\9(;64H \&F%TO:)4?ZG$BN4Z$>D0?%(^FG=LHZ$H=G,I!@9& L\.S"
M(..:!N'F2'/L#>UF?)#T8BZM3Y WDZ^3C-.\.C^28EBD00@,7?4[-7A7'&3K
MI!#"DCO;39WAIDP=:3U^QY?.SI#YV6SH_63QYR]SQ+,I$8B+Y4H@SB6DJ%
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MJ"2M;BS+E"4RAU_P2R,*;?Q0?U1@>G HR\A(TX,3 ?^""RW,#J@M81V*C[?
M.+TC'FRT"I%(@;BXJ:+^@)B 6T,QTB0&:N(8]EZ0DP1 ^#)HT_N&(9<?HY3G
M0\'.(Y*1@^.CQST&XLF!FS&,MO',:J]@HUE&E@75!U2G4C ^&1\DLU.<8 8&
MDVDFX87U,LF*6(LLW7C>O+^\V&R6@*Y(4!5G!9&:'"TR_@;T!5XH,916D3E=
M'(9L,JS?-EQ_'D.\+6WIOEF1Y-.AZXK0_MLA^,90 W!1"D .:+M;*(" 6N5K
M@+#'S@'LQ *^A:N(%!:\<BQFKFP&=)8%3<4 EHQN&2P$?L>3!%P / 4_!CA1
M<66W5)BW39HO](CX>QD FKWKL6HCZ;P W"@(G<^#S^#<#!I=<HJ GP$S-C!6
M)XD$<&L)B00UF*,G"'$1TIJX :@.)K< *:":.1BH WS($^=^SA$?*.%=-,!N
M0,EY# 'VK(.^O*AO=#K:Q;HB/ $>[.#\/#JT;H"0ABDT"7&/!K85W*,Q3L#@
M1>F)@(O&J09+,'% O03F$8'Q)]B 6,":\<;![[#B0'K/D!GB/=QDZ+!8=39*
MXFL\OI4&]=];9D^O<LSS@C#T7W +PM'.B]UMR_H*+%%1F4);X9,BM:7M@14,
M9!D063I9@(W6\E48NE%\J",'H+FJ8@K.)EV"NYR694/#<[+E@IL<?P(+P8R1
M!Z'%@BE7$*7#Q^#&"FY*5A7:Y6QXB8F=K$[<3.;F73+!;65"&@W=1\M7H@<I
MX$O<&(D7.<I6/J@PL"19H-?;:)'YY?S\'?O5KWRS9:2RCO+ !F O$GD> F@X
M6R?D; TL:A:##00UF2<TA 0(*X2+"3:-!6)_BSF\?H=F/7B.CFZ0X9%P2*/4
M)3Z^2:J"D)65 >,!-%,(GD9"@:'99+EX59/QNE:0K1"3!_>?')^R5(\%()X>
M9L-C+9!O93 R<,5/I^RA?$2&@UFN0)J$=3<^E/!Y+&T$+$,,:L <<9NR@<Y!
M_IJ+X"H^)AS[4$@"E709"!*"Y7+RJ+$B5BM@M[=29),\H@0Q0.D!QRR&,L)[
M=2%,C7UKI-R!S55NA*+M?<"CR[CD9/&A'#WR4PH3IHFAZ0PS@QE1BI-63!:2
MV4)$,I'P%(>5R7;"Y*2.<3IH\715DDYU,_80%%-ZA[%ES@@-.EQK94RHU(A(
MD#KZ''L"](<U^>?%%2E[ _K;<<6T]<:1G;DG7S$2\"P7HA3<K0*F3[X$%TIZ
M3F1A.H+( >Y-2I]O%WGLH $/*\=%N;P_W0%/:H4& (A2BAP\:B"'T9#&?XID
MQ]G6A (VT9+"B/.HXF0&"&<3'@4>T9)FQF^/&Q;O%AEF#5? #"H72D*0,Q7=
MM%8P.]>_!LNW A4261<APZ4BC6&DMS"@>IG&E!$9!A@B'Y(Z3@+C$O #>@P?
MDRU:2-6"QYAZZBN1P)R/]Y[<3M?^P1%>]L5#H,/5C?#3=7NT>7,[[=#R>.\(
M:72>YQ78&6_;264=RVP*5J5/'RA@9!]AH#/P=7"P1!EV;/NZ;'M/@$L7M]BD
M'1N^!1O &8.CDLX&4JG>CB5K8\DUN&R(0Q =NJA$&ZI,Z'Q6Y7+'H_7QZ%T+
M+U.,2 "_C:(_A4%/'B]+@3X_&YCG=Q^T+01LR^*C'6#;/MT)A6NME,L>6\B-
M=ITYR ?%,"<4/0-^6UAY[M5AO[F%#R!0KLK96Q8J6?OOU#32,838R@A^TZ<P
M\X2K,9_8>Y]4('_+,W?"^,V$\<."--_.M:X/_HP$IC9V'%@7!]X(2K/J3.QX
ML"X>7'*3(X!A U<0'<J_>ZSD'S$O'(LF9.OYNDD$1W]NP1;GY8NK#R_/-Y 5
MJQ0O["3_ZTK^*YB-=3MX]4[*SAFLC1VOY1^5C''GJ=YW=7L1EHVQ[13W%G@A
M$44U>U_TH4U9 O'6CG7K0U*T83W#-[^13>TPOOJBQ<+F6VZM6);#F%-QO&/I
M-X(%,TP5X9N"MCX@GMG*^KMM*[^[KKO/7%7!>5,]=-UTD]WM[-U5NZFNW9HH
M;2@[ID('5_,CEC3=Z81:&>>6_\256%0XO:PY;U&A6*L>VO?G_6OO_=YT8U[/
M)Q?Q#ARI7LZ"!5"CF<&68URE,,87)1DQDKJR"FEB*Q'/7R*5*6!-BVRMR:]Y
MQ2'@>53](EVU3'N4U4;HL4%5NIF,=:5BWPA)U7+-<-AN52_:UV:XU8XA3 DT
M:(I!0FE[4WV"5@T(?\N5O:GZ[+%4*C !NU&S066L""4A$"DE0E)_JR\1%!\C
M8>WR/?^Z1&,PH7MFRJQ#\0J55J1&B%!I0R2D*I<)F%_+9):)&$(RK,?!Z$S$
MX;886W'G%;TOTI&I2L2VC&U\B]MKK6^ T-$->T=,W$#GVND:O;5DY+,XN-C*
M2=<]#2*C)-@=>!KJ?/V0KL1'.E35$C;C5N=\H+!KBK0SY:/F&M^EO<KD%EJM
M1L=)GT,!6GN"'*ZN3-F#,8:5XB5>A=B?]EV4&'*LQN15F6H## &]TO&$Q700
M0Z=O')_KIT%F?U4KN7BV>Z&IO.,>] #<J2]$UM0O/L+^$;@A%^YQ5%4U727N
M36@L"D&^EP!S0I5SJ<A]4PW-:\%$D=")5"*^XR57UXZB]3[;;46#.E<M3UH3
MT]OJNHJN8Y?G6&54FJ;2;R" D#GU^-$L)*!@8482< "V;L_>WR.I_AS;- ]N
MGJ,0+B#C\4I49!MI)K&W"NF(D,<2IIGN2&/<E9!2PU7+4[8WP[W;=T<VP/7+
M)*3G*W/!T"K1,1<I,3)2$)=2W6<+JE&+&,6LM_2=F057P)BZDTVEFMO6<J:=
MVI=T]@M=Q7:&<-O6DGHY!1([XN@*S<\SY Y[W]39!J-WMTT[NE/NU@X:M]2P
MMVJ037 ('NGX$9PF3)OQ=MVX=P'>CZSXX%:L0FAH( 2V@<BX"1>GGYER/#/'
M7>GJI/4*#OVVUEM_IHV?]CQZ4/@R ,#&552Y!@"R66 (^B7_B'.1WT.!]FKQ
M&%";LLBNY:%7!YFWH3:RP3))@.GH? :B' N/,1J1HEBS'MT+$6^ACH< 3 C1
M%GQ";0H4 :LJ*X"U&0%>A)'H]A[Y$Y):D@ZCM1$Z25JSL*)0D^ M:I%;4N?D
M@Y06-9R TRX)53ZS0FNUA$:W83*78@!1Y26((S[==Y'0H0O@Z"70<A).@<*,
M@-^CH54/AQ *H-=KYE+W_('F55'=X(?B_LFKWRE$K1!SNH"H/:E$RY(*D#<?
M !(< P8&V]-KR^<26YU7V< %I4U=HV^X[SRZGE33PCECP/U8MVA#,\#GZ,65
M3SZU)D= D9X!8-5$TF(7D<MJ"9?K<T_Q"Z0I8:1'MUBMXD\S-3,4:SVB;@NZ
MXS)\A7M)V-\6T7D,PG21NP^ER8R"S-4^=,HF?[+A<DD%-6E,$9U/EW4.>YL/
MK3OZ$/QR!PNLKR0QW++B8:Y?<Y.,YG2X@861GQ$ K5U+IA-3=3H/C U,.*.X
MT=LS.J&H1L(+MDORZ5;*K+&+N=L:K-6RU]%(DOCZ7,C8GQ;-VXV)G;.6ZB[*
M.7/>TBAUV\+47P&.:FIG;38=[[97Z9X02B);NP[<F7/GGFHE6LW>O3:X:6F&
MXF.G 9DC8T+I=*0C:M52+X/NC/C0\RF=3M-!:*-6$N;9I QV52]K*I%P"39G
M*CO[@XF+GY:RNK4%@0$6[>GO.+DF3EHA;AP?F_T%]%U#=%G@AQ3M+GDGZ!O=
M>S7F!T,@RE)YL&>Y@D]* S-,1'N_"BQ' &3UIC'%$N$(  IW=H*P3D'028*\
M;")#--LB#NB=P/_,F4/$WC$( M/C3K(N;#W.30WN&+U.1D>(5)6B7;RJI/-2
M\-\^/0 Z6X6"Q4XRPI5>P<4/[C]^=JK-KF)Q<UA:\IM0/.4,+M9<Q=*?RUJ;
M=G\F2H'@KO0G2A)DNR7EOJ6AQ[;%'F\TX*989+E, $][D LZ][Z*,.&GS9T_
MQ;5Q'>YX87<6E2/)@KHQRSA"%>L2CTJ[Q"CEPT+=VXJ)KJFC[>L#CL.QQJA*
MPKV9@8*=\%R\;-ZTW&Z%-#!&3LE].CRKQ_ SV_-[_)H.FVT.G\:7J'3+?+"<
MTAVGQV\Y366#M?'J/UNFB[A=781JIDO']>\M%^ T()1RK5KI.??$QT:MJESA
M$)0V:[9L:=L"=$UFA4$O1>F$SSF%^;H"S3S8?]D_^/('+I.!D>ZHK]:9<\G7
M.(EY*[5\VY3\"M/]8%S+[^ @WZYJX]E_3>THOHTBD((D'<_6*PWV K0/5J<#
M.UG&;P3YO*G7!.0";0/'35 \Z4@7!NNV* G XY&TI&SA?4*\\[J%J5I@3*S[
M5S.5[F4PON*VF<M -#/VI\S"Q/(\;(2&\P%!E6CGZ8Z<S[Z=5F';</@E;0MA
M"=-+D."[;A;F(%Y1$X"3FKR-2HV[[X<]]RK4C6^.F,_!C2)\Y^U,CO)4F8$F
M]O9*O!4JM]&LFKIV&^Z)R1Q_.J3:8:6O8Q6WS2R>AU>&N:S$A\;YWW43V580
MW):DEZ=U\,CL6U'\QFFS9]I6])G[02OQ_&TALA:0FGZC'O5&;J8&LEDB!7 X
M!2*;/H9M5=MMT]NWE$MJRAG8-=ZV:BYQP3O.UO1*,WP]F7LGNZ^Z]$L*+__L
MO)D2?5GL#N0&57(=)RZC"&(K*ABB-Y,R]RV 1*&I9Y 31<G&MZB-N%2ATJZ]
MY554QE8\;TX)!RVHM<Y*( DWX5VK.#],JC3GQO.A$7XOM5-KV?H<5=\/4W]:
MAQO=M*%?SZ*Y+M:_[Z[V;NX;Z_W?V%@)/](R4\__#U!+ P04    "  #AVY7
M-&V,?V,(  #!*@  &0   &5X,S$Q7V-E;S,P,F-E<G0Y,S R,RYH=&WM6FU3
M&S<0_MY?H<(TA1G;^&R,P1!F'' :9EI(C9FTGSKR2<=IT)VNDL[&_?5=K<YO
MV :3DL1TP@?@K-5JM?OLLRN=3V*;R-.3F%-V^L/)C^4R.5=AGO#4DE!S:CDC
MN1'I+?G$N+DCY7(A=::RD1:WL26U:JU./BE])P;4CUMA)3\=ZSG9\\\G>[C(
M25^QT>D)$P,BV-LMT3RLUJ)FL\'9(=UO-%B?!?M-5HNBVE'SH$K#OX(MF KB
M?HZQ(\G?;B4B+<?<K=]JUC)[/!3,QJV@6OUI:T[.\GM;IE+<IBVT%D8C!7LK
MAD,EE6YM5_'GV(V4(YH(.6K]W!,)-^22#TE7)33]N61H:LJ&:Q%Y02/^X:W
M+8Z/0V_-/NB1(N5CZX*:,ZES'XN^L*0>5(*3/2<_WM/"SF8L#L%[7']QDYM+
M33[K='L7[R_.VKV+JTOR\:9[?=.^[)'>%>G>_-JY)D&=EH/]';I+VI?G)&BP
MXNGF\KS3);T/'7+=.;OI7O0N0+CSQ]F']N4O'=(^ZY&K]R0XJN^72/N:M,^O
M/O8ZYW/Z81ZN6:_6G*Q3->^S#?36=;O[KGW9N2Y?_?%KY\_Q-FO5:FVEZ0G5
MMX!BJ[+6838&)J2'/GW>E*^-Y8L2^50AOU$=D@]<VW]*)(0_(AH1&U/[9KMQ
M>+SA&R Q'7"B^4#P(?";C84AO^=4 WSDB'1YIK0E*B7OE4Y(4"W_3B*E08R3
MOR=2&:RM&.$I PW7/+,\Z7/]9CLXJ![7JR7/BBHBOW0OR#NA2N0B#2O@G*-U
MG7.<4<: >,N21[95/X!/$.P"5DQMJQQ\.P<&E?$>OO[J\VXY<CYX1PW$ .*5
MC,A=JH:2LUM>\F'5/IA,P?JI@IH&ZJE("4U')$^MSCF8#U4."QZ$BY($GK2@
MDD0TA(\T40D0MU5>;D$@Y2$WANJ1$TGH'4><3'0:^(R!,;"DQ&H):SB!4&BH
MCB"6PG2PA'%-AK$(8V)R]VLZ?\@U+Y2X#23"2"BCKB(/A8UA@R;C(1KH]!:P
M#-4 IC'2'\VZ >&WFDM?#?YJKP1_G$0BA0@[L$PC6@+P@3@,ZYEQD0+' +0$
MZ!%I*'/'*X":F?"5 '$"N0>"[O#J<"SE%) %%LR#I0'S3#C%)2>12Q  %"J
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MLL*(]([]%H*Y9]5J*76NLK$6=W'.&O5&D_VF]+T8<C>>BUS"NXF>LP/W?'9
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M.!$IT[BFTE=%OMZ"30H#GTJ#[9BCSY]PF#_IQ2D!P7D"[7%''US@]0,NW![
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M?]GK!]3(;>TYZL#]=/2 ?K+Z?U!+ P04    "  #AVY73O,W!,,%   6&0
M'@   &5X,S(Q7V-E;W-E8W1I;VXY,#9C97)T.3,P+FAT;>U9;5/;.!#^?K]B
M+\Q1F$F,[1!>DI29-*1M9GJ$)N':^W0CVW*LJ6RYDD)(?_VM9+LD!'H,0PN]
M*1\8[%WMZR-Y']%-=,I/N@DET<EOW=\;#3@5X3REF8904J)I!'/%LAE\B*CZ
M!(U&J=47^5*R6:+!=_TF?!#R$[LDA5PSS>E)9:>[5SQW]ZR3;B"BY4DW8I?
MHI<U1@,24AJT]LEA<Y\$A\=N<]\GK2B,O,/XH!G^X]5P*:H7:Y1><OJREK*L
MD5#COWWHY[JS8)%.VI[K_E%;T]/T2C<(9[.L;:-%:2PPMU(<"BYD>\NU/QTC
M:<0D97S9?C%E*55P1A<P%BG)7M05R51#4<GB0E&Q+[3M&>?V<5%$LX]V.,MH
M%9WGFY &5PD+F(:F[WC=/:-?Y;21V4K$(5:/RN\>\N&M(?<'X^GP];#?FPY'
M9S!Z#>?CX5E_>-Y[!X./@_[%=/C7 %^CQF"\GM(S3.;\8CRYZ)U-83H"[P@N
MG(G3=V RZ-ODO&;+K3_[''H3Z)V.SJ>#4UA)Y]F'717YV#TP*)J^'<"D-W[5
M.QM,&J./[P9_0Z\_-1+?=?V-;(J8\="0)P^0_>AM/JS#!P?^)#*$MU3J+W4X
MEU2QR)RF)(N@GS :P^"*AG/-+BF,XIB%5(*(X<UX"*^8J,,P"QW8T0F%[:TC
MWW<[?9'F)%O:)Z^S6X=(0$(E#9: :S6+EW7(YU+-"7K18A7?--1,9 6^@2@@
MD<C-B;ZJ7BF9_F <QO&$R(!D5#5&5YPNH1=J(S']J:.<V&5&+Z#*2M(E?,K$
M@M-H1K>W6D>=1VMCU<"<1!%^A!J<QKK=/,!F6'BSS)2VW?".\J<ZV3VG"OK'
M>^^LE>78U,"TY?V<2-SO? ECF@N)+<K@M9 I>&[C?=7C$E40"VF?/Q>+@&))
M(P0%XB0-J-S>\@[<3A/A8S_SJ[B\Z:8"*,1SCB]#=, 9IKI@.K$N)/T\9Y*:
MF4"9,*[AN4-V >/P6CO1[E<0XB:13!L+@ZLP(=F,5DCTCIO[!9Y3&RYB[KAC
M-MC_#%O^\\,6RQ P*;%]"]$$P641OH5;@1<39IYR/ 1-T^M&D7 .: !C(APA
MH7)$@:K;]3'+2!::]V@Z8M:).391:\X+S(B<2NM=W05D5& B4I53C$Z;TY)E
MSB-^7#0).*T:$@@94=G OG"2*]JN_NA$3.6<+-LLL]6UBSHID3,<7@.AM4C;
M+6S%I3G%0\++K[5%7R&^'FL=MQAM-8:CH\IS*7:L:$]'FS*_Y32/6W>*7<>[
M4_8MLU[+\8_N7OI@LP=.ZZ#YZ&:;1T[SX'[1[MD"%T7&/BJ$ULM:LW;CK&C[
M^15XU4E1M,WLDYNM++I8>YJ)Q +F%'>:_23#F;A<.=&]_>)$OT%&RO)\(W/7
MY%V[E^HM1;(<[,XJ/46!7BW7)Y8'I?7-WC]%5MM;^X<=97^O3Z1K>99@KX*K
M++1L@Q\-!H^K6AZV6N1MU 4E.(O %+1SJY%[[N<G2^=G M5_ NE7E1^ARO=B
MC+^J_YVJOW,N&8Z@.<Z@&T7?W:SZGIWI?L;["L_';*=FZ!:2SH2YX2UN$[ 3
M=O!F"OF]>1W/9<94@H,T'K84QWED_R0,R[';C-SEM'^O2PC$-%K.A*ZL,XZ6
MS?".RW.AZ#HU/'H '5SS@K$$AK:$ JU+>Y\=+)%1Q,@)LM!(3#J&/S!NXEEG
M%758)-3P!Z0LD;GP,-4R5)7$ABP;S0AMVOL8$=?1[HS(B%-ELS!F9S1#QL)7
M(C!Y<8Q_3F;&/:AYF)3>'>B!PCV 00H<E9 .\2(@3&:!V6N*ZAH=VOOYDD_;
MA%9O<1)B6H>JN127S-#Y\KZFHDJF/ N&/"PPI+SD<,%R0^>Z\Z6!E288^==&
MX**4*64"P-HPI&H891S#/,<W)DRJ]";]NC%WV'M\1(#E?6U).3&;[\Z;_9)
MN==+2(  G>O-)7=NO+7?Q?\E]NS_0_X%4$L#!!0    (  .';E>B7Z$EN 4
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M$+:^8@C<\H)8 C.LA *M2WMU':QQCHAQ$DA#(S'AF*F!<8-G>Y:HPFI!S=2
M@TIDKCE,MLR 2F(S(AO-"&W:6Q@15]'NG,B(4V6C,&;G-,4YA6\@,'%QQ+\D
M<^,>U#)<%-X=Z(/"/8 @!39(2$"> \)@5AB]IJBNT:&]BB^F:!O0YMW-@IC2
MH6HFQ0TS0WQQ2U,.2"8]*X;35V!&\6)R"]8[.G>5+PQL%,'(/Q<"%R5,*0,
M<\-P0$.4<0S+#+\Q,*G2NT/7O5[#7MDC ^RTUY&48ZINZ-Y+_&)L<N^6D  )
MNM2[2_9NO*W_^4\0)_:GCW\!4$L! A0#%     @  X=N5]C-QYE6Y0  /P +
M !D              ( !     &-K,# P,3@R-#(Y,RTR,#(S,#DS,"YH=&U0
M2P$"% ,4    "  #AVY7GSHOW-L/  "BJP  &0              @ &-Y0
M8VLP,# Q.#(T,CDS+3(P,C,P.3,P+GAS9%!+ 0(4 Q0    (  .';E?=#DKH
MY!(  ,.K   =              "  9_U  !C:S P,#$X,C0R.3,M,C R,S Y
M,S!?8V%L+GAM;%!+ 0(4 Q0    (  .';E=>=+8=O48   @1 P =
M      "  ;X( 0!C:S P,#$X,C0R.3,M,C R,S Y,S!?9&5F+GAM;%!+ 0(4
M Q0    (  .';E=8/P1/$TH" /%@ P <              "  ;9/ 0!C:S P
M,#$X,C0R.3,M,C R,S Y,S!?9S$N:G!G4$L! A0#%     @  X=N5V/_2"SB
MJ@  I%4' !T              ( ! YH# &-K,# P,3@R-#(Y,RTR,#(S,#DS
M,%]L86(N>&UL4$L! A0#%     @  X=N5\%+^4P[=   D2,% !T
M     ( !($4$ &-K,# P,3@R-#(Y,RTR,#(S,#DS,%]P<F4N>&UL4$L! A0#
M%     @  X=N5]_JZUX4$0  2X   !X              ( !EKD$ &5X,3 S
M7V=R:2UC;&%W8F%C:W!O;&EC>7-E+FAT;5!+ 0(4 Q0    (  .';E<T;8Q_
M8P@  ,$J   9              "  >;*! !E>#,Q,5]C96\S,#)C97)T.3,P
M,C,N:'1M4$L! A0#%     @  X=N5RW550]="   N2H  !D
M ( !@-,$ &5X,S$R7V-F;S,P,F-E<G0Y,S R,RYH=&U02P$"% ,4    "  #
MAVY73O,W!,,%   6&0  '@              @ $4W 0 97@S,C%?8V5O<V5C
M=&EO;CDP-F-E<G0Y,S N:'1M4$L! A0#%     @  X=N5Z)?H26X!0   1D
M !X              ( !$^($ &5X,S(R7V-F;W-E8W1I;VXY,#9C97)T.3,P
:+FAT;5!+!08     #  , '8#   'Z 0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
